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Abstract 
Control of disease progression in certain HIV-1 infected individuals is often associated with 
CD8+ T cell responses directed towards Gag-derived epitopes presented on HLA class I 
molecules. This indicates that such responses play a crucial role in combating virus replication. 
However, both the large variability of HIV-1 and the diversity of HLA alleles impose a challenge 
on the elicitation of protective CD8+ T cell responses by vaccination.  
To address this problem, an algorithm was conceived to generate Gag antigens enriched with 
patient-derived CD8+ T cell epitopes. Since the function of Gag to produce virus-like particles 
(VLPs) was deemed important for priming of an adequate CD8+ T cell response, the program 
excluded all epitopes with budding-deleterious properties. To achieve this, all amino acid 
substitutions (AAS) that had been identified in the epitope set through mapping them to a Gag 
reference sequence, were assessed using a trained classifier that considers structural-energy- 
and sequence-conservation-based features to predict whether each AAS is compatible with 
budding. These predictions were validated experimentally for over 100 variants, showing a 
precision of 100% regarding classification of budding competence. Next, epitopes that contain 
only budding-retaining AAS were assigned a score that considers various customizable epitope-
specific properties, like frequencies of HLA class I molecules presenting the epitope in a given 
population, subtype affiliation, and conservation status. Using a genetic algorithm, as many 
compatible epitopes as possible were combined into a novel Gag antigen sequence, aiming to 
maximize their cumulative score. After each round of antigen generation, all previously 
integrated epitopes were eliminated from the input data set. Thus, in subsequent rounds only the 
remaining epitopes were used, which resulted in a set of complementary antigens. To evaluate 
the performance of the algorithm, a trivalent set of globally applicable CD8+ T cell epitope-
enriched Gag antigens (teeGags1-3) was generated and computationally validated in this thesis. 
It could be shown that the teeGags are superior to any known, naturally found or in silico 
generated Gag sequence from previously published work regarding the number and quality of 
epitopes, as well as the population coverage, defined as the average number of epitopes 
presented per person. The shape and size of teeGag VLPs were examined biochemically and 
wildtype-like characteristics were observed for teeGag1 and teeGag3. teeGag2, however, 
exhibited some aberrant, tubular structures and slightly larger particles, probably due to a set of 
mutations within the p2 region of Gag. To characterize the increased immunological breadth of 
the teeGags, a method to directly identify HLA-class-I-presented epitopes was conceived. For 
this, the conditioned supernatant from cells that produce soluble forms of HLA (sHLA) was used 
for HLA-affinity chromatography. Peptides from the isolated sHLA complexes were further 
purified and employed for sequencing through LC-MS/MS analysis. It was shown in this thesis 
that this method can be used to identify sHLA-restricted peptides. However, the sensitivity has to 
be further increased to allow examination of the immunological breadth of antigens.   
In conclusion, with the in silico validated enhanced immunological breadth and the biochemically 
verified structural conservation, the presented designer teeGags qualify as next-generation 
vaccine antigens that potentially elicit superior CD8+ T cell responses.  
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A Introduction 
A.1 Human immunodeficiency virus type-1 (HIV-1) 
A.1.1 Epidemiology of HIV-1 and AIDS 
HIV-1 was first described in 1983 by Gallo et al.1 and Barré-Sinoussi et al.2 as cause of acquired 
immune deficiency syndrome (AIDS), that had been discovered just two years before3. Since 
then, HIV/AIDS became a global pandemic4 with a total of 78 million infected people and 36.7 
million people living with HIV in 20155,6. Most stricken by HIV/AIDS are Eastern and Southern 
Africa, which accounted for 46% of all global new HIV infections in 20157. Mainly due to a scale 
up of antiretroviral therapy, that reached a worldwide coverage of 46% in 2015, the number of 
AIDS-related deaths continuously declined, from 2 million in 2005 to 1.1 million in 2015. 
However, the number of new HIV infections among adults remained nearly static in the last 
years, with 1.9 million in 2015. In Eastern Europe and Central Asia there even has been a steep 
rise in new infections since 20105. 
 
Figure 1. Regional distribution of HIV-1 subtypes, CRFs, and URFs in 2004-2007 (licensed reuse from 
Hemelaar et al.
8
). For the figure the world was divided into regions, as indicated by differential color shading. Pie-
charts symbolize subtype, CRF, and URF frequencies in the respective region, according to the color-coded legend 
on the lower-left. Areas of the pie-charts are relative to the number of HIV-1 infected people in the regions. 
HIV-1 is classified into four groups: M, N, O, and P, which arose at the beginning of the 20th 
century through at least four independent zoonotic transmissions of the chimpanzee simian 
immunodeficiency virus (SIVCPZ) to humans
9,10 or for P possibly from gorilla SIV (SIVGOR)
11. 
Group M is responsible for most infections worldwide, while group O only infected around 10,000 
people and groups N and P far less12. Group M is further partitioned into 9 phylogenetically 
linked subtypes, or clades, (A–D, F–H, J, and K). In dually infected persons, recombination can 
11 
give rise to circulating or unique recombinant forms (CRFs or URFs) of two or more subtypes. If 
a recombinant was identified in at least three people with no direct epidemiologic linkage it is 
called CRF, otherwise URF. As of now, there are 79 HIV-1 CRFs registereda and they are 
becoming more widespread8. The regional distribution of subtypes and CRFs is very uneven 
(Figure 1). The globally most frequent (48% of all people living with HIV; Figure 18) subtype C is 
prevailing in the epidemic regions of Southern Africa (98%). In Western and Central Europe, as 
well as North America, in contrast, subtype B is most frequent (85% and 94%, respectively), 
although only 11% of all worldwide infections are with subtype B viruses. In other regions 
different subtypes prevail: For example subtype A in Eastern Europe and central Asia (80%) or 
CRF01_AE in south and southeast Asia (79%)8. 
A.1.2 HIV-1 structure and genome organization 
 
 
HIV-1 and its close relative HIV-2 are the only two human lentiviruses of the retroviridae family. 
HIV-1 is roughly spherical with a diameter of 100-120 nm and enveloped by a host-cell-derived 
membrane13 (Figure 2). The only HIV-1 protein presented on the particle surface is the envelope 
protein Env, constituted of two non-covalently linked subunits, gp120 and the membrane-
anchored gp41. Three of these heterodimers form the natural trimeric spike structure of Env14. 
Every viral particle displays around 14 such envelope protein trimers15. To the other side of the 
membrane, within the virus, the matrix (MA, p17) protein is bound through an N-terminally 
attached myristoyl group. A conical capsid, made solely of capsid (CA, p24) protein, contains 
enzymes reverse transcriptase (RT), integrase (IN), and protease (PR) that are important for the 
virus replication16. Also, the viral genome, comprised of two identical (+)ssRNA copies, which 
are tightly bound to nucleocapsid (NC, p7) proteins, is stored within the capsid17. The genome 
has a size of about 9,700 to 9,800 nt and consists, besides several structural motifs, of nine 
genes: the structural genes gag (coding for p17, p24, p7, p6, p1, and p2), pol (RT, IN, and PR), 
and env (gp120 and gp41), as well as the regulatory and accessory genes vif, vpr, tat, rev, vpu, 
and nef. The ssRNA genome has a 5’ cap and a 3’ poly(A) tail, showing characteristics of 
eukaryotic mRNA. The genes are partially overlapping within the genome and are translated 
after alternative splicing from different reading frames. 
a
 http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html   (last modified April 5 2016) 
Figure 2. Schematic structure of a 
mature HIV-1 particle (kindly provided 
by Benedikt Asbach). HIV-1 proteins are 
highlighted in different shades of blue. Env 
proteins gp41 and gp120 are the only viral 
surface molecules and are anchored in the 
host-derived lipid-membrane. Gag is 
processed by PR to p24 (CA) that forms 
the conical capsid, the lipid-membrane 
attached p17 (MA), and p7 (NC) that 
associates with the viral RNA genome (in 
red). Enzymes RT and IN are stored within 
the capsid structure 
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A.1.3 Replication cycle of HIV-1 
HIV-1 replication is a multistep process, starting with the interaction of gp120 with the CD4 
surface receptor18 (Figure 3 - step 1), presented by CD4+ T cells and macrophages. The 
engagement triggers conformational changes between inner and outer domains of gp120 
monomers. A newly formed bridging sheet exposes the binding site of the HIV-1 co-receptor, 
either chemokine receptor CCR5 or CXCR419. Only after co-receptor binding, gp41 inserts a 
fusion peptide into the cell membrane, inducing formation of a six-helix hairpin structure that 
brings the viral and cellular membranes in close proximity, necessary for fusion (2). After 
uncoating through CA shell disintegration, the heterodimeric RT binds to the ssRNA viral 
genome20 (3). The two functionally active sites of RT, an RNA- and DNA-dependent DNA 
polymerase and an RNase H that digests the RNA strands of RNA-DNA hybrids, transform the 
ssRNA genome into dsDNA (4). Together with IN and other viral and host proteins, the reverse 
transcribed dsDNA viral genome forms the pre-integration complex (PIC). This complex enters 
the nucleus through the nuclear pore complex (5). IN then cleaves the long terminal repeat 
(LTR) of HIV-1, as well as a random sequence within the host genome, unveiling 5’ termini 
overlaps. Viral DNA ends are ligated by IN to the target DNA 5’phosphates and host enzymes 
complete the integration by repairing the single-strand gaps, generating a stable integrated 
provirus genome (6).  
 
Figure 3. Schematic presentation of HIV-1 replication (Reprinted by permission from Macmillan Publishers 
Ltd: Nat Rev Microbiol. 10(4):279-90,
21
 ©2012). The individual steps of the replication cycle are described in detail in 
the text (A.1.3). Grey boxes show host restriction factors, inhibiting viral replication and white boxes indicate sites of 
action of clinical inhibitors. 
The post-integration phase of HIV-1 replication focuses on gene expression, as well as 
assembly and release of new viral particles. The transcription of HIV genes is initiated by a 
promoter within the upstream LTR. The viral mRNA harbors various splice donor and acceptor 
sites resulting in a variety of alternatively spliced species (7). Fully spliced mRNAs coding for 
Tat, Rev, and Nef are exported readily through the Tap-p15 cellular export pathway (8). The 
proteins Tat and Rev (9) are both transported back into the nucleus. Whereas the viral 
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transactivator protein Tat increases transcription efficiency manifold, Rev is necessary to export 
intron-containing, singly spliced (coding for Env, Vif, Vpr, and Vpu) or unspliced (coding for 
group-specific antigen (Gag) and Pol) viral mRNAs. Rev thereby acts as an adapter to the 
secondary RNA motif Rev response element (RRE) and the host nuclear export factor CRM1 
(8). Env mRNA gets translated directly into the ER and the protein is subsequently transported 
through the Golgi apparatus to the cell surface. On its way, Env gets highly glycosylated and 
then cleaved by cellular Furin proteases into its gp41 and gp120 subunits. Gag on the other 
hand is expressed in the cytoplasm as precursor polyprotein (p55 or Pr55Gag), containing the 
structural proteins p17, p24 p7, p6 and spacers p1 and p2. The GagPol polyprotein is translated 
in a 1:20 ratio compared to Gag from the same template RNA, due to a ribosomal frameshift 
event at the slippery site, consisting of six uridines within gag (9). By N-terminal myristoylation22 
and conserved basic amino acids within MA23, Gag and GagPol are anchored at the inner leaflet 
of the plasma membrane. Gag is sufficient for assembly (10) and budding (11) of viral particles, 
but in natural HIV-1 replication, unspliced genomic viral ssRNA is encapsidated by binding to the 
p7 part of Gag24, and Env is probably included by p17 and gp41 coupling25. For release from the 
cell, the particle must undergo membrane abscission, mediated by the cellular endosomal 
sorting complexes required for transport (ESCRT) machinery (12). Gag-particle assembly and 
release is described in detail below (A.3.1). Shortly after, or concomitant to virus budding, the 
viral protease PR cleaves Gag and GagPol into p17, p24, p7, PR, RT, and IN, resulting in a 
rearrangement of proteins: p17 remains membrane bound, whereas p7 accumulates at the viral 
RNA, and p24 forms the conical capsid, embedding the ssRNA genome, RT, and IN (13). Only 
after this maturation HIV-1 is infectious and ready for the next replication round. 
A.1.4 HIV-1 transmission, pathogenesis, and treatment 
The main transmission route for HIV-1 is by sexual contact, whereas men who have sex with 
men, female sex workers, and transgender women are at especially high risk of acquisition. High 
viral load, measured as HIV-1 RNA level in the plasma, is the most important risk factor that 
increases probability of transmission26. With every log10 elevated viral plasma titer the infection 
risk increases 2.5 times27. Besides sexual transmission, shared needles for injection drug 
users28 and mother-to-child transmissions, perinatal or through breastfeeding, are other possible 
infection routes. Sexual transmission is mostly established by a single founder virus, that is more 
likely CCR5- than CXCR4-tropic29. Main targets after crossing mucosal membranes are 
activated CD4+ T cells, but other cells expressing CD4 and the appropriate chemokine receptor, 
like resting CD4+ T cells and macrophages, can be infected as well26. After transmission, during 
the acute phase of the infection, rapidly increased HIV replication causes high viral loads30 and 
also a striking immune activation.  
At the beginning of the adaptive immune response, mainly CD8+ T-cell-mediated killing of 
infected cells occurs. Neutralizing antibodies arise only about 3 months after infection. About 
20% of all HIV+ people generate broadly neutralizing antibodies (bNAbs)31, capable of 
neutralizing a variety of isolates. However, these bNAbs require often years to develop and, 
because of rapidly established escape-mutations, provide no benefits for patients26. During the 
acute infection, the CD4+ T cell levels are transiently reduced and the virus rapidly disseminates 
to the lymphoid organs. Over the course of roughly 4-6 weeks the host innate and adaptive 
immune responses reduce the plasma virus concentration considerably, triggering the virus to 
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enter the chronic phase and clinical latency. The level at which the viral load stabilizes, the so 
called viral set point, depends strongly on the quality of the cellular immune response (A.2.1.4).  
With establishment of chronic infection and immune-system-mediated viral control, the CD4+ T 
cell numbers recover initially. The chronic infection is also characterized by a distinct, continuous 
immune activation that progressively results in immune dysfunction, immune cell depletion and 
increased virus production. If untreated, the CD4+ T cell levels gradually decrease to about 50-
100 cells per µl and the patient develops a high-level viremia, which marks the transition of the 
clinical latency to AIDS. Due to the dysfunctional immune system, opportunistic diseases arise 
quickly and without intervention the patient’s median survival is only 11 months32.  
However, due to effective treatment, an HIV-1 infection that was formerly considered lethal is 
now a manageable chronic disease21. This antiretroviral treatment (ART) combines nucleoside 
RT inhibitors with non-nucleoside RT, protease, or integrase inhibitors that act on different steps 
of viral replication (Figure 3). Until recently, the treatment was normally started, if a limit CD4+ T 
cell count (200 or 500 per µl) was undercut. The latest guideline on when to start antiretroviral 
therapy however recommends that “antiretroviral therapy (ART) should be initiated in everyone 
living with HIV at any CD4 cell count”33, since early initiation might slow disease progression34. 
Treatment lowers plasma viral load to concentrations below the limit of detection and can restore 
normal CD4+ T cell levels. Besides near-normal life expectancy in these treated patients35, the 
transmission risk is strongly reduced due to their aviremia. However, due to long-living cellular 
reservoirs, an HIV-1 infection is never eliminated with current treatment concepts. Main HIV-1 
reservoirs are latently-infected resting memory CD4+ T cells36,37 and especially lymph-node-
located TFH cells
38. The latter are able to produce replication-and infection-competent HIV-1 
particles even after >14 years of ART treatment, if activated38. It was estimated that 70 years of 
ART are necessary to eradicate all latent reservoirs39. 
As long as no sterilizing (i.e. viral eradication) or at least functional (complete, sustained control 
of infection without treatment) cure of HIV-1 is possible, prevention of infection is the most 
important action to control the epidemic. There are different approaches to avoid HIV-1 
transmission, like pre-exposure prophylaxis, post-exposure prophylaxis, medical male 
circumcision, behavior interventions, and vaginal- and rectal-microbicides26. Some of these 
methods showed very promising initial protection in small, selected cohorts, but had problems 
when used for a broad implementation, due to low adherence40. Therefore the easiest and most 
practicable way to contain and eventually even eliminate the HIV-1 epidemic would be an 
effective prophylactic vaccine. 
A.1.5 HIV-1 vaccine development 
Since the discovery of HIV as cause of AIDS, the search for a vaccine had been a top priority 
among researchers. Against initial expectations that this would be achievable within few years, 
an effective, prophylactic vaccine remains elusive even today, 33 years later. Main obstacles for 
researchers are the unusually high genetic variability of HIV-1 (A.3.3), uncertainty about the 
correlates of protection, the lack of adequate animal models, and the difficulty to develop highly 
immunogenic antigens. Of the few phase IIb/III clinical studies performed to analyze the efficacy 
of HIV-1 vaccines concepts, most showed sobering results. The earliest trials, VAX00341 and 
VAX00442, where a mixture of different gp120 proteins was administered, aiming to elicit a 
protective antibody response, showed no efficacy. The STEP (HVTN 502)43 and the similar 
Phambili (HVTN 503)44 phase IIb studies tested an adenovirus type 5 (Ad5) viral vector-
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delivered HIV-1 gag/pol/nef antigen combination as cell-mediated immunity vaccine. However, 
neither approach caused protection. On the contrary, in Ad5 seropositive and uncircumcised 
men, the incidence of infection even increased. A following study, HVTN 505, that also 
employed Ad5 as viral vector was halted at interim-analysis for futility45. The only clinical study 
that showed modest and transient protection from HIV-1 infection was the phase III RV144 
(Thai) trial46. Through a heterologous prime (recombinant canarypox vector coding for Env, Gag, 
and PR) and boost (recombinant gp120 protein) regimen a 31.2% protection-efficacy at 
42 months (with a p-value of 0.04) as primary endpoint was achieved. The greatest protection 
was observed 1 year after vaccination (60% efficacy), but the effect decreased over time. 
Assessing the immune correlates for protection indicated that the risk of HIV-1 infection 
correlated inversely with humoral immune responses against the V1V2 regions of Env and 
correlated directly with Env-specific, plasma IgA antibodies47. Also, Env-specific CD4+ T cell 
responses and antibodies eliciting Fc-mediated antibody-dependent cellular cytotoxicity (ADCC) 
responses to Env have been connected to reduced risk of acquisition48. Between vaccinated and 
unvaccinated persons, who got infected, no difference concerning viral loads was observed, 
possibly, because nearly no CD8+ T cell responses were elicited through the RV144 
vaccination. 
A.1.5.1 Broadly neutralizing antibodies 
Although not identified as a correlate of protection in the RV144 trial, nowadays most HIV-1 
vaccine research focuses on the induction of broadly neutralizing antibodies in vaccinees. In 
natural infections, these bNAbs evolve in about a fifth of all infected persons, through continuous 
reciprocal evolution of HIV-1 antibodies and the virus: antibodies against Env drive viral escape 
through mutations, which in turn induces antibodies against the mutated virus and so on. 
Eventually, in some cases, antibodies against conserved epitopes are elicited that can neutralize 
multiple HIV-1 viral strains. Despite their broad specificity, bNAbs shaped during primary 
infection have little to no effect on disease progression in patients, due to rapid viral Env 
adaptations that prevent neutralization, or even recognition (viral escape)49. However, inclusion 
of bNAbs in HIV-1 immunotherapy to suppress viremia, generated some promising results in 
humanized mice50 and preliminary human studies51. Resistant viral strains emerged in humans 
within 28 days though, showing that this is not yet a therapeutic option and also illustrating how 
fast escape mutations are generated. The main focus is therefore on a prophylactic vaccine that 
elicits high titers of bNAbs to eliminate the virus before an infection is established. This 
hypothesis is mainly based on the fact that passive immunization with monoclonal, broadly 
neutralizing, Env-specific bNAbs can completely protect non-human primates (NHP) from 
challenge with pathogenic chimeric simian/human immunodeficiency viruses (SHIV), expressing 
HIV-1 Env52,53. bNAbs often exhibit unusual features, like a long heavy chain complementarity 
determining region 3 (CDR3), poly-reactivity towards non-HIV-1 proteins, or a high frequency of 
somatic mutations that often take years to develop and are substantial obstacles to their 
elicitation through vaccination54,55. No vaccine regimen so far has been able to reliably induce 
the production of such bNAbs. Research therefore aims at improving the immunogen design, 
like for instance the development of native-like trimers with higher affinity to bNAbs, and 
mimicking the bNAb maturation process in patients to elicit bNAb responses56. 
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A.1.5.2 Vaccine-induced HIV-1 T cell responses 
In natural HIV-1 infections, T cell responses are the first adaptive immune responses to occur. 
Although these de novo T cell responses cannot eradicate the virus, especially CD8+ T cell 
responses help to control the virus replication and reduce the viremia during acute infections57. 
Some HIV-1 infected persons, called long-term nonprogressors (LTNP), can even suppress the 
virus for up to 30 years without treatment, therefore delaying the development of AIDS. This 
control in LTNP is often associated with the presence of high-quality CD8+ T cells that are 
polyfunctional, highly-efficiently kill HIV-1-infected cells and are reactive against more epitopes 
(=enhanced breadth), as well as exhibit a higher cross-reactivity to epitope variants (=enhanced 
depth) as compared to disease progressors58. A prophylactic vaccine that elicits CD8+ T cell 
memory (A.2.2.3) could respond to a primary HIV-1 infection with an early, high magnitude and 
broad CD8+ T cell effector response that might more effectively inhibit viral infection and limit 
establishment of viral escape and latent reservoirs. Whether T cell memory responses could 
contribute to a sterilizing immunity against HIV-1 spawned some controversy. For example, HIV-
exposed seronegative (HESN) individuals developed robust Gag-specific CD8+ T cells that 
might have reduced the infection risk59,60. There is however no clear evidence that these CD8+ T 
cell responses are a correlate of protection in these individuals61. Archiving sterilizing immunity 
through T cells seems difficult, since most vaccine-induced T cells require an anamnestic 
response. Therefore HIV-1 is confronted by the T cells only after the infection is established62, 
which helps to reduce viral loads but does not achieve eradication. 
The Gag protein is the main target for a cellular HIV-1 vaccine, because of all HIV-1 proteins, 
mainly Gag specific T cell responses have been associated with a reduced viremia63. 
Additionally, although Gag is not expressed by early genes in a natural infection, the high 
amount of protein incoming from the viral particle is sufficient for CD8+ T cells to recognize 
infected cells as early as two hours post-infection, even before proviral genome integration and 
viral protein synthesis64. This quick response could lower the acute phase viremia and control 
the infection before the appearance of escape mutations. The viral function of Gag and its use 
as an antigen for vaccination is described in detail in chapter A.3. 
A.2 Cell-mediated immune responses 
A.2.1 Antigen processing and presentation on MHC class I 
To be recognized by host T cells, viral antigens have to be processed and presented on the cell 
surface by major histocompatibility complex (MHC) class I or class II molecules. In the classical 
pathways exogenous antigens are presented by MHC class II molecules, which interact with 
CD4+ T cells, and antigens of intracellular origin by MHC class I molecules, able to activate 
CD8+ T cells. These interactions are, however, not mutually exclusive, and in APCs, exogenous 
antigens can be loaded onto MHC class I through cross-presentation (A.2.1.2). Also, 
endogenous proteins can be presented by MHC class II when they are degraded by 
autophagy65. Since priming of a protective CD8+ T cell response is dependent on efficient 
antigen processing and MHC class I presentation, those molecular pathways are described in 
detail in the following chapters. 
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A.2.1.1 Classical MHC I pathway 
MHC class I molecules are expressed by all nucleated cells, in contrast to MHC class II 
complexes that under normal conditions are only associated with APCs. To be presented 
through the classical MHC class I pathway, antigens have to be located in the cell cytoplasm or 
nucleus. If these endogenous proteins reach the end of their functional live or are defective due 
to erroneous transcription or translation, so called defective ribosomal products (DRiPs)66, they 
get degraded by the ubiquitin-dependent proteasome67. The decomposition of DRiPs is the 
reason that antigen presentation kinetics are not necessarily correlated with the protein half-
lives68 and stable viral proteins can be presented immediately after infection and first translation. 
The proteasome is a protein complex composed of a 20S core barrel with two 19S cap proteins 
at both ends. In immune cells or under immune activation, subunits within the 20S barrel that 
form the catalytic center, responsible for peptide bond cleavage, are substituted, altering 
degradation patterns69. This so called immunoproteasome caused a better antigen presentation 
through selectively generating more immunogenic peptides or simply by a higher turnover, 
producing larger amounts of peptides70,71. Proteasome-degraded peptides that possess a length 
between 8 to 16 amino acids can be transported by the transporter associated with antigen 
presentation (TAP) into the ER72. TAP is a heterodimeric (consisting of TAP1 and TAP2) ABC 
transporter that forms a pore across the ER membrane and translocates peptides from the 
cytosol to the ER lumen, driven by ATP hydrolysis73,74. Directly after entering the ER, peptides 
with a length of 8 to 11 amino acids and a suitable binding motif are loaded onto immature MHC 
class I complexes. Longer peptides are first further trimmed N-terminally75 by the two human ER 
aminopeptidases (ERAP1 and ERAP2) to a length of not less than 8 to 9 amino acids76,77.  
The immature MHC class I complex, consisting of a polymorphic (A.2.1.3) heavy/α-chain and the 
invariant light chain beta-2-microglobulin (β2m), is only stable after a high affinity peptide has 
been bound to the peptide-binding groove, which is made up by the α1 and α2 domains of the 
heavy chain. Until appropriate peptide binding, the heavy chain and β2m intermediary complex 
is stabilized by the cellular chaperone proteins tapasin, calreticulin, and ERp57. All these 
proteins are associated through tapasin to TAP, and the whole assembly is called the peptide-
loading complex (PLC). Through binding of a sufficiently stabilizing peptide the chaperones are 
released and the mature peptide-MHC class I complexes (further called pMHC) are transported 
through the Golgi apparatus to the cell surface, presenting the peptide, called epitope, to CD8+ 
T cells. MHC class I molecules that fail to connect to a suitable peptide are transported back to 
the cytoplasm through the ERAD (ER associated protein degradation) machinery for 
proteasomal degradation78. 
A.2.1.2 Cross-presentation 
Although all nucleated cells can present viral epitopes on MHC class I molecules, only 
professional APCs are able to prime naïve antigen-specific CD8+ T cells (A.2.2.1). If these 
APCs get directly infected, they can readily present epitopes through the classical direct 
presentation pathway (A.2.1.1). However, if a virus does not target APCs directly, the pathogen 
has to be taken up exogenously and presented on MHC class I through an alternative pathway 
called cross-presentation. The APC population mainly involved in vivo in cross-presentation are 
dendritic cells (DCs)79. Most molecular and cellular mechanisms associated with cross-
presentation are poorly understood, but there seem to be two main pathways, by which DCs can 
present exogenous antigens on MHC class I molecules: the cytosolic and the vacuolar pathway 
(Figure 4). 
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Figure 4. Antigen cross-presentation in dendritic cells (Reprinted by permission from Macmillan Publishers 
Ltd: Nat Rev Immunol. 12(8):557-69,
80
 ©2012). After uptake of exogenous antigen, dendritic cells can cross-present 
it to MHC class I molecules through two main pathways: The cytosolic pathway (left), which makes use of the classical 
MHC class I processing machinery, or the vacuolar pathway, where antigen loading takes place in the phagosome 
(see text A.2.1.2).  
In the cytosolic pathway exogenous antigen gets internalized via phagocytosis or 
macropinocytosis and can then access the cytosol. The transport of antigens from endocytic 
compartments into the cytoplasm is most probably achieved through the ERAD machinery that is 
recruited to the phagosomes and endosomes81. Pathogen-derived antigens are then degraded 
by the proteasome and enter the normal direct-presentation pathway as described before 
(A.2.1.1). Besides normal MHC class I loading by the PLC after transport via TAP into the ER, it 
has been proposed that degraded antigen peptides can reenter the phagosomes and are loaded 
there onto class I complexes that are subsequently transported to the cell surface82. For this 
alternative loading in the cytosolic pathway, TAP and the PLC are recruited to phagosomes and 
endosomes.  
The vacuolar cross-presentation pathway is independent of antigen entering the cytoplasm. 
Antigen uptake, degradation, and pMHC loading all take place in the endocytic compartments. 
The MHC class I heavy chain and β2m in the phagosome originate thereby either from recycled 
complexes from the plasma membrane83 or through recruitment of novel molecules from the 
ER84. 
DCs seem to be the preferred APC for cross-presentation, because of the low concentration of 
lysosomal proteases and their reduced activity in the endocytic compartments due to a higher 
pH value. This limited lysosomal antigen degradation correlates with efficient cross-presentation, 
since it retains potential MHC class I epitopes80,85.  
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A.2.1.3 Human MHC class I polymorphism 
In humans, the MHC is called human leukocyte antigen (HLA) and the class I heavy chain genes 
are encoded by three loci (HLA-A, -B, and –C), located on the short arm of chromosome 6. HLA 
heavy chains are highly polymorphic and are among the most variable human genes, with 
already 11,100 different class I alleles being listedb. The polymorphic residues cluster especially 
in the region of the peptide binding grooves, resulting in different epitope-binding motifs for 
distinct HLA alleles. For most alleles, the motif is defined by two conserved anchor amino 
acids87, located at the second (P2) and at the last position of the epitope (PΩ). These anchors, 
in combination with hydrogen bond interactions of the N- and C-termini88 of the epitope, are 
responsible for mediating sufficient binding to the peptide binding groove. Depending on the 
allele, specific secondary interactions of residues from the epitope with the HLA molecules, so 
called secondary anchors, also influence binding affinity89,90. The remaining amino acid 
composition of the epitope mostly follows no observable hierarchy. 
Since a single person can have up to 6 different class I HLA alleles, the presentation of a broad 
range of different epitopes is possible, aiding in the eradication of infections. These 
combinations of HLA alleles, called HLA haplotype, are highly variable, enhancing the 
population-wide protection by presenting a wide range of epitopes. But this diversity also 
hampers the development of universal T cell antigens, especially for highly variable pathogens 
like HIV-1, because the set of cell-surface-presented epitopes is highly diverse from person to 
person.  
On a typical nucleated cell, there are around 1-5 x 105 HLA class I complexes presenting around 
104 distinct epitopes. Epitope lengths range from 8-11 amino acids, but around 95% are 9-mers. 
The number of one specific epitopes ranges from 1 to 10,000 per cell, with a mean of about 5091. 
The 50 most abundant epitopes, however, already fill 27% of all HLA class I molecules92. 
 
A.2.1.4 Role of HLA class I presentation during primary HIV-1 infections 
In a primary HIV-1 infection an effective CD8+ T cell response is the major determinant for a low 
viral load set point. Targeting epitopes, where virus escape is accompanied by substantial viral 
fitness loss, reduces the virus load. The HLA haplotype heterogeneity of the general population 
results in variable presentation of susceptible epitopes and is therefore a major determinant for 
HIV-1 control93. 
Certain alleles like HLA B*2794, where escape is accompanied by a dramatic fitness loss95, or 
B*5796 are frequently found in LTNPs and confer control of virus replication. Contrary, persons 
with HLA alleles like B*35 or with class I homozygosity, which reduces the breadth of possible 
epitopes, are susceptible for rapid HIV-1 disease progression to AIDS97. 
To inhibit CD8+ T cell mediated killing, HIV-1 has evolved an immune evasion mechanism that 
modulates the HLA pathway. The HIV-1 protein Nef diverts the trafficking of HLA-A and -B 
molecules from the Golgi apparatus to lysosomal compartments for degradation98, thereby 
downregulating HLA surface presentation, which inhibits effective epitope display. In contrast, 
HLA-C and HLA-E presentation is not altered by Nef, to avoid lysis through natural killer cells, 
which recognize altered or infected cells with reduced HLA expression99. 
b
 http://hla.alleles.org/nomenclature/stats.html
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A.2.1.5 In vitro antigen processing and presentation analysis 
Since MHC-class-I-presented peptides derive from intracellular proteins, they can be seen as a 
fingerprint of the cells constitution. Alteration of the cell composition, for example through viral 
infections or transformation, also changes these fingerprints, leading to the presentation of 
different peptides on the cell surface. Scrutinizing CD8+ T cell can recognize these alterations 
and kill the aberrant cells (A.2.2). Knowledge of these MHC-class-I-presented epitopes, referred 
to as the immunopeptidome, could help to develop efficient targets for therapeutic tumor 
approaches and provide valuable information for T cell vaccine design. Easy identification of 
epitopes would also constitute an excellent tool to validated antigen candidates and check, if 
epitopes are processed and presented efficiently, and whether these are identical to those 
observed in natural infections. An easy way to identify the presented and immunogenic peptides 
of an antigen would be to administer it in vivo and to read out the primed T-cell responses, for 
example with synthetic peptides. For antigens that are designed for use in humans, this 
however, often is not an option, since an adequate animal model is missing. Another approach 
would be to use epitope-specific CD8+ T cell clones, recognizing individual pMHCs on cells. But 
this method is limited by the low number of readily accessible clones and the laborious work to 
identify all presented epitopes. 
An elegant way to circumvent these problems is to directly isolate and identify the naturally 
processed epitopes. Several different approaches for epitope isolation have been published 
including acidified cell lysates100,101, elution of peptides from the cell surface by mild acid 
washing, which destabilizes pMHCs and releases the peptides102, and immunoaffinity 
chromatography purification of pMHCs. The immunoaffinity method exhibits the highest 
sensitivity and is therefore the most prevalent nowadays. This technique exploits antibodies that 
bind either to specific or a broad spectrum of MHC alleles, to isolate them from a mixture of 
proteins. The most widely used antibody in human systems is the monoclonal mouse antibody 
W6/32, which recognizes most HLA A, B, and C alleles103. Additionally, this antibody ensures 
isolation of peptide bound HLA class I complexes, since it binds at the interface of β2m and the 
heavy chain of the heterodimer that is only stable if also a peptide is bound in the peptide 
binding groove104. The complexes can be either isolated from detergent-solubilized cell lysates87 
or directly from the conditioned medium, if soluble variants of MHC class I molecules (sMHC or 
for human variants sHLA) are introduced into the cells105. For the latter case, the heavy chain is 
deprived of its transmembrane domain, inhibiting anchorage in the plasma membrane, as 
infrequently found in vivo for the non-classical HLA-G106 and classical HLA proteins107,108. In 
these cases, after peptide loading in the ER the soluble pMHC complexes get secreted 
actively109 into the extracellular environment. Compared to MHC isolation from cell lysates this 
has the advantage that it can be harvested from the same cells multiple times, by just 
exchanging the medium, and that it allows to focus on a single MHC allele and not just get a 
pool of peptides originated from the cells’ haplotype. Between immunopeptidomes presented on 
membrane-bound and soluble HLA molecules, substantial overlap was observed110,111, indicating 
that the use of sHLA molecules allows the identification of naturally processed CD8+ T cell 
epitopes. Additionally, C-terminally added epitope tags to sHLA do not alter the 
immunopeptidome112, but allow purification irrespective of a suitable HLA-specific antibody, that 
in some cases might alter peptide composition. 
After isolation, the amino acid sequences of the peptides are determined by tandem mass 
spectrometry. In this process, the peptides are first separated by liquid chromatography and then 
detected in a mass spectrometer according to their mass-to-charge ratio. For the sequence 
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analysis, peaks of the chromatogram are selected for fragmentation in a second mass 
spectrometry analysis. To identify the epitopes, the fragmentation pattern can be used for a 
search against possible epitopes from a set of proteins, like all human proteins or the protein of 
interest. The first use of mass spectrometry to identify MHC-bound peptides was described by 
Don Hunt and Vic Engelhard113, and with methodical advances in mass spectrometry it became 
suitable for broad application. Nowadays the sensitivity is high enough to realize detection of 
peptides down to attomole levels, which facilitate the theoretical identification of complete 
immunopeptidomes. Affinity purification combined with mass spectrometry have already been 
used to identify the endogenous self-epitopes presented in the absence of any alteration92,110,114, 
infection-specific epitopes115–119, tumor-specific epitopes120, infection- and tumor-induced 
changes in the presentation of self-epitopes121–124, and epitopes presented by vaccine 
candidates125, partly using soluble HLA proteins110,119,121,122,124 as peptide source. 
A.2.2 CD8+ T cell immune response  
In the previous chapter the pathways by which endogenous and exogenous antigen can be 
loaded onto MHC class I molecules were described. If these pMHC molecules display pathogen-
derived epitopes, scrutinizing naïve CD8+ T cells could recognize it, get primed (A.2.2.1) and 
consequently differentiate to effector T cells that kill infected cells (A.2.2.2) or to memory T cells 
that prevent the host from a recurrent infection with the same pathogen (A.2.2.3). 
A.2.2.1 Priming of naïve T cells 
Naïve CD8+ T cells originate in the thymus and are specified by a membrane-bound T cell 
receptor (TCR). The TCR is a heterodimer, normally consisting of an α and β chain, and is 
generated through extensive gene rearrangement in the TCR loci. Since the diversity of possible 
TCR rearrangement combinations is with about 1015 far higher than the number of T cells within 
a person, each cell most likely expresses a unique TCR126.  
T cells undergo two rounds of selection before leaving the thymus as mature naïve CD8+ T 
cells127. First, a positive selection, where only CD8+ T cells that show low avidity towards self-
peptides presented on MHC class I receive a pro-survival signal, thereby eliminating non-
functional TCRs that show no reactivity against MHC molecules. Second, in the negative 
selection round auto-reactivity is prevented by inducing apoptosis in all T cells that are highly 
reactive against self-peptides. The mature, naïve CD8+ T cells migrate through peripheral 
lymphoid tissues and highly efficiently scrutinize pMHCs on APCs. The APCs primarily involved 
in priming of naïve CD8+ T cells are DCs, which can either get infected with pathogens and 
thereby directly present pMHCs (A.2.1.1) or take up exogenous antigens and cross-present 
them80 (A.2.1.2). Initial contact between APCs and T-cells is mediated by cell-adhesion 
molecules. Next, the TCR complex, consisting of the variable α- and β- T cell receptor chains 
and the invariant signaling proteins CD3 and a ζ chain-homodimer, samples the pMHC. If 
suitable, the variable part of the TCR recognizes the presented antigenic peptide through the 
highly variable CDR3 loops, as well as the MHC molecule with the more conserved CDR1 and 
CDR2 loops126. The interaction is stabilized by the heavily glycosylated disulfide-linked 
heterodimeric CD8 co-receptor expressed by CD8+ T cells, that binds to invariant sites of MHC 
class I molecules. The pMHC-TCR interaction induces cell plasma membrane convergence, 
which ensues spatial exclusion of the inhibiting CD45 phosphatase and most probably is the 
reason T cells get activated128. In this kinetic segregation model, the kinase Lck at the inner 
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leaflet of the membrane phosphorylates immunoreceptor tyrosine-based activation motifs 
(ITAMs) of CD3 and ζ chains, thereby activating the TCR complex.  
Importantly, in addition to the binding of the TCR to pMHC, a secondary signal is needed to 
prime naïve T cells. For CD8+ T cells, this is mainly the co-stimulatory receptor CD28, which 
gets activated by binding of DC cell surface proteins CD80 or CD86. These molecules are, for 
example, highly expressed on DCs that matured through active infection, therefore building a 
bridge to innate immunity and activation of DCs, for example by TLR signaling. If there is no co-
stimulus, antigen recognition alone induces functional inactivation and clonal deletion of 
peripheral T cells. This ensures that T cells are only primed during ongoing infections, and is a 
fact that has to be considered for any vaccine design. Downstream signaling after activation of 
the TCR complex and CD28 causes translocation of selected transcription factors to the 
nucleus. This in turn leads to transcription of genes, most importantly IL-2 that drives T cell 
proliferation, clonal expansion and differentiation. Besides CD28 activation additional help, 
provided by CD4+ effector T cells that recognize MHC class II presented antigen on the same 
APC, is required most of time for thorough priming of CD8+ T cells. On the one hand, the CD40 
ligand from CD4+ T cells binds to CD40 on DCs, which increases the expression of CD80 and 
CD86. On the other hand activated CD4+ T cells directly help to prime CD8+ T cells by 
producing abundant IL-2.  
The complete so-called primary cell-mediated immune response primes the CD8+ T cell to 
differentiate into effector (A.2.2.2) or memory cells (A.2.2.3), both recognizing the same pMHC 
as the original naïve T cell129. 
 
A.2.2.2 CD8+ T-cell-mediated cytotoxicity 
Primed naïve CD8+ T cells proliferate and differentiate to cytotoxic effector T cells, also called 
cytotoxic T lymphocytes (CTL). These effector cells are guided by chemokines and newly 
expressed adhesion molecules to the site of infection and scrutinize pMHCs. As soon as they 
encounter the appropriate pathogen-derived pMHC, they respond quickly, and efficiently kill the 
infected cell without the need of any co-stimulatory signal. The CTL are therefore able to act on 
any virus-infected cell. The interaction between pMHCs and the TCR complex together with 
additional nonspecific adhesion molecules forms a tight “immunological synapse” between the 
CTL and the target cell, which enables highly selective targeting of effector molecules to the 
infected, antigen bearing cell. Stimulated CTLs release cytokines like IFNγ, which can inhibit 
viral replication and increase MHC expression as well as antigen processing in the target cell. 
The main mode of operation is, however, to kill the infected cell by release of the cytotoxins 
perforin, granulysin, and granzymes that are stored in granulae. Perforin forms a pore in the 
target cell, which allows granzymes to enter the cytoplasm of the infected cell. Granzymes are a 
family of serine proteases that induce apoptosis in the target cell. Most notable, granzyme B is 
responsible for cleavage and activation of caspase 3 and also induces release of cytochrome c 
from the mitochondria, both events being gateways for programmed cell death. Granulysin has 
antimicrobial activity and might additionally induce apoptosis. Cells that undergo cell death 
through the cytotoxic armory of the CTL are rapidly ingested by phagocytic cells. Killing of the 
infected cells allows CTLs to detach and search for new targets129. 
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A.2.2.3 Memory CD8+ T cell response 
The process from priming of naïve T cells that induces clonal expansion, differentiation to 
effector cells, and finally enables eradication of an infection requires several days. Pathogen 
clearance is accompanied by apoptosis of most effector cells and generation of a small set of 
memory T cells. Although memory CD8+ T cells seem to require some CD28 co-stimulation to 
get fully activated130, they are far quicker and more efficient at killing infected cells in response to 
an antigen stimulus, than naïve T cells. These memory T cells responses are long-lived with an 
approximate half-life between 8 and 15 years and are the hallmark of adaptive immunity that 
protects the host from subsequent challenge by the same pathogen129.  
CD8+ T cells can either differentiate into effector memory (TEM) or central memory T cells 
(TCM)
131. Effector memory T cells can upon restimulation immediately exert effector functions, 
thus quickly killing target cells, but they show only limited expansion potential132. Contrary to the 
TEM-mediated protective memory, the central memory T cells represent the reactive memory 
reservoir133. TCM reside in the T cell zones of lymphoid tissues, have no immediate effector 
function, but are highly sensitive to antigenic stimulation, which readily induces proliferation and 
differentiation into effector cells. TCM show a high expansion potential
132, but their anamnestic 
response-driven effector functions are delayed compared to the immediate action of TEM. 
Thus, the aim of an HIV-1 cellular-immunity vaccine would be to elicit a broad range of high-
quality (A.1.5.1) memory T cells, preferable of effector memory phenotype, to control or even 
prevent viral infection62. 
 
A.3 The Gag protein and virus-like particles in vaccinations 
A.3.1 HIV-1 Gag VLP assembly and release 
The group-specific antigen (Gag) is the main structural protein of HIV-1 and the driving force in 
the assembly and release of viral particles (Figure 5). Gag is expressed as 55kDa precursor 
protein that gets processed by the virus PR into the proteins p17, p24 p7, p6 and the spacer 
peptides p2 and p1 only after viral release (A.1.3). Expression of Gag alone in a cell is sufficient 
for the formation and release of so called virus-like particles (VLPs)134. These VLPs resemble 
immature viral particles in size and form, but are, due to the absence of a viral genome and any 
other viral proteins, not infectious134.  
Because of its size and flexible linker between the domains, the structure of the precursor 
55 kDa Gag has not been resolved yet. However, atomic-level 3D-structures of the subunits 
provide valuable information about Gag’s functions during assembly of viral particles: The N-
terminal p17 matrix domain of the Gag polyprotein folds into a globular structure (composed of 
five α-helices, a short 310 helical stretch, and a three-stranded mixed β-sheet), with a C-terminal 
α-helix projecting away, to connect it p17 with the p24 domain135. Co-translational covalent 
attachment of a myristic acid moiety to the N-terminus of p17 targets Gag to the plasma 
membrane. The p24 capsid domain folds into two distinct, mostly independent domains. The 
largely helical N-terminal domain (NTD) and C-terminal domain (CTD) are connected by a 
flexible linker136,137. The CTD contains a dimer interface, the main determinant, which drives Gag 
multimerization, and the major homology region (MHR), which is necessary for particle assembly 
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and is highly conserved throughout all orthoretroviruses138. The p7 nucleocapsid structure 
contains two zinc finger domains that interact with the viral genomic RNA in natural HIV-1 
infections, to recruit the RNA to the particle assembly site139. The Gag C-terminal domain p6 is 
largely unstructured140 and recruits the endosomal sorting complex required for transport 
(ESCRT) to the assembly site, which catalyzes the membrane fission and therefore the particle 
release from the cells. 
 
 
 
For particle assembly the Gag polyprotein associates with the host cell’s plasma membrane. The 
mechanism by which Gag targets only the plasma membrane and no other cellular membranes, 
is most probably linked to the ability of the myristic acid moiety to adopt two different 
conformations: a sequestered and an exposed one141. In newly translated Gag the myristic acid 
is concealed, but interaction between p17 and phosphatidylinositol‑4,5‑bisphosphate 
(PtdIns(4,5)P2), which is highly enriched at the inner leaflet of the plasma membrane triggers a 
conformation change142,143. Thereby, the myristic acid group gets exposed and facilitates 
interaction with the plasma membrane. A cluster of basic amino acids within p17 additionally 
strengthens the Gag interaction with the inner leaflet of the plasma membrane135. The integrated 
Gag recruits sphingolipid- and cholesterol-enriched membrane microdomains, so called lipid 
rafts, which form the platforms for particle assembly144. The next step necessary for budding is 
Gag multimerization at the assembly site. Although Gag-RNA interactions have a supportive 
role, the main and sufficient determinant for the Gag clustering is the CTD of p24. Cryo-electron 
tomography revealed that the Gag-multimeric lattice has a hexameric arrangement in VLPs. To 
form a closed lattice that accounts for the curvature necessary to form particles with a diameter 
of ~100-120 nm, Gag would also have to generate pentameric structures. But since Gag only 
forms hexamers, the continuous lattice includes small areas devoid of Gag and one large gap145, 
Figure 5. Post-integration phase of 
HIV-1 replication (Reprinted by 
permission from Macmillan 
Publishers Ltd: Nat Rev Microbiol. 
13(8): 484-96, ©2015). Env is 
synthesized in the ER and transported 
to the plasma membrane, whereas 
Gag and GagPol synthesis happens 
in the cytoplasm. Gag alone is 
sufficient to induce viral particle 
assembly. It anchors in the plasma 
membrane and multimerizes there. In 
natural infections the viral ssRNA 
genome, GagPol and Env get also 
incorporated into the viral particle. 
Release of the particles is facilitated 
by the host-cellular ESCRT machinery 
and afterwards PR induces virus 
maturation by cleaving Gag. In the 
presence of only Gag virus-like 
particles bud from the cell, which 
resemble immature virions in size and 
form (details in the text of chapters 
A.3.1 and A.1.3). 
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forming an incomplete, roughly spherical shell (Figure 6). The aligned Gag molecules are 
packed radially, with the N-terminal p17 located at the membrane and the C-terminus oriented to 
the particle-center146. HIV-1 virions, as well as VLPs, are both reported to contain roughly 2000 
copies of the Gag protein147,148. To release the viral-particle, late domains (comprised of two 
distinct motifs: P(T/S)AP and YPXL, as well as one unknown domain149), located at the N-
terminal region of p6, recruit the host-cellular ESCRT machinery. ESCRT consists of about 20 
proteins that form several multiprotein complexes that are important for a range of cellular 
membrane fission processes. HIV-1 requires only a subset of these proteins, especially ESCRT-
I and several subunits of ESCRT-III, for membrane abscission and viral-particle budding from 
the cell149. The precise mechanism by which the ESCRT machinery accomplishes this release is 
not understood, but ESCRT III might help to constrict the membrane at the budding site by 
assembling into circular spirals150 and thereby facilitate release of the immature VLPs. Since PR 
is missing in Gag-only VLPs, no maturation - characterized by processing of Gag into its 
subunits and subsequent protein rearrangements - occurs. 
 
 
Figure 6. Global lattice map of Gag virus-like particles (adapted from Briggs et al.
145
). Gag protein clusters in a 
hexameric arrangement during particle assembly, which forms a continuous, but incomplete spherical shell. The 
picture indicates these Gag-hexamers and the areas void of any Gag. 
 
A.3.2 Gag and HIV-1 VLPs as antigens 
In natural infections, control of the viral load in LTNP and elite controller (EC, infected person 
without detectable viral loads) is often associated with robust cellular immune responses 
towards Gag151,152. Other HIV-1 proteins that induce a strong T cell response, like Nef, are not 
associated with lowered viremia153. Therefore, an optimal cellular-immunity vaccine, centered on 
Gag, that elicits a broad, poly-functional, and high-magnitude T cell response might control 
viremia and inhibit disease progression in vaccinees, once an HIV-1 infection is established. 
Moreover, a rapid memory response might mediate early control at the site of infection and 
thwart spread from the entry portal, possibly preventing HIV-1 infection from manifesting at all154, 
as indicated by robust Gag-specific CD8+ T cell responses in HESN women60 (A.1.5.2). 
Moreover in NHPs, the best available animal model to validate HIV-1 vaccine concepts, 
administering a prime-boost vaccine regimen, based on recombinant vesicular stomatitis virus 
(VSV) and an alphavirus replicon expressing SIV Gag and SIV Env, led to sterilizing immunity 
against high-dose challenges with SIVsmE660155. If only SIV Env was used for vaccination, no 
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protection was achieved, indicating that Gag, or the combination of Gag and Env, are required to 
elicit the sterilizing immunity156, highlighting the importance of Gag. 
As for HIV-1, a strong cellular immunity against Gag, but not Pol- or Env, has been implicated 
with control of SIV replication in NHP157. Such T cell mediated viral inhibition in NHP was most 
prominently shown when rhesus cytomegalovirus (RhCMV) was applied as viral vector to deliver 
the SIV proteins Gag, Rev-Tat-Nef and Env158,159. About 50% of all RhCMV/SIV-vaccinated 
monkeys that got intrarectally infected with the highly pathogenic SIVmac developed an early 
and stringent viral control. After initial viremia, the virus was not detectable any more, with 
exception of periodical, low level blips. These short periods of measureable viremia, however, 
gradually waned158 and control has been stable in all but one of 17 protected monkeys, raising 
the possibility of ultimately eliminating the SIV infection through continuous immune 
surveillance62. Control was mainly accomplished by CD8+ T cell responses158 in the absence of 
neutralizing antibodies158,159. In contrast to classical vaccinations, the CD8+ T cell memory 
responses did not have a TCM phenotype, but the TEM character for persistent pathogens 
prevalent, allowing a quick non-anamnestic effector response after primary infection158,159. 
Through the deletion of two genes (Rh157.5 and Rh157.4, which are coding for two proteins of 
the pentameric receptor complex involved in infection of nonfibroblasts160) from the RhCMV 
vector expressing Gag, the elicited CD8+ T cell responses turned out not to be classically MHC-
class-I-restricted, but rather MHC-class-II-161 or MHC-Ib/E-restricted162.  
During primary SIV infection these unconventionally restricted CD8+ T cells do not get efficiently 
primed, but effector T cells that were previously primed through RhCMV/SIVgag can get 
reactivated162. MHC-class-II- and MHC-E-restricted CD8+ T cells represent therefore an 
interesting target for vaccination, as they might also circumvent pathogen immune-evasion 
adaptations, like Nef-mediated MHC class I downregulation (A.2.1.4). As MHC-E is even up-
regulated in SIV or HIV infected cells as a result of the evasion from NK-cell-mediated killing, 
such MHC-E-restricted responses may facilitate control162. Since CMV is species-specific, it is 
currently unknown, whether human CMV would also mediate control and prime such non-MHC-
class-I-restricted CD8+ T cells. 
Besides the excellent immunological characteristics, also the functional properties of Gag to 
form VLPs can be put to use. Compared to direct, soluble antigen, such particle-based antigens 
appear to be favorable for DC uptake via macropinocytosis and endocytosis163 with subsequent 
antigen cross-presentation164 and are capable of inducing better cellular and humoral immune 
responses165. The intake of a single HIV-1 VLP for example feeds about 2000 Gag molecules to 
a single cell, thereby helping to overcome antigen processing thresholds70. Efficient uptake and 
immune responses of baculovirus- or yeast-derived HIV-1 Gag-VLPs was observed in ex vivo 
experiments166,167, as well as in mice168,169 and NHP170 immunized with Gag-VLP. In NHP, 
strong, broad, and long-lived CD8+ T cell responses were elicited, in the absence of any 
adjuvants. HIV-1 Gag VLPs also exhibit some adjuvants properties per se, through activating 
and maturating DCs171, which is necessary for efficiently CD8+ T cell priming as outlined 
above(A.2.2.1).  
As an alternative, besides directly applying VLPs as antigen, naked DNA or viral vectors that 
code for Gag can be administered. The addressed cells are then able to synthesize Gag 
proteins that can self-assemble into budding VLPs, which then can presumably prime CD8+ T 
cell responses through cross-presentation. The importance of functional Gag in such antigens 
has previously been demonstrated in our group. In a first antigen-generation, based on the 
CRF07_BC 97CN54 isolate172, the possibility for Gag to form VLPs was, due to safety concerns, 
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inactivated by a mutation inhibiting addition of the myristic acid moiety (i.e. the G2A mutation). 
Additionally the natural frameshift within Gag was deleted and Gag was fused to an artificial, 
safety-optimized PolNef protein (i.e. IN deleted, PR inactivated, and a scrambled Nef replaced 
the active part of RT, that was put at the C-terminus), resulting in the read-through protein 
GagPolNef. This construct was administered together with gp120 in a heterologous DNA-prime 
and NYVAC boost regimen. In mice173, as well as in NHPs174, the combination was safe and 
highly immunogenic. These findings were confirmed in a clinical phase I trial (EuroVacc02), 
where reliably, poly-functional, and long-lasting T cell responses were induced175. However, the 
T cell responses were, as already observed in the NHP studies, unbalanced and mainly directed 
against Env and not the preferred Gag antigen.  
Therefore, for the next antigen generation a more natural constitution was restored, by allowing 
myristoylation and therefore budding of Gag-VLPs. Additionally, the frameshift was reinserted, 
resulting in a Gag to GagPolNef ratio of 20:1, and gp140 was used instead of gp120 in order to 
elicit better antibody responses. This time, both, the Gag and the gp140, sequences were taken 
from C clade isolate 96ZM651. In mouse experiments, these combinations showed greatly 
improved T cell response ratios between Gag and Env176,177. In NHPs receiving these second 
generation antigens in a heterologous DNA prime and NYVAC plus gp120 protein boost178 a 
log10 increased T cell response magnitude was obtained as compared to the first generation, 
with a balanced CD4+ T cell response. Importantly, mainly Gag-targeting CD8+ T cells were 
observed. These findings emphasize the importance to employ functional Gag in HIV-1 cellular-
immunity vaccines. 
Another feature that makes VLPs a favorable target for vaccine design is the possibility to 
incorporate other molecules like viral envelope proteins. The obvious first choice for an 
additional protein would be the HIV-1 Env. Env incorporated into VLPs resembles the natural 
HIV-1 virion structure and could be a combinatorial approach, to elicit both, protective broadly 
neutralizing Env-specific antibodies (A.1.5.1) and also broad, efficient Gag-specific CD8+ T cell 
responses, to control breakthrough infections. Gag from the VLPs could also contribute to an 
improved humoral response by intrastructural help of Gag-specific CD4+ T cells179. It was 
already shown that rabbits immunized with native, membrane-expressed Env trimers presented 
on Gag VLPs were able to elicit autologously Tier 2 HIV-1 neutralizing antibodies180. Other 
surface proteins could be used to broaden the cell tropism of VLPs, like the incorporation of 
VSV-G that increased Gag T cell responses in mice and lowered viremia in challenged NHPs181. 
Other molecules can be included to enhance the adjuvants properties of VLPs, as shown for 
GM-CSF and CD40 ligand in SIV Gag based VLPs182.  
In conclusion, there are many reasons to choose Gag as the main target for a cellular HIV-1 
vaccine, and its ability to self-assemble into VLPs can be utilized to improve immunogenicity.  
A.3.3 T cell antigens to address HIV-1’s variability 
The biggest obstacle in designing an effective cellular HIV-1 vaccine is the enormous viral 
diversity. It was shown that the HIV-1 variation in a single infected patient over the course of 6 
years is equivalent to the worldwide variation of influenza virus in a year183. The high variability 
of HIV-1 is mainly due to the lack of proofreading functions of the HIV RT and the host cell DNA-
dependent RNA polymerase II (RNA pol II), that synthesizes the viral genome. The combined 
error rate for both polymerases is approximately 2 × 10−5 per nucleotide in every replication 
cycle184. This feature, together with the early onset of HIV-1 replication, the vast number of 
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replications, influences of the host immune pressure185,186, and the tolerance of a high degree of 
genome variability without loss of virus fitness, lead to the enormous diversity among HIV-1 
strains and quickly establishes genetically distinct quasispecies in an infected person12,62. Amino 
acid diversity between HIV-1 subtypes (A.1.1) is on average 18% and within subtypes about 
12%187. The variability is protein-dependent and highest for gp120, while Gag variability within a 
clade is on average below 10%188. This, for HIV-1, comparably low diversity makes Gag a 
preferable target for T cell vaccines, but nevertheless a potential antigen still has to elicit a broad 
response to be protective. 
The STEP trial failed to induce protective cellular immune responses, but used only an inferior 
Gag antigen based on a single B clade isolate (CAM-1 - GenBank D10112)43. It was stated that 
a higher magnitude and especially a broader CD8+ T cell response is needed to confer 
immunity189. In the only clinical trial that showed moderate protection (RV144) T cell responses 
against Gag were not identified as a correlate of protection and no T cell driven sieve effect in 
HIV-1 breakthrough isolates was noted190. However, like for the STEP trial, only a single B clade 
Gag sequence from a natural isolate (LAI IIIB/Bru - GenBank A04321) was used for vaccination 
and the Gag T cell responses elicited were very low46. Both trials indicate that the T cell 
responses against Gag were not good enough and next-generation vaccines should aim to 
improve breadth and magnitude191. 
In the last years, some novel antigens that deal with the viral diversity were developed. One 
strategy is the use of consensus, ancestral, and center-of-tree HIV-1 sequences (described in 
detail in B.1.1.3). These sequences are designed to minimize the genetic distance in a given set 
of diverse viral sequences192, thereby reducing the abrogating effect of viral variability, with the 
idea to cover a broad spectrum of viral strains.  
A second approach is to focus CD8+ T cell responses only on conserved regions of HIV-1 and 
excluding highly variable sequences 193,194. This would reduce the possibility for viral escape, 
since mutations in these conserved regions are detrimental for viral fitness. In a natural infection, 
these responses are rarely primed, because of immunodominant responses to variable epitopes, 
which facilitate viral escape. If CD8+ T cells however are primed against conserved epitopes 
through a vaccine, it might help to control the virus infection195. Conserved regions antigens 
were shown to elicit broad T cell responses in mice196 and NHP197 and vaccination against 
conserved regions of SIV induces even partial protection against SIVmac251 challenge198.  
A third, promising strategy to address the variability of HIV-1 is the mosaic approach199. Therein, 
a polyvalent set of HIV-1 protein sequences is designed, based on a set of naturally occurring 
viral sequences in a way to best cover the most frequently occurring 9-mers, which here are 
used as a surrogate for CD8+ T cell epitopes. In NHP studies mosaic variants of HIV-1 Gag, Pol 
and Env antigens augmented breadth, depth and magnitude of antigen-specific T cell responses 
compared to consensus or natural sequence HIV-1 antigens200. Since it was shown that a broad 
Gag-specific cellular immune response correlates with efficient viral control in NHP201 and 
humans63, Gag antigens based on the broadening mosaic approach, seem to be most favorable 
for a T cell vaccine. The mosaic design, however, does, like all other methods not account for 
the naturally processed epitopes that are excellent characterized for HIV-1. 
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A.4 Objective 
As outlined in the precious section, there is reason to believe that a broad and potent Gag-
specific CD8+ T cell response elicited through vaccination is important to control HIV-1 infection, 
as it might help to lower the virus set point through an early response63. Additionally, such 
responses might help to prevent establishment of latent infection altogether154 or at least 
mediate a functional cure, as was for example shown for RhCMV-vector-induced TEM responses 
to SIV159. This leads to the working hypothesis that a greater breadth and depth of presented 
HIV-1 Gag epitopes increases the chance of matching epitopes from a transmitted HIV-1 isolate 
and consequently the ability to control the virus. 
Therefore, the objective of this work was to design Gag vaccine-antigens that elicit a broad 
CD8+ T cell response against immunologically potent Gag epitopes, while simultaneously 
preserving protein functionality, defined as budding of virus-like particles, which showed 
beneficial immunological characteristics. The antigens should contain as many of the most 
potent epitopes as possible. To ensure in vivo processing and presentation the set of epitopes 
should be based only on experimentally validated sequences that have been found in natural 
infections or vaccination studies.  
Due to the high HIV-1 sequence variability, inclusion of epitopes often requires introduction of 
mutations compared to a natural Gag reference sequence. Since these amino acid substitutions 
(AAS) might compromise the protein’s functionality and therefore reduce the release of VLPs, 
each of these mutations should be assessed for budding-preservation and be excluded if the 
AAS turns out to be detrimental in this regard. Since the high number of possible mutations 
excludes experimental classification into budding-competent and -detrimental ones, this 
discrimination should be done through an in silico implemented multidimensional classifier. Next, 
a quality score should be assigned to all compatible epitopes that takes various immunological 
parameters derived from the epitopes' metadata into account. For proof of concept antigens, 
presented in this thesis, the score of epitopes should be mainly computed based on their ability 
to benefit a global vaccine approach. Finally, the best epitopes should be combined in a 
polyvalent antigen set consisting of as few components as possible, since the practicability of a 
vaccine formulation consisting of more than three components is deemed very low154. To 
highlight the increased immunological potential of the designed Gag antigens they should be 
analyzed and compared to other antigens regarding number and quality of included epitopes, as 
well as their potential to cover the worldwide population, as well as the global virus distribution. 
Following design, the Gag antigens should also be characterized biochemically for their ability to 
form VLPs that resemble wildtype particles in structure and size. Additionally, to assess the 
immunological breadth of these novel CD8+ T cell antigens, an in vitro method for direct 
interrogation of HLA class I presented epitopes through mass spectrometric LC-MS/MS peptide 
sequencing should be established. 
 
 
 
 
 
 
  
30 
B Datasets and computational methods 
B.1 Datasets 
B.1.1 HIV-1 Gag sequence sets 
B.1.1.1 HIV-1 Gag sequence alignments 
Various steps of the antigen generation, as well as in in silico validation required HIV-Gag 
sequence alignments. The Los Alamos National Laboratory (LANL) HIV Database 
(www.hiv.lanl.gov, Los Alamos, USA) stores the most comprehensive online collection of HIV 
sequences202 and provides premade DNA or protein alignments, either of the whole genome or 
of specific genes or proteins.  
 
Protein Alignment 
For this work, the premade “Filtered Web Alignment” for the HIV-1 Gag protein from the year 
2013 (Options: Organism: “HIV-1/SIVcpz”; Subtype: “All”; DNA/Protein: “Protein”) was 
downloaded in FASTA format. The Filtered Web Alignment is a subset of the Web Alignment, 
excluding sequences with large insertions, high content of ambiguity codes, and multiple 
frameshifts. The Web Alignment in turn is the most complete set offered by LANL, containing all 
sequences of the database, except that only one sequence per patient is included and very 
similar and problematic sequences are removed. For the purpose of this work, the downloaded 
alignment was manually edited by deletion of all group N, O, and P sequences, all SIV 
sequences (subtype CPZ), as well as by removal of all entries with unclassified (U) sequence 
elements.  
 
Nucleotide Alignment  
Besides the protein alignment, an alignment of Gag nucleotide sequences was required, too. For 
this the “Filtered Web Alignment” from the year 2013 was downloaded with the same 
specifications as for the protein alignment, except DNA/Protein selection was changed to “DNA”. 
B.1.1.2 Reference sequence 
For the alignment of epitopes and the identification of amino acid substitutions, a Gag amino 
acid sequence, hereafter called “reference sequence”, was necessary. Best suited for this is the 
sequence of HIV-1 subtype B isolate HXB2 described in 1985(GenBank accession number 
K03455)203, because it is one of the most commonly used strains in many different kinds of 
functional and structural studies and also all HIV numbering positions in the HIV database are 
relative to the complete HXB2 genome204. The HXB2 Gag protein (GenBank accession number 
AAB50258.1) consists of 500 amino acids and comprises the domains p17 (amino acids 1-132), 
p24 (133-363), p2 (364-377), p7 (378-432), p1 (433-448), and p6 (449-500). 
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B.1.1.3 Other Gag Sequences 
As benchmarks to compare newly designed 
antigens, various other Gag sequences that have 
been proposed as antigen candidates were 
collected. These were either specially designed 
artificial sequences, like consensus, ancestral, 
mosaic, or center-of-tree, or sequences of natural 
isolate that were previously included in phase 
IIb/III clinical trials. 
Consensus (hereafter termed »con«), ancestral 
(»anc«), and center-of-tree (»cot«) variants of 
Gag all address the issue of viral diversity by 
calculating a sequence that minimizes the genetic 
distance in a given set of viral sequences192 
(Figure 7205). Consensus sequences are designed 
by choosing the most common amino acid at each 
position of a multiple sequence alignment (MSA). 
Consensus sequences of Gag based on various 
HIV-1 subtype sequence sets, and an M group 
consensus based on all subtype-specific 
consensus sequences (with same weighting for rare and common clades), were downloaded 
from the LANL as a premade protein sequence alignment as FASTA file (Options: Alignment 
type: “Consensus/Ancestral”; Organism: “HIV-1/SIVcpz”; Subtype: “All”; DNA/Protein: “Protein”; 
Year: “2004”)206. Ancestral sequences are computed to represent the most recent common 
ancestor of an MSA. Subtype-specific ancestral Gag sequences, as well as an M group 
ancestral sequence were included in the same alignment downloaded for the consensus antigen 
set206. Center-of-tree sequences are calculated by minimizing the phylogenetic distance of viral 
sequences of a sequence population. The design of a center-of-tree sequences based on 
subtype B was described before207,208. This sequence, together with subtype C and M group 
center-of-tree sequences, was kindly provided by Dr. James I. Mullins (University of Washington, 
USA). Mosaic sequences (»mos«) do not aim to minimize the genetic distance but to include as 
many naturally occurring 9-amino-acid peptide sequences (hereafter called »9-mer«) as possible 
in a protein sequence. Gag-specific mosaic sequences haven been published for subtype B and 
C, as well as for the M group199. They were designed as sequence sets of different size 
(combinations of up to six subtype-specific sequences), always aiming for maximal 9-mer 
coverage. Each set is to be used as an entity. Therefore the mono- and trivalent mosaic-sets 
were employed for comparison to the here presented antigen-sets that comprise the same 
numbers of sequences. 
Lastly, for evaluation purposes, Gag sequences of natural isolates included in phase IIB/III 
clinical trials were collected. All of the four trials that included a Gag component in their vaccine 
used well-characterized subtype B isolates: CAM-1 (GenBank D10112) for the HVTN 502 
(STEP) trial43 and the HVTN 503 (Phambili) trial44,209, LAI (IIIB/Bru; GenBank A04321) for the 
RV144 (Thai) trial46,47, and HXB2 for the HVTN 505 trial45. Protein sequences of these isolates 
were downloaded from the LANL HIV sequence database using the search interface. The earlier 
conducted VAX00441 and VAX00342 clinical phase III trials, solely administered Env as 
immunogen in their vaccine regimens. 
 
Figure 7. Visualization of different phylogenetic 
shapes and location of designed antigen 
sequences. All reconstructed sequences perform 
well at minimizing the genetic distance for 
symmetric phylogenies (A+B). For asymmetric 
phylogenies (C+D) only cot minimizes the distance 
satisfactorily. (From Science 299(5612):1515-8 
©2003. Reprinted with permission from AAAS). 
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B.1.2 CTL/CD8+ T cell epitope database 
In addition to the considerable collection of HIV-1 sequences the LANL HIV database also offers 
an “Immunology Database”210, where experimentally validated HIV-1 cytotoxic and helper T cell 
epitopes, as well as antibody binding sites, from diverse publications are collected with 
annotations.  
By using the “CTL/CD8+ T-cell epitope database” search interface, epitopes of interest for the 
herein described newly designed antigens were identified. Since there is no web service or 
interface for direct access, the set of epitopes was downloaded as HTML file and subsequently 
converted to a text-based comma-separated values (CSV) file. The final epitope list contains the 
epitope’s sequence represented as string, together with other useful information, which are 
associated with the epitope entry (Table 1). 
 
Table 1. Epitope associated attributes directly extracted from the LANL immunology database. (Attribute 
description: http://www.hiv.lanl.gov/content/immunology/search_help.html) 
a
Attributes that are not directly relevant for 
antigen design, but are annotated in all entries and allow a more detailed epitope description. 
b
Attribute data type: int 
represents an integer and string a text based data field. 
Attribute Type
b
 Description 
Record Number
a
 int A unique epitope identification number assigned by the database 
Protein string 
Location of the epitope within the Gag polyprotein (three possible 
values: p17, p24 or p2p7p1p6) 
Start int Start position in the defined protein 
End int End position in the defined protein 
Author Location
a
 string Epitope location specified by the author 
Epitope string Amino acid sequence of the epitope entry 
Subtype string Subtype under study for the entry (not specified for subtype B) 
Species
a
 string Species in which the immune response to the epitope was stimulated 
Immunogen
a
 string Stimulus of the original immune response 
HLA string HLA alleles presenting the epitope in question 
Donor HLA
a
 string 
HLA haplotype of the person in which the immune response was 
detected 
Country
a
 string 
Country where the samples were obtained (not specified for studies 
conducted in the United States) 
Experimental 
Method
a
 
string Methods used to test the immunological response 
Keyword
a
 string Catchwords describing the HIV immunological study of interest 
Notes
a
 string 
Comments explaining the context in which an immune response to 
the epitope was found and what was learnt about the epitope in 
question 
References
a
 string Associated primary publications  
 
Besides the directly accessible features for an epitope, each entry was also examined manually 
for additional, immunologically valuable information (Table 2). These were either gathered by 
checking the textual additional notes by the authors, the primary reference or by other epitope 
metadata as described below. The epitope list was screened for erroneously recorded 
sequences and false annotations by checking the primary publications given for a questionable 
database entry. If possible the entry was patched or else deleted. 
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Table 2. Additional epitope information extracted from the metadata. 
a
Attribute data type: double represents a 
floating point number and Boolean a Boolean data field that only can be one of two values: false or true. 
Attribute Type
a
 Description 
Response in LTNP Boolean True if the epitope is associated with responses in LTNP 
% response double 
Percentage of persons in the study which show an immune response 
to the epitope. Normalized to the frequency of the presenting HLA 
allele (B.2.2.5) 
Conservation double Conservation score of the epitope (B.2.2.4) 
 
The epitope list had to be further processed due to two special issues (Figure 8): 
(1) Because the extracted data from the LANL immunology database is a collection of 
information gathered from various studies and primary publications, some epitope entries are 
redundant, i.e. they may describe peptides with identical sequence and location. These 
database entries were merged into one consensus entry by unifying all available relevant 
information. In case of information given as a string value (HLA and subtype) all information 
were summarized in one joint record. For numerical values (%response and conservation), the 
mean of all entries with non-empty fields for this value was calculated. For the LTNPs Boolean 
field, a majority voting, i.e. selection of the alternative for which most entries are specified, was 
performed in case of contradicting information. 
(2) In some cases, epitopes (subepitope) are fully embedded in another epitope (superepitope). 
Since the subepitopes are automatically included if the respective superepitope is incorporated 
into a new antigen (but not the other way round), all immunologically important characteristics 
from the subepitopes were added to the superepitopes. This was done in the same way as 
described for the handling of identical epitopes in (1), except for that the subepitope was kept 
with its original data as separate entry in the input data set.  
 
Figure 8. Alignment of CD8+ T cell epitopes to the HXB2-Gag reference sequence, duplicate merging, and 
sub/superepitope attribute transfer. All epitopes of the input data set were aligned to the HXB2-Gag reference 
amino acid sequence. (1) In case of multiple entries for the same epitope (i.e. identical string sequence and matching 
start/end positions) epitope-specific attributes were merged into one consensus entry. (2) If an epitope (subepitope) 
was fully embedded in another epitope (superepitope) all attributes of the subepitope were added to the superepitope, 
but not the other way round. Both epitopes were kept in the input set. 
B.2 The Optimizer Algorithm 
The first version of the Optimizer Algorithm for designing epitope-enriched HIV-1 Gag T cell 
antigens was developed by Matthias Pfeifer211. It consists of four distinct, successive steps 
(Figure 9): (1) All input epitopes are mapped to a given reference sequence and all amino acid 
mismatches are identified. (2) Each of these epitope-associated amino acid substitutions (AAS) 
is then separately analyzed, to determine if the integration of the mutation would result in a 
functionally impaired protein with defective or reduced VLP budding capacity.  
 
34 
 
Figure 9. Workflow of the Optimizer Algorithm used to design CD8+ T cell epitope-enriched Gag antigens with 
preserved structure and function (adapted from Matthias Pfeifer
211
). (see B.2) 
 
For the classification of the AAS, structural features as well as sequence conservation properties 
are taken into account. All epitopes including at least one AAS with budding-deleterious 
implications are removed from the input data set. (3) In the third part all remaining epitopes get 
ranked based on a numerical, multi-parametric scoring scheme, which considers weighted 
immunological, demographical and virological features. (4) The antigen candidate is generated 
by integrating as many compatible epitopes as possible into the reference sequence in a way 
that maximizes the overall combined score. For a polyvalent antigen set this last optimization 
step can be repeated, but all epitopes that are already incorporated, are neglected for each new 
iteration. This leads to a combination of sequences which complement each other in their overall 
score and epitope coverage. All these methods are implemented in the Optimizer Algorithm for 
fully-automatically design of T cell epitope-enriched antigens, as described in detail by Matthias 
Pfeifer211. The mode of operation is summarized below, especially pointing out steps of the 
algorithm that were improved in this thesis. 
 
B.2.1 Functional assessment 
Single amino acid substitutions (AAS) in Gag might lead to a partly or completely misfolded 
protein or influence essential interactions and thereby reduce or inhibit viral particle assembly 
and budding212. To identify epitopes with AAS that would be detrimental for the Gag structure 
and function, without elaborate experimental validation, a computer-aided screening system was 
conceived. For this AAS-specific structure- and sequence-based classification features are 
evaluated by a multidimensional classifier that is based on a supervised machine learning 
approach, to identify mutations with budding-deleterious effects.  
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B.2.1.1 Structure-based classification features 
Since the protein conformation has crucial influence on the function, differences in the three-
dimensional (3D) structures and hence their energetic profiles are indicators to evaluate the 
effects of amino acid substitutions. To assess such energetic changes each AAS was separately 
integrated into the reference sequence. Afterwards, the energetic profile of this sequence, 
mutated at one position, was compared to the profile of the native sequence to identify distinct 
local or global differences that can be applied as discriminatory features for the classifier. 
 
Homology modeling and Discrete Optimized Protein Energy 
For the structural validation of AAS, tertiary structures of the reference, as well as of the mutated 
sequence with the integrated AAS were required. To generate these 3D structures homology 
modeling was used. This computational approach utilizes the biological observation, that tertiary 
structural folds and motifs are far more conserved than their underlying primary amino acid 
sequence213,214. Referring to this principle, a high degree of identity between two sequences is 
mostly also a sign of similarities on a structural level. Homology modeling predicts the tertiary 
structure of a protein target sequence primarily based on its alignment to at least one similar 
template sequence with known structure215,216. One of the most widely used programs for 
homology modeling is MODELLER215, which can automatically calculate a structural model by 
optimally satisfying spatial restraints derived from the target-template-alignment217,218. 
Additionally, the tool also implements some auxiliary tasks, like aligning sequences and 
structures as well as model evaluation by energy-based calculations. One of these intrinsic 
evaluation methods is the Discrete Optimized Protein Energy (DOPE)219, an atomic-distance-
dependent statistical potential, grounded entirely in the probability theory. For all homology 
modeling of structures and conformational energy predictions via DOPE calculations the 
MODELLER v9.7 was utilized. 
 
Three dimensional structures of the reference sequence 
The reference sequences, needed for 
modeling sequences with single AAS, as 
well as for the energy landscape 
comparisons, were also generated via 
homology modeling. The required 
template sequences were identified with 
a BLASTP (Protein Basic Local 
Alignment Search Tool, 
http://blast.ncbi.nlm.nih.gov) 220,221 search 
against the Protein Data Bank (PDB, 
www.rcsb.org)222. From the BLASTP hits 
with a sequence identity of at least 90%, 
the templates were selected in 
descending order of query coverage until 
the entire target was covered by at least 
one template structure. Target-template 
alignment and model building were 
performed with the fully-automated tools 
implemented in MODELLER. 
Table 3. Templates for homology modelling of the reference 
sequence. Possible templates were identified in a BLASTP 
search against the PDB. Templates were chosen in descending 
order of query coverage of all search hits with a sequence 
identity greater than 90%. Selection was proceeded until the 
complete target sequence was covered by at least one template. 
Protein 
Template 
[PDB ID] 
Identity 
[%] 
Coverage 
[%] 
p17 
1L6N 93.89 99.24 
1TAM 99.17 90.01 
p24 
3H47 97.51 87.01 
3GV2 97.26 94.81 
2K1C 95.89 31.60 
p2 1U57 100.00 100.00 
p7 1AAF 94.55 100.00 
p1 no suitable structures found 
p6 2C55 90.38 100.00 
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Identification of suitable templates (Table 3) and structure modeling was done before by 
Matthias Pfeifer211, except for p1, because there was no sequence available fulfilling the 
predefined criteria. 
 
Protein free energy changes as classification features 
Analysis of AAS-induced energy changes compared to the native structure can provide evidence 
for conformational perturbations. Such differences can lead to malfunctions and might influence 
the viral budding in the context of Gag.  
To analyze the energy landscape alterations accompanied by the introduction of AAS, 
sequences based on the reference sequence with only one single AAS at a time were 
generated. For each mutated sequence, five 3D-structures were generated by homology 
modeling using the automodel class of MODELLER with the previously designed reference 
structures as template. The corresponding structure with the lowest DOPE Model Score was 
chosen for calculating a residue-by-residue energy profile based on the DOPE energy function. 
This gives a position-specific energy ek for every residue of a protein, with an amino acid 
sequence length n. As potential features to classify the AAS, the following four different 
structural energy parameters were computed. 
f1,DOPE: The first feature is the DOPE potential of the mutated structure (mut) at the residue (k) 
with the AAS itself. 
 
𝑓1,𝐷𝑂𝑃𝐸 = 𝑒𝑚𝑢𝑡,𝑘  
 
f2,ΔDOPE: This feature represents the differences in DOPE at the mutation site compared to the 
reference (ref) at the same position. 
 
𝑓2,∆𝐷𝑂𝑃𝐸 = 𝑒𝑟𝑒𝑓,𝑘  − 𝑒𝑚𝑢𝑡,𝑘   
 
f3,ΔDOPE-global: Global DOPE differences compared to the reference are used for feature three. This 
value was calculated by analyzing the energy profile differences at all n amino acid positions 
separately and summing them up. 
 
𝑓3,∆𝐷𝑂𝑃𝐸−𝑔𝑙𝑜𝑏𝑎𝑙 = ∑(𝑒𝑟𝑒𝑓,𝑖 − 𝑒𝑚𝑢𝑡,𝑖)
𝑛
𝑖=1
  
 
f4,ΔDOPE-local: As last feature local energy differences in the structure were analyzed, by only 
comparing the residues in close proximity to the AAS to those of the native reference structure. 
The optimal window size of 12 amino acids, 6 in N-terminal and 5 in C-terminal direction from k, 
to analyze these local energy drifts was determined before211. 
 
𝑓4,∆𝐷𝑂𝑃𝐸−𝑙𝑜𝑐𝑎𝑙 = ∑ (𝑒𝑟𝑒𝑓,𝑖 − 𝑒𝑚𝑢𝑡,𝑖)
𝑘+5
𝑖=𝑘−6
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B.2.1.2 Sequence-based classification feature 
In addition to the structural-energy-based features, the sequence-position-specific conservation 
of each AAS was calculated as a potential criterion to classify budding-deleterious mutations. 
The underlying premise is that functionally and structurally important sites of proteins are highly 
conserved and mutations here would be detrimental for the protein223,224.  
The amino acid substitutions were analyzed with a position-specific substitution matrix 
(PSSM)225. The procedure first uses a premade Gag protein alignment (B.1.1.1) to calculate the 
frequency (count) of each amino acid for each position separately. Since the alignment is only 
an incomplete representation of all naturally occurring sequences the counts were then 
broadened by pseudo-counts226,227. These pseudo-counts were determined on the basis of the 
natural frequencies with which different amino acids substitute for each other228 and were 
calculated for each position separately according to its overall diversity229, with conserved 
positions getting less pseudo-counts than variable ones. As sequence-based feature for the 
classifier, the PSSM-score was calculated as logarithm of the odds-ratio of the probability pca of 
finding an amino acid a on the observed position c in the alignment to the probability pa of 
observing this amino acid by chance alone (i.e. the random distribution of the amino acid in 
proteinsc). 
 
𝑓5,𝑠𝑒𝑞 = log (
𝑝𝑐𝑎
𝑝𝑎
)  
B.2.1.3 A supervised machine learning AAS classifier 
To discriminate between AAS with no 
effect on the budding of VLPs and 
those detrimental to it, a Fisher’s 
Linear Discriminant Analysis (FLD)230 
was performed. This machine learning 
algorithm reads the entries of a 
training-set consisting of 
experimentally verified AAS212, which 
were sorted into two different classes, 
namely budding-deleterious and 
budding-retaining mutations (Table 4). 
The classifier features of this set were 
used by the FLD to calculate a 
one-dimensional hyperplane, in a way 
that the two classes of AAS are best 
separated. Considering this 
hyperplane, AAS with unknown effect 
on budding can be classified using 
only the structural and sequence-
based discriminatory features of this 
mutation. Finally all epitopes containing at least one budding-deleterious AAS were removed 
from the input data set. 
c
 obtained from http://www.pseudogene.org/composition/index.cgi 
Table 4. Training-set of classified AAS based on data from 
Freed et al (1994). The publication describes the introduction of 
37 single AAS into p17 of the HIV-1 infectious molecular clone 
NL4-3. All AAS integrated into the molecular clone that were 
described to show no detectable virus production or delayed 
kinetics relative to the wild type, as determined by reverse 
transcriptase activity, were classified as budding-deleterious 
mutation for the training-set. 
budding-retaining AAS 
budding-deleterious 
AAS 
A5D S72I G2A Y86G 
G10E N80G S6I C87D 
R20L K98G V7R C87S 
L21E E106V A37E V88E 
P23E K113T L50D H89G 
K26T K114T G56E D96L 
K27T A120E C57D A100E 
K32A D121L C57S  
R43A V128E I60E  
E52G Q130G L85R  
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To review the quality of the classifier without laborious experiments and also to find the optimal 
combination of the five classification features, a repeated k-fold cross-validation was 
performed231. For this, the training-set was randomly subdivided into k equally sized disjoint 
subsets (or folds). All but one of the k subsets were then applied to train the classifier. The 
remaining subset containing AAS with known effects was used to test the accuracy and 
precision of the created respective classifier (Table 5). This was repeated k times, until the 
predictions had been calculated for every fold as test-set. The final quality is presented as mean 
of all k-tests. Since this procedure is highly dependent on the split of the training-set, the k-fold 
cross-validation was repeated multiple times with different divisions of the data set. For 
calculating the k-fold cross-validation output, budding-retaining AAS were defined as positive 
regarding condition and test-outcome (Table 5). 
 
Table 5. Contingency table of binary classification outcomes. To assess the quality of the FLD predicted 
classification the experimentally validated training-set AAS (“Gold standard”) were tested in a k-fold cross-validation. 
Maintenance of budding was thereby defined as positive event. True positive (tp), false positive (fp), false negative 
(fn), and true negative (tn) classifications of the “Gold standard” were applied to calculate accuracy, sensitivity, 
specificity, positive predictive value (PPV, precision), and negative predictive value (NPV) as described in the table. 
  
Condition (experimentally validated training-
set = “Gold standard”) 
 
  Budding-retaining Budding-deleterious  
Test 
outcome 
(FLD 
classification) 
Budding-
retaining 
True positives (tp) False positives (fp) 
PPV 
(precision) 
= tp/(tp+fp) 
Budding-
deleterious 
False negatives (fn) True negatives (tn) 
NPV 
= tn/(fn+tn) 
Accuracy 
= (tp+tn)/(tp+fp+fn+tn) 
Sensitivity 
= tp/(tp+fn) 
Specificity 
= tn/(fp+tn) 
 
B.2.2 Epitope scoring 
After the functional analysis the epitopes get ranked based on a score calculated by considering 
immunological, demographical and virological characteristics. The higher the score the more 
favorable the epitope would be for integration into the newly designed antigens. For the 
calculations, multiple entries for the same epitope, as well as the assessment of sub- and 
superepitopes, were handled as described above (B.1.2). 
In this thesis, the frequencies of HLA class I molecules presenting the epitope, the subtype 
affiliation, the association with LTNPs, the conservation status, and the expected population-
wide immune response against the epitope were applied as attributes to calculate the specific 
score s(e) for each epitope e. However, the algorithm is implemented to work with any number 
of Boolean or positive numerical values for score considerations. With positive weighting 
parameters waℕ0 for each attribute a the epitope ranking can be further modified according to 
user preferences. 
 
𝑠(𝑒) =  ∑(𝑤𝑎  ∙ 𝑎(𝑒))
𝑎∈𝐴
 
 
In the next chapters the different attributes contributing to the epitope-specific score are 
explained in detail. 
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B.2.2.1 HLA score 
The HLA class I alleles represent some of the most variable human genes and the haplotype of 
a person greatly influences which epitopes can be presented to CD8+ T cells. The frequency 
variations of HLA class I alleles across different human populations is quite severe. Since the 
aim for a vaccine would be to protect as many people of the target population as possible, 
epitopes presented by alleles with higher frequencies in the respective population should be 
included more favorably.  
To rank the epitopes an HLA class I score aHLA(e) was calculated by summing up the 
frequencies of all alleles h from the complete set of HLA class I alleles H that are specified in the 
database entry as being able to present the epitope e. If more than one population is of interest, 
the mean HLA class I frequency 𝑓 ̅was used to compute the score 
 
𝑎𝐻𝐿𝐴(𝑒) =  ∑(𝑟(𝑒, ℎ)  ∙  𝑓̅(ℎ)) ;     𝑤𝑖𝑡ℎ 𝑟(𝑒, ℎ) = {
 
 
 
1
0
  
𝑖𝑓 𝑒 𝑖𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑒𝑑 𝑏𝑦 ℎ
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 
ℎ∈𝐻
 
 
The HLA score was normalized to the interval [0, 1], with 1 being the highest and 0 the lowest 
calculated score. 
B.2.2.2 Subtype score 
Due to the high variability of HIV-1, many different subtypes emerged. However these subtypes 
are not equally distributed and are highly region-specific. The higher the epitope-affiliated 
subtype-frequency in the target region is, the more favorably it should be included in the newly 
designed antigens. 
To account for the targeted subtype-diversity a subtype score with an adjustable weighting 
parameter wsℕ0 for each subtype s of all specified subtypes S was conceived. Each epitope e 
subtype score aSubtype(e) was computed by summing up the weights of all subtypes s that are 
specified for the epitope in its LANL HIV database entry. 
 
𝑎𝑆𝑢𝑏𝑡𝑦𝑝𝑒(𝑒) =  ∑(𝑟(𝑒, 𝑠)  ∙  𝑤𝑠) ;     𝑤𝑖𝑡ℎ 𝑟(𝑒, ℎ) = {
 
 
 
1
0
  
𝑖𝑓 𝑒 𝑖𝑠 𝑎𝑓𝑓𝑖𝑙𝑖𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑠
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 
𝑠∈𝑆
 
 
As for the HLA score, the subtype score was also normalized to the interval [0, 1], with 1 being 
the highest and 0 the lowest computed score. 
B.2.2.3 LTNP Score 
If an epitope is associated with LTNPs it might have a beneficial impact on protection, if it is 
integrated in an antigen. Therefore the notes section of each database entry was checked, if 
affiliation with LTNPs had been reported. Since this is a Boolean question the LTNP score aLTNP 
can only be 1, if it is true (i.e. the epitope e is associated with LTNPs) or otherwise 0. 
 
𝑎𝐿𝑇𝑁𝑃(𝑒) = {
 
 
 
1
0
  
𝑖𝑓 𝑒 𝑖𝑠 𝑎𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝐿𝑇𝑁𝑃
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
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B.2.2.4 Conservation score 
Another feature for evaluating epitopes was based on their conservation among different HIV-1 
subtypes. The higher the conservation, the more favorably a sequence should be rated for 
inclusion in the newly designed antigens, since a broader spectrum of different viral clades can 
be addressed with one epitope. To assess and compare the epitope set (B.1.2), a conservation 
score was calculated for each entry. For this, a reference set of proteins sequences with 
specified subtype affiliation, the epitope entries, and a list of all subtypes S with a customizable 
weighting were needed. At first, the frequency of every epitope e in all reference sequences with 
subtype s was determined. This frequency f(e,s) was calculated by dividing the number of 
subtype s sequences, which include the epitope e [sequences(e,s)], by the count of all subtype s 
sequences in the reference set [sequences(s)]. 
 
𝑓(𝑒, 𝑠) =  
𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑠(𝑒, 𝑠)
𝑠𝑒𝑞𝑢𝑒𝑛𝑐𝑒𝑠(𝑠)
 
 
Each subtype was assigned a customizable positive weighting parameter wsℕ0, by which the 
subtypes were ranked so that their effect on score calculations could be varied. The epitope-e-
specific conservation score aCons was then computed as the sum of all ws weighted subtype sS 
epitope frequencies f(e,s). 
𝑎𝐶𝑜𝑛𝑠(𝑒) =  ∑(𝑤𝑠 ∙  𝑓(𝑒, 𝑠))
𝑠∈𝑆
 
 
The score was finally normalized to the interval [0, 1], with 0 meaning epitope e was found in 
none of the reference sequences (i.e. conservation of 0%) and 1 that it was found in every 
sequence (i.e. conservation of 100%). 
B.2.2.5 Expected immune response score 
Many of the CD8+ T cell epitopes in the LANL immunology database were identified in studies 
with large cohorts. For these entries, the percentage of people responding to the specified 
epitope was retrieved from the metadata. Depending on the type of the underlying study the data 
was applied differently to calculate an expected immune response score a%Resp. 
(1) If the study was based on a large population p with random HLA class I haplotype distribution 
the score was the fraction of people responding to the epitope p(e). 
 
𝑎%𝑅𝑒𝑠𝑝 =  
𝑝(𝑒)
𝑝
 
 
(2) If the target population was a selection of people with one specific HLA class I allele h, 
shown to present the epitope e, the response score was computed by taking the allele frequency 
𝑓̅(ℎ) (B.2.2.1) into account. The population-fraction possessing the allele h was calculated by 
considering the diploid human chromosomes (2 ∙ 𝑓̅(ℎ)) and also homozygote persons 
(subtracting 𝑓̅(ℎ)2). This term was then multiplied by the fraction of the study population p that 
had responded to the epitope p(e). 
 
𝑎%𝑅𝑒𝑠𝑝 =  
𝑝(𝑒)
𝑝
 ∙  (2 ∙ 𝑓̅(ℎ) −  𝑓̅(ℎ)2) 
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B.2.3 Antigen generation 
After removing all epitopes with functionally 
detrimental properties and scoring of the 
remaining ones, the highest-scoring epitopes 
were to be combined and integrated into the 
reference sequence to generate the optimal 
antigen candidate. But, since the epitopes are 
derived from a broad spectrum of variable HIV-1 
isolates, many have non-matching overlaps to 
other epitopes and their incorporation into the 
reference sequence is mutually exclusive (see 
examples in Table 6). 
To represent these incompatibilities, a graph theoretic approach was conceived. Therein, an 
undirected incompatibility graph G illustrates all epitopes as vertexes with edges between two 
epitopes representing their incompatibility. The connected elements were identified with a 
straightforward depth-first search232. Based on this graph, an independent set of epitopes, i.e. a 
combination of vertexes connected by no edge, with the maximal overall epitope score (or 
weight) should be selected. Since the computing of this so-called maximum weight independent 
set (MWIS) of an arbitrary graph is an NP-hard problem233, meaning that the computational run 
time increases exponentially with the input size, already the calculation of the optimal solution for 
a small input set is infeasible. To calculate a set near the MWIS, heuristics have to be applied. 
Many modern heuristic algorithms are inspired by natural phenomena234, like the genetic 
algorithm used here, which uses evolutionary principles, like mutations and survival of the fittest, 
to select an optimum near the MWIS235. Compared to others, like sequential greedy heuristics233, 
a genetic algorithm has the advantage that it does not aim to find just a local, but a global 
maximum to a given problem.  
The implemented genetic algorithm for constructing the best combination of high scoring 
epitopes consists of various steps. Initially, a parent population of 70 randomly selected 
independent sets of epitopes, called chromosomes, is generated. The chromosomes are 
encoded as bit strings of length E for all epitopes, with each bit representing one epitope of the 
input graph. If the epitope ei is included in the set, the bit xi gets assigned the value 1, otherwise 
0. All chromosomes get ranked by their fitness, which is calculated by a function f(x) which sums 
up all scores s of epitopes included in the set and that also accounts for the number of 
incorporated sub-(nsub) and superepitopes (nsup) in the solution. The differential weighting of 
those three factors was empirically determined by testing several parameters and choosing the 
best-performing combination. 
 
𝑓(𝑥) = (∑(𝑥𝑖 ∙ 𝑠(𝑒𝑖))
𝐸
𝑖=1
)
2
+ 20 ∙ 𝑛𝑠𝑢𝑝(𝑥) +  𝑛𝑠𝑢𝑏(𝑥);  𝑤𝑖𝑡ℎ 𝑥𝑖 = {
 
 
 
1
0
  
𝑖𝑓 𝑒𝑖 𝑖𝑠 𝑖𝑛𝑐𝑙𝑢𝑑𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑒𝑡
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
   
 
The fittest chromosome of the newly generated parent population is initially selected as the 
solution representative, i.e. the best combination of compatible epitopes found by the algorithm. 
The evolutionary procedure starts by choosing two of the parent chromosomes. The first one is 
selected with a probability proportional to its fitness. The second one is selected the same way 
or, with a probability of 0.4 a randomly generated new chromosome is utilized in order to 
Table 6. Compatible and incompatible 
epitopes. Many epitopes show an overlap among 
each other, when aligned to the reference 
sequence. (A) If the shared sequence of the 
overlapping epitopes is identical (marked in 
green), both epitopes can be incorporated into the 
antigen. (B) However if there are differences in the 
overlap (marked in red), the integration of the 
epitopes is mutually exclusive 
A. Compatibility B. Incompatibility 
MGARASVLS MGARASVLS 
     SVLSGGELD      SILSGGELD 
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maintain genetic variability. By a three-point crossover of the parents a “child” chromosome is 
created that inherits bit strings, i.e. epitopes from both parents. The sites for the crossover are 
chosen randomly but are restricted by the fitness of the parent chromosomes, i.e. the fitter the 
parent the more bits are passed on to the child. During each evolutionary step, subpopulation 
pool containing 24 sequences is filled with child chromosomes, or with a chance of 0.05, with a 
randomly initialized chromosome, again to maintain genetic variability. If one of the 
subpopulation chromosomes is identical to one in the parent population, it is rejected. Otherwise 
its fitness is compared to four randomly selected parent chromosomes. If the fitness is higher 
than any of them, it replaces the lowest scoring one in the parent pool and if it has also a higher 
fitness than the current solution, it also substitutes this one. In each evolutionary round all 
chromosomes undergo spontaneous mutation. Through this, the inclusion of each epitope e in 
the respective set is changed with the probability 0.01, i.e. the bit value is switched between 0 
and 1. Since both three-point crossover and spontaneous mutations could introduce new epitope 
incompatibilities, a repair method is implemented after both procedures. For this, the epitopes 
with the most incompatibilities are subsequently removed until the set is independent again. 
After 2000 evolutionary generations, the MWIS search is terminated and the solution 
representative is used as antigen candidate. After excluding all epitopes already represented in 
the solution set, the next round of the genetic algorithm can be performed, resulting in a 
polyvalent set of complementary CD8+ T cell epitope-enriched antigens. 
B.3 Antigen evaluation 
B.3.1 Phylogenetic tree calculations 
For phylogenetic classification, the Gag protein sequence reference set236 from the year 2010, 
comprising of all group M subtypes and CRFs, was downloaded from the LANL HIV sequence 
databased. The set was manually modified by removing all CRFs except CRF01_AE and 
CRF02_AG and adding antigen sequences of interest. Alignment of all sequences and 
phylogenetic tree reconstruction was performed with standard implementations of ClustalX 
2.1237. The tree was visualized using the Rainbow Tree238,239 tool from the LANL HIV databasee. 
B.3.2 Antigen score 
To address the quality of an antigen a (or a polyvalent combination of antigens), the score of all 
epitopes from the complete set of CD8+ T cell epitopes E (B.1.2) that are incorporated in the 
respective antigen a was summed up to an antigen-specific score (Figure 10). The epitope-e-
specific score s(e) is calculated based on the same formulas as described above (B.2.2). Since 
superepitopes include all attributes (B.1.2) from their associated subepitopes, the antigen score 
calculations were only based on epitopes that were not also represented by a superepitope in 
antigen a. Applying this restriction the epitope-e-associated score s(e,a) for a specific antigen a 
can be either s(e) or 0, depending on the incorporation into antigen a (r(e,a)) and the presence 
of superepitopes (z(e,a)). 
d
 http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html#ref 
e
 http://www.hiv.lanl.gov/content/sequence/RAINBOWTREE/rainbowtree.html 
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𝑠(𝑒, 𝑎) =  𝑟(𝑒, 𝑎) ∙ 𝑧(𝑒, 𝑎) ∙ 𝑠(𝑒) 
 
𝑤𝑖𝑡ℎ 𝑟(𝑒, 𝑎) = {
 
 
 
1
0
  
𝑖𝑓 𝑒 𝑖𝑠 𝑖𝑛𝑐𝑙𝑢𝑑𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑎
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
   
 
𝑎𝑛𝑑 𝑧(𝑒, 𝑎) = {
 
 
 
0
1
  
𝑖𝑓 𝑒 ℎ𝑎𝑠 𝑎 𝑠𝑢𝑝𝑒𝑟𝑒𝑝𝑖𝑡𝑜𝑝𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑛𝑡𝑖𝑔𝑒𝑛 𝑎
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
   
 
The score of antigen a (or a polyvalent combination of antigens) was finally calculated as sum of 
the corresponding scores s(e,a) of all epitopes 𝑒 ∈ 𝐸. Additionally, the number of incorporated 
epitopes was captured for each antigen a. 
 
𝐴𝑛𝑡𝑖𝑔𝑒𝑛𝑆𝑐𝑜𝑟𝑒(𝑎) =  ∑(𝑠(𝑒𝑖, 𝑎))
𝐸
𝑖=1
 
 
B.3.3 Population coverage 
HLA alleles are distributed quite heterogeneously across the human population. An efficient 
vaccine candidate should be able to present a broad range of immunologically valuable epitopes 
on various HLA alleles of the particular target population 
To assess the potential breadth of an immune response against antigen a (i.e. the number of 
different epitopes from a targeted by CTLs) an in silico analysis tool (called “Population 
coverage”, Figure 11) was implemented. In a first step a target population of size P, specified by 
different HLA haplotypes Y was generated. The haplotype allele selection was done separately 
for each class I HLA gene locus, HLA-A, -B, or -C. Due to the diploid nature of the human 
genome, two alleles were randomly chosen for each locus with a probability proportional to the 
allele frequency 𝑓 ̅ (B.2.2.1) within the target population. Thus a test-person p of the target 
population P is defined by its HLA haplotype Yp, consisting of six alleles.  
 
 
Figure 10. Antigen score. To evaluate 
and compare antigens an antigen score 
was calculated. For this first the antigen a 
was compared against the complete CD8+ 
T cell epitope set. The score of all epitopes 
found in antigen a was calculated as 
described above (B.2.2) based on the 
frequencies of HLA class I molecules 
presenting the epitope, subtype affiliation, 
the association with LTNPs, the 
conservation status, and the expected 
population-wide immune response against 
the epitope. The text size in the word cloud 
symbolizes the weighting of the different 
attributes. The antigen score was 
calculated by summing up the scores of all 
epitopes that are included in the antigen 
without those already being represented by 
a superepitope in the antigen a. 
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Figure 11. Population coverage. To assess how well an antigen fits to its target-population, a test-population of size 
P, defined by different HLA haplotypes Y was generated. For each test-person p∈P two HLA-A, -B, and -C alleles 
were randomly selected proportionally to the allele frequency for each gene locus (as symbolized by the font size in 
the word clouds). For population coverage calculation of an antigen a all epitopes of a given set E found in a and also 
presented by at least one allele of the test-person p’s haplotype Yp got included in the test-person-specific epitope-
set. The score of this set was calculated as described before (B.3.2). The population coverage of a was determined 
for every p∈P. 
 
In the next step, all in antigen a (or sets of polyvalent antigens) incorporated epitopes from a 
given CD8+ T cell epitope list E were identified. These antigen-a-specific epitopes were then 
tested against each test person p. If an epitope e can be presented on at least one HLA allele 
(i.e. if the HLA is denoted in the epitope’s database entry) of the test-person-p-specific haplotype 
Yp it was included into this test person’s epitope set, otherwise it was rejected. Each of these P 
test-person-specific epitope sets were finally analyzed for the number of epitopes in the set and 
their cumulative epitope scores s(e,a) (B.3.2): 
 
 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑆𝑐𝑜𝑟𝑒(𝑝, 𝑎) =  ∑ (𝑟(𝑒𝑖 , 𝑌𝑝) ∙ 𝑠(𝑒𝑖 , 𝑎))
𝐸
𝑖=1
 
 
𝑤𝑖𝑡ℎ  𝑟(𝑒𝑖, 𝑌𝑝) = {
 
 
 
1
0
  
𝑖𝑓 𝑒𝑖 𝑖𝑠 𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑒𝑑 𝑏𝑦 𝑎𝑡 𝑙𝑒𝑎𝑠𝑡 𝑜𝑛𝑒 𝑎𝑙𝑙𝑒𝑙𝑒 𝑜𝑓 𝐻𝐿𝐴 ℎ𝑎𝑝𝑙𝑜𝑡𝑦𝑝𝑒 𝑌𝑝
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
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B.3.4 Pathogen coverage 
 
Figure 12. Pathogen coverage. To validate how well an antigen a covers a target-region’s subtype distribution, first a 
test-pathogen set of size V was generated. The subtype x of each test-virus v was selected by a random selection 
proportional to the denoted clade distribution (symbolized by the font size in the subtype word cloud). The test-
pathogen v was then initialized by selecting a natural HIV-1 Gag sequence of subtype x. For pathogen coverage 
calculation of an antigen a, all epitopes of a given set E found in a and also in the test-virus-v-associated Gag 
sequence, got included in the test-pathogen-specific epitope-set. The score of this set was calculated as described 
above (B.3.2). The pathogen coverage of a was determined for all v∈V. 
 
In addition to a broad targeting of the target population, an antigen should also be able to cover 
as many different HIV-1 isolates as possible. To assess the degree with which an antigen covers 
the pathogen distribution in a specific region of the world another computational tool (called 
“Pathogen Coverage”, Figure 12) was developed. This tool first generates a test-pathogen set of 
size V. The subtype x of each pathogen v∈V was based on a random selection with a probability 
proportional to the given clade frequency in the target region. A Gag sequence of this subtype x 
was then randomly picked from the set of natural Gag sequences (i.e. the curated filtered web 
alignment of Gag - B.1.1.1) and assigned to the pathogen v. Then, an antigen-a-specific epitope 
set was determined again (B.3.3), based on a given antigen a and a CD8+ T cell epitope list E. 
All epitopes included in antigen a that could also be found in the Gag sequence of the respective 
test pathogen v, were added to the test-pathogen’s epitope set. All V test pathogen sets were 
reviewed for number of epitopes and the cumulative epitope scores s(e,a) (B.3.2). 
 
𝑃𝑎𝑡ℎ𝑜𝑔𝑒𝑛𝑆𝑐𝑜𝑟𝑒(𝑣, 𝑎) =  ∑(𝑟(𝑒𝑖, 𝑣) ∙ 𝑠(𝑒𝑖 , 𝑎))
𝐸
𝑖=1
 
 
𝑤𝑖𝑡ℎ 𝑟(𝑒𝑖, 𝑣) = {
 
 
 
1
0
  
𝑖𝑓 𝑒𝑖 𝑖𝑠 𝑖𝑛𝑐𝑙𝑢𝑑𝑒𝑑 𝑖𝑛 𝑝𝑎𝑡ℎ𝑜𝑔𝑒𝑛 𝑣
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
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B.4 Codon adaptation 
The genetic code is degenerated and up to six codons code for the same amino acid. 
Depending on the organism, these codons are used with different frequencies240. For an efficient 
heterologous gene expression system, an adaption to the host’s codon usage is highly 
beneficial241,242.  
B.4.1 Human codon adaptation 
For expression in human cell lines, the HXB2-Gag and the newly designed T cell epitope-
enriched Gag antigens were optimized with the online tool “Geneart Geneoptimizer”243,244 
(Thermo Fisher) based on the homo sapiens codon usage. 
B.4.2 HIV-1-Gag-specific codon adaptation 
Besides the individual expression in human cell lines, the newly designed teeGags were also 
incorporated into an HIV-1 molecular clone. For this, the Gag sequences had to be adapted to 
the unusually high adenine and low cytosine content in HIV-1245. However there are subtle 
differences in base composition across the HIV-1 genome, with the adenine content for example 
ranging from 25.0% (LTR R3-U-R5) to 38.6% (Vpu-ORF) and with the Gag-ORF (36.9%) located 
fairly close to the maximum percentage246. This instance and the fact that the viral replication is 
regulated by conserved, mostly uncharacterized genomic RNA structures247 prohibited a random 
codon-optimization based on HIV codon frequencies, which would probably not result in a 
functional virus. To circumvent this problem the natural Gag nucleotide sequence of the 
reference HXB2 (GenBank K03455) was employed as scaffold to integrate the mutations 
accumulated during the optimization process.  
Based on a Gag nucleotide alignment (B.1.1.1), including the reference sequence, a position-
specific codon usage matrix was generated. This was an n×64 matrix, where n is the number of 
codons of the query sequence (for HXB2-Gag n=500). For each position of the matrix, the 
counts were determined by summing up the respective codons in the alignment. For the 
teeGags, the HXB2 nucleotide sequences was used as backbone and for each AAS compared 
to the HXB2 reference, the most common codon for this mutation at the respective position was 
incorporated into the scaffold. 
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C Material and experimental methods 
C.1 Material 
C.1.1 DNA 
C.1.1.1 Oligonucleotides 
Oligonucleotides were ordered at Eurofins (Luxembourg) or at Biomers (Ulm, Germany) 
 
Name Sequence (5’3’) Description 
pc31 fwd CTATATAAGCAGAGCTCTCTGGC 
Standard cloning and sequencing primer for pcDNA3.1. 
Binds at the 3’ end of the CMV promoter. 
pc31 rev GCAACTAGAAGGCACAGTCG 
Standard cloning and sequencing primer for pcDNA3.1. 
Binds at the 5’ end of the BGH polyA site. 
teeGag-His rev 
GACTCTCGAGTCATCAGTGGTGATGGTG
GTGGTGGCTGCCTCTCTGGCTGCTGGG
GT 
Primer for C-terminal addition of a 6x-His epitope tag 
(RGSHHHHHH) to teeGag1-3, HXB2-Gag, and HXB2-
Gag
Myr-
. Contains an XhoI restriction site for cloning. 
teeGag1-GL9-GS 
fwd 
GGCCCAAGCCACAAAGCCAGAGTGCTG 
Forward binding mutation primer for fusion PCR. Introduces 
a G to S mutation in teeGag1 to change its GL9 epitope 
sequence to GPSHKARVL. 
teeGag1-GL9-GS 
rev 
TTTGTGGCTTGGGCCTCCCACG 
Reverse binding mutation primer for fusion PCR. Introduces 
a G to S mutation in teeGag1 to change its GL9 epitope 
sequence to GPSHKARVL. 
teeGag3-GL9-IV 
fwd 
GCCAGAGTGCTGGCCGAGGCCA 
Forward binding mutation primer for fusion PCR. Introduces 
an I to V mutation in teeGag3 to change its GL9 epitope 
sequence to GPSHKARVL. 
teeGag3-GL9-IV 
rev 
GGCCAGCACTCTGGCCTTGTGAGAAGG 
Reverse binding mutation primer for fusion PCR. Introduces 
an I to V mutation in teeGag3 to change its GL9 epitope 
sequence to GPSHKARVL. 
HXB2-Gag-GL9-GS 
fwd 
CGGACCTAGCCACAAAGCCAGAGTGCTG 
Forward binding mutation primer for fusion PCR. Introduces 
a G to S mutation in the HXB2-Gag reference sequence to 
change its GL9 epitope sequence to GPSHKARVL. 
HXB2-Gag-GL9-GS 
rev 
GCTTTGTGGCTAGGTCCGCCCACG 
Reverse binding mutation primer for fusion PCR. Introduces 
a G to S mutation in the HXB2-Gag reference sequence to 
change its GL9 epitope sequence to GPSHKARVL. 
teeGag-AL-fwd CAGCGCGCACGGCAA 
Forward binding primer used for teeGag proviral cloning. 
Binds at the BssHII restriction site in the 5’ UTR. 
teeGag-AL-rev TAAAAAATTGGCTTGTGACGAGGGGTCG 
Reverse binding primer used for teeGag proviral cloning. 
Binds at the 3’ end of all p6 and harbors an overlap to p6* of 
the pNL4-3_AL vector. 
N4-3-AL-fwd 
CCTCGTCACAAGCCAATTTTTTAGGGTAG
ATCTGGC 
Forward binding primer used for teeGag proviral cloning. 
Binds at the 5’ end of p6* and harbors an overlap to p6 of 
teeGag1-3 and HXB2-Gag. 
NL4-3-AL-rev ACCCTGCAGGATGTGGTATTCC 
Reverse binding primer used for teeGag proviral cloning. 
Binds at the SbfI restriction site within the pol reading frame 
of pNL4-3_AL. 
HXB2-AL fwd 
GCCTAGTTATAAAGGGCGCCCGGGTAAC
TTCCTCCAGAGCAGACCAGAGCCAAC 
Forward binding primer used for teeGag proviral cloning. 
Binds in front of the HXB2-Gag slippery site and Introduces 
mutations to destroy the Gag-Pol frameshift. 
HXB2-AL rev 
CGCCCTTTATAACTAGGCCAAATTTTACC
CAGGAAATTAGCCTGTCTCTCAGTACAAT
CTTTC 
Reverse binding primer used for teeGag proviral cloning. 
Binds after the HXB2-Gag slippery site and Introduces 
mutations to destroy the Gag-Pol frameshift. 
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G2A-AL fwd 
AGAGATGGCAGCGAGAGCGTCAGTATTA
AGCG 
Forward binding mutation primer for fusion PCR. Introduces 
the G2S mutation in HXB2-Gag to change generate the 
budding deficient HXB-Gag
Myr-
. 
G2A-AL rev 
CGCTCTCGCTGCCATCTCTCTCCTTCTA
GCCTCCG 
Reverse binding mutation primer for fusion PCR. Introduces 
the G2S mutation in HXB2-Gag to change generate the 
budding deficient HXB-Gag
Myr-
. 
sHLA A*02:01 fwd CTAAAGCTTATGGCCGTCATGGCG 
Forward binding cloning primer for sHLA A*02:01 
construction. Binds directly at the start codon and introduces 
a 5’ HindIII restriction site. 
sHLA B*07:02 fwd CTAAAGCTTATGCTGGTCATGGCGC 
Forward binding cloning primer for sHLA B*07:02 
construction. Binds directly at the start codon and introduces 
a 5’ HindIII restriction site. 
sHLA-exon4+His 
rev 
CTAGCTCGAGTCAGTGGTGATGGTGGTG
GTGGCTGCCTCTCCATCTCAGGGTGAGG
GG 
Reverse binding cloning primer for sHLA construction. Binds 
at 3’ end of HLA exon 4 and introduces a C-terminal 6x-His 
epitope tag (RGSHHHHHH) and an XhoI restriction site for 
subcloning. 
 
Primers used for AAS single site mutations are listed in Extended Data Table 6 and Extended 
Data Table 7. 
C.1.1.2 Vectors 
Description Selectable marker Specification (Supplier - Product no.) 
p5’ Amp
R
 
The 5' half of HIV-1 from pHXB2gpt
248
 was cloned into the 
standard cloning vector pGEM-3Z as a 5978 bp fragment 
(NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
p5' from Drs. Dean Winslow and Lee Bacheler
249
) 
pBluescript KS 
(-) CMV-SEAP 
Amp
R
 
Bacterial expression vector. pBluescript backbone with 
integration of a CMV promotor for mammalian expression of 
secreted alkaline phosphatase (SEAP) (Addgene, 
Cambridge, USA - plasmid #24595) 
pcDNA3.1(+) Amp
R
, Neo
R
 
Mammalian expression vector (Thermo Fisher, Waltham, 
USA - V79020) 
pcDNA5/FRT 
Amp
R
, Hygro
R
 (no 
ATG) 
Mammalian expression vector. Designed for generation of 
stable cell lines with the Flp-In
TM
 system. Hygromycin 
resistance gene is only expressed after integration at the 
flippase recognition target (FRT) site (Thermo Fisher - 
V601020). 
pcDNA5/FRT/TO 
Amp
R
, Hygro
R
 (no 
ATG) 
Inducible Mammalian expression vector. Designed for 
generation of stable cell lines with the Flp-In
TM
 TREx
TM
 
system. Hygromycin resistance gene is only expressed after 
integration at the FRT site (Thermo Fisher - V652020). 
pNL4-3_AL Amp
R
 
Molecular HIV-1 clone. For production of infectious isolate 
NL4-3 HIV-1 particle. Derived from NL4-3_(Nef-R71)
250
 with 
shifted slippery site to uncouple the overlapping part of gag 
and pol reading frames
251
 (in-house). 
pOG44 Amp
R
 
Mammalian vector for transient expression of the Flp 
recombinase
252
 (Thermo Fisher - V600520) 
VRC-8400 Kan
R
 
Mammalian expression vector (G. Nabel, Vaccine Research 
Center, NIAID, Bethesda, USA). 
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C.1.2 Antibodies 
Description Conjugate Clone Supplier (Cat #) Specifications (Application
f
/Dilution) 
α-6x-His 
Epitope Tag 
Biotin HIS.H8 
Thermo Fisher 
(MA1-21315-
BTIN) 
Monoclonal mouse IgG2b anti-6x-His 
synthetic peptide antibody (WB/1:2,000; 
ELISA/1:1,000; SLOT: 1:1,000) 
α-β2m HRP - 
Thermo Fisher 
(PA1-29662) 
Polyclonal rabbit IgG anti-beta-2-
microglobulin antibodies (WB/1:500) 
α-CD1a PE HI149 
BD, East 
Rutherford, USA 
(555807) 
Monoclonal mouse IgG1, κ anti-human-
CD1a antibody (FC/1:66) 
α-CD8α FITC RPA-T8 
BioLegend, San 
Diego, USA 
(301006) 
Monoclonal mouse IgG1, κ anti-human-
CD8a antibody (FC/1:100) 
α-CD14 FITC MφP9 BD (345784) 
Monoclonal mouse IgG2a, κ anti-human-
CD14 antibody (FC/1:33) 
α-HLA-ABC - EMR8-5 
Abcam, 
Cambridge, UK 
(ab70328) 
Monoclonal mouse IgG1, κ anti-human-
pan-HLA ABC antibody (WB/1:3,000) 
α-HLA-ABC - W6/32 
BioLegend 
(311402) 
Monoclonal mouse IgG2a, κ anti-human-
pan--HLA ABC antibody (ELISA/1:500) 
α-IFN-γ APC 4S.B3 
BioLegend 
(502512) 
Monoclonal mouse IgG1, κ anti-human-
IFN-γ antibody (FC/1:100) 
α-mouse Ig HRP - 
Dako, Agilent, 
Santa Clara, USA 
(P0260) 
Polyclonal rabbit anti-mouse Ig purified Ig 
fraction (WB 1:2,000) 
α-p24/p55 - 37G12 
Polymun, 
Klosterneuburg, 
Austria (AB005) 
Monoclonal human anti-HIV-1-p24 
antibody. Also reactive against HIV-1 p55. 
Epitope unknown (ELISA/Lot dependent) 
α-p24/p55 - CB-13/5 
Hybridoma cell 
line 
Monoclonal mouse IgG1, κ anti-HIV-1-
p24 antibody. Also reactive against HIV-1 
p55. Epitope described as 
(VHQAISPRTL)NAWVK
253–255
. 
(WB/1:1,000) 
α-p24/p55 - 
M01-
16/4/1 
Polymun (AB006) 
Monoclonal mouse IgG2a, κ anti-HIV-1-
p24 antibody. Also reactive against HIV-1 
p55. Epitope described by supplier as 
GATPQDLNTML. (ELISA/Lot dependent) 
α-p24/p55 RD1 KC57 
Beckman Coulter, 
Brea, USA 
(41116015) 
Monoclonal mouse IgG1 anti-HIV-1-p24 
antibody. Also reactive against HIV-1 p55. 
Epitope unknown. (FC/1:200) 
α-rabbit Ig HRP - Dako (P0448) 
Polyclonal goat anti-rabbit Ig antibodies 
(WB 1:1,000) 
α-VSV-G - P5D4 
Sigma Aldrich, St. 
Louis, USA 
(V5507) 
Monoclonal mouse IgG1 anti- Vesicular 
Stomatitis Virus Glycoprotein (VSV-G) 
antibody. (WB/1:10,000) 
Isotype 
control 
PE MOPC-21 
BioLegend 
(400114) 
Monoclonal mouse IgG1, κ isotype control 
(FC/assay dependent) 
f
 WB = Western Blotting; FC = Flow Cytometry; ELISA = Enzyme-linked Immunosorbent Assay; SLOT = Slot Blotting 
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C.1.3 Peptides 
Description Specifications Supplier 
GL9 
Sequence: GPGHKARVL 
Origin: HIV-1 Gag p24 
Residues: 223-231 
Purity: >91.20% 
Centic Biotec, 
Heidelberg, 
Germany 
GL9-GS 
Sequence: GPSHKARVL 
Origin: HIV-1 Gag p24 
Residues: 223-231 
Purity: >96.24% 
Centic Biotec 
C.2 Experimental methods 
C.2.1 Microbiological techniques 
C.2.1.1 Cultivation and selection of bacterial cultures 
Strain Genotype 
DH5α 
F- supE44 ΔlacU169 (φ80 lacZΔM15) hsdR1 recA1 endA1 gyrA96 thi- 
1 relA1 
256
 
DH10B 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR 
Δ(ara,leu)7697 araD139 galU galK nupG rpsL λ- 
257
 
 
Cultivation of E. coli was performed overnight at 37°C in lysogeny broth medium (LB-medium) 
on an orbital shaker at 220 rpm. For selection of transformed cells, antibiotics (100 µg/ml 
ampicillin or 50 µg/ml kanamycin) were added to the medium. 
 
LB-medium  0.5% (w/v) yeast extract, 1% (w/v) tryptone, 
1% (w/v) NaCl 
C.2.1.2 Transformation of chemically competent bacteria 
For E. coli transformation, the bacterial cells were made chemically competent with the RbCl2 
method256,258 and stored at -80°C until further use. To introduce heterologous DNA, 100 µl of 
these competent cells were thawed on ice and then incubated with either 1 µg plasmid DNA or a 
ligation mix (C.2.2.1) for 30 min on ice. To induce the DNA uptake, the cells were treated with a 
45 s heat shock in a 42°C water bath, followed by 2 min incubation on ice. For cell rescue, 
0.9 ml LB-medium were added and the tubes were subsequently incubated for 1 h at 37°C and 
300 rpm in an orbital shaker. For selection of positive clones, the E. coli bacteria were plated on 
LB agar plates with an appropriate antibiotic. 
 
LB-agar  LB-medium, 1.5% (w/v) agar, antibiotic (100 µg/ml 
ampicillin or 50 µg/ml kanamycin) 
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C.2.2 Molecular biology techniques 
C.2.2.1 Standard cloning procedure 
For cloning of genes, standard cloning techniques259 were applied. Vector backbones were 
digested using restriction endonucleases, dephosphorylated with CIP and purified from a 1% 
agarose gel employing the QIAquick Gel Extraction Kit. Inserts for cloning were generated using 
(1) digestion of plasmids with suitable restriction endonucleases or (2) PCR amplification, 
applying the proof-reading Phusion High-Fidelity DNA Polymerase with subsequent digestion 
with restriction endonucleases. The inserts were also extracted from a 1% agarose gel with the 
QIAquick Gel Extraction Kit. Restriction sites and protein tags were introduced with primer 
extension PCR. 
For ligation of insert and vector with matching cohesive ends the Quick Ligation™ Kit was 
utilized, according to the manufacture’s protocol. The complete ligation mix was applied to 
transform chemically competent E. coli (C.2.1.2). LB medium with the respective antibiotic was 
inoculated with single colonies. After cultivation, the plasmid DNA was purified using alkaline 
lysis with subsequent isopropanol precipitation260. To verify the correct cloning, the DNA was 
sequenced (SeqLab, Göttingen, Germany). 
 
Alkaline Phosphatase, Calf 
Intestinal (CIP) 
 New England Biolabs, Ipswich, USA (M0290) 
Phusion® High-Fidelity DNA 
Polymerase 
 New England Biolabs (M0530) 
QIAquick Gel Extraction Kit  Qiagen, Hilden, Germany (28706) 
Quick Ligation™ Kit  New England Biolabs (M2200) 
Restriction endonucleases  New England Biolabs (various) 
C.2.2.2 Fusion PCR for site-specific mutations 
 
Figure 13. Fusion PCR for site-specific mutations. For site-specific sequence mutations, primers binding at the site 
of interest and harboring the mutation (fwd/rev mut primer) were combined in a first PCR (1a+b) with primers binding 
outside the gene of interest (fwd/rev outside primer). Due to a designed overlap, the two PCR products could be 
combined in a second reaction (PCR 2) applying the outside binding primers again. 
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For the introduction of site-specific mutations, a PCR fusion-based approach was employed 
(Figure 13). In a first PCR amplification (PCR 1a) step, a forward primer, binding outside the 
gene of interest (GOI), was combined with a reverse primer binding in front of the mutation site, 
harboring the desired mutation, and a 5’ overhang complementary to the GOI. In the same way, 
a forward primer, with the respective mutation and an overhang binding after the mutation site 
was combined with a reverse primer binding outside the GOI in a second PCR reaction (PCR 
1b). Both PCR products, which share the introduced overlap and mutation, were combined as 
template in an equimolar ratio in a third PCR amplification (PCR 2) with the same outside 
binding primers as before. The amplicon was then cloned using the standard cloning techniques 
(C.2.2.1).  
C.2.2.3 Purification of plasmid DNA for transfections 
Depending on the needed amount, the QIAprep Spin Miniprep Kit or the QIAGEN Plasmid 
Midi/Maxi/Mega Kit was used for purification of plasmid DNA. 
 
QIAprep Spin Miniprep Kit  Qiagen (27106) 
QIAGEN Plasmid Midi/Maxi/Mega 
Kit 
 Qiagen (12143/12163/12183) 
 
C.2.3 Cell culture techniques 
C.2.3.1 Cell line cultivation 
 
Table 7. Cell lines 
Cell Line Description 
CB-13/5 hybridoma 
Mouse hybridoma cell line producing the monoclonal mouse anti-
p24/p55 antibody CB-13/5
261
. 
Flp-In™ T-Rex™ 293 sus 
Derived from the HEK293 cell line. Contains a single stably 
integrated FRT site for rapid generation of stable cell lines (Thermo 
Fisher - R78007). Adapted for suspension (sus) growth in serum-
free medium
262
. 
FreeStyle™ 293-F 
Derived from the HEK293 cell line and adapted for suspension 
growth in serum-free medium (Thermo Fisher - R79007) 
GL9-CTL clone 
CD8+ T cell clone isolated from an HLA B*07:02 HIV+ patient, 
specific for the p24-GL9 (GPGHKARVL) peptide (kind gift from 
Cornelis Melief, Leiden University Medical Center, Leiden, 
Netherlands) 
HEK293T 
Ad5-transformed human embryonic kidney cell line
263
, expressing 
the “SV40 large T-antigen”
264
 
LCL 554 
EBV-transformed human lymphoblastoid cell line from an HLA 
B*07:02 positive donor (Vaecgene Biotech, Munich, Germany) 
W6/32 hybridoma 
Mouse hybridoma cell line producing the monoclonal mouse anti-
HLA-ABC antibody W6/32 
103
 (Sigma Aldrich - 84112003) 
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Table 8. Cell culture media and additives 
Description Ingredients 
2-Mercaptoethanol (50 mM) Thermo Fisher (31350-010) 
CTL freezing medium IMDM, 40% (v/v) FBS, 10% (v/v) DMSO 
Dimethyl sulfoxide (DMSO) Sigma Aldrich (D8418) 
DMEM (=DMEM-0) 
Dulbecco’s Modified Eagle Medium (Thermo Fisher 
- 41966052) 
DMEM-10 
DMEM, 10% (v/v) FBS, 100 U/ml penicillin, 
0.1 mg/ml streptomycin 
DMEM-PS DMEM, 100 U/ml penicillin, 0.1 mg/ml streptomycin 
Fetal Bovine Serum (FBS) Sigma Aldrich (F7524 – Lot: 123M3398) 
FreeStyle medium 
FreeStyle™ 293 Expression Medium (Thermo 
Fisher - 12338026) 
FreeStyle-0.5 medium 
FreeStyle Medium, 50 U/ml penicillin, 0.05 mg/ml 
streptomycin 
L-Glutamine (200 mM) PAN Biotech, Aidenbach, Germany (P04-80100) 
MEM Non-Essential Amino Acids Solution 
(100X) 
Thermo Fisher (11140-035) 
MEM Vitamin Solution (100X) Thermo Fisher (11120-052) 
Penicillin(10,000 U/ml) / Streptomycin 
(10 mg/ml) 
PAN Biotech (P06-07100) 
RPMI 1640 
Roswell Park Memorial Institute 1640 medium 
(PAN Biotech - P04-16500) 
RPMI-10 
RPMI 1640, 10% (v/v) FBS, 100 U/ml penicillin, 
0.1 mg/ml streptomycin 
Sodium Pyruvate (100 mM) Thermo Fisher (11360-039) 
 
 
FreeStyle™ 293-F and Flp-InTM T-RexTM 293 sus expression cells were cultured at 37°C, 8% 
CO2 and 90 rpm using 1 L polycarbonate or 1 L borosilicate glass Erlenmeyer flasks containing 
300 ml Freestyle-0.5 medium. By subculturing, the density was maintained between 0.2 - 
2106 cells/ml. 
All other cell lines were maintained at 37°C and 5% CO2. Adherent HEK293T cells were grown 
in DMEM-10 medium and subcultured in a 1:10 ratio twice a week. Hybridoma suspension cells 
were maintained between 3 - 9105 cells/ml in RPMI-10. LCL 554 cells were subcultured in a 1:5 
ratio twice a week in RPMI-10. 
 
Dulbecco’s Phosphate Buffered Saline 
(DPBS) 
 Sigma Aldrich (D8537) 
Trypsin 0.05 %/EDTA 0.02 % in PBS  PAN Biotech (P10-023100) 
Corning® Erlenmeyer cell culture flasks 
(capacity: 1 L; material: polycarbonate) 
 Sigma Aldrich (CLS431147) 
Duran® Erlenmeyer narrow-neck flasks 
(capacity: 1 L; material: borosilicate 
glass) 
 Sigma Aldrich (Z232858) 
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C.2.3.2 Transient transfection 
HEK293T cells 
For transient transfection of plasmid DNA, HEK293T cells were cultured in DMEM-10 to a 
confluency of 80%. Afterwards the medium was aspirated and changed to DMEM without any 
additives (DMEM-0). The DNA was diluted in DMEM-0 and then mixed with the cationic polymer 
PEI (1 mg/ml in PEI-buffer, pH 7.5) in a 1:5 (w/w) ratio (Table 9). This transfection mix was 
incubated at room temperature for 10 min to allow the formation of DNA/PEI complexes. The 
transfection mix was subsequently added dropwise onto the HEK293T cells to a final 
concentration of 2 µg/ml DNA and 10 µg/ml PEI. After incubation at 37°C and 5% CO2 for 6 h, 
the medium was changed again to DMEM-10. 
Table 9. Transfection mixtures for different cell culture cultivation scales 
Per reaction 
Transfection 
mix volume [µl] 
DNA 
[µg] 
PEI 
[µg] 
Final cell culture 
volume [ml] 
2.2 cm dish (12 well) 50 1 5 0.5 
3.5 cm dish (6 well) 100 2 10 1 
15 cm dish 1800 36 180 18 
 
FreeStyle™ 293-F cells and Flp-InTM T-RexTM 293 sus expression cells 
For transient transfection of suspension cells the concentration was adjusted to 1106 cells/ml in 
300 ml FreeStyle medium. 300 µg DNA were diluted in 6.5 ml DMEM-0 and 1.2 ml PEI were 
also diluted in 6.5 ml DMEM-0. After 5 min pre-incubation at room temperature the diluted PEI 
was added to the DNA (never the other way round). This transfection mix was incubated at room 
temperature for another 20 min to allow DNA/PEI complex formation and was subsequently 
added dropwise to the cells. After a 6 h incubation period at 37°C, 8% CO2 and 90 rpm the 
medium of the cells was changed to FreeStyle-0.5. 
 
PEI-buffer  25 mM HEPES, 150 mM NaCl 
Polyethylenimine (PEI), linear, 
MW 25,000 
 Polysciences, Warrington, USA (23966) 
C.2.3.3 Generation of stable expression cell lines 
For generating stable mammalian expression cell lines, the Flp-recombinase-mediated 
integration system from Thermo Fisher was utilized. As target, Flp-In™ T-Rex™ 293 sus cells 
that are adapted for growth in suspension262 were employed. These cells stably express a lacZ-
ZeocinTM fusion gene under the control of an SV40 early promotor and harbor a single Flp-In 
target site (FRT) directly after the start-codon of the fusion gene. Co-transfecting the Flp-In™ T-
Rex™ 293 with the Flp recombinase expression plasmid, pOG44, and the gene of interest 
cloned into a pcDNA5/FRT vector, mediates an integration of the pcDNA5/FRT expression 
construct through FRT site-specific DNA recombination in some cells252,265. Thereby, the 
ZeocinTM resistance gene is disrupted and the hygromycin resistance gene from the 
pcDNA5/FRT vector, which lacked a promotor and the ATG initiation-codon, gets activated by in-
frame-insertion downstream of the SV40 early promoter and the start-codon (Figure 14). By 
adding hygromycin B to the medium, one can screen for successfully generated stable 
transfectants. 
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Figure 14. Generation of stable Flp-In
TM
 T-Rex
TM
 293 sus expression cell lines. (A) The Zeocin
TM
-resistant (by 
stable lacZ-Zeocin
TM
 fusion gene expression) Flp-In
TM
 T-Rex 293 sus cells were co-transfected with pcDNA5/FRT 
containing the gene of interest (GOI) and pOG44. The pOG44-expressed Flp recombinase catalyzes a homologous 
recombination (indicated by the dashed line) between the FRT sites in the cells and the pcDNA5/FRT vector. (B) 
Integration of the expression vector downstream of the start codon of the lacZ-Zeocin
TM
 fusion gene confers Zeocin
TM
 
sensitivity and hygromycin resistance, while allowing CMV promoter driven GOI expression. 
To start the stable cell line generation, 5105 Flp-In™ T-Rex™ 293 cells were plated in a 3.5 cm 
dish (6 well plate) with 2 ml medium (FreeStyle medium, 5% (v/v) FBS, 50 U/ml penicillin, 
0.05 mg/ml streptomycin, 100 µg/ml ZeocinTM) and grown as adherent cells. The next day, the 
medium was changed to FreeStyle medium without any additives. Afterwards the cells were 
transiently transfected (C.2.3.2) with a 4:1 (w/w) mixture of the pcDNA5/FRT vector carrying the 
GOI and pOG44. After 6 h the medium was changed to FreeStyle medium with 5% (v/v) FBS, 
50 U/ml penicillin and 0.05 mg/ml streptomycin. After 5 days, the cells were transferred into a 
75 cm2 cell culture flask. 6 h later; hygromycin B was added to a final concentration of 
100 µg/ml, thereby starting the selection process for successful stable integration. Hygromycin-
B-resistant isogenic foci were pooled and expanded to a cell count of 6107 cells. These cells 
were than detached with trypsin/EDTA and transferred into a 1 L polycarbonate Erlenmeyer flask 
containing 300 ml FreeStyle-0.5 supplemented with 100 µg/ml hygromycin B and henceforth 
cultured as suspension cells at 37°C, 8% CO2 and 90 rpm. By cloning the GOI into the 
tetracycline-independent expression vector pcDNA5/FRT a constitutive expression was 
achieved, bypassing the inducible expression characteristic of the Flp-In™ T-Rex™ 293 cells. 
Hygromycin B  Invivogen, San Diego, USA (ant-hg) 
Zeocin
TM
  Invivogen (ant-zn) 
Other cell culture media and 
additives 
 See Table 8  
C.2.3.4 Generation of monocyte-derived dendritic cells 
For the differentiation of monocyte-derived dendritic cells (mdDCs), a modified protocol as 
described by Thurner et al.266 was applied. First human peripheral blood mononuclear cells 
(PBMCs) were isolated from 60 ml heparinized blood, drawn from healthy donors using Ficoll-
PaqueTM Plus density gradient centrifugation as follows: In two 50 ml tubes, 30 ml blood were 
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layered on top of 15 ml Ficoll-PaqueTM Plus each, and centrifuged at 1000 g for 15 min without 
active breaking. The buffy coat was transferred to a new 50 ml tube and added up to 50 ml with 
P2 buffer.  
Afterwards, CD14+ monocytes were isolated from the PBMCs via the magnetic-activated cell 
sorting (MACS) technology from Miltenyi Biotech. The PBMCs were pelleted (600 g, 10 min) and 
resuspended in 800 µl MACS buffer. 50 µl of human CD14 MicroBeads were added for positive 
selection of monocytes. After incubation at 4°C for 15 min, cells were washed two times 
(pelleted each time by centrifugation at 600 g for 10 min) with 5 ml MACS buffer to remove 
unbound MicroBeads and were finally resuspended in 500 µl MACS buffer. For magnetic 
separation a MS column was placed in the magnetic field of an OctoMACS Separator and 
equilibrated with 500 µl MACS buffer. The PBMCs were applied onto the column and washed 
three times with 500 µl MACS buffer to remove unlabeled cells. The column was then unplugged 
from the magnetic field and positively selected CD14+ cells were flushed out with 1 ml MACS 
buffer. The purity of the isolated cells was determined by assessing CD14 expression via flow 
cytometry (C.2.6.1). 
For differentiation of the CD14+ monocytes to mdDCs, the eluted cells were pelleted (500 g, 
10 min) and cultivated in mdDC medium at a concentration of 1106 cells/ml over a six-day 
period. To promote mdDC differentiation, 1000 U/ml GM-CSF and 1000 U/ml IL-4 were added to 
the medium. After two days the medium was renewed. The final quality of the mdDCs was 
evaluated in a flow cytometric analysis (C.2.6.1) with surface staining for the dendritic cell 
marker CD1a.  
 
CD14 MicroBeads, human  Miltenyi Biotec, Bergisch Gladbach, Germany 
(130-050-201) 
Ficoll-Paque
TM
 PLUS  GE Healthcare, Little Chalfont, UK (17-1440-02) 
Heparin  Heparin-Natrium-5000-ratiopharm, Ulm Germany 
MACS buffer  DPBS, 1% (v/v) FBS, 20 mM EDTA, degassed 
mdDC medium  RPMI 1640, 10% (v/v) FBS, 100 U/ml penicillin, 
0.1 mg/ml streptomycin, 1x non-essential amino 
acids solution, 1x vitamin solution, 2 mM L-
glutamine, 1 mM sodium pyruvate, 100 µM 2-
Mercaptoethanol, 1,000 U/ml IL-4, 1,000 U/ml 
GM-CSF 
MS columns  Miltenyi Biotec (130-042-201) 
OctoMACS™ Separator  Miltenyi Biotec (130-042-109) 
P2 buffer  DPBS, 1% (v/v) FBS 
Recombinant human GM-CSF  Miltenyi Biotech (130-093-865) 
Recombinant human IL-4  Miltenyi Biotech (130-093-921) 
Other cell culture media and 
additives 
 See Table 8 
C.2.3.5 Proliferation of CTL clones 
For p24-GL9-peptide-specific (C.1.3) cytotoxic T cell (CTL) clone proliferation, the cells were 
stimulated with peptide-pulsed HLA-B*07:02 expressing LCL 554 feeder cells.  
For this, an aliquot of the previously expanded GL9 CTL clone was thawed and adjusted to a 
concentration of 1x105 cells/ml in IMDM-8+. 100 µl/well of this cell suspension were seeded in a 
96 round bottom well plate and cultivated at 37°C and 5% CO2. Two days later, LCL cells were 
adjusted in RPMI-10 to a concentration of 1107 cells/ml, pulsed with 30 µg synthetic GL9-
peptide per 1107 cells and incubated for 3 h at 37°C. The feeder cells were subsequently 
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irradiated in a gamma-ray device with 60 gy and afterwards adjusted with IMDM-8+ to 1x106 
cells/ml. Co-cultivation was started by adding 100 µl of LCL cells to each well of the previously 
seeded CTL clones, resulting in a 10-times excess of LCL cells over CTLs. Every 3 days 70 µl of 
conditioned medium were carefully aspirated and replaced with 100 µl fresh medium. After 14 
days, the proliferating CTLs were pooled, adjusted to 1105 cells/ml in IMDM-8+, and again 
stimulated with pulsed LCL cells, as described above. After another 10 days of cultivation, the 
cells were pooled, pelleted through centrifugation (200 g, 10 min), adjusted to 1107 cells/ml in 
CTL freezing medium and frozen in 1 ml aliquots with assistance of the Ice Cube 14S computer-
controlled freezing device (SY-LAB), and stored in a liquid nitrogen cryopreservation system. 
 
IMDM  Iscove’s Modified Dulbecco’s Medium (Thermo 
Fisher - 21980032) 
IMDM-8+  IMDM, 10% (v/v) FBS, 8% (v/v) TCGF, 10 ng/ml 
IL-15, 50 U/ml penicillin, 0.05 mg/ml streptomycin 
Natural human interleukin-2 (IL-2) / T 
cell growth factor (TCGF) (500 BRMP 
units/ml) 
 Helvetica Health Care, Geneva, Switzerland 
(0801017) 
Recombinant human IL-15  CellGenix, Freiburg im Breisgau, Germany (1413-
010) 
Other cell culture media and additives  See Table 8 
 
C.2.3.6 VLP-mdDC co-cultivation 
The protocol for VLP co-cultivation was optimized together with Tanja Stief267. At first, 5105 
mdDCs/well were seeded in a 96 round bottom well plate in 100 µl mdDC medium (C.2.3.4). 
After a 3 h cultivation period, varying amounts of VLPs were directly added to the mdDCs. 
Another two hours later, the cells were pelleted (500g, 5min), the medium aspirated, the cells 
washed with 200 µl DPBS and finally resuspended in 100 µl RPMI-10. After another 4 h 
incubation period, the cells were employed for CTL restimulation experiments (C.2.3.8). 
 
Cell culture media and additives  See Table 8 
C.2.3.7 Peptide pulsing 
For peptide pulsing experiments, 5105 mdDCs/well were seeded into a 96 round bottom well 
plate in 100 µl mdDC medium (C.2.3.4). After a 3 h incubation period, 1 µl of varying peptide 
(C.1.3) concentrations, dissolved and diluted in DPBS, was directly pipetted to the mdDCs. 
Another 2 hours later the cells were pelleted (500 g, 5 min), the medium aspirated, the cells 
washed two times with 100 µl DPBS and finally resuspended in 100 µl RPMI-10. These cells 
were used for CTL restimulation assays (C.2.3.8) instantaneously. 
 
Cell culture media and additives  See Table 8 
C.2.3.8 mdDC and CTL mixed leukocyte reaction 
Liquid-nitrogen-frozen CTLs (C.2.3.5) were quickly thawed and adjusted to 5105 cells/ml with 
RPMI-10 3 hours prior to starting the co-cultivation. For the mixed leukocyte reaction, 100 µl of 
CTL cells were added to already seeded mdDCs (C.2.3.6 and C.2.3.7), resulting in an effector-
to-target ratio of 1:1. To inhibit the secretion of cytokines, Brefeldin A was added to a final 
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concentration of 1 µg/ml. The mixed leukocyte reaction (MLA) was performed for 6 h at 37°C 
and 5% CO2. Cells were then directly employed for flow cytometry analysis (C.2.6). 
 
Brefeldin A (BFA)  Sigma Aldrich (B6542) 
Other cell culture media and additives  See Table 8 
C.2.4 Virological techniques 
C.2.4.1 HIV-1 production 
To produce HIV-1 viral particles, HEK-293T cells were transiently transfected in 6-well plates 
(C.2.3.2) with molecular clones of full-length, replication- and infection-competent HIV-1. 24, 48 
and 72 h after transfection the virus-containing supernatant was completely harvested and 
replaced with fresh medium. The conditioned medium was cleared by centrifugation (1000 g, 
5 min). For virus inactivation and solubilization of Gag, the virus containing, cell-free supernatant 
was incubated with Triton X-100 in a final concentration of 1% (v/v) for a minimum of 4 h268,269. 
 
Triton
TM
 X-100  Sigma Aldrich (T8787) 
C.2.4.2 RT-Assay for virus quantification 
To determine the amount of virus produced, the RT activity was quantified with the RetroSysTM 
RT Activity Kit270. The assay procedure consists of two steps. First, the RT in the virus-
containing medium synthesizes a DNA strand using an immobilized polyA template and an oligo-
dT primer. Bromo-deoxyuridine triphosphate (BrdUTP), which is added to the reaction, gets 
incorporated into the DNA, and, in the second step, gets quantified with a BrdU-binding antibody 
conjugated to alkaline phosphatase. The activity of the alkaline phosphatase is measured in a 
colorimetric reaction and is proportional to the RT activity of the sample. 
The assay was performed according to the manufacture’s protocol for quantification of RT 
activity, with the exception that the RT reaction step was always carried out overnight.  
 
RetroSys
TM
 RT Activity Kit  Innovagen, Lund, Sweden (RT-001 - discontinued) 
 
C.2.5 Protein biochemistry techniques 
C.2.5.1 Antibody biotinylation 
Biotinylation of antibodies is an excellent way to detect them with high specificity. For the Gag 
ELISA (C.2.5.2), the detection-antibody 37G12 had to be biotinylated. The protocol for it was 
based on personal communication with the distributer of the antibody (Polymun Scientific, 
Klosterneuburg, Austria). First the buffer of the antibody was exchanged to DPBS using NAP-5 
gel filtration columns according to the manufacturer’s instructions. The antibody was eluted from 
the column stepwise with 100 µl DPBS. Protein containing fractions, as determined 
spectrophotometrically with the NanoDrop ND-1000 at 280 nm, were pooled. Next, a 10 mM 
solution of the biotinylation reagent EZ-Link-NHS-LC-Biotin in dimethylformamide was prepared. 
The biotin reagent was added in a 75 molar excess to the antibody in PBS (40.5 µl 10 mM EZ-
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Link-NHS-LC-Biotin per 1 mg antibody). After an incubation period of 1 h at room temperature, 
the buffer was changed to DPBS by NAP-5 column chromatography eluting the antibody 
stepwise with 100 µl DPBS. Antibody-containing fractions were pooled and stabilized by adding 
BSA and NaN3 to a final concentration of 0.1% (w/v) and 0.2% (w/v), respectively. 
 
Dulbecco’s Phosphate Buffered 
Saline (DPBS) 
 Sigma Aldrich (D8537) 
EZ-Link-NHS-LC-Biotin  Thermo Fisher (21336) 
NAP-5 gelfiltration columns  GE Healthcare Life Sciences (17-0853-01) 
Antibodies  See C.1.2 
C.2.5.2 Gag-ELISA 
Gag concentrations in cell culture supernatants were determined in a quantitative p24-sandwich-
ELISA271. Both antibodies used in this assay bind to the HIV-1 capsid protein p24, but also 
recognize the full-length Gag protein, which makes it applicable for VLP-, as well as for virus-
quantification. 
First, a MaxiSorp 96 flat bottom well plate was coated with 0.25 µg/well of the M01-16/4/1 
antibody in 100 µl coating buffer and incubated at 4°C overnight. The next day, the plate was 
washed with 3 well volumes of PBS-T using the HydroFlex plate washer (Tecan, Männedorf, 
Switzerland). Afterwards, 100 µl/well of Triton-treated (0.5% (v/v) final concentration, incubated 
for 1 h at room temperature) conditioned medium that had been cleared by centrifugation (two 
subsequent centrifugations at 500 g and 1000 g for 5 min each), and different dilutions of 
recombinant p24 protein in medium as standard were added to the plate and incubated for 1 h at 
37°C. Following another washing step with 6 well volumes PBS-T, 6.8 ng of the biotinylated 
(C.2.5.1) detection antibody 37G12 in 100 µl PBS with 1% (w/v) BSA were added per well and 
incubated for 1 h at room temperature. The plate was then washed with 10 well volumes of PBS-
T. Subsequently 5 mU horseradish peroxidase conjugated streptavidin, which binds specific and 
with high affinity to biotin, in 100 µl PBS with 1% (w/v) BSA were added per well. The plate was 
incubated for 30 min at room temperature and then washed with 10 well volumes of PBS-T. The 
colorimetric quantification-reaction was started by adding 100 µl/well of freshly prepared TMB 
substrate and stopped after 2 min by pipetting 50 µl of 1 M H2SO4 into each well. The 
colorimetric reaction was measured at 450 nm with a microplate reader (Model 680 - Bio-Rad 
Laboratories, Hercules, USA) and the Gag concentration in the samples was determined by 
reference to the recombinant p24 protein as standard in a nonlinear regression analysis with 
GraphPad Prism 5 (variable slope (four parameter) equation).  
 
Coating buffer  0.1 M carbonate, pH 9.5 
Nunc MaxiSorp® flat-bottom 96 well 
plate 
 NeoLab, Schwabing-Freimann, Germany 
(104342404) 
PBS  137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 
mM KH2PO4, adjusted to pH 7.4 with HCl 
PBS-T  PBS, 0.05% (v/v) Tween-20 
Recombinant HIV-1 p24 protein  Abcam (ab43037) 
Streptavidin-POD  Sigma Aldrich (11089153001) 
3,3’,5,5’-Tetramethylbenzidin (TMB)  Carl Roth, Karlsruhe, Germany(R6350) 
TMB A  30 mM tri-potassium citrate-monohydrate adjusted 
to pH 4.1 with 10% (w/v) citric acid 
TMB B  0.24% (w/v) TMB, 10% (v/v) acetone, 90% (v/v) 
ethanol, 80 mM H2O2 
TMB substrate  TMB A and TMB 2 mixed in a 20:1 ratio 
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Triton
TM
 X-100  Sigma Aldrich (T8787) 
Tween-20  Merck Millipore, Darmstadt, Germany (822184) 
Antibodies  See C.1.2 
C.2.5.3 sHLA ELISA 
Relative concentrations of intact sHLA complexes in conditioned medium were determined in a 
quaternary-structure-dependent sandwich ELISA. This ELISA utilizes the characteristic of the 
monoclonal α-pan-HLA antibody103 W6/32 that binds only intact HLA/sHLA complexes, 
consisting of the HLA α-chain, β2m, and a peptide bound to the epitope binding groove104. 
First, a MaxiSorp 96 well plate was coated with 0.1 µg/well W6/32 antibody in 100 µl coating 
buffer and incubated overnight at 4°C. After washing with 3 well volumes of PBS-T, free binding 
sites of the plate were blocked with 3% (w/v) BSA in PBS overnight at 4°C. The next day, each 
well was washed again with 3 well volumes of PBS-T and 100 µl of centrifugation-cleared 
(500 g, 5 min) sample-supernatant were pipetted into each well. After incubation for 1 h at 37°C, 
all wells were washed with 6 well volumes PBS-T. For detection of bound sHLA complexes, 
0.1 µg biotinylated α-6x-His Epitope Tag antibody in 100 µl PBS with 1% (w/v) BSA were added 
per well, incubated for 1 h at room temperature, and subsequently washed with 6 well volumes 
PBS-T. Finally, 5 mU horseradish-peroxidase-conjugated streptavidin in 100 µl PBS with 
1% (w/v) BSA were added per well. The plate was incubated for 30 min at room temperature 
and then washed with 10 well volumes of PBS-T. The colorimetric quantification-reaction was 
started by adding 100 µl/well of freshly prepared TMB substrate and stopped after about 10-
15 min, depending on the experiment, by pipetting 50 µl of 1 M H2SO4 into each well. The 
colorimetric reaction was measured at 450 nm in a microplate reader (Model 680 - Bio-Rad 
Laboratories). 
 
Buffers and substrates  See C.2.5.2 
Antibodies  See C.1.2 
C.2.5.4 SEAP Assay 
To account for variables like transfection efficiency or varying cell numbers in transfection 
experiments, normalization based on the expression of the reporter gene secreted embryonic 
alkaline phosphatase (SEAP) was established previously272,273. SEAP gets secreted by the cells 
and can be quantified directly in the supernatant using a colorimetric assay274. 
For the assay, the pBluescript KS(-) CMV-SEAP vector, which expresses SEAP under control of 
the CMV promoter, was co-transfected (B.4.3.2) with the plasmid expressing the GOI in a 1:20 
(w/w) ratio. The supernatant was harvested after the indicated time and clarified by two 
subsequent centrifugations (500 g and 1000 g for 5 min each). The samples were then diluted 
with DMEM-PS if needed. After heating at 65°C for 10 min, 10µl of the samples were mixed with 
90 µl dH2O and 100 µl 2xSEAP assay buffer. The heating and the L-homoarginine in the buffer 
inhibit endogenous alkaline phosphatase activities275. The samples were then pre-warmed to 
37°C for 10 min in a 96-flat bottom well plate. To start the colorimetric reaction, 20 µl of 120 mM 
para-nitrophenyl phosphate dissolved in 1xSEAP assay buffer were added to each well. The 
hydrolysis of the substrate by SEAP accompanies an increased in absorbance at 405 nm over 
time276, which was measured with a microplate reader (Model 680 - Bio-Rad Laboratories) at 
37°C. To quantify the measurements, a relative SEAP reference standard was included in every 
experiment and analyzed in a linear regression analysis (Excel 2010). 
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L-homoarginine hydrochloride   MP Biomedicals, Santa Ana, USA (05221003) 
Para-nitrophenyl phosphate disodium 
salt 6H2O 
 AppliChem (A1442) 
SEAP buffer (1x)  1 M Diethanolamine, 0.5 mM MgCl2,10 mM L-
homoarginine, adjusted to pH 9.8 with HCl 
Other cell culture media and additives  See Table 8 
 
C.2.5.5 Bradford Assay 
To quantify protein samples via the method by Bradford277 the “Bio-Rad Protein Assay” was 
applied according to the manufacturer’s instructions, using BSA in different concentrations as 
protein standard. 
 
Bovine serum albumin (BSA), fraction 
V 
 Biomol, Hamburg, Germany (01400) 
Bio-Rad Protein Assay Kit  Bio-Rad, Hercules, USA (5000001) 
 
C.2.5.6 VLP production 
For VLP production, varying quantities of HEK293T cells, depending on the experiment, were 
transiently transfected (C.2.3.2) with Gag-expression-plasmids. For VSV-G pseudotyped VLPs 
Gag DNA was mixed with the VSG-G plasmid 1:1 (w/w). The VLP-containing supernatant was 
harvested 48 h post transfection and clarified by centrifugation (3000 g, 15 min, and 4°C). To 
concentrate the VLPs, 30 ml of the supernatant were pipetted onto a 5 ml 30% (w/w) sucrose (in 
DPBS) cushion in 38.5 ml centrifuge tubes and centrifuged at 100,000 g for 2 h at 4°C in an 
ultracentrifuge (Optima L-90K, Beckman Coulter with rotor SW 32 Ti). Afterwards the pelleted 
VLPs were resuspended in an appropriate amount of DPBS. 
 
Dulbecco’s Phosphate Buffered 
Saline (DPBS) 
 Sigma Aldrich (D8537) 
Centrifuge tubes (38.5 ml, 25x89 mm)  Beckman Coulter (326823) 
 
C.2.5.7 Sucrose density gradient centrifugation 
To purify VLPs according to their density, the concentrated VLPs (C.2.5.6), or the clarified 
supernatant directly, were loaded onto a 10-50% (w/w) sucrose gradient (2 ml of 10, 20, 30, 40 
and 50% each) in 14 ml centrifuge tubes and centrifuged for 2.5 h at 100,000 g and 4°C (Optima 
L-90K, Beckman Coulter with rotor SW 40 Ti). Then, fractions of 550 µl each were collected and 
analyzed for the presence of Gag-VLPs by Gag-ELISA (C.2.5.2) and by immunodetection 
(C.2.5.14) after Western blotting (C.2.5.12). The density of each fraction was determined by 
weighing on a high-precision scale (Sartorius analytic). 
 
Centrifuge tubes (14 ml, 14x95 mm)  Beckman Coulter (344060) 
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C.2.5.8 Transmission and scanning electron microscopy 
VLP-containing sucrose gradient fractions (C.2.5.7) were pooled, transferred to a 38.5 ml 
centrifuge tube and filled up with DPBS. After an ultracentrifuge run (Optima L-90K, Beckman 
Coulter with rotor SW 32 Ti) at 100,000 g for 2 h at 4°C, the pelleted VLPs were resuspended in 
200 µl DPBS. To fixate the samples for electron microscopy 180 µl of the VLPs in DPBS were 
mixed with 20 µl of a 25% (w/w) glutaraldehyde solution. The 2.5%-glutaraldehyde-fixed 
samples were analyzed via transmission electron microscopy (TEM) and field emission scanning 
electron microscopy (FESEM) by Professor Gerhard Wanner at the department for ultrastructure 
research of the Ludwig-Maximilian University of Munich, as described briefly below. 
For TEM, the fixed samples were deposited on carbon-coated copper grids and negatively 
stained with 2.0% (w/v) phosphotungstic acid (PTA), pH 7.0. Transmission electron micrographs 
of samples were taken with an EM 912 electron microscope (Zeiss, Oberkochen, Germany) 
equipped with an integrated OMEGA energy filter operated at 80 kV in the zero loss mode. 
For FESEM, drops of the fixed sample were placed onto a glass slide, covered with a coverslip, 
and rapidly frozen with liquid nitrogen. The coverslip was removed with a razor blade and the 
glass slide was immediately fixed with 2.5% (w/v) glutaraldehyde in fixative buffer, postfixed with 
1% (w/v) osmium tetroxide in fixative buffer, dehydrated in a graded series of acetone solutions, 
and critical-point dried from liquid CO2. Specimens were mounted on stubs, coated with 3 nm 
platinum using a magnetron sputter coater, and examined with a Zeiss Auriga scanning electron 
microscope operated at 1 kV. 
 
Centrifuge tubes (38.5 ml, 25x89 mm)  Beckman Coulter (326823) 
Dulbecco’s Phosphate Buffered 
Saline (DPBS) 
 Sigma Aldrich (D8537) 
Fixative buffer  50 mM cacodylate buffer, pH 7.0 
Glutaraldehyde solution, 25% in H2O  Sigma Aldrich (G5882) 
C.2.5.9 Dynamic light scattering 
Virus-like particle size analysis was performed using dynamic light scattering (DLS). For this, 
sample preparation was identical as described for electron microscopy imaging (C.2.5.8) except 
that no fixation was performed. The purified VLPs were diluted in DPBS as required and 
examined with a High Performance Particle Sizer (Malvern Instruments, Malvern, UK) at the 
Biochemistry I department of the University of Regensburg using a predefined standard protocol 
for particles solved in PBS.  
 
Dulbecco’s Phosphate Buffered 
Saline (DPBS) 
 Sigma Aldrich (D8537) 
C.2.5.10 SDS-PAGE 
Proteins were separated according to their size via sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE)278. Protein-containing samples were mixed with 2x Laemmli buffer 
and boiled at 95°C for 5 min and subsequently shortly centrifuged (30 s, 5000 g). Samples were 
then loaded together with a prestained protein ladder for reference on a 10-15% (depending on 
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the respective experiment) SDS gel and electrophoresis was performed at 30 mA using the 
Mighty small II (8x7cm) system (Serva Electrophoresis; Heidelberg, Germany). 
 
Laemmli buffer (1x)  62.5 mM Tris, 1% (w/v) SDS, 5% (v/v) β 
mercaptoethanol, 0.5 mM EDTA, 5% (v/v) 
glycerol, 0.005% (w/v) bromophenol blue, pH 6.8 
PageRuler
TM
 Plus Prestained Protein 
Ladder 
 Thermo Fisher (26620) 
C.2.5.11 Coomassie staining 
For direct visualization of all proteins, SDS gels were incubated in Coomassie staining solution 
for 15 min and afterwards destained in dH2O. Approximate protein quantification was achieved 
by densitometrical analysis with comparison to BSA reference samples that were also loaded on 
the same gel. 
 
Coomassie Brilliant Blue R-250  AppliChem (A1092) 
Coomassie staining solution  1.25% (w/v) Coomassie Brilliant Blue R-250, 50% 
(v/v) ethanol, 7% (v/v) acetic acid 
C.2.5.12 Western blot 
For Western blotting of the SDS-PAGE-separated proteins (C.2.5.10) onto a nitrocellulose 
membrane (pore size 0.2 µm or 0.45 µm, depending on the protein of interest’s size) the 
BlueFlash-L semi-dry blotting unit (Serva Electrophoresis) was utilized according to the 
manufacturer’s instructions (with 2.5 mA/cm2 gel for 1.5 h). Uniform loading and blotting was 
checked by reversible staining of the membrane with Ponceau S staining solution for 1 min and 
subsequent destaining with H2O. 
 
Nitrocellulose Membrane, Amersham 
Protran (pore size 0.2 µm/0.45 µm) 
 GE Healthcare Life Sciences (10600001 / 
10600003) 
Ponceau S staining solution  0.2% (w/v) Ponceau S, 1% (v/v) acetic acid 
Whatman
TM
 3MM Chr Blotting Paper  GE Healthcare Life Sciences (3030-917) 
C.2.5.13 Slot blot 
To transfer protein solutions directly to nitrocellulose membranes, the Bio-Dot® SF microfiltration 
apparatus (Bio-Rad, Hercules, USA) was used. The membrane (9x12 cm) was pre-incubated in 
transfer buffer for 10 min and then placed in the Bio-Dot apparatus on top of five transfer-buffer-
moistened Whatman blotting papers (7.7x11.3 cm). Gentle vacuum was applied and the 
apparatus was equilibrated with 250 µl transfer buffer per well. Afterwards, 10 µl of the protein 
sample dilutions in 200 µl PBS were loaded per well and then washed with 250 µl transfer buffer. 
 
Nitrocellulose Membrane, Amersham 
Protran (pore size 0.2 µm/0.45 µm) 
 GE Healthcare Life Sciences (10600001 / 
10600003) 
PBS  137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 
mM KH2PO4, adjusted to pH 7.4 with HCl 
Transfer buffer  25mM Tris, 150mM glycine, 10% (v/v) methanol 
Whatman
TM
 3MM Chr Blotting Paper  GE Healthcare Life Sciences (3030-917) 
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C.2.5.14 Immunodetection on membrane 
For immunodetection of specific proteins after Western or slot blots, the membrane was blocked 
overnight at 4°C in TBS-M. After washing 3 times with TBS-T and incubation with the primary 
antibody in TBS (for antibody concentrations see C.1.2) for 1 h at room temperature, the 
membrane was washed again 3 times with TBS-T. The secondary HRP-conjugated antibody or 
streptavidin-POD (diluted 1:2,000) in TBS were added and again incubated for 1 h. Last, the 
membrane was subjected to 3 washing steps with TBS-T and incubated with ECL substrate 
solution. After 5 min, the substrate was removed and the chemiluminescence emitted by the 
peroxidase activity was detected with a ChemiluxPro device (Intas, Göttingen, Germany). If 
necessary, to reach higher sensitivity the SuperSignal™ Femto Substrate was used instead 
of the standard ECL substrate. 
In order to reuse a membrane for detection of another protein, the primary and secondary 
antibodies were removed by incubating with stripping buffer for 30 min at 50°C. After two 
washing steps with TBS-T, the membrane was blocked with TBS-M and subjected to another 
immunodetection round. 
 
ECL substrate solution  100 mM Tris/HCl pH 8.5, 12.5 mM luminol, 1.98 
mM coumaric acid, 305 μl/l 30% (v/v) H2O2 
Streptavidin-POD  Sigma Aldrich (11089153001) 
Stripping buffer  62.5 mM Tris pH6.6, 100 mM β-mercaptoethanol, 
2% (w/v) SDS 
SuperSignal™ West Femto Maximum 
Sensitivity Substrate 
 Thermo Fisher (34095)  
Tris buffered saline (TBS)  50 mM Tris/HCl, 150 mM NaCl, adjusted to pH 7.5 
with HCl 
TBS-M  TBS, 5% (w/v) skimmed powdered milk 
TBS-T  TBS, 0.05% (v/v) Tween-20 
Antibodies  See C.1.2 
C.2.6 Flow-cytometry 
Flow-cytometric multi-parametric analysis of cells was performed with the FACSCantoTM II cell 
analyzer (BD, Franklin Lakes, USA) along with the provided FACSDivaTM software. For the 
individual antibody concentrations used, see C.1.2. 
 
C.2.6.1 Surface marker staining 
To stain for expression of cell surface markers, 5105 cells were washed 2 times by adding 
100 µl FC buffer, followed by centrifugation (500 g, 5 min, 4°C) and aspiration of the buffer. The 
cells were then incubated with a fluorophore conjugated antibody (diluted in 50 µl FC buffer) for 
25 min at 4°C. To remove unbound antibody, the cells were washed 3 times with FC buffer, as 
described above, and finally resuspended in 100 µl FC buffer. 
 
FC buffer  PBS, 1% (v/v) FBS 
Antibodies  See C.1.2 
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C.2.6.2 Intracellular staining (ICS) 
Staining for intracellularly expressed molecules was achieved by washing 5105 cells 2 times by 
adding 100 µl PBS, followed by centrifugation (500 g, 5 min, 4°C) and aspiration of the buffer. 
Afterward, permeabilization and fixation of the cells was achieved by incubation with 50 µl 
cytofix/cytoperm for 20 min at 4°C. After 3 washing steps with 100 µl perm/wash buffer, as 
described above, the cells were incubated with the fluorophore-conjugated antibody (diluted in 
50 µl perm/wash buffer) for 25 min at 4°C. After another 3 wash steps with 100 µl perm/wash 
buffer, the cells were resuspended in 100 µl FC buffer. 
 
Cytofix/cytoperm  4% (w/v) paraformaldehyde, 1% (w/v) saponin 
FC buffer  PBS, 1% (v/v) FBS 
Paraformaldehyde  Merck Millipore (104005) 
Perm/wash buffer  PBS, 0.1% (w/v) Saponin 
PBS  137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 
mM KH2PO4, adjusted to pH 7.4 with HCl 
Saponin from quillaja bark  Sigma Aldrich (S4521) 
Antibodies  See C.1.2 
C.2.7 Epitope sequencing 
To avoid contaminations and sample loss during preparation steps, only protein low-bind or low-
retention plastic-ware was used. Solutions and buffers were prepared in clean glass ware. 
C.2.7.1 W6/32 affinity matrix preparation 
sHLA purification from conditioned cell medium was based on affinity chromatography 
techniques. The affinity matrix was composed of the α-pan-HLA W6/32 antibody (C.1.2) 
crosslinked to Protein A-Sepharose279,280.  
First, for every 1 l of conditioned sHLA containing medium, 100 mg of the lyophilized Protein A-
Sepharose were swollen in 2 ml borate buffer for 30 min at room temperature. The resin was 
subsequently poured onto the porous polyethylene disc of a 5 ml disposable column and 
washed with 5 column volumes (cv) of borate buffer. Afterwards, 2 mg of W6/32 antibody per 
100 mg Protein A were applied to the column. Protein A binds the Fc portion of the mouse IgG2a 
antibody W6/32 with strong affinity, while leaving the antigen-specific sites for sHLA affinity 
chromatography untouched. As source for the antibody, the conditioned W6/32 hybridoma cell 
supernatant (antibody concentration was lot dependent, but always about 40µg/ml, as 
determined by immunodetection after Western blotting and comparison to purified W6/32 
antibody as standard) was employed. The medium was cleared by centrifugation (1000 g, 
10 min), mixed 1:1 with borate buffer, loaded onto the column with a peristaltic pump, and 
allowed to empty by gravity flow. Residual unspecific proteins were removed by washing with 
10 cv borate buffer. To avoid elution of the antibody in later steps, crosslinking to Protein A was 
performed. For this, the column was equilibrated with 5 cv of crosslinking coupling buffer (CCB) 
and then washed with 2 cv 40 mM dimethyl pimelimidate (DMP), a bifunctional coupling reagent, 
in CCB. Following, the bottom cap was secured on the column tip and the Protein A-Sepharose 
was resuspended in 2 cv 40 mM DMP in CCB. After 1h at room temperature, the bottom cap 
was removed, the column was allowed to empty by gravity flow, and then was washed with 5 cv 
CCB. The crosslinking reaction was quenched by washing with 2 cv of ice-cold crosslinking 
66 
termination buffer (CTB) and subsequent incubation with 2 cv CTB for 10 min (performed as 
described above for DMP incubation). After subsequent washing with 5 cv CTB and 5 cv borate 
buffer, all not covalently bound antibody was eliminated by washing with 5 cv acid wash buffer. 
After a final washing step with 10 cv borate buffer the column was stored in borate buffer with 
0.02% (w/v) NaN3 at 4°C until further use. 
 
Acid wash buffer  0.58% (v/v) acetic acid, 150 mM NaCl 
Borate-buffer  0.1M Boric acid, adjusted to pH 8.2 with NaOH 
Crosslinking coupling buffer (CCB)  0.2 M triethanolamine, adjusted to pH 8.2 with HCl 
Crosslinking termination buffer (CTB)  0.1 M ethanolamine, adjusted to pH 8.2 with HCl 
Disposable Columns, 5 mL, Pierce
TM
  Thermo Fisher (29922) 
Dimethyl pimelimidate dihydrochloride 
(DMP) 
 Sigma Aldrich (D8388) 
Ethanolamine  Carl Roth (0342) 
Protein A-Sepharose CL-4B  Sigma Aldrich (P3391) 
Triethanolamine  Carl Roth (6300) 
C.2.7.2 Affinity chromatography of peptide bound sHLA complexes 
The antibody W6/32 has the unusual quality to only bind intact complexes consisting of the HLA 
α-chain, β2m and a binding groove attached peptide. This property was harnessed to isolate 
only peptide-bound sHLA complexes by affinity chromatography of sHLA containing cell 
supernatant.  
The pre-cleared (centrifugation at 1000 g, 10 min) and subsequently filtered supernatant was 
mixed in a 3:1 ratio with borate buffer and applied onto the prepared affinity column (C.2.7.1) 
using a peristaltic pump (Pump P1, Pharmacia, New Jersey, USA) and allowed to empty by 
gravity flow at 4°C. The column was subsequently washed with 15 cv borate buffer and 5 cv 
dH2O. The sHLA complexes were eluted stepwise with 1 cv 10% acetic acid each, until the 
eluate reached a baseline absorbance at 280 nm, determined at a NanoDrop ND-1000. 
 
Acetic acid  Sigma Aldrich (33209-1L-GL) 
Borate-buffer  0.1M Boric acid, adjusted to pH 8.2 with NaOH 
Steritop-GP vacuum filtration system 
(0.22µm) 
 Merck Millipore (SCGPT02RE) 
C.2.7.3 Peptide purification 
To dissociate peptides from the sHLA-heavy chain and β2m, the protein-containing eluate 
fractions (identified by 280 nm absorbance at a NanoDrop ND-1000) from the affinity 
chromatography (C.2.7.2) were heated to 78°C for 10 min119. Following this “acid boil” step, the 
peptides were purified by centrifugation using a centrifugal filter with a nominal molecular weight 
limit cutoff of 3 kDa (3 kDa cut-off filter) according to the manufacturer’s instructions. The 
concentrate containing all proteins bigger than 3 kDa was saved for analytical purposes. The 
filtrate that contained the dissociated peptides was dried to complete dryness in a vacuum 
concentrator (Bachofer). 
 
Centrifugal filter; Amicon®  
Ultra-0.5 - 3 kDa  
 Sigma Aldrich (Z740169) 
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C.2.7.4 HPLC and LC-MS/MS 
Purified peptide samples (C.2.7.3) were examined and sequenced at the proteomics core facility 
of the “Helmholtz Zentrum München” as follows. SpeedVac-dried samples were resuspended in 
2% acetonitrile (ACN) in 0.5% trifluoroacetic acid (TFA) and LC-MS/MS analysis was performed 
as described previously using an Ultimate 3000 nano-RSLC (Dionex, Sunnyvale, USA) coupled 
to a LTQ-Orbitrap XL mass spectrometer (Thermo Fisher Scientific)281. Before loading, the 
samples were centrifuged for 5 min at 4°C. Every sample was automatically injected and loaded 
onto the trap column (Acclaim PepMap100, C18, 5 µm, 100 Å, 300 µm i.d. x 5 mm, Dionex) at a 
flow rate of 30 μl/min. After 5 min, the peptides were eluted from the trap column and separated 
on the analytical column (Acclaim PepMap RSLC C18, 2 µm, 100 Å, 75 µm i.d. x 25 cm, Dionex) 
by a 60 min gradient from 5 to 30% of ACN in 0.1% formic acid (FA) at 300 nl/min flow rate 
followed by a short gradient from 30 to 73% ACN in 0.1% FA in 5 min. Between each sample, 
the gradient was set back to 5% ACN in 0.1% FA and left to equilibrate for 20 min. From the MS 
prescan, the 10 most abundant peptide ions were selected for fragmentation in the linear ion 
trap if they exceeded an intensity of at least 200 counts and if they were of charge states +1 to 
+3, with a dynamic exclusion of 30 sec. During fragment analysis, a high-resolution (60,000 full-
width half maximum) MS spectrum was acquired in the Orbitrap with a mass range from 300 to 
1500 Da. 
C.2.7.5 Spectrum analysis and Databases 
The acquired spectra were loaded to the MaxQuant software with the corresponding search 
engine Andromeda282,283. For identification in the Ensembl Human protein database284 (release 
72, 40,047,703 residues, 105,287 sequences) the following search settings were used: charges 
of +1 to +3 were allowed, length 7-15 amino acids, cleavage unspecific, MS tolerance 10 ppm, 
MSMS tolerance 0.6 Da, 1% false discovery rate (FDR) on peptide and protein level, methionine 
oxidation and asparagine or glutamine deamidation were allowed as variable modifications.  
C.2.8 Software and Statistics 
Band intensities of Coomassie gels, Western-, and Slot Blots were analyzed with the Java-
based ImageJ (version 1.47, NIH, USA) program285. 
Prediction of peptide binding to HLA molecules were performed at the web-interface 
(http://www.cbs.dtu.dk/services/NetMHC/) of the artificial neural networks server NetMHC 
4.0286,287.  
Sequence logos288, as a more detailed alternative to consensus sequences, were created with 
the online accessible tool WebLogo 3.4289 (http://weblogo.threeplusone.com/). 
GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, USA) was used for most statistical 
analyses, regression analyses, and 2D graphing. Significance levels α were set to 0.05 
(indicated by *), 0.01(**), and 0.001(***). For multiple comparisons Bonferroni corrected 
significance levels290 were calculated by dividing α by the number of tested hypotheses. 
The Optimizer Algorithm (B.2) and all in silico antigen evaluation programs (B.3.2 to B.3.4) were 
implemented in Java 1.8 (Oracle, Redwood City, USA), using the integrated development 
environment Eclipse SDK (version 4.2.1, Eclipse Foundation, Ottawa, Canada). Python (version 
2.6, Python Software Foundation, Delaware, USA) was used for communications with 
MODELLER v9.7.  
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D Results 
D.1 Design of epitope-enriched HIV-1-Gag antigens 
The objective of this thesis was to design breadth-optimized Gag antigens, by combining as 
many potent CD8+ T cell epitopes as possible in maximal three full-length Gag sequences, while 
also preserving the Gag function to release VLPs. The Optimizer Algorithm (B.2) was used to 
create these antigens using patient-derived epitopes. In this chapter the data retrieved as input 
for the algorithm (D.1.1), the use of the FLD to preserve Gag structure and function (D.1.2), the 
ranking of CD8+ T cell epitopes (D.1.3), and finally the generation of novel proof of concept 
CD8+ T cell epitope-enriched Gag antigens (teeGags) (D.1.4) is described. 
D.1.1 Analysis of input data sets 
The Optimizer Algorithm requires a variety of input data, as described in B.2. In addition to an 
alignment of natural Gag sequences (D.1.1.1) and CD8+ T cell epitopes (D.1.1.2), also HLA 
class I allele- (D.1.1.3) and HIV-1 subtype-frequencies (D.1.1.4) in the target population have to 
be specified. The data used for the proof of concept teeGags, designed for worldwide 
application, are described below. 
D.1.1.1 HIV-1 Gag alignments 
 
As representation of the genetic universe of Gag 
sequences, the Filtered Web Alignment from the LANL 
HIV database was downloaded and curated (B.1.1.1). 
From the originally 5085 sequences, 84 were deleted, 
due to their HIV-1 group- or subtype-association (Table 
10), leaving 5001 sequences in the final alignment. 
D.1.1.2 CD8+ T cell epitopes 
CD8+ T cell epitopes were downloaded (B.1.2) from the 
LANL molecular immunology database on April 24, 
2015. In the search mask, the parameters p17, p24, and 
p2p7p1p6 (this nomenclature for the N-terminal domains 
p2, p7, p1, and p6 was retained in the Optimizer 
Algorithm) were specified for the HIV proteins, selecting human as species, and keeping the 
remaining options on default. The 2688 matching records found were downloaded and 
converted into a CSV file. All database entries were subjected to a manual quality control to 
remove or correct questionable and erroneous sequences and annotations. Epitope entries with 
HIV-2-based sequence, unclear sequence (marked by “?” after epitope sequence), a sequence 
longer than 20 amino acids, and those described as only computer predicted, without any 
experimental validation, were deleted. Additionally, all epitopes, which could not be found at 
Table 10. Sequences omitted from the 
Gag alignment. Number and affiliation of 
non-group M or unclassified Gag 
sequences that were removed from the 
LANL Filtered Web Alignment (B.1.1.1) 
HIV-1 group or 
subtype 
Number of deleted 
sequences 
Group N 8 
Group O 26 
Group P 2 
CPZ 16 
U (unclassified) 32 
Overall 84 
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least once in any natural Gag sequence (resulting in a conservation score of 0; see B.2.2.4) of 
the 2013 Filtered Web Alignment (D.1.1.1) or in a subsequent search in the complete, unfiltered 
LANL sequence set (using the online sequence search interfaceg), were further evaluated by 
double-checking the primary publication given for the respective database entry. If possible the 
epitope sequence of the entry was patched, or otherwise deleted. Furthermore, in some cases 
the epitope annotations, like HLA-association, virus subtype, or epitope start- and end-positions 
had to be changed. For example all subtype “A1” annotations were changed to “A”, because in 
many cases only “A” is specified, allowing no differentiation between A1 and A2. Overall, 99 
database entries were removed and 154 modified. All epitope database modifications performed 
are summarized in Table 11 and a detailed changelog can be found in Extended Data Table 1.  
 
Table 11. Overview of deleted and modified epitope database entries. The 2688 Gag-specific human epitope 
entries downloaded from the LANL molecular immunology database were curated for erroneous or improper entries. If 
feasible, the entries were modified (right column), or otherwise omitted (left column). 
Omitted epitope entries Modified epitope entries 
Reason Count Changed field Count 
Unclear sequence (“?”) 4 Epitope sequence 37 
Sequence >20aa 19 HLA 15 
Computer prediction 3 Start-end annotation 12 
HIV-2 sequence 31 Subtype 93 
Conservation score = 0 39   
Other 3   
 
The residual 2589 epitope entries were analyzed for entries describing the identical epitope 
sequence at the same protein position. Such multiple records were merged into one consensus 
entry as described in B.1.2. This measure reduced the input data to a set of 691 unique epitopes 
that are listed, together with all relevant database information, in Extended Data Table 2 .  
 
 
Figure 15. Total number of epitopes, super-, and subepitopes in the different Gag proteins. The graph displays 
the absolute numbers of superepitopes (grey bars) and subepitopes (white bars) for the complete Gag (All), or the 
domains p17, p24, and p2p7p1p6. Epitopes located on the interface of two protein domains were counted as epitope 
for both proteins (e.g. an epitope spanning over the p17-p24 boundary was counted as p17-, as well as p24-located 
epitope). 
g
 http://www.hiv.lanl.gov/components/sequence/HIV/search/search.html 
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According to B.1.2, the unique entries were partitioned into 253 super- and 438 subepitopes 
(Figure 15). Most epitopes (427 total epitopes, 125 superepitopes, and 302 subepitopes) were 
located in the capsid p24 protein, followed by matrix p17 protein (157 total, 70 super-, and 87 
subepitopes), and finally, with the least epitopes, the joined N-terminal domains p2p7p1p6 (84 
total, 46 super-, and 38 subepitopes). Some epitopes spanned over the defined amino acid 
boundary of p17 to p24 (8 total, 4 super-, and 4 subepitopes) or p24 to p2p7p1p6 (15 total, 8 
super-, and 7 subepitopes). These epitopes were for subsequent analysis counted as epitope for 
both proteins (Figure 15). Normalized to the protein length, p17, p24, and p2p7p1p6 were 
represented by 1.3 (0.6 superepitopes and 0.7 subepitopes), 1.9 (0.6 and 1.4), and 0.7 (0.4 and 
0.3) total epitopes per amino acid, respectively. 
 
 
Figure 16. Epitope Distribution across the HXB2-Gag sequence. (A) Coverage of each amino acid position in the 
epitope set alignment to the HXB2-Gag sequence (back line). The score at each position (grey line) was calculated by 
adding up the scores (B.2.2) of all epitopes that contain the respective positon. (B) The proportional location of all 
unique epitopes within HXB2-Gag that was divided into p17, p24, and the joined N-terminal domains p2p7p1p6. Each 
line represents one epitope at its exact location drawn to scale. 
 
The complete set of unique epitopes was aligned to the HXB2-Gag reference sequence (Figure 
16). The distribution of epitopes and hence the amino acid position coverage was not uniform. 
The p17 matrix protein, for examples, comprises two epitope “hotspots” around HXB2-Gag 
numbering positions 28 and 85, with over 30 epitopes covering these locations. Between these 
hotspots the coverage declined rapidly and position 113 was even covered by none of the 691 
epitopes. For the capsid protein, the epitope distribution was more equal, but also here the 
coverage ranges from 5 to 43 epitopes per amino acid position. The epitope distribution for 
p2p7p1p6 is on a similar, low level for the complete, jointed protein length. 
To identify in the epitopes variable and conserved Gag positions, all 691 unique epitopes were 
aligned with the reference HXB2-Gag sequence. Most Gag amino acid positions (372) were 
conserved and epitopes harbored no mutations compared to the reference. However 128 
variable positions were identified in the epitope-to-reference-alignment. In most cases (102) only 
one amino acid substitution was observed at the variable positions, but 22 times 2 different and 
4 times 3 different amino acids were identified. Summed up, 158 unique AAS were found in the 
epitopes compared to the reference sequence. Each unique epitope contained on average 0.74 
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AAS, with a range from 0 to 10 (Figure 17). However, most epitopes (380 epitopes, 55% of 
complete set) were identical to the HXB2-Gag reference sequence. Epitopes with mutations as 
compared to the reference mostly only harbored one (188, 27%) or two (83, 12%) AAS. Epitopes 
with many mutations are mostly due to amino acid insertions or deletions, which prevent a gap-
free alignment to HXB2. 
 
 
Figure 17. Number of AAS per epitopes identified in an alignment with the reference HXB2-Gag sequence.  
D.1.1.3 HLA allele frequencies 
For a proof of concept first generation of the newly-designed teeGags, it was decided to aim for 
a global vaccine approach. Due to this, information about the worldwide HLA class I allele 
frequency distribution was required for epitope scoring (B.2.2.1) and population score 
calculations (B.3.3).  
The most comprehensive publication, summarizing broad global patterns of allelic differentiation 
was published by Solberg et al.291. Therein, the HLA allele frequencies of 497 population studies 
and approximately 66,800 individuals from throughout the world were reviewed in a meta-
analysis. The overall average HLA allele frequencies for loci A, B, and C, across all population 
samples (data available in the online supporting materialh) were used in this thesis as 
representation of the worldwide allele distribution. Since some primary references of the LANL 
epitope entries describe the HLA alleles only in a low resolution (e.g. A*02 instead of A*02:01 or 
A*02:02), the high resolution published by Solberg et al. had to be adapted. Hence, all specific 
HLA protein frequencies were summed up in their corresponding allele group frequency (e.g. 
A*02 consists of the cumulative frequencies of A*02:01, A*02:02,…). The complete list of the 
calculated HLA class I allele group frequencies is given in the Extended Data Table 3. 
D.1.1.4 HIV-1 subtype weighting 
For the immunological scoring of epitopes (B.2.2.2), as well as for the validation of antigens 
(pathogen coverage B.3.4), a ranking of the circulating HIV-1 subtypes was required. Since a 
holistic approach should be implemented for the first generation teeGags, the subtype weighting 
was oriented at the global distribution (Figure 18), as published by Hemelaar et al.8. Therein, 
country-specific epidemiology data from 2004-2007 were combined with estimated numbers of 
h
 www.pypop.org/popdata/ 
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HIV-infected people in the respective countries. The weighting of subtypes and circulating 
recombinant forms (CRFs) was chosen directly proportional to the described global frequencies 
(Table 12). Rare CRFs and unique recombinant forms (URFs) were assigned a weight of 0. For 
the scoring, this had no distinct impact, since except one primary reference, reporting epitopes 
derived from B/C recombinant viruses292, none of the LANL entries were associated with any of 
the rare CRFs or URFs. 
 
 
Figure 18. Global HIV-1 subtype, CRF, and URF 
frequencies as described by Hemelaar et al.
8
. In 
the publication rare CRFs (Other CRFs) and unique 
recombinant forms (URFs) were summed up to one 
entry each. 
Table 12. Subtype and recombinant weighting 
proportional to the global frequency. All rare CRFs 
and URFs were assigned a weight of 0. 
Subtype or 
recombinant 
Global 
frequency [%] 
Weight 
A 12.03 1203 
B 11.33 1133 
C 48.23 4823 
D 2.49 249 
F 0.45 45 
G 4.60 460 
H 0.26 26 
J 0.12 12 
K 0.01 1 
CRF01_AE 5.09 509 
CRF02_AG 7.73 773 
CRF03_AB 0.00 0 
Other CRFs 3.65 0 
URFs 4.01 0 
 
D.1.2 Functional assessment of AAS 
As a main feature of the Optimizer Algorithm, all AAS with negative influence on the release of 
virus-like particles should be excluded for teeGag design. To determine, if an AAS is compatible 
the budding of VLPs or detrimental to its function, a computational multidimensional classifier 
was implemented. This method employs combinations of structural and sequence-based 
properties (D.1.2.1), to classify unknown AAS (D.1.2.2 and D.1.2.3), based on a training-set of 
mutations with experimentally determined phenotype and is in detail described in B.2.1.  
D.1.2.1 Classifier feature selection 
To assess the effect of AAS on VLP budding, structural features that interpret energetic 
landscape alterations of protein structure models, introduced by the AAS, were defined (B.2.1.1). 
For this, 3D-structures and the energy profile as DOPE (B.2.1.1, section “Homology modeling 
and Discrete Optimized Protein Energy”) for the p17-, p24-, p2-, p7-, and p6-protein of the 
reference HXB2-Gag, as well as for Gag-domains with integrated single AAS, were calculated 
using homology modelling, except for p1, because no suitable template could be identified.  
Four different DOPE-based energetic observations were tested as classification feature, namely 
(I) the DOPE at the AAS position (f1,DOPE), (II) DOPE difference between the reference and the 
mutated structure at the AAS position (f2,ΔDOPE), (III) the sum of all DOPE difference values 
between the reference and mutated 3D-model at all amino acids of the Gag protein where the 
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AAS was located (f3,ΔDOPE-global), and (IV) the sum of DOPE value differences between reference 
and mutated structure for all amino acids in a window of six in N- and five in C-terminal direction 
around the AAS (f4,ΔDOPE-local). A fifth feature (f5,seq) originated from sequence-specific 
characteristics and is a measure of sequence conservation at the respective positon, displayed 
as PSSM score (B.2.1.2). To assess the performance of the five features, to discriminate 
between budding-deleterious and budding-retaining mutations, a training-set with known 
phenotypes was analyzed (Table 4). Five entries of this set were removed beforehand: the G2A 
mutations, since the negative effect is not based on structural properties, but on inhibition of a 
posttranslational myristoylation and four additional AAS (A5D, S6I, V128E, and Q130G), which 
are positioned too close to the beginning or end of the sequence, prohibiting f4,ΔDOPE-local 
calculations. Statistical analysis of the budding-deleterious (-) and budding-retaining (+) groups 
of the training-set with the nonparametric Mann-Whitney test revealed significant group 
separation for all features, except f1,DOPE (Figure 19). On its own f1,DOPE therefore allows no 
discrimination between the two classes. Better, but with a p-value of 0.031 the second-worst, 
was the PSSM score displayed by f5,seq. The best features concerning significance were f2,ΔDOPE, 
f3,ΔDOPE-global, and f4,ΔDOPE-local. All three rely on energetic comparison between mutated and 
reference structures. 
 
 
Figure 19. Group separation of training-set data for all five classification features. AAS with experimentally 
determined phenotype were classified in budding-retaining (marked “+”) and budding-deleterious (“-“) mutations and 
their respective feature scores are depicted. p-values of group separation of the four structural-energy- and the 
sequence-based features were computed with the non-parametric Mann-Whitney test. Boxes represent the median 
and 50 % quartiles, whiskers the 10-90 % percentile, and black dots the outliers. 
 
However, even for the features with highly significant group separation, there was still 
substantial overlap between AAS with different effects on budding. To improve the 
differentiation, it was tested to base predictions on combinations of selected features. The 
training-set values of feature combinations were used in a Fisher’s Linear Discriminant Analysis 
(B.2.1.3). During the FLD, a vector d was calculated that projects the multidimensional feature 
data combinations onto a 1D-subspace t (Figure 20). The reduction onto the 1D-space was done 
in a way that best separates the two classes (i.e. budding-retaining and budding-deleterious 
AAS) of the training-set data. To discriminate between the groups, a hyperplane Z between 
projections of the means of both classes was computed. This allowed sorting of AAS with 
unknown function into the budding-retaining or budding-deleterious group, solely based on its 
structural and sequence-based features.  
74 
 
Figure 20. Fisher’s Linear Discriminant Analysis of the training-set data. The experimentally validated training-
set entries were classified into the budding-retaining (green) or budding-deleterious (red) group and all possible 
combinations of discriminatory features were analyzed in a FLD. Combining f3,ΔDOPE-global and f5,seq (left graph) resulted 
in the highest 10-fold cross-validation (100 repeats) precision (98%, Extended Data Table 4) and had a calibration 
precision of 100%. The worst double combination was f1,DOPE with f5,seq (right graph). Both depicted graphs show all 
training-set entries, located according to their respective feature data. In both cases, all AASs were projected with the 
vector d onto the 1D-space t. Frequency distribution above t indicates the achieved group separation. Hyperplane Z 
represents the actual computed group discrimination rule. 
 
To identify the best discriminatory combination for the classifier, all possible feature 
permutations were tested using the training-set in a 10-fold-crossvalidation (B.2.1.3) with 100 
repeats each. To rank all possible combinations, the accuracy, sensitivity, specificity, PPV 
(precision), and NPV (Table 5) of the binary classification predictions were computed. As 
preservation of budding-competence was considered mandatory, for the design of the T cell 
epitope-enriched Gag antigens, it was decided on a high PPV as most important quality 
characteristic for the classifier. This value is calculated as percentage of the true positives 
among all positives, i.e. as budding-retaining predicted AAS. A high PPV engenders only few 
false positives, which had to be avoided, since incorporation of a single false positive AAS could 
destroy the whole Gag functionality.  
 
 
Figure 21. Probability of realization. Depending on the precision of classifying budding-retaining AAS, the 
probability of including only true positive predictions, therefore resulting in functional Gag, diminishes in different rates 
with increasing numbers of AAS combined in the same sequence (x-axis). The graph shows theses probabilities (y-
axis) of realization based on various precision.  
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The importance of a high precision is exemplified by the probability of realization (Figure 21). 
This is the probability of being able to combine x different AAS in a single Gag protein, without 
incorporation of a single false-positive predicted AAS, which probably would inhibit VLP 
production. It is calculated as the precision to the power of x. A high precision of 99% for 
example, would mean, that only 1 of 100 budding-retaining classifications would be a false 
positive. Because of this many mutations can be combined, without risk of including false 
positives that potentially would inhibit viral release (e.g. combination of 30 AAS would still have a 
realization probability of 74%). For lower precisions the realization quickly diminishes. 
Combining 30 AAS at a precision of 80%, for example, would only have a realization probability 
of 12%. 
The complete list of feature permutations sorted first by PPV and then accuracy is summarized 
in Extended Data Table 4. The top position was occupied by the combination of feature f3,ΔDOPE-
global and f5,seq with a precision of 98% and an accuracy of 86%. The calibration accuracy (90.6%) 
and calibration precision (100%), calculated on basis of the actual classification of all AAS, 
within the entire training-set, were even higher (Figure 20, therein compared to the worst 
combination of two features - f1,DOPE and f5,seq ). The worst discrimination was determined for 
f1,DOPE alone, with an accuracy of only 58% (precision: 64%), which means that it is just slightly 
better than a classification by chance. This was however expected, since this feature was the 
only one that showed no significant separation of the two groups (Figure 19). This entails also 
that almost every time when f1,DOPE was included, the classification result was worse than for the 
same feature combination without f1,DOPE (e.g. f1,DOPE+ f2,ΔDOPE + f3,ΔDOPE-global had an accuracy of 
71% and a precision 83%, but without f1,DOPE the values increased to 75% and 85%, 
respectively). Vice versa, inclusion of f5,seq, despite being the second-worst single feature 
(accuracy: 72%, precision: 76%), increased the accuracy and precision of the prediction almost 
in every combination, compared to the same feature set without f5,seq. Although f4,ΔDOPE-local was 
the best single feature (accuracy: 80%, precision: 86%), no combination with any other one had 
a beneficial effect on the classification. 
 
D.1.2.2 Classification of unknown AAS from epitope set 
After determining the optimal combination of classification features (f3,ΔDOPE-global and f5,seq), the 
group affiliation of all unique AAS, identified in the Gag CD8+ T cell epitope set, was examined. 
This fully implemented classification is illustrated in Figure 22. All AAS with unknown effect were 
plotted according to their f3,ΔDOPE-global and f5,seq values. Appling decision boundary Z, calculated 
before by reference to the training-set (Figure 20), the AAS were grouped into budding-retaining 
and budding-deleterious mutations (Figure 22).  
The 158 AAS identified in the epitope input data set were distributed quite homogenously across 
p17, p24, and p2p7p1p6 with 48, 60, and 50 occurrences, respectively (Figure 23). Normalized 
to the domain length, p24 has the fewest with one AAS every 3.85 amino acids, as compared to 
2.75 and 2.74 for p17 and p2p7p1p6. Of all AAS identified in the epitope input dataset, 18 
(11.4%) were classified as budding deleterious. For one AAS (Y441H) no classification was 
possible, because it was located in the p1-domain, of which no suitable template structure for 
homology modelling was available. To prevent incorporation of this unclassified mutation, it was 
precautionally classified as budding-deleterious. 
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Figure 22. Classification of unknown natural occurring AAS into budding-deleterious and budding-retaining 
mutations. All 158 AAS, identified from the alignment of all unique CD8+ T cell epitope to the HXB2-Gag reference 
sequence, were plotted according to their respective f3,ΔDOPE-global and f5,seq values. Using the hyperplane Z, calculated 
on the basis of the training-set, the unknown AAS were classified either in the budding-deleterious or the budding-
retaining class. 
Most AAS with negative effect on budding were located in p24 (13 = 21.7% of all AAS in the 
protein domain) with a hotspot between positions 267 to 273. In this area, 7 as budding-
deleterious predicted AAS accumulated (E.2.1). For p17, only 3 (6.3%), and for p2p7p1p6, 2 
(4% - with p1 3 (6%)) mutations were classified as functionally detrimental, respectively. From 
the 691 unique epitopes in the input data, 21 entries harbor at least one of the 19 (including the 
p1 located mutation) as budding-deleterious classified AAS, and were therefore removed for all 
subsequent processes. Thereby, 670 unique epitopes remained for the design of the T cell 
epitope-enriched Gag antigens. 
 
 
Figure 23. Distribution of naturally occurring AAS per position of HXB2 reference sequence. Gag was divided 
in p17, p24, and p2p7p1p6 protein domains. AAS classified as budding-deleterious are highlighted in red. The 
respective sum of all identified AAS and the number budding-negative grouped mutations (in red) is stated below 
each protein domain. 
D.1.2.3 Classification of all possible Gag AAS 
Besides classifying all naturally occurring Gag AAS, all theoretically possible mutations were 
analyzed. For this, each amino acid position of the reference HXB2-Gag was permutated to all 
other 19 amino acids. For all these sequences, containing a single AAS each, a 3D-model was 
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generated using homology modelling. Afterwards, as above, the decision boundary Z, generated 
via the FLD and the features f3,ΔDOPE-global and f5,seq of the training-set, was applied to classify all 
possible 9,196 AAS in p17, p24, and p2p7(p1)p6. Again, all amino acids located in p1 were 
excluded from this permutation analysis, due to the lack of a template structure for homology 
modeling.  
The three defined protein domains of Gag were examined separately (Figure 24). The relatively 
conserved p24 had the highest rate of budding-deleterious predicted AAS (83.6% of all 4,389 in 
p24 located AAS). This is mainly due to the fact that the f3,ΔDOPE-global values shifted into a more 
negative range and hence across the decision boundary Z (Figure 24 middle panel). For p17 
and p2p7(p1)p6, in contrast, most AAS (66.9% of 2,508 and 85.3% of 2,299) were classified to 
have no negative influence on Gag functionality. For the complete Gag sequence, 4,839 AAS 
(52.6%) were predicted as budding-deleterious.  
 
  
Figure 24. FDA of all possible permuted Gag AAS. The 9,196 AAS, generated by per-muting each amino acid 
position of HXB2-Gag separately to all other 19 possible amino acids, were partitioned into p17, p24, and p2p7(p1)p6. 
Each AAS is plotted according to their f3,ΔDOPE-global and f5,seq values and classified using the hyperplane Z. The three 
depicted graphs show the location of all AAS as heatmap. For the generation of the heatmap, data points were 
condensed with a bin width of 0.5 for the PSSM score and a bin width of 0.025 for the DOPE value. The percentage of 
budding-retaining (indicated by “+”) and budding-deleterious (“-“) AAS is given for each protein domain. 
 
Counting the number of as budding-retaining or as budding-deleterious predicted AAS for each 
Gag amino acid position, highlights the difference between the protein domains (Figure 25). The 
data depicts clearly that the rate of as budding-deleterious predicted AAS is far higher for p24 
compared to p17 or p2p7(p1)p6. As a measure of variation, the Shannon entropy at each 
position was calculated using the LANL web-tool “Entropy-one”i. Shannon entropy is a 
quantitative measure of uncertainty at an alignment position, i.e. it describes how heterogeneous 
the position is in a set of defined sequences. As sample input, the curated filtered web alignment 
was used. The computed values illustrate the relative variation at the different amino acid 
positions. A high Shannon entropy implies therefore a high variability at the respective position.  
The entropy values correlate significantly with the number of as budding-retaining predicted AAS 
(Figure 25) with a Pearson product-moment correlation coefficient of r=0.56 and a p-value 
<0.0001 (data not shown). This indicates that variable positions (i.e. high entropy) tolerate more 
mutations, without destroying the Gag functionality. For conserved positions (i.e. low entropy), 
on the other hand, the probability that a mutation leads to a non-functional Gag is elevated. This 
suggests, that the conserved positions have important function during assembles and release of 
VLPs. 
i
 http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy_one.html 
78 
 
Figure 25. Amino-acid-position-specific distribution of budding-retaining and budding-deleterious AAS. For 
each amino acid position of the reference HXB2-Gag (partitioned in p17, p24, and p2p7p1p6), all 19 permutations 
were classified. The numbers of budding-retaining AAS are depicted in the upper graph (green) and the budding-
deleterious AAS in the lower graph (red). p1 was excluded from the analysis, because of a missing template for 
homology modelling. Additionally, the position-specific Shannon entropy, as a measure of the sequence variability, is 
plotted in the upper graph (orange). 
D.1.3 Epitope score evaluation 
After the functional assessment of all naturally occurring 
AAS, and the subsequent removal of all epitopes with at 
least one as budding-deleterious predicted AAS, the 
remaining epitopes were ranked according to their 
immunological, demographical and virological 
characteristics. Each epitope e was assigned a specific 
score s(e), which was calculated based on multiple, 
differently weighted attributes a.  
For our proof of concept T cell epitope-enriched antigens, (i) 
the frequencies of class I HLA molecules presenting the 
epitope (aHLA), (ii) the subtype affiliation (aSubtype), (iii) the 
association with LTNPs (aLTNP), (iv) the conservation status (aCons), and (v) the expected 
population-wide immune response to the respective epitope (a%Resp) were used as scoring 
attributes. The influence of each attribute a on the s(e) was further specified with a weighting 
parameter wa (Table 13). For score calculations, all attribute data of subepitopes were added to 
their associated superepitopes, as described in the methods (B.1.2). 
As one of the most important features the presentation of epitopes on frequent HLA class I 
alleles was defined, thus it was assigned a high weight (wa=6). The HLA score aHLA was 
calculated as the sum of frequencies of all defined HLA allele groups able to present the epitope 
in question (B.2.2.1). Of the 72 annotated HLA allele groups (Extended Data Table 3), 49 were 
specified by at least one epitope entry of the complete set. In detail, 14 of all 22 HLA-A allele 
groups, 22 of the 36 HLA-B allele groups, and 13 of the 14 HLA-C allele groups known today 
Table 13. Attribute weighting for 
epitope score s(e) calculations 
Attribute 
a 
Weighting 
wa 
aHLA 6 
aSubtype 3 
aLTNP 6 
aCons 3 
a%Resp 1 
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were covered. Adding up the frequencies of all groups represented at least once in the epitope 
set, 94.9%, 88.2%, and 95.6% of the HLA-A,-B, and -C diversity were covered, respectively. 
Most epitopes (205; 29.7%) were assigned to exactly one allele group. However, 364 (52.7%) 
epitopes were associated with at least two different HLA allele groups with a maximum of 15 
different groups (Figure 26 A). For the residual 122 (17.7%), the epitope entry annotation was 
incomplete and the presenting HLA allele was not stated. The number of epitopes associated 
with HLA allele groups correlates significantly with the global frequency of the respective group 
(r=0.61, p<0.0001 Figure 26 B). This can be seen as indication that the epitope set is 
representative of the target population (i.e., here, the worldwide population, due to the HLA 
frequencies used - D.1.1.3). In a frequency distribution of HLA scores aHLA (normalized to the 
interval [0, 1] - bin width 0.05; Figure 26 C) the highest peak is around 0 due to those epitopes 
without an annotated HLA allele group (Figure 26 A). Most other epitopes have an HLA score 
between 0 and 0.25. aHLA higher than 0.5 was observed rarely (only in 9.4% of all epitopes).  
As second feature, with a lower attribute weight (wa=3), the affiliation with different HIV-1 
subtypes was applied to derive the subtype score aSubtype. It was calculated by summing up all 
frequency-weighted (D.1.1.4) subtypes that are reported to be associated with the particular 
epitope, and finally normalizing to the interval [0, 1]. Due to the fact that, if the clade affiliation 
was not specified in the LANL epitope entry, the standard subtype B was allocated, every 
epitope had at least one subtype listed (Figure 26 E). Partly because of this correction, most 
epitopes (37.6%) were assigned to exactly one subtype. However, there are various entries with 
more than one subtype (up to 9 of the overall 13 subtypes stated in the epitope set). Although 
the worldwide frequency of subtypes (Figure 18) correlates significantly with the respective 
amounts of epitopes affiliated with it (r=0.56, p=0.039; data not shown), there are some major 
imbalances. Most prominently the subtype B is largely overrepresented in the epitope set, 
whereas the globally by far most frequent subtype C (48%) is only on the third position (Figure 
26 D). Due to the high number of epitopes, which are only B-clade-associated, the highest peak 
in the frequency distribution (Figure 26 F) of the subtype score clusters at a low value (~0.12). 
The score of the remaining epitopes was distributed quite homogenously between 0 and 1. 
To estimate the fraction of the target population that is expected to prime a T cell response 
against a specific epitope, the expected immune response a%Resp was computed (described in 
B.2.2.5). For 53.7% (371 of 691) of the epitopes this value was denoted, partly due to the data 
inheritance from sub- to superepitopes. Since the response is normalized to the associated HLA 
allele group frequency, most values were below 0.1 (Figure 26 G). Because this feature is 
derived from the epitope entry metadata and was not available for a large proportion of the 
entries, a low weight for was assigned to a%Resp (wa=1). 
Association with LTNP-status was defined as Boolean value. Hence, the high-weighted (wa=6) 
LTNP score aLTNP could only attain 1, if defined as connected to an LTNP, or no value otherwise. 
In a distribution of LTNP-associated epitopes across the Gag protein, six different peaks can be 
observed (Figure 26 H). Most (5) of those are located in the capsid protein region. The 
importance of p24 in LTNPs was expected, since it is the most conserved domain of Gag and 
mutations in conserved regions are associated with high loss of viral fitness58. Therefore, CD8+ 
T cells addressing these vulnerable sites can confer long-lasting viral control, since rapid escape 
of the virus is less likely. 
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Figure 26. Attributes and epitope scores. (A) Number of HLA allele groups registered per epitope. (B) Correlation 
between the numbers of epitopes specified to be presented by an HLA allele group and the global frequency of the 
respective HLA allele group. (C) HLA score aHLA frequency distribution (bin width 0.05) of all epitopes. (D) Pie chart of 
the number of epitopes assigned to each subtype or CRF. (E) Number of subtypes listed per epitope. (F) Subtype 
score aSubtype frequency distribution (bin width 0.05) of all epitopes. (G) Expected immune response a%Resp frequency 
distribution (bin width 0.01) of all epitopes. (H) Location of epitopes registered as associated with LTNPs. (I) 
Conservation score aCons frequency distribution (bin width 0.05) of all epitopes. (J) Frequency distribution (bin width 
0.5) of all calculated epitope scores s(e).  
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As last scoring attribute aCons (wa=3), the conservation of an epitope was calculated as the 
proportion of sequences from the filtered web alignment that include the epitope, while also 
accounting for the global frequency of the subtypes (B.2.2.4). The computed conservation 
scores were spread quite homogeneously between 0 (i.e. epitope found in no sequence) and 1 
(i.e. epitope found in every sequence) (Figure 26 I). 
By virtue of their design, each scoring attribute attained a value between 0 and 1, before the 
calculation of the epitope score s(e). To compute s(e), the five different weighed attributes were 
summed up according to the scoring function (B.2.2). Due to the pre-defined weighting of the 
attributes (Table 13), the theoretical maximum score of an epitope was 19. The highest-scoring 
epitopes with a value 17.1 was fairly close to the maximum. Most epitopes however cluster 
between a value of 1 to 5 (Figure 26 J). Calculating the score at each Gag position (Figure 16 
A), by adding up the scores of all epitopes that are located at the respective position, matched 
the absolute number of epitopes significantly (r=0.94, p<0.0001; data not shown). 
 
D.1.4 Generation of T cell epitope-enriched Gag antigens 
In the final step of the design algorithm for the teeGags, as many high scoring epitopes as 
possible were combined into a new sequence, aiming for the highest possible overall score. For 
this, incompatibilities between overlapping sequences were identified and a genetic algorithm 
(B.2.3) was applied to find the set of compatible epitopes that best satisfy the fitness function 
f(x).  
Multiple iterations of this antigen generation were performed and after each of these 
“optimization” rounds, all epitopes included in the solution antigen of the current round were 
excluded from the input data. By this, the next iteration had to incorporate new epitopes, 
resulting in a complementary, polyvalent set of teeGags. By virtue of their design, teeGags of 
higher iterations should never be employed alone, but only in combination with all the teeGags 
generated in previous rounds. For instance teeGag1, as the first antigen generated, was 
conceived so that it can be applied alone, however, teeGag2 was designed solely to improve 
teeGag1, and therefore may only be administered in combination with teeGag1. 
After 11 iterations, all of the 670 epitopes that were predicted to have no negative effect on Gag 
functionality were incorporated into teeGags. However, already after three iterations (teeGag1, 
teeGag2, and teeGag3; amino acid sequences are displayed in Extended Data Sequences 
F.2.3.1) 87.8% of all epitopes and 91.0% of the maximal possible score were covered, 
compared to a mean 58.4% and 59.5% in random selections (100,000 repeats) of three natural 
Gag sequences from the filtered web alignment (Figure 27 C+D). Any further generated teeGag 
only contributed marginally to the coverage of epitopes and score.  
This is further clarified by the fact that the number of AAS compared to the reference rapidly 
diminished after iteration 3 (Figure 27 A). In the last two rounds, only one AAS and one new 
epitope were added. Nonetheless, any combination of iterative complementary teeGags was far 
superior to any same-sized selection of randomly picked natural sequences (Figure 27 C+D). 
The fact that in each iteration the highest scoring epitopes were included can be seen by the 
declining mean score of the epitopes in the antigens (B.3.2, Figure 27 B).  
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Figure 27. teeGag generation. (A) Number of AAS compared to the HXB2-Gag reference sequence in every teeGag 
iteration. (B) Mean score of every epitope that was used to calculate the score in every teeGag iteration. (C+D) 
Progress of total epitope (C) and score (D) coverage of complementary teeGags and random combinations of natural 
sequences from the filtered web alignment. The iteratively generated teeGags were combined as indicated on the x-
axis and the overall number of epitopes or score are displayed. For comparison, the corresponding values for all 
natural 5001 Gag sequences from the filtered web alignment (round 1) or 100,000 combinations of 2 to 11 randomly 
selected natural sequences are shown as mean with 1-σ-interval. 
 
D.2 In silico analysis of optimized Gag antigens 
After the design of the teeGags, the newly conceived candidate antigens were evaluated in 
various in silico regarding virological properties (D.2.1) and enhanced immunological breadth 
(D.2.2 - D.2.5). The setup of the computational tools used is described in detail in B.3. 
D.2.1 Phylogenetic classification of teeGags 
For phylogenetic tree reconstruction (B.3.1), teeGag1-3, conM, ancM, cotM, and mosM1.1 were 
aligned to a curated set of 45 carefully selected Gag reference sequences236. In this reference 
set, each HIV-1 group M subtype, as well as CRF01_AE and CRF02_AG were represented by 2 
to 4 sequences. Location of the antigens in the final phylogenetic tree (Figure 28) gives some 
indication of the subtype affiliation. As expected due to the underlying design principle, conM 
and ancM were located close to the center of the phylogenetic tree. However, cotM and 
mosM1.1 that were also expected near the center of the unrooted tree, clustered with the 
subtype B and C reference sequences, respectively. All analyzed teeGag sequences were 
located near clade B, but whereas teeGag1 was in the midst of the subtype B sequences, 
teeGag2+3 were genetically more distant. 
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Figure 28. Phylogenetic tree reconstruction of artificial Gag antigens among a set of subtype reference Gag 
sequences. Sequence alignment and tree reconstructions were performed with ClustalX 2.1. Phylogenetic 
classification of subtypes (color-coded and lettered accordingly) and antigens of interest (indicated in grey) was 
visualized with Rainbow Tree. The unit of branch length indicates the amino acid substitutions per site. 
D.2.2 Antigen score 
To assess the quality of the newly designed teeGags, the number of unique epitopes from the 
input set included, and the correspondingly calculated antigen score (B.3.2), were determined. In 
a vaccine including only a single Gag antigen (monovalent regimen), teeGag1 would, by virtue of 
the design, be the most potent of the herein described novel T cell epitope-enriched variants, 
since it includes the highest scoring epitopes (Figure 27). Regarding the number of incorporated 
epitopes, as well as the overall antigen score, teeGag1 (Epitopes e: 402; Score s: 590) was 
clearly superior to all 5001 natural Gag variants from the filtered web alignment (Figure 29 A). 
Due to the overrepresentation of B-clade-derived epitopes, nearly all of the natural sequences 
with a high number of epitopes were B-clade-associated. As a consequence of the different 
weighting of the subtypes for the scoring function, this B clade bias was equalized to some 
extent for the antigen score (Figure 29 A - highlighted in dark grey). In addition to natural Gag 
sequences, teeGag1 was also compared to other in silico computed antigens and Gags that had 
been administered in clinical phase IIb/III studies so far. teeGag1 surpassed them all regarding 
the number of epitopes and the score (Extended Data Table 5). In Figure 29, the group M 
variants for the consensus (conM; e: 283; s: 424), ancestral (ancM; e: 293; s: 426), center-of-
tree (cotM; e: 311; s: 450), and mosaic Gag sequences (mosM1.1; e: 277; s: 466) are 
presented, since those are the most comparable sequences to our proof of concept teeGags 
that were designed as pan-clade vaccine candidates.  
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Figure 29. Epitope and antigen score coverage of mono-, di-, and trivalent sequence sets of natural or 
artificially designed Gag sequences. (A) Frequency of all 5001 natural Gag sequences that include the respective 
number of epitopes (left panel) or attain the respective antigen score (right panel) as indicated on the x-axis. Values of 
all B clade sequences from the natural set are highlighted in dark grey. Number of epitopes and scores of the 
examined Gag antigen designs are indicated by dashed lines. (B) Number of epitopes and score frequencies of 
100,000 combinations of two randomly selected natural Gag sequences (grey). The values of the divalent teeGag1+2 
are indicated by the dashed lines. (C) Frequencies regarding number of epitopes and score of a 100,000 trivalent, 
randomly combined natural Gag sequences (grey) and trivalent artificial Gag antigens (dashed lines). 
Combinations of Gag variants derived from the first two or three iterations of the algorithm 
(teeGag1+2 or teeGag1-3), in a presumable di- or trivalent vaccine regimen, have a calculated 
epitope coverage and overall score that is far better than of any of 100,000 combinations 
created of two or three randomly picked natural Gag sequences (Figure 29 B+C). Due to their 
design principle, there can only be one consensus, ancestral, and center-of-tree sequence for 
each set of sequences (i.e. there are no polyvalent sets for these designs). Hence, the trivalent 
teeGag set was compared to the combination of the consensus and ancestral sequences of the 
three most frequent subtypes (conA1+B+C and ancA1+B+C) and to the center-of-tree 
sequences for group M, subtype B, and subtype C (cotM+B+C). Since the mosaic antigens were 
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conceived as polyvalent vaccine candidates, there was an M-group-specific trivalent set 
available (mosM3.1-3) for comparison. Of all those trivalent antigen designs, teeGag1-3 (e: 588; 
s: 949) was the best concerning epitope coverage and score followed by conA1+B+C (e: 551; s: 
867), mosM3.1-3 (e: 524; s: 808), cotM+B+C (e: 504; s: 828), and finally ancA1+B+C (e: 493; s: 
752) (Figure 29 C). 
D.2.3 Population coverage 
By accounting for the allele group frequencies of HLA molecules during epitope scoring (D.1.3), 
the teeGags were created for optimal coverage of the target population, which for our proof of 
concept antigens described here, would be the general population world-wide, thus the global 
allele frequencies were applied as target population attributes. To review the actual achieved 
population coverage of the teeGags, a target population with 1,000 individuals was simulated in 
silico (B.3.3). Each person of this population is specified by an HLA haplotype consisting of two 
HLA-A, -B and -C allele groups each. The allele groups were chosen randomly, with reference to 
the reported target population frequencies. Next, each epitope of the set was analyzed, whether 
it was included in the antigen and also could be presented by at least one of the test person’s 
corresponding HLA alleles. If this was the case, the epitope got included in the test person’s 
epitope set, or otherwise it was rejected. This was repeated for all 1,000 test persons. The test-
person-specific epitope sets were finally analyzed for the number of epitopes and the overall 
score. 
 
 
Figure 30. Population coverage of mono- and trivalent antigen sets. For each antigen or combination of antigens, 
a population of 1,000 persons, defined by their HLA haplotypes that were randomly selected according to the allele 
frequencies, was generated. The epitopes (left panel) and score (right panel) covered per person are given for (A) 
monovalent or (B) trivalent Gag antigens. Boxes represent the median with 50 % quartiles, whiskers the 10 and 90 % 
percentiles. Natural sequences (monovalent) or combinations of three natural sequences (trivalent) were randomly 
selected from the Gag curated filtered web alignment. 
86 
Applying this population coverage calculation, values of cotM (median epitopes: 122; median 
score: 289), ancM (e: 112; s: 281), mosM1.1 (e: 92; s: 260), and conM (e: 104; s: 260) exceed 
those of natural Gag sequences (e: 69; s: 188) that were randomly chosen from the Gag 
sequence alignment for each test-person. However, teeGag1 clearly surpassed all of the 
monovalent antigen designs, regarding both the number of epitopes and the score (e: 163; s: 
419; Figure 30 A). In a trivalent setting, the complementary teeGag1-3 were still the best (e: 215; 
s: 589), but the difference to the other antigen designs, especially conA1+B+C (e: 200; s: 548), 
decreased. The combination of three randomly picked natural Gag sequences was clearly 
inferior (e: 134; s: 366; Figure 30 B). The examined population coverages for a larger set of Gag 
sequences are displayed in Extended Data Figure 1. 
D.2.4 Pathogen coverage 
In addition of optimized targeting of the target population, teeGags were conceived to cover the 
prevailing viruses, as defined by the HIV subtype distribution of the target area, in case of the 
herein described proof of concept teeGags the worldwide clade distribution. For computational 
validation of this pathogen coverage (B.3.4), a test pathogen set, comprised of various Gag 
sequences, was generated. First, for each virus of this set, an HIV subtype was randomly 
selected proportionally to the natural subtype frequencies in the target region of the conceived 
vaccine. 
 
 
Figure 31. Pathogen coverage of mono- and trivalent antigen sets. For each antigen or combination of antigens, 
a set of 1,000 test viruses (“pathogens”) was generated. Each pathogen represents a Gag sequence that was 
randomly selected from the filtered web alignment, with regard to the global subtype frequencies. The number of 
epitopes (left panel) and the score (right panel) covered per pathogen are given for (A) monovalent or (B) trivalent 
Gag antigens. Boxes represent the median with 50 % quartiles, whiskers the 10 and 90 % percentiles. Natural antigen 
sequences (monovalent) or combinations of three natural sequences (trivalent) were randomly selected from the Gag 
curated filtered web alignment. 
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Since the teeGag design was based on the global subtype frequencies (D.1.1.4), the same 
values were initially applied for the assembly of the test pathogen set. After picking the virus 
subtype, a Gag sequence from the 5001 natural sequences with this subtype was randomly 
selected as the test pathogens sequence. Next, for each epitope of the input data set, it was 
checked, if it was included in the antigen of interest, as well as in the test pathogen. If this was 
the case, the epitope was added to the test-pathogen-specific epitope set, or otherwise it was 
rejected. The test pathogen selection and computation of the associated epitope set was 
repeated 1,000 times. For each of these sets, the number of included epitopes and the overall 
score was calculated.  
The pathogen coverage, expressed as the number of epitopes and their score per pathogen, of 
teeGag1 was far superior to randomly selected natural Gag sequences. However, teeGag1 was 
slightly inferior to ancM, mosM1.1, and conM and on the same level as cotM (Figure 31 A). This 
seems to be due to the fact that the epitopes’ subtype distribution (Figure 32 C - pie chart) in the 
database does not resemble the global HIV-1 clade frequencies (Figure 18). This is in line with 
the phylogenetic tree reconstruction, where teeGag1 and also cotM clustered with the B clade 
reference sequences. 
 
 
Figure 32. Pathogen coverage for monovalent antigens with differently weighted subtype selections. Pathogen 
selection was done considering only (A) subtype B or (B) subtype C entries or (C) proportional to the abundance of 
each subtype in the epitope dataset. For each approach the pathogen set subtype frequencies (left panel) and the 
calculated pathogen coverage expressed as number of epitopes (middle panel) and overall score (right panel) per 
pathogen are given. Boxes represent the median with 50 % quartiles, whiskers the 10 and 90 % percentiles. 
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This B clade bias could be confirmed, when the pathogen coverage was calculated considering 
only subtype B sequences (Figure 32 A) or based on the abundance of each subtype in the 
epitope database (Figure 32 C). In both cases, teeGag1, and also cotM, showed a higher 
epitope and score coverage per pathogen compared to conM, ancM, mosM1.1, or random 
natural Gag sequences. On the other hand, if only subtype C viruses were considered for the 
pathogen set, teeGag1 was inferior to conM, ancM, and mosM1.1, yet still superior to natural 
sequences (Figure 32 B). By far the best design in covering clade C viruses was mosM1.1. This 
was not surprising, since mosM1.1 was located near the subtype C reference sequences in the 
phylogenetic classification, unlike conM and ancM that were both located near the center of the 
unrooted tree (Figure 28). Hence, it seems that the pathogen score highly depends on that the 
antigen subtype matches the composition of the tested pathogen set.  
There is nearly no difference in pathogen coverage concerning the number of epitopes and 
score between trivalent teeGag1-3, ancA1+B+C, mosM3.1-3, and conA1+B+C, although 
teeGag1-3 had the highest median value in both cases (Figure 31 B). Random selection and 
combination of three natural Gag sequences resulted in a far inferior pathogen coverage. 
Coverage scores for the complete set of antigens analyzed are depicted in Extended Data 
Figure 2.  
D.2.5 Mosaic analysis tools 
The LANL HIV-1 database offers, besides the possibility to design mosaic (mos) sequences199, a 
suite of web-based tools293 to calculate the coverage of k-mers, representing potential T cell 
epitopes (PTEs). PTEs are not based on any experimentally validated or through in silico 
processing and HLA binding predicted epitope sequences, but are only defined as possible k-
mers from a set of viral sequences. To analyze the teeGags according to the criteria used for the 
mosaic design, their published evaluation tools to calculate the coverage of PTEs (i.e. k-mers) 
was used. For this, the programs Epicover and Posicover were applied to compare the coverage 
of the curated filtered web alignment by different antigen sets. For Epicover, the nominal epitope 
length k for computing the coverage was set to 9, since this is the most frequent length of HLA-
class-I-presented epitopes294. Due to the size of the filtered web alignment the threshold for rare 
sequences was as recommended increased (set to 5), the remaining options were kept on 
default. As before, the mono- and trivalent combinations of anc, mos, con, and cot sequences 
were compared to the newly designed teeGags. As output, the fraction of 9-mers shared with the 
respective antigen set is given as per-sequence mean of all sequences in the Gag alignment. 
The coverage is divided in exact (i.e. 9 of 9 amino acids match; Off-by-0), off-by-1 (i.e. at least 
8/9 match), and off-by-2 (i.e. at least 7/9 match) fits. In a monovalent setting (Figure 33 A - left) 
there was no difference (exact match always between 0.40 and 0.42) between the five different 
antigens concerning 9-mer coverage of the curated filtered web alignment. Since mosM3.1-3, 
was optimized to cover naturally occurring 9-mers it exhibited, as expected, the highest 
coverage of all trivalent antigen sets (Off-by-0: 0.66). Second best was conA1+B+C (0.62) 
followed by the similar ancA1+B+C (0.59), teeGag1-3 (0.58), and cotM+B+C (0.57) (Figure 33 A 
- right). 
With the Posicover algorithm, the fraction of antigen-covered 9-mers from the curated filtered 
web alignment was calculated for each position in the alignment. A sliding window of length 9 
was applied for the complete length of Gag, generating up to 9 unique epitopes for each 
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position. Next, the number of these unique 9-mers covered by the antigen set was calculated for 
each position of each Gag alignment entry. 
For each antigen set, the results are given as fraction of matched 9-mers of the Gag alignment. 
In Figure 33 B the alignment positions are sorted by coverage. Like for the overall coverage 
(Figure 33 A), there were no differences between the monovalent Gag antigens (Figure 33 B left 
panels) regarding coverage per position. Only cotM had a slightly higher percentage in the 
middle fraction range of matched 9-mers.  
For the trivalent antigen sets mosM3.1-3 (Figure 33 B right panels) was the best option across 
most positions. This was expected because it had by far the best overall 9-mer coverage (Figure 
33 A). Keeping this in mind, it was not surprising that conA1+B+C showed the next best 
coverage by position followed by the similar teeGag1-3, ancA1+B+C, and cotM+B+C.  
 
 
Figure 33. 9-mer coverage of mono- and trivalent antigen sets. For each antigen set, the covered fraction of 
potential 9-mers from the curated filtered web alignment was calculated. (A) Per-sequence coverage mean by 
monovalent (left) or trivalent (right) antigen sets as calculated by Epicover. The color code highlights the exact (off-by-
0, red), off-by-1 (orange), and off-by-2 (yellow) covered 9-mers. (B+C) Posicover-computed, alignment-position-
specific 9-mer coverage rates. Positons on the x-axis were ranked by coverage. Analysis was spilt into (B) matched 
and (C) missed 9-mers for monovalent (left) and trivalent (right) antigens. 
In Extended Data Figure 3, the coverage was mapped on the filtered web-alignment, indicating 
high and low fractions of matched 9-mers by position of all individual sequences. The Gag 
alignment sequences were partitioned according to their subtypes. As for the phylogenetic tree 
reconstruction and the pathogen coverage, here, again the B clade bias for teeGag1 was 
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apparent, since the highest 9-mer coverage was observed for subtype B sequences. cotM 
coverage was similar to teeGag1, also with best coverage for subtype B, whereas mosM1.1 best 
matched the 9-mers of subtype C Gag sequences. For ancM and conM no clade preference 
could be observed.  
For the trivalent antigen combinations the coverage was more homogeneous across all HIV-1 
subtypes. By displaying the antigen-matched 9-mers not by coverage rank, but by natural 
alignment position, differences between the Gag protein domains became obvious (Extended 
Data Figure 4). For the most conserved region, p24, the 9-mer coverage by all antigens was 
highest. This is in good accordance with the number of as budding-retaining classified AAS and 
the position-specific Shannon entropy that both were also distinctly influenced by the low 
variability of p24 (Figure 25). 
 
D.3 Validation of functional conservation 
After the Optimizer Algorithm was shown in computational analyses (D.2) of being able to design 
antigens with an enhanced breadth of immunologically potent CD8+ T cell epitopes, the second 
feature of the program, the ability to preserve Gag functionality was addressed experimentally. 
First, the FLD classified AAS were examined separately to validate the predictions (D.3.1). 
Afterwards, the novel teeGags were biochemically characterized (D.3.2) to show that the 
incorporation of up to 40 AAS did not alter their ability to release VLPs. 
D.3.1 Effects of single amino acid substitutions on VLP budding 
To determine the quality of the FLD classification predictions, all AAS present in teeGag1, 2, or 3 
(84 different AAS; Extended Data Table 6) and all as negative predicted AAS (18 AAS; 
Extended Data Table 7) were validated experimentally. As template, the human codon-optimized 
HXB2-Gag was ordered from GeneArt (Regensburg, Germany) and cloned using the KpnI and 
XhoI restrictions sites into pcDNA3.1(+). Afterwards, AAS were separately introduced into the 
reference sequence, resulting in Gag sequences with single site mutations compared to HXB-
Gag. The mutations were introduced by fusion PCR (C.2.2.2) using mutagenesis 
oligonucleotides (with pc31 fwd/rev as outside binding primers), to change the codon of the 
original amino acid to the most frequent human codon for the desired mutation. A first batch of 
single AAS Gag sequences was provided directly by GeneArt and was also inserted into 
pcDNA3.1(+). Cloning of all 102 variants was verified by sequencing. DNA for transfection 
experiments was prepared with the “QIAprep Spin Miniprep Kit”. 
To quantify the VLP release of the single AAS Gag variants, HEK293T cells were co-transfected 
in a 12-well plate with 1 µg of the Gag-plasmid and 0.05 µg pBluescript KS(-) CMV-SEAP vector 
using PEI (C.2.3.2). After 6 h, the medium was changed to DMEM-0. Conditioned supernatant 
was harvested after 48 h and cleared by two subsequent centrifugation steps. The cell-free 
supernatant was treated for 1 h with 0.5 % Triton X-100. Budding capacity was examined using 
a Gag-ELISA (C.2.5.2). Additionally, the SEAP concentration was determined in an enzymatic 
activity test to normalize for differences in transfection efficiency (C.2.5.4). The relative budding 
(RB) of all single AAS Gag proteins was calculated by dividing the Gag to SEAP concentration 
ratios of the mutated variant (AAS) and the HXB2-Gag wildtype protein (wt): 
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𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑏𝑢𝑑𝑑𝑖𝑛𝑔 (𝑅𝐵) =  
    
𝑐(𝐺𝑎𝑔)𝐴𝐴𝑆
𝑐(𝑆𝐸𝐴𝑃)𝐴𝐴𝑆
    
  
𝑐(𝐺𝑎𝑔)𝑤𝑡
𝑐(𝑆𝐸𝐴𝑃)𝑤𝑡
  
  
 
Figure 34 shows the RB for all 84 Gag sequences with a positively predicted (+) AAS, as well as 
the entire set of 18 negatively predicted (-) AAS sequences (individual RB values in Extended 
Data Table 6 and Extended Data Table 7). Analyzing the two groups with the Mann-Whitney test 
revealed a significant (p=0.0007) reduced RB in the group of as budding-deleterious predicted 
AAS. Further, when analyzing all individual AAS in a Bonferroni corrected t-test, 9 of the 18 
budding-deleterious predicted AAS showed significantly reduced budding (marked in red) 
compared to the overall mean budding. These were hence categorized as true negative AAS. 
 
 
Figure 34. Relative budding (RB) of Gag proteins harboring a single AAS. AAS were grouped into budding-
retaining (+) and as budding-deleterious (-) classified mutations. Each data point in the graph represents the RB of 
one AAS, as determined by at least six independent experiments. Significant reduced budding for single AAS Gags 
compared to the mean budding of all tested proteins was defined in a Bonferroni corrected two-sided t-test with 
unequal variance and are highlighted in red. Inter-group (represented as mean ± SD) differences were analyzed with 
a Mann-Whitney test (p=0.0007). 
 
The experimentally determined accuracy was 91% (Table 14) and thus higher than that 
calculated using the computational 10-fold cross-validation (86%; Extended Data Table 4). Due 
to the fact that no as budding-retaining predicted AAS showed significantly reduced budding, the 
specificity, as well as the PPV, were both 100% and therefore even higher than initially predicted 
(cross-validation: 99% and 98%). The experimentally determined sensitivity was with 90% also 
higher than expected (75%), which is partly due to the huge amount of budding-retaining AAS 
tested. Only the NPV, with just 50% was clearly reduced in the experimental setting, compared 
to the 10-fold cross-validation predictions (78%). This means that only half of the AAS predicted 
to be budding-deleterious result in a significantly reduced budding, if they are included in the 
HXB2-Gag reference sequence. On the other hand, a PPV of 100% shows that all as budding-
retaining predicted AAS indeed have no negative influence on budding, which had been 
declared as the most important feature of the classifier beforehand. 
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Table 14. Contingency table of experimentally validated binary classification predictions. 84 as budding-
retaining and all 18 as budding-deleterious predicted AAS were validated experimentally regarding their effect on VLP 
budding. Accuracy, sensitivity, specificity, positive predictive value (PPV, precision), and negative predictive value 
(NPV) were calculated as described in Table 5. 
  Experimentally validated data   
  Budding-retaining Budding-deleterious Sum  
FLD 
classification 
Budding-
retaining 84 0 
84 
PPV 
(precision) 
100% 
Budding-
deleterious 9 9 
18 
NPV: 
50.0% 
Sum 93 9 102  
Accuracy: 91.2% Sensitivity: 90.3% Specificity: 100%   
 
D.3.2 Biochemical characterization of teeGags 
D.3.2.1 Budding capacity of teeGags1-3 
After validating the quality of the classifier predictions, which showed that the Optimizer 
Algorithm can successfully exclude epitope with negative effect on VLP production, the teeGags 
were biochemically examined. Since the Gag variants designed in the first three iterations of the 
Optimizer Algorithm already contained 88% of all possible epitopes that account for 91% of the 
maximum score, only teeGag1, teeGag2, and teeGag3 were characterized in detail.  
The antigens were ordered as human-codon-optimized nucleotide sequences from GeneArt. 
Because of the incorporation of up to 40 mutations in the teeGags as compared to the HXB2-
Gag reference sequence, alterations of the antibody binding affinity for ELISA quantification 
could not be excluded. Therefore, to address the budding capacity in a sequence-independent 
analysis, a 6x-His epitope tag was added to the C-terminus of the teeGags, the HXB2-Gag and 
the budding-incompetent G2A-mutated reference HXB2-GagMyr-. The tag was appended to the 
sequences with primer extension PCR (primer teeGag-His rev) and cloned into pcDNA3.1(+) 
using KpnI and XhoI restriction enzymes. HEK293T cells were co-transfected with the 
pcDNA3.1(+)-Gag variant and pBluescript KS(-) CMV-SEAP as described above (D.3.1). The 
conditioned medium was harvested 48 h later as described above (D.3.1). Dilutions of the 
samples and a reference standard were transferred to a 0.45 µm nitrocellulose membrane in a 
slot blot assay (C.2.5.13). The membrane was blocked overnight at 4°C with TBS-M. Gag 
protein was detected using a biotinylated α-6x-His Epitope Tag antibody followed by incubation 
with peroxidase conjugated streptavidin. ECL substrate was added and the amount of His-
tagged Gag was measured densitometrically. Relative budding was again described as the 
SEAP normalized ratios of the variant Gag and the wildtype reference Gag concentrations 
(D.3.1).  
Although all three teeGag variants examined were able to release VLPs into the supernatant 
(Figure 35), teeGag2 had a slightly, but statistically significant (as determined in a Bonferroni-
corrected t-test) reduced RB (0.78). teeGag1 and teeGag3, however, exhibited wildtype like 
behavior. As expected, almost no Gag could be detected in the supernatant of HXB2-GagMyr-. As 
all proof of concept teeGags showed sufficient VLP release, they were further characterized. 
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Figure 35. Budding-capacity of novel T cell epitope-enriched Gag antigens: The densitometrically determined, 
SEAP-normalized RB is plotted on the y-axis. For each 6xHis-epitope-tagged Gag protein, the mean ± SEM of six 
independent experiments is given. Statistical significance compared to the reference HXB2-Gag was calculated with a 
Bonferroni-corrected two-sided t-test with equal variance. 
 
D.3.2.2 Sucrose gradient ultracentrifugation for teeGag particle size analysis 
Gag virus-like particles have a rather defined size of 100-120 nm and can be purified in a 
sucrose gradient due to their characteristic density. Wildtype HXB2-Gag-like density would be a 
good quality criterion for the teeGags, indicating normally-sized particles. To assess the density 
plasmids encoding all three teeGags, HXB2-Gag, and HXB2-GagMyr- (all with C-terminal 6x-His 
epitope tag) were transfected into HEK293T cells in a 6-well plate. The conditioned supernatants 
were harvested after 48 h and pre-cleared by centrifugation. Afterwards, 2 ml of the supernatant 
were directly loaded onto a 10-50% sucrose gradient (C.2.5.7). Particles were separated 
according to their density in an ultracentrifugation run. 21 fraction of 550 µl each were taken by 
pipetting from the top and their density was determined by weighing. Gag-containing fractions 
were identified via immunoblotting using the α-p24/p55 antibody CB-13/5 and an HRP-
conjugated α-mouse secondary antibody. The identified fractions, and those in close vicinity, 
were further analyzed in a Gag-ELISA. The concentrations are presented as percent, relative to 
the maximum value of each gradient in Figure 36.  
Density, immunoblot and ELISA data for all Gags are summarized in Figure 36. After the 
ultracentrifugation run, each gradient showed a rather linear density increase across the 21 
fractions ranging from ρ=0.96g/ml to ρ=1.24g/ml. As expected, no immunoblot signal could be 
detected for the budding deficient HXB2-GagMyr-. The reference protein HXB2-Gag, as well as all 
three teeGags on the other hands showed clear bands, restricted to fractions 14 and 15. These 
findings were supported by the Gag-ELISA that also peaked at fraction 15. The density of the 
fractions with the highest Gag concentration was, with 1.16 g/ml, identical for teeGag1, teeGag3, 
and HXB2-Gag. Only for teeGag2, the density of the fraction with maximal Gag content was 
slightly higher (ρ=1.18 g/ml). In conclusion, all Gags, except the negative control, displayed the 
expected gradient distribution, indicating well-constructed virus-like particles. 
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Figure 36. Sucrose gradient ultracentrifugation analysis. VLP containing conditioned supernatants were laid onto 
a 10-50% sucrose gradient and particles were separated, according to their density, in an ultracentrifugation run. After 
the run, fractions of 550 µl each were taken, their density (ρ, indicated by white circles) measured, and screened for 
Gag protein via immunoblot (with α-p24/p55 antibody CB-13/5 and HRP-conjugated α-mouse secondary antibody) 
and a Gag-ELISA (black triangles, relative to the maximum concentration for each Gag). For each Gag variant, the 
graph shows the density of all fractions combined with immunoblot and ELISA data for a selected range. The density 
of the most prominent immunoblot band is stated above. 
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D.3.2.3 Particle morphologies revealed through electron microscopy 
For a more direct way to examine their structure, purified VLPs of all three teeGags, as well as 
the wildtype HXB2-Gag were visualized through electron microscopy. For each Gag variant (with 
6x-His epitope tag), three 15 cm plates of HEK293T cells were transfected. After 48 h, the 
centrifugally cleared, conditioned medium was ultracentrifuged over a 30% sucrose cushion. The 
pelleted VLPs were resuspended in PBS and further purified in a 10-50% sucrose gradient 
centrifugation. The Gag VLP containing fractions, visible to the naked eye (Figure 37 A; 
confirmed by SDS-PAGE and Coomassie staining, data not shown) were pooled, diluted with 
DPBS, and again pelleted by ultracentrifugation.  
The purified VLPs were resuspended in DPBS, fixed in 2.5% glutaraldehyde and analyzed at the 
department of ultrastructure research of the Ludwig-Maximilian University of Munich using 
transmission and scanning electron microscopy technologies (C.2.5.8). As quality control, the 
Gag content of VLPs was also verified in α-6x-His epitope tag- (with biotinylated α-6x-His 
Epitope Tag antibody and streptavidin-POD) and α-p24/p55-immunoblots (with α-p24/p55 
antibody CB-13/5 and HRP-conjugated α-mouse secondary antibody) (Figure 37 B). 
Field emission scanning electron microscopy (FESEM) showed mostly spherical particles for all 
four different Gag proteins (Figure 38 A+B). The reference HXB2-Gag, teeGag1, and teeGag3 
were comparable in size, with a median diameter, determined by image analysis, of about 
100 nm. teeGag2, however, was significantly (p=3.6x10-15) larger compared to the HXB2-Gag 
reference with a median diameter of 145 nm (Figure 37 C). Also some aberrant, tubular 
structures were observed uniquely for teeGag2. Negatively stained spherical VLPs were 
visualized using transmission electron microscopy (TEM). The spherical particles appeared as 
electron-dense cores surrounded by a lighter lipid envelope for all Gags (Figure 38 C). For 
teeGag2 aberrant structures were observed, again. 
 
 
Figure 37. (A) Ring of concentrated VLPs after density ultracentrifugation over a 10-50% sucrose gradient. (B) 
Immunoblots to validate the presence of Gag in the final samples used for EM analysis. The upper blot was treated 
with biotinylated α-6x-His Epitope tag Antibody (1:1,000) followed by streptavidin-POD (1:2,000) and the lower blot 
with α-p24/p55 antibody CB-13/5 (1:1,000) with subsequent HRP-conjugated α-mouse secondary antibody (1:2,000). 
(C) VLP diameter (y-axis) as determined by analysis of SEM images. Every dot represents the size of an individually 
measured VLP of the Gag variant, as indicated on the x-axis. For each Gag variant about 50 particles were analyzed. 
Significant difference to HXB2 was determined by a two-sided t-test with equal variance. 
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Figure 38. FESEM and TEM images of HIV-1 Gag VLPs. (A+B) FESEM images of VLPs from the respective Gag 
variant indicated on the left of each row in (A) 20,000x and (B) 50,000x magnification, examined with a Zeiss Auriga 
scanning electron microscope operated at 1 kV. (C) TEM images taken with an EM 912 electron microscope (Zeiss) in 
various magnifications, representing the spherical VLPs with electro-dense cores. For teeGag2 the observed aberrant 
structure was also resolved in a TEM image. The white scale bar always represents 200 nm. 
D.3.2.4 Dynamic light scattering for particle size comparison 
In addition to analysis of electron microscopy images, the size of Gag particles was also 
compared via dynamic light scattering (DLS) analysis. For this, the VLPs were purified as 
described before (D.3.2.3), but without glutaraldehyde fixation, and measured with a Malvern 
High Performance Particle Sizer (C.2.5.9). Although the particle diameters, determined using 
DLS, were distinctly greater than in the EM analysis (E.2.2.1), teeGag1 and HXB2-Gag were 
again identical, when comparing their size distributions (Figure 39 A) and median diameters 
(Figure 39 B). The size of teeGag3 was slightly, but significantly (p=0.04) increased and, as 
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observed before, teeGag2 was distinctly (p=0.03) larger than the reference VLPs (Figure 39 B). 
The differences of teeGag2 and teeGag3 to the reference can also be observed in a shift to the 
right (higher diameter) in the size distribution histograms (Figure 39 A). 
 
 
Figure 39. Dynamic light scattering analysis of HIV-1 Gag VLPs. Purified VLPs from Gag proteins were examined 
in a High Performance Particle Sizer in three replicates. Determined particle diameters are given as (A) size 
distribution histogram or (B) mean ± SD of the centers of nonlinear regression analysis of the log-normally distributed 
particle diameters. Significant difference to the reference was calculated with a two-sided t-test with equal variance. 
D.3.3 Initial immunological characterization of teeGags-VLPs 
After the biochemical characterization, some initial immunological analyses were performed to 
assess if VLPs of the newly designed teeGags had a similar immunological potential than the 
wildtype HXB2-Gag VLPs. For this, the capacity of the Gag particles to restimulate a Gag-
specific CTL clone was examined. A protocol had been established by Tanja Stief267, who 
showed that, for efficient ex vivo restimulation, the VLPs had to be pseudotyped with VSV-G. 
The CTL clone used herein is HLA B*07:02-restricted and recognizes the GL9 peptide at HXB2-
Gag numbering positons 355 to 363, at the C-terminal end of p24. During the generation of the 
teeGags mutations had been introduced within this epitope sequence in teeGag2 (G637S) and 
teeGag3 (G637S and V362I). Such mutations could potentially reduce or abolish the binding to 
HLA B*07:02 or the recognition by the GL9-CTL clone. For an unbiased comparison of the 
immunological potential of Gag particles, the epitope sequence of teeGag1-3 and HXB2-Gag 
had to be unified. The optimal epitope sequence was determined by using synthetic peptides of 
naturally occurring GL9 variants for restimulation of the CTL clone. Complemented by in silico 
HLA B*07:02 binding predictions the most promising sequence was GPSHKARVL (data not 
shown). This epitope harbors a glycine to serine mutation at the third position compared to the 
HXB2-Gag reference and can, for example, be found in the 96ZM651 C clade isolate. This 
epitope was harmonized in all His-tagged teeGags (teeGag2 already had the appropriate 
sequence) and HXB2-Gag using fusion PCR (C.2.2.2) and subcloned again into pcDNA3.1(+) 
making use of the KpnI and XhoI restrictions sites. VSV-G pseudotyped VLPs were produced by 
co-transfecting HEK293T cells with the Gag vectors and pcDNA5/FRT/TO coding for VSV-G in a 
1:1 ratio. For each Gag variant, one 15 cm plate was transfected, and after 48 h the VLPs were 
98 
concentrated from conditioned, cell-free medium by ultracentrifugation over a 30% sucrose 
cushion. The pellet was resuspended in DPBS and frozen at -80°C until further use. The Gag 
concentration of the VLP samples was quantified in a slot blot as described before (D.3.2.1). As 
reference for absolute quantification, HXB2-Gag protein of known concentration, as determined 
by a Gag-ELISA, was used. Monocytes were isolated from an HLA B*07:02 positive donor by 
MACS sorting with CD14 microbeads and differentiated to mdDCs by cultivation with 1000 U/ml 
IL-4 and GM-CSF over a 6-day period (C.2.3.4). The quality of differentiation was assessed by 
surface staining and flow cytometry analysis with the DC-specific α-CD1a antibody (Figure 40 
A). Monocyte differentiation to mdDCs was sufficient, with 72.6% of the cells positive for CD1a 
expression (Figure 40 A). Analysis of the VLPs in α-VSV-G and α-p24/p55 immunoblots of the 
concentrated VLPs (Figure 40 B) exhibited the expected bands. The minor height differences of 
the bands, as determined in the α-p24/p55 immunoblot are probably due to the different amino 
acid composition of the Gag variants. For the co-cultivation assay, mdDCs (5105 each in a 96-
U-bottom well plate) were pulsed with various amounts of VLPs, washed 2 h later and incubated 
for another 4 h (C.2.3.6). Subsequently, BFA-treated CTLs were added to the mdDCs in a 1:1 
effector to target ratio (C.2.3.8). This mixed leukocyte reaction (MLR) was continued for 6 h. Co-
cultivation was stopped by treatment with cytofix/cytoperm, followed by immune-staining for 
CD8+ IFN-γ-producing cells and analysis with a FACS Canto II flow cytometer. 
 
 
Figure 40. CTL restimulation rates in a mixed leukocyte reaction with mdDCs pulsed with VSV-G pseudotyped 
VLP. (A) Quality control of the differentiation of MACS-isolated monocytes to mdDCs. Cells were stained with a PE-
conjugated α-CD1a antibody or an isotype control antibody and analyzed by flow cytometry. The histogram plot shows 
the percentage of CD1a expressing cells. (B) Immunoblots of samples concentrated by ultracentrifugation through a 
sucrose cushion, detecting the VSV-G protein (upper blot), by α-VSV-G and HRP-conjugated α-mouse Ig antibodies 
and detecting Gag (lower blot), via α-Gag CB-13/5 and HRP-conjugated α-mouse Ig antibodies. (C) mdDCs were 
pulsed with various Gag-VLP amounts, as indicated on the x-axis, and employed in a mixed leukocyte reaction with 
GL9-peptide-specific CTLs. As measure of restimulation, the percentages of CD8+ IFN-γ producing cells, determined 
via flow cytometry analysis, are plotted on the y-axis as mean ± SD of triplicates. EC50 values calculated in a variable 
slope nonlinear regression model are given. (D) Restimulation rates for 0.5 ng p24 equivalents of Gag VLPs used for 
pulsing with extended controls panel. For the sample “HXB2-Gag+VSV-G” both proteins were purified separately and 
mixed only before mdDC pulsing. Statistical significance was calculated in a Bonferroni-corrected two-sided t-test with 
equal variance with reference to the VSV-G pseudotyped HXB2-Gag VLPs. 
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In the MLR, increasing concentrations of VSV-G pseudotyped VLPs induced higher CTL 
restimulation, shown as percentage of IFN-γ producing CD8 positive cells. Analyzing the 
restimulation rates of the various Gag variants in a variable slope nonlinear regression model, 
EC50 values ranging from 0.5 to 3.4 ng p24 (Figure 40 C) were calculated. The least 
restimulation was determined for the pseudotyped teeGag2, followed by the reference HXB2-
Gag and with the highest EC50 teeGag1 and teeGag3. HXB2-Gag VLPs that were not 
pseudotyped with VSV-G, did not cause restimulation of the CTL clone as demonstrated by the 
absence of IFN-γ-producing cells. CTL restimulation with 0.5 ng p24 protein equivalents of VLPs 
was analyzed in more detail (Figure 40 D), showing significantly higher rates for teeGag3 
compared to the pseudotyped HXB2-Gag VLPs. On the other side, the percentage of IFN-γ 
producing T cells was clearly reduced for teeGag2, and absent for the controls, that consisted of 
non-pseudotyped HXB2-Gag VLPs, purified VSV-G, or the combination of both mixed just before 
pulsing. Summarizing the immunological characterization, it was shown that all VLPs based on 
teeGags are similar immunogenic as HXB2-Gag reference VLPs. This further highlights that the 
in the teeGags incorporated mutations did not alter Gag functionality, the VLPs are still able to 
incorporate viral surface proteins (here VSV-G), and the VLPs get normally processed in 
mdDCs. 
D.3.4 Virological characterization of teeGags integrated in a HIV-1 
molecular clone 
The biochemical characterization of the teeGags showed that their capability to produce VLPs 
was comparable to the reference HXB2-Gag. However, these experiments were based on 
human-codon-optimized genes and produced via mammalian expression vectors. Whether 
teeGags would still be able to form viral particles in a natural virus setting was unknown. To 
address this, HIV-codon-optimized (B.4.2) teeGag sequences with uncoupled gag and pol 
reading frames as described by Leiherer et al.251 were ordered from GeneArt. These ranged 
from the unique 5’ BssHII restriction site located in the UTR up to the end of Gag. HXB2-Gag 
was not synthesized, but amplified per PCR from the p5’ vector, which contains the 5’ half of an 
HXB2 molecular clone (kindly provided by Prof. Barbara Schmidt, University of Regensburg). By 
using suitable primers the gag and pol reading frames of HXB2-Gag were uncoupled (by 
removing the slippery site and destabilizing the following stem loop) in a fusion PCR reaction 
(C.2.2.2, with HXB2-AL fwd/rev as mutation primer and teeGag-AL fwd/rev as outside binding 
primer). HXB2-Gag and teeGag1-3 (amplified with primer teeGag-AL fwd/rev) were fused to a 
fragment of pNL4-3_AL (amplified with primer pNL4-3AL fwd/rev) ranging from p6* to the unique 
SbfI restriction site by overlap extension PCR (primer teeGag-AL fwd and NL4-3-AL rev). 
Budding-deficient HXB2-GagMyr- was constructed by introducing the G2A mutation via fusion 
PCR (C.2.2.2; mutation primer: G2A-AL rev/fwd; outside binding primer: teeGag-AL fwd and 
NL4-3-AL rev). The frameshift-depleted versions of teeGag1-3, HXB2-Gag, and HXB2-GagMyr- 
were subcloned into the pNL4-3_AL vector, using BssHII and SbfI restriction endonucleases. 
Cloning was verified by restriction enzyme digestion and sequencing. HEK293T cells were 
transfected in a 6-well plate with the pNL4-3_AL plasmid containing the NL4-3 HIV genome with 
either wildtype NL4-3-AL Gag or teeGag1-3, HXB2-Gag, or HXB2-GagMyr-. The supernatants 
were harvested and renewed every 24 h, for three days, and analyzed by Gag-ELISA, reverse 
transcriptase assay and by immunoblot.  
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Comparing the wildtype pNL4-3-Gag to HXB2-Gag 48 h after transfection, no difference 
between the Gag concentrations in the supernatant, as determined by a Gag-ELISA (C.2.5.2), 
was detected (Figure 41 A). This showed that the exchange of Gag had no implication on 
budding of the artificial molecular clone. HXB2-Gag was therefore used as sole reference 
construct hereafter. For HXB2-GagMyr-, included as negative control, the amount released into 
the medium was, as expected, strongly reduced. Next, the supernatants of cells transfected with 
teeGag1-3 were compared to the reference HXB2-Gag and HXB2-GagMyr- in a Gag immunoblot 
(Figure 41 B). teeGag1 showed rather reference-like behavior with a strong band at 24 kDa 
representing the processed p24 and two other bands for the partially cleaved p41 and the full-
length p55 Gag at approximately 41 and 55 kDa. teeGag3, on the other hand had a pattern 
comparable to the budding-incompetent HXB-GagMyr-. Only a weak band for p24 and nearly no 
signal for p41 and p55 was observable. teeGag2 showed characteristics of both other variants 
with a band for p24, but weaker as for teeGag1 and also a signal representing p41. These initial 
immunoblot results were further analyzed by a Gag-ELISA and an RT-assay (C.2.4.2) of the 
conditioned supernatants (Figure 41 C+D). In both assays, teeGag1 exhibited a similar behavior 
as HXB2-Gag, with distinct Gag and RT concentrations in the supernatant, both peaking after 
48 h. For teeGag2 and teeGag3 however nearly no Gag or RT-activity was measured in the 
supernatants. Both variants showed similarities to HXB2-GagMyr-, as all three had significantly 
reduced Gag and RT concentrations in comparison to the HXB2-Gag reference, indicating 
defects in viral release. 
 
Figure 41. Viral particle release capacity of teeGags integrated into an HIV molecular clone. The wildtype Gag 
protein of the HIV molecular clone pNL4-3-AL was substituted with frameshift-deleted teeGag1-3, HXB2-Gag, or 
HXB2-Gag
Myr-
. HEK293T cells were transfected with these plasmids and the supernatants were harvested every 24 h 
for 3 days. (A) pNL4-3-AL wildtype Gag concentration in the supernatant 48 hpt, as determined by Gag-ELISA, 
compared to HXB2-Gag and HXB2-Gag
Myr-
. (B) Immunoblot of conditioned medium 48 hpt. Gag was detected by α-
Gag CB-13/5 and α-mouse Ig antibodies. (C) Gag ELISA and (D) RT-assay data of the conditioned media. Statistical 
comparison to reference controls was performed with as two-sided t-test with equal variance. 
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D.4 Method development for in vitro assessment of 
immunological breadth 
In addition to the functional conservation, the other main feature of the teeGags was the 
incorporation of as many immunologically potent, patient-derived CTL epitopes as possible. 
Experimental in vivo validation that teeGags induce a broader T cell response is quite difficult, 
since animal models are not applicable, due to the fact that the design targets only human HLAs 
and their associated epitopes. To bypass this limitation and analyze the immunological breadth 
of antigens, an in vitro analysis for epitope presentation was conceived. This method employs 
cells that produce soluble variants of HLA molecules (sHLA). When these cells also express the 
antigens of interest, the proteins should be processed through the classical HLA I machinery. 
Antigen-derived peptides should then be capable of forming a complex with the sHLA protein 
and the endogenously provided β2m. Since these complexes get secreted to the supernatant, 
they can be isolated directly from the conditioned medium. After complex destabilization and 
further purification of the peptides, they can eventually directly be sequenced using tandem 
mass spectrometry. Through this method HLA-presented epitopes can be identified. Since the 
presence of a suitable TCR is also required (A.2.2.1), not all identified epitopes are necessary 
able to a prime CD8+ cell response. Additionally, as long as no complete sequencing of the 
immunopeptidome can be ensured, it is not possible to conclude that not identified epitopes do 
not get presented. 
D.4.1 Soluble HLA class I molecule design 
For establishing epitope sequencing of sHLA-presented peptides via mass spectrometry, two 
model HLA class I alleles, A*02:01 and B*07:02, were chosen. Both are among the globally most 
frequent alleles in the respective gene locus (Extended Data Table 3). HLA B*07:02 was of 
special interest, since the p24 CTL clone recognizing the GL9 peptide used beforehand (D.3.3), 
is HLA B*07:02-restricted. To generate sHLA expression plasmids, RNA of HEK293T cells, that 
have a reported HLA haplotype consisting of A*02:01/A*03:01 and B*07:02/ B*07:02295 was 
isolated with the RNeasy Plus Mini Kit (Qiagen). The HEK293T mRNA was used in a first-strand 
cDNA synthesis with random hexamer primers applying the SuperScriptTM III Reverse 
Transcriptase kit (Thermo Fisher). The cDNA was added as template to a PCR reaction 
amplifying HLA A*02:01 (primers sHLA A*02:01 fwd and sHLA-exon4+His rev) and HLA B*07:02 
(primers sHLA B*07:02 fwd and sHLA-exon4+His rev) fragments, each ranging from the start 
codon till after exon 4, therefore cutting off the transmembrane region encoded in exon 5 and the 
following cytoplasmic part. These sHLA proteins hence comprise the signal peptide coded by 
exon 1 and the three alpha subunits of the HLA molecule, coded by exons 2-4. A C-terminal His-
tag (introduced by reverse binding primer sHLA-exon4+His rev) that was shown to not distort 
peptide specificity112, was added for analytical purposes and as an alternative purification 
possibility. Both sHLA variants were cloned into the expression plasmids pcDNA3.1(+) and 
pcDNA5/FRT using HindIII and XhoI restriction sites that were introduced previously by PCR. 
With the pcDNA5/FRT vectors, coding for sHLA A*02:01 (sA02) and sHLA B*07:02 (sB07), 
stable expression Flp-In™ T-Rex™ 293 sus cells (C.2.3.3) were generated. Expression of 
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soluble HLA complexes was validated in a sHLA-specific ELISA (C.2.5.3). Compared to 
transient transfection with pcDNA3.1(+), the stable cell lines had the advantage that all cells 
produce the sHLA protein and therefore a significant higher concentration in the supernatant 
could be achieved (data not shown). Moreover, using stable cell lines is far less laborious, since 
large amounts of plasmid DNA had to be prepared for transient transfection. 
D.4.2 Affinity chromatography of sHLA-peptide complexes 
Isolation of sHLA-epitope complexes was performed by affinity chromatography with the murine 
pan-HLA class I reactive W6/32 antibody. The special feature of this antibody is that it binds to 
the interface of the heavy HLA chain and the β2m. The interaction of β2m and heavy HLA chain 
is only stable, if there is also an peptide bound in the peptide binding groove of the HLA 
molecule296 and also a prerequisite for the complex to leave the ER. Because of this, the W6/32 
antibody allows a specific isolation of complete HLA complexes consisting in this case of the 
sHLA chain, β2m, and a bound peptide104. The W6/32 antibody was produced by a hybridoma 
cell line and the conditioned medium was run over a self-packed Protein A-Sepharose column 
that binds the Fc part of antibodies with high affinity (C.2.7.1). Next, the supernatant containing 
the sHLA complexes was applied to the column using gravity flow. At the end, the sHLA 
complexes were eluted with 10% acetic acid (C.2.7.2). Crosslinking of the antibody to the 
Protein A beads before affinity chromatography resulted in a cleaner elution of the HLA 
complexes, since the antibody remained bound to the beads (data not shown). Additionally, the 
column could then be reused multiple times. The eluted sHLA complexes were heated to 78°C 
for 10 min. This acid boil step destabilizes the sHLA complexes and they disaggregate into their 
components. Peptides were further purified over a 3 kDa cut-off filter (C.2.7.3). The filtrate (i.e. 
the fraction with substances smaller than 3 kDa), containing the peptides, was used for CTL 
restimulation experiments and mass spectrometry sequencing, whereas the concentrate (i.e. 
fraction bigger 3 kDa) was employed for quality controls. 
D.4.3 CTL restimulation with isolated peptides 
As a first proof of concept experiment, peptides were isolated from the conditioned medium of 
the cell lines stably expressing sB07 or sA02 that were additionally transiently transfected either 
with a Gag expression or a control plasmid. The isolated peptides were used for peptide pulsing 
experiments (C.2.3.7) and subsequent reactivation of the HLA B*07:02-restricted GL9 CTL clone 
(C.2.3.8). The Gag sequence of the 96ZM651 isolate was chosen, because in previous 
processing and presentation experiments it exhibited the best GL9 CTL restimulation capacity of 
all tested natural isolates (data not shown). For each test 6x108 stably sHLA (sA02 or sB07) 
expressing cells were transfected (600 ml scale) either with pcDNA3.1(+) coding for the human-
codon-optimized 96ZM651-Gag or, as negative control, the pcDNA3.1(+) plasmid without any 
insert. Production of proteins was confirmed via flow-cytometry after α-p24/p55 ICS (with KC57-
RD1 antibody) and sHLA-ELISA (data not shown). After 48 h, the conditioned medium was 
harvested and cleared by centrifugation. Until further use the cleared supernatant, containing the 
sHLA complexes, was stored at -80°C. For column preparations 400 mg Protein A Sepharose 
beads were swollen in borate buffer and afterwards loaded with 8 mg W6/32 antibody in a 
disposable column. After DMP-crosslinking and an acid wash step to remove unbound antibody, 
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the beads were equally divided onto four columns, one for each test. Next, the sHLA-complex-
containing supernatant was thawed and filtered through a 0.22 µm pore sized membrane. The 
cleared supernatant was mixed with borate buffer and then applied to the W6/32 affinity matrix. 
After washing, sHLA complexes were eluted stepwise with 500 µl 10% acetic acid until the 
baseline at 280 nm was reached (measured by UV-absorption at 280 nm of regularly taken 
aliquots). After acid boiling of the protein-containing fractions, peptides were purified using a 
3 kDa cut off filter. The peptides-containing flow-through was dried in a SpeedVac run and 
reconstituted in 50 µl DPBS. The fraction bigger 3 kDa contained the sHLA protein, β2m, and 
residual W6/32 antibody. For quality control, Protein A beads before (Bb) and after (Ba) elution, 
as well as the concentrate of the filtration were separated by SDS-PAGE and stained with 
Coomassie (Figure 42 A). For all four tests, the beads before the elution and the eluate showed 
a distinct band for the sHLA protein at about 35kDa.  
The protein identity was verified using an α-pan-HLA-ABC and an α-6x-His epitope tag 
immunoblot (Figure 42 A). Since the murine α-pan-HLA-ABC was detected with a polyclonal α-
mouse Ig antibody, also the murine W6/32 antibody used for affinity chromatography that was 
bound to the beads was visualized. The α-His epitope tag immunoblot, however, showed only 
one specific band for the C-terminal 6x-His-epitope-tagged sHLA protein. The isolation of 
complete HLA complexes was finally checked in an α-β2m immunoblot. Again, only for the 
beads before elution, and the concentrate, a β2m-signal was observed. In conclusion, using the 
W6/32 antibody for affinity chromatography, results in the isolation of intact sHLA complexes 
consisting of the sHLA heavy chain and β2m. Due to the crosslinking, nearly no affinity antibody 
is eluted from the Protein A Sepharose, resulting in a rather pure eluate. 
 
Figure 42. HLA-specific epitope purification. (A) Protein A Sepharose beads before elution (Bb) and after elution 
(Ba), as well as the concentrate (i.e. fraction >3 kDa after filtration) of the eluate were separated using an SDS-PAGE. 
For unspecific visualization of all proteins the Gel was stained using Coomassie Brilliant Blue (top row). For 
identification of protein-specific signals, three different immunoblots were performed: Visualizing the HLA heavy chain 
(second row; detected with α-HLA-ABC EMR8-5 and HRP-conjugated α-mouse Ig antibodies), the 6x-His epitope tag 
(third row; detected with biotinylated α-6x-His Epitope Tag antibody and streptavidin-POD), or β2m (bottom row; 
detected with polyclonal α-β2m and HRP-conjugated α-rabbit Ig antibodies). (B) mdDCs from an HLA 
B*07:02/A*02:01 positive donor were pulsed with 1.5 µg affinity chromatography purified peptides or PBS as negative 
control and examined for their capacity to restimulate the HLA B*07:02-restricted GL9-CTL clone. Restimulation was 
determined as percentage of IFNγ producing CD8+ cells, as determined by flow cytometry and is given as mean with 
standard deviation of 6 replicates. Significant difference to the negative control (PBS) was calculated in a two-sided t-
test with equal variance. 
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To test the GL9-CTL-restimulation capacity of the isolated peptides, monocytes of an HLA 
B*07:02 and HLA A*02:01 positive donor were isolated and differentiated to mdDCs. 5x104 
mdDCs were seeded in each well of a 96-round-bottom well plate. Next, for each test 1.5 µg of 
the reconstituted peptides, as determined by UV-absorption at 280 nm, were added to the 
mdDCs. Two hours after the peptide pulsing, GL9-specific, BFA-treated CTLs were added in a 
1:1 target-effector cell ratio. After 6 h, the MLR was stopped by fixation and permeabilization. 
After staining with appropriate antibodies (α-IFN-γ-APC and α-CD8-FITC), the percentage of 
IFN-γ producing CD8+ cells was determined in a flow cytometry analysis. Only the peptides 
isolated from the conditioned medium of sB07 stably transfected cells also expressing Gag 
(sB07-Gag), induced a CTL restimulation that was significant higher than the background level 
(only PBS added) (Figure 42 B). Since the HIV-1-Gag-specific GL9-CTL clone is HLA B*07:02 
restricted, as expected, all other isolated peptides (sA02-mock, sB07-mock, and sA02-Gag) 
showed no restimulation. This was taken as evidence that through sHLA affinity chromatography 
HLA-specific Gag epitopes can be isolated. 
 
Figure 43. Scaled-up HLA B*07:02-restricted peptide purification for CTL restimulation. Peptides were purified 
from the supernatant of a stable sB07 expression cell line that was transiently transfected with pcDNA3.1(+)-
96ZM651-Gag. (A) Coomassie stained SDS-PAGE as affinity chromatography quality control. Protein A Sepharose 
beads before elution (Bb), beads after elution (Ba), and the 3 kDa cut off filtration concentrate of the eluate (E) were 
loaded. (B) Immunoblots detecting the HLA heavy chain (top row; detected with α-HLA-ABC EMR8-5 and HRP-
conjugated α-mouse Ig antibodies), the 6x-His epitope tag (second row; detected with biotinylated α-6x-His Epitope 
Tag antibody and streptavidin-POD), or β2m (bottom row; detected with polyclonal α-β2m and HRP-conjugated α-
rabbit Ig antibodies). (C) mdDCs derived from an HLA B*07:02 positive donor were pulsed with affinity 
chromatography-purified peptide, a mock control (PBS), synthetic GL9-GS peptide (10
-4
 M) or the same concentration 
of an irrelevant peptide. The graph shows the mean ± SD (from triplicates) percentage of IFNγ producing CD8+ cells 
after a MLR with peptide-pulsed mdDCs and HLA B*07:02-restricted GL9 CTL clone, as determined by flow 
cytometry. Significance was determined by calculating p-values in a two-sided t-test with equal variance. (D) 
Exemplified calibration curve generated by pulsing HLA B*07:02+ mdDCs with different concentrations of synthetic 
GL-GS peptide and determining the percentage of IFNγ producing CD8+ cells after the MLR with GL9-CTLs. Curve 
fitting was computed in variable slope nonlinear regression analysis. 
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Another CTL restimulation experiment aimed at quantifying the amount of GL9 peptide that can 
be purified. For this, the volume of stable sB07 transfected cells, that were additionally 
transiently transfected with 96ZM651-Gag, was scaled up. Overall 3.3 l with a concentration of 
1x106 sB07 expressing cells/ml were used for the transfection with pcDNA3.1(+)-96ZM651-Gag. 
The conditioned supernatant was harvested 48 h post transfection, cleared by centrifugation, 
and stored at -80°C. 300 mg of Protein A Sepharose was swollen in borate buffer, transferred to 
a disposable column, and loaded with 6 mg W6/32 antibody that was subsequently crosslinked 
to the beads. Afterwards the conditioned sHLA-containing medium was thawed, filtered through 
a 0.22 µm membrane and applied to the W6/32-Protein A resin column using a peristaltic pump. 
After extensive washing steps, the sHLA complexes were eluted stepwise in 1 ml fractions with 
10% acetic acid until the baseline at 280 nm was reached. Protein-containing eluate fractions 
were pooled and, after acid boiling, the peptides were purified using a 3 kDa cut-off filter. The 
filtrate was dried in a SpeedVac and reconstituted in 100 µl DPBS. 
Analyzing the fraction bigger than 3 kDa in a Coomassie stained SDS-PAGE (Figure 43 A), a 
clear band for the sHLA protein again could be observed for the beads before elution (Bb) and 
the filtration-concentrated eluate fraction (E). Elution with 10% acetic acid removes nearly all 
sHLA protein, while the crosslinked W6/32 antibody remains bound to the beads (Ba). This could 
also be verified in immunoblots (Figure 43 B) against the sHLA protein, the sHLA C-terminally 
added 6x-His epitope tag, and β2m, where a signal could be observed in the lanes for the beads 
before elution and the concentrate of the eluate  
For the restimulation experiments, mdDCs were generated from monocytes of an HLA B*07:02 
positive donor. 5x104 mdDCs were seeded per well of a 96-round-bottom plate and pulsed with 
1% or 10% of the affinity-chromatography-purified peptides or known concentrations of the 
synthetic GL9-GS peptide. After 2 h, GL9-specific CTLs were added in a 1:1 ratio to the mdDCs 
and incubated for another 6 h. The mixed leukocyte reaction was stopped by fixation and 
permeabilization of the cells, followed by immunostaining (with α-IFN-γ-APC and α-CD8-FITC 
antibodies) and flow cytometric analysis for IFN-γ producing CD8+ cells. 
10% of the final peptide preparation that contains a mixture of all isolated peptides was applied 
for the mdDC pulsing and CTL restimulation. This led to a restimulation of 14.6% of all CD8+ 
cells, as measured by IFN-γ-production (Figure 43 C). Using a calibration curve (exemplified in 
Figure 43 D), where mdDCs were pulsed with known amounts of the synthetic GL9-GS peptide, 
the overall amount of GL9-GS in the isolated peptides was determined as 1.3 pmol. Each 
isolated sHLA molecule should consist of one sHLA heavy chain, one β2m protein, and one 
peptide. Hence the amount of sHLA could be used to estimate the overall amount of peptide 
isolated by affinity chromatography.  
Of the overall 292 µg protein in the concentrate after filtration, as determined by a Bradford 
assay, about 89 µg were sHLA protein, as calculated by image analysis of the Coomassie 
stained SDS-PAGE. Hence, in a very rough estimation, 2.0 nmol of sHLA complexes and 
therefore the same amount of peptides were isolated. This means that the GL9-GS peptide 
(1.3 pmol) represent 0.07% of the overall quantity of isolated peptides. Since a cell presents 
about 104 distinct epitopes91, the determined concentration for the GL9-GS epitope seems to be 
in a reasonable range. Since tandem mass spectrometry can identify peptides in a femto- down 
to attomole range297, the amount of peptides isolated using the presented method were 
expected to be sufficient for identification via LC-MS/MS. 
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D.4.4 Peptide identification using LC-MS/MS de novo sequencing 
After the promising proof of concept experiments, that used affinity-chromatography-isolated 
peptides to restimulate a Gag-specific CTL clone, the peptides should be sequenced employing 
tandem mass spectrometry. Three different peptide isolation experiments were performed. Two 
of them were performed as described above with stable sB07 expression cell lines transiently 
transfected one time with 96ZM651-Gag (#1) and one time with teeGag1 (#2). In the third 
experiment, HEK293F cells were transiently co-transfected with pcDNA3.1(+)-sB07 and 
pcDNA3.1(+)-teeGag1 (#3). For all three approaches the affinity chromatography and peptide 
purification was identical to the procedure described above (900 ml scale). The purified, 
SpeedVac-dried peptides were analyzed at the proteomics core facility of the “Helmholtz 
Zentrum München” in an LC-MS/MS peptide sequencing experiment (C.2.7.4). The obtained 
spectra were loaded to the MaxQuant software with the corresponding search engine 
Andromeda282,283 to identify endogenous human-protein-derived peptides as well as Gag-specific 
epitopes (C.2.7.5). 
 
Figure 44: Identification of HLA B*07:02 restricted epitopes using LC-MS/MS de novo sequencing. (A) Length 
distribution of all 213 identified peptides given in absolute numbers (left y-axis) or percent (right y-axis). (B) Amino 
acid distribution of all eluted 8-12mer peptides pooled from all three independent experiments visualized as sequence 
logos (WebLogo 3.4). The height of symbols within the stack is scaled to the relative frequency of the corresponding 
amino acid at the indicated position. (C) In silico calculated (NetMHC 4.0) binding affinities to HLA B*07:02 for all 
identified epitopes, given as frequency distribution in absolute numbers (left y-axis) or percent (right y-axis). (D) 
Calculated binding affinities separated by sequences with matching HLA B*07:02 binding motif (+) and those without 
(-). Line and whiskers represent median with interquartile range. Significance analysis was performed with the non-
parametric Mann-Whitney test. (E) Venn diagram of the numbers of all eluted peptides partitioned according to the 
experiment (#1-#3) in which they were identified. Numbers in overlapping areas symbolize sequences found in two, or 
all three experiments. 
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Although in no experiment any Gag epitope could be observed, a total number of 213 peptides 
sequences were identified (about 90 per experiment). Of those, 35 sequences were identified in 
at least two independent experiments (Figure 44 E). Analyzing the length distribution (Figure 44 
A) of the epitopes showed that most epitopes (~50%) have a length of 9 amino acids, followed 
by lengths of 10 and 11, which is characteristic for CD8+ T cell epitopes. Epitopes of one HLA 
allele can be quite diverse, but the anchor positions at P2 (i.e. second amino acid) and PΩ (i.e. 
last amino acid) are highly conserved298,299. Therefore, the quality of sequenced epitopes can be 
validated based on their anchor positions. For HLA B*07:02 the amino acid at P2 is nearly 
always a proline. At PΩ, most nonpolar amino acids (L, F, M, A, I, and V) are toleratedj. 67% of 
the identified peptides had a proline at P2 and 79% one of the tolerated nonpolar amino acids at 
the last position. Combination of the appropriate residues at P2 and PΩ was observed for 61% 
of all peptides. Sequence logos of all 8 to 12mer epitopes, displaying the amino acid distribution, 
are shown in Figure 44 B. Based on the amino acid compositions of human proteins301,302, the 
probability of observing a random peptide with the HLA B*07:02 binding motif would be only 
2.1%. Hence the enrichment of HLA B*07:02 epitopes with the affinity chromatography 
procedure performed here was highly significant (p<0.0001), as determined in a Fisher’s exact 
test, showing that these are indeed HLA B*07:02-restricted CD8+ T cell epitopes. 
 
 
Figure 45. Total ion chromatograms of an LC-MS/MS de novo sequencing experiment. The TIC was created by 
summing up intensities (shown as relative abundance on the y-axis) of mass spectral peaks at every point (i.e. 
retention time as plotted on the x-axis) of the analysis for the same scan. The peptide signals are superimposed by 
PEG contamination signal, prohibiting sensitive epitope identification. 
 
Using NetMHC to predict the binding affinities of all isolated peptides to HLA B*07:02, showed 
that 50% had a very high affinity (<100 nM) and the top 66% had at least a medium affinity 
(<1000 nM) (Figure 44 C). Analyzing only peptides with the correct HLA B*07:02 anchor 
positions, a median affinity of 29 nM was calculated. This was a distinctly (p<0.0001 as 
determined with Mann-Whitney test) lower affinity as for the remaining epitopes (with a median 
affinity of 18.5 µM), indicating that those peptides were most likely not HLA B*07:02-associated 
peptides (Figure 44 D). In conclusion, the LC-MS/MS results show that mainly HLA B*07:02 
restricted epitopes were identified. However, the sensitivity has to be improved, since no Gag 
epitopes were found, although the CTL restimulation experiments had proven the presence of at 
least the p24-GL9 epitope in high concentration. The low sensitivity is likely due to the presence 
of impurities in the sample. The total ion chromatograms (TIC) displayed a polyethylenglycol 
(PEG) contamination that superimposes most peptide signals (Figure 45). Avoiding, or at least 
reducing, this contamination should result in a far higher amount of identifiable peptides and 
allow to retrieve Gag-specific epitopes.  
j
 Immune epitope database
300
 published HLA B*07:02 binding motif: http://www.iedb.org/MHCalleleId/251 
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E Discussion 
Three decades after the discovery of HIV-1 as cause of AIDS, a protective prophylactic vaccine 
still remains elusive. Even encouraging advances, like the moderate and transient protection 
observed in the RV144 trial, are only first steps towards a worldwide solution. Nowadays, 
development of a protective vaccine mainly focuses on the elicitation of broadly neutralizing 
antibodies in vaccinees. There is, however, broad consent that efficient control of the HIV-1 
epidemic relies on both, a strong humoral bNAb response to reduce infection rates as well as a 
robust and particularly a broad cellular immune response154. Cellular immunity, mainly mediated 
by CD8+ T cells, could control breakthrough infections and thereby improve disease prognosis 
and reduce transmission. All phase IIb/III HIV-1 vaccine trials so far failed to induce a broad 
cellular response, like in the RV14446, where T cell responses were very low and no correlate of 
protection190, or in the STEP study189, where the breadth of CD8+ T cell responses was 
extremely limited, with a median of only one epitope per antigen protein303. These failures 
illustrate the lack of a vaccine strategy that elicits a greater breadth of high-quality (A.1.5.2) 
CD8+ T cell responses to account for the enormous variability of HIV-1. 
The subject of this thesis was to address HIV-1’s extraordinarily high sequence diversity by 
designing T cell epitope-enriched Gag antigens (teeGags) containing a maximized amount of 
naturally occurring CD8+ T cell epitopes (D.1). Since the formation of virus-like particles (VLPs) 
by Gag is considered favorable for the induction of immune responses, retaining this important 
function was also ensured through appropriate computational assessment. Functional 
predictions and antigen design features were confirmed by in silico evaluations (D.2), as well as 
through biochemical in vitro characterization (D.3). Additionally, to examine the enhanced 
breadth of the novel teeGags, a method to directly identify presented CD8+ T cell epitopes 
through mass spectrometry was established (D.4). 
E.1 Designing global T cell epitope-enriched antigens 
A potential protective HIV-1 vaccine would ideally be globally applicable. There are four different 
strategies described to achieve this304: (1) designing antigens tailored to each geographic 
region, based on the prevailing circulating strains, (2) eliciting bNAbs capable of neutralizing all 
HIV-1 subtypes, (3) focusing cellular immunity on highly conserved HIV-1 sequences, or (4) 
eliciting an HIV-1-specific immune response that is highly diverse, matching the viral variability. 
The algorithm presented in this work is highly flexible, allowing design of antigens for a specific 
geographic region, by altering the epitope scoring weights or changing the input data set. The 
design can also be focused on conserved regions, by excluding undesired epitopes in variable 
regions, where viral escape is achieved more easily. For this thesis however, the proof of 
concept teeGags were designed to elicit a highly variable response, mimicking the global HIV-1 
diversity as well as the worldwide population’s HLA class I allele frequencies. The algorithm was 
furthermore implemented to preserve the functionality of Gag, because of the immunologically 
beneficial properties of VLPs (A.3.2). For instance, the uptake of a single VLP feeds about 2000 
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Gag proteins to the cell148. This is a crucial advantage of VLPs over soluble antigen, because it 
helps to overcome MHC processing thresholds, where normally only 0.1% of all processed 
peptides escape destruction by cytosolic peptidases and associate with MHC class I molecules. 
This implies that only proteins present in a copy number higher than 1,000 will be recognized by 
the immune system70. 
E.1.1 The patient-derived input data exhibits a strong B clade bias 
The set of Gag-specific CD8+ T cell epitopes to initiate the Optimizer Algorithm was downloaded 
from the LANL HIV Immunology database and subsequently curated manually (D.1.1.2). Since 
the entry of the first CTL epitope in 1987, the database grew almost exponentially and at the end 
of 2015 harbored over 8300 epitopes spanning all HIV-1 proteins, an increase of around 500 
entries as compared to the year before210,305. Although multiple entries might describe the same 
epitope and reduce the number of unique epitopes, it nonetheless demonstrates the impressive 
number of patient-derived epitopes that can be employed for the teeGag design. Compared to 
other designer-antigens (B.1.1.3) that maximize the number of all naturally occurring 9-mers 
(mos) or calculate artificial sequences that minimize the genetic distance in a given set of viral 
sequences (anc, con, and cot), employing experimentally validated epitopes to improve 
immunological breadth has several advantages. During the multi-step epitope processing 
(A.2.1), for example, multiple factors, like the specificities of the proteasome or 
immunoproteasome, ERAAP/ERAP1, tapasin, TAP, and finally the HLA allele influence which 
epitopes are presented306. The complete procedure is extremely selective and only 1-2 of every 
10,000 peptides generated by the proteasome will eventually bind to MHC class I molecules307. 
By using patient-derived epitopes that are known to be presented on the surface of infected 
cells, these limitations in the predictability of epitope presentation might be circumvented. These 
epitopes also represent peptides of all lengths, whereas the mosaic antigens only maximize 
coverage of PTEs with a single pre-defined length. Additionally, since most epitopes in the 
database were identified by screening for reactive T cells, it ensures that a TCR recognizing the 
pMHC-complex with sufficient avidity can be among a given patients’ TCR repertoire. As 
mentioned before (A.2.2.1), any TCR undergoes a positive and a negative selection process that 
eliminates all nonfunctional and all self-reactive receptors, respectively. The patient-derived 
epitopes should therefore only contain sequences that are recognized by TCRs that prevailed in 
this selection process and should therefore be able to elicit a CD8+ T cell response in at least a 
fraction of people. 
A disadvantage, however, of employing the epitope set from the LANL database is that most 
were identified by stimulating T cells from HIV-1+ patients with synthetic peptides. These 
peptides are usually between 11 and 15 amino acids in length and hence longer than the actual 
epitope, which is in 95% a 9-mer91. An epitope entry does therefore not necessarily map the 
optimal epitope. To compensate for this, features from subepitopes were allocated to their 
respective superepitopes during teeGag design (B.1.2), thus refining epitope mapping by 
exploiting the wealth of database entries. Thereby, a superepitope represents all epitopes that 
are fully embedded within it. Synthetic peptides also entail the problem that their sequence does 
not have to resemble the natural antigen, but might be a so called mimotope. Mimotopes are 
similar, but not identical sequences to the actual T cell epitope, which are still recognized by the 
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TCR. However, this effect might even be beneficial, since such epitopes would increase the 
depth of the immune response, allowing coverage of variable sequences by a single epitope. 
Although, the LANL HIV database publishes the best compilation of HIV-1 CD8+ T cell epitopes 
that were identified in a broad range of studies from the last 30 years, it is still updated manually 
and therefore somewhat error-prone. This was evident from the 39 epitope entries that had to be 
deleted and the over 60 that had to be modified due to errors or inaccuracies, which occurred 
during the transfer to the database or that were already erroneous in the respective primary 
publication. Through intensive manual curation, a more accurate epitope data set was generated 
for this thesis (D.1.1.2). However, due to its size of 2688 epitope entries, it is still probable that 
there are individual inaccuracies in the metadata, whereas all major defects, like indel mutations 
or erroneous start-end annotations, were reliably removed. Additionally, although the LANL-
published epitopes are a conglomerate from studies all over the world, the subtypes associated 
with the epitopes do not match the global clade frequencies. Subtype B isolates, for example, 
are only responsible for 11% of all global infections (Figure 18), but are largely overrepresented 
in the epitope list (30% of all registered epitope subtypes, Figure 26 D). This B clade bias is 
even more obvious for the filtered Gag sequence alignment that was used (D.1.1.1), where 38% 
are registered as subtype B sequences. This overrepresentation is probably due to the fact that 
subtype B is prevalent in Europe and Northern America (Figure 1), where most of the research 
has been performed. 
The alignment of all Gag-specific CD8+ T cell epitopes to the HXB2-Gag reference sequence 
revealed 158 AAS at 128 variable positions (D.1.1.2). 372 positions were consequently 
conserved, meaning no AAS was detected. Since the epitopes are derived from all major HIV-1 
subtypes, the number of variable positions was expected to be higher. In an alignment of 12,543 
Gag sequences (including subtypes A1, B; C, D, F1, G, CRF01_AE, and CRF02_AG) against 
HXB2, Li et al.188 detected 258 polymorphic positons and far over 600 AAS. The large difference 
between natural Gag polymorphism and the one observed in the epitope set might have several 
reasons: (1) the epitope set does not feature all subtypes equally and mainly B-clade-specific 
AAS are found. (2) Epitopes are determined by restimulation of patient’s T cell repertoire with 
synthetic peptides. As these peptides are often based on consensus sequences or specific 
isolates (e.g. HXB2 for B clade sequences), not all polymorphic positions can be identified, 
either because the synthetic peptide does not restimulate the T cell reactive against the 
polymorphic epitope or it is a mimotope and can therefore not be differentiated. (3) Mutations 
might alter processing and presentation and certain polymorphic peptides are hence not 
presented. (4) Some TCRs, reactive against polymorphic epitopes do not pass through thymic 
selection. This shows that the quality of breadth-enhanced antigens, designed by the Optimizer 
Algorithm, is highly depending on the quality of the input data set. The steep annually increase 
of published epitopes (see above) therefore helps to increase the functionality of Optimizer 
Algorithm gradually. 
E.1.2 Structure/sequence combination for best classification  
To exclude integration of AAS in the teeGags that are harmful to VLP budding, a supervised, 
multidimensional FLD classifier was conceived (B.2.1). Four structural and one sequence-based 
feature were tested to discriminate between budding-retaining and budding-deleterious AAS. 
Since particle assembly and release is driven by the full-length Gag, a 3D-structure of the p55 
111 
Gag precursor protein (A.3.1) would be preferable for calculation of structure-based classifier 
features. Because such a structure was not available, domain-models were applied (B.2.1.1), 
which is likely an acceptable strategy, since the domains are mostly independent and behave 
like beads on a string308. 
The best feature combination for the FLD classifier (D.1.2.1), determined by 10-fold cross-
validation (Extended Data Table 4), was f3,ΔDOPE-global together with f5,seq, which exhibited a 
prediction precision of 98%. Even for teeGag3, that with 40 AAS has the most combined 
mutations of all teeGags, this high precision would still entail a 45% probability of realization (i.e. 
45% chance that none of the AAS is a false positive, see Figure 21). The calibration precision 
with 100% was even higher and would mean that the classification boundary is set in a way that 
it prohibits false positives (Figure 20). Any additional feature reduced the precision. This is 
especially evident for the combination of all five features that only exhibited a precision of 83%. 
For teeGag1, with only 28 AAS this low precision would result in a probability of realization of 
less than 1%. In other words, there would be an over 99% chance that at least one AAS was 
classified as false positive, which would possibly reduce or prohibit VLP budding and highlights 
the importance of choosing the classifier features carefully. 
Since f1,DOPE on its own was not able to efficiently separate the training-set data (p=0.56, Figure 
19), it can be excluded as suitable classifier feature in general. Interestingly, for the tested 
feature combinations, f5,seq was nearly always required to achieve a satisfactory prediction 
precision. This might be due to the fact that f2,ΔDOPE, f3,ΔDOPE-global, and f4,ΔDOPE-local are all based on 
energy-changes between mutated and reference 3D-structures and might therefore be partially 
redundant (B.2.1.1). f5,seq, by contrast, represents the sequence conservation on the respective 
AAS positon, addressing a completely different facet (B.2.1.2). Combining the sequence feature 
with any energy-function-based feature (except f1,DOPE) improves classification by adducting two 
different aspects of an AAS introduced into the reference sequence (Extended Data Table 4). 
 
 
Figure 46. Schematic representation for a good fit and for overfitting of a classifier. The graphs depicts training-
set entries of two different groups (red crosses or green circles) that are plotted according to their discriminatory 
features x and y. For a good fit (left) the training-set is used to calculate a discriminatory boundary (in blue) that 
separates both classes in the training-set, but is also able to classify new unknown data efficiently. Through overfitting 
of the classifier (right) the boundary is modeled too close to the training-set, which reduces the potential to group new 
data correctly. 
 
However, this does not explain why f2,ΔDOPE or f4,ΔDOPE-local, which both performed best on their 
own (p<0.0001 each, Figure 19), had negative effects on accuracy and precision, when added in 
a multidimensional FLD to f3,ΔDOPE-global and f5,seq. It seems that the addition of these features 
resulted in an overfitting of the classifier. Overfitting refers to a classification boundary that is 
modeled too close to the training-set data, by providing too many adjustable parameters. 
Thereby, random fluctuations in the training data are picked up and learned as concepts for the 
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classifier. These tightly fit classifier concepts might then not apply to new data (i.e. unknown 
AAS) and negatively impact the classifier’s capacity to distinguish between the two groups309 
(Figure 46). As observed here, overfitting in FLD is described to show up in unstable results, 
especially during cross-validation310 and can be circumvented by reduction to the essential 
features, here f3,ΔDOPE-global and f5,seq. 
A limitation of determining functional conservation only through assessing single amino acid 
substitutions is that it cannot predict the effects of combining mutations, as was later on done 
during the generation of teeGags. Combination of two or more as positive predicted AAS might 
result in steric hindrance or other detrimental interactions, which could result in reduced or 
abolished formation of VLPs. Yet, the other way round is also conceivable: a negative effect of 
an as budding-deleterious predicted AAS might thereby get rescued through a second 
compensatory mutation. Addressing the consequences of such interactions in silico is difficult, 
since a suitable training-set to supervise an algorithm is not available and, in addition, the 
number of possible AAS-combinations rapidly outgrows the feasible number. For p24 with 60 
naturally occurring AAS for example, the number of all combinations is 1.15x1018. To compute 
the structure and energy profile of each combination is hence not realizable. But, since AAS that 
are located on different domains are spatially apart and the fact that all mutations are derived 
from natural, probably viable isolates, it seems reasonable to assume that combinations of 
budding-competent mutations should not alter the Gag functionality severely. 
Interestingly, the percentage of as budding-deleterious predicted AAS was far higher for the 
permutation set (53%, D.1.2.3), than observed for the natural AAS identified in the epitope set 
(11%, D.1.2.2). This shows –as expected– that the natural CD8+ T cell epitopes are significantly 
depleted of budding-incompatible AAS (p < 0.0001 in Fisher's exact test). Of all Gag domains, 
by far the highest percentage of as budding-deleterious predicted AAS (83.6%) were observed 
for p24, the most conserved protein domain188. This supports the validity of the classifier, since 
highly conserved positions are most probably vital for functional Gag and mutations would more 
likely result in a defective protein. It is also in line with observations that p24 exhibits an 
enormous genetic fragility and tolerates only few substitutions311. Although all training-set data 
was based on AAS with known effects located in p17 (Table 4), the classification of unknown 
mutations in p24 or p2p7p1p6 still was very good, as the goal of avoiding false positives was 
reached. This might be due to the fact that f5,seq computes the position-specific conservation, 
irrespective of the protein. With an expanded set of validated AAS covering the complete Gag 
protein, future classifications might even get improved. 
E.1.3 Flexible design of breadth-enhanced Gag antigens 
Besides structural conservation of the Gag protein, the main focus for teeGag design was to 
combine as many immunologically-potent CD8+ T cells in as few antigens as possible. The 
quality-assessment of epitopes is very flexible and can include any number of epitope metadata 
characteristics (B.2.2). Only HLA- (B.2.2.1) and subtype score (B.2.2.2) were predefined, 
because they require an additional datasets containing frequencies of HLA allele groups and 
subtypes, respectively, for calculations, which makes it possible to adopt antigens to a specific 
target region. Both can also be excluded for score calculations, by assigning them a zero weight. 
A third predefined scoring parameter that is implemented in the Optimizer Algorithm, is that a list 
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of epitopes can be specified that get an additional scoring advantage. For the proof of concept 
teeGags this attribute was, however, not used. 
The teeGags were designed as a globally applicable set of antigens. Through using the 
worldwide subtype frequencies (D.1.1.4), it was possible to reduce the effect of the B clade bias, 
which is evident in Figure 29 A: All depicted natural sequences that include high numbers of 
CD8+ T cell epitopes are derived from B clade isolates (Figure 29 A - left). Through assigning a 
lower subtype score to B clade epitopes than for example to those from clade C, the natural 
sequences are more balanced with regard to their antigen score (Figure 29 A - right). By 
choosing a more selective input epitope set or through different subtype attribute weighting, this 
B clade bias might be further reduced. 
The teeGag sequences that were finally generated (D.1.4), already covered 87.8% of all 
epitopes and 91.0% of the maximally possible score within the first three iterations (teeGag1-3, 
Figure 27), making further antigens far less beneficial. This also meets the objective to restrict 
possible vaccine candidates to a maximum of three components154. For teeGag1, all but 6 amino 
acid positions were covered by at least one epitope. The non-covered positions were “filled” with 
the reference HXB2 Gag sequence. For each sequence generated in the following Optimizer 
Algorithm iterations, the fraction of the sequence that was covered got smaller, and more of the 
antigen was therefore completed with the reference. Filling the blanks with the respective amino 
acids from the reference sequence most likely maintains budding, but for future applications it 
might be advantageous to fill non-covered areas with compatible high-scoring epitopes. For the 
proof of concept, this was not important, since most high-scoring epitopes are B-clade-derived 
and are already integrated in HXB2 (Extended Data Table 5). It might however be unfavorable, 
for example, to use a subtype B sequence to fill non-covered positions, when designing a 
region-specific C clade antigen. 
E.1.4 In silico validations highlight the reliability of the algorithm, but 
also the B clade bias in the input data 
Through phylogenetic tree reconstruction, the teeGags and other antigen designs could be 
classified with regard to a preselected HIV-1 subtype reference set (Figure 28). Due to the B 
clade bias in the epitope data set and the fact that HXB2-Gag was applied as reference and to 
fill up non-covered areas, teeGag1-3 all cluster at the subtype B branch of the tree. As expected, 
conM and ancM, both designed to minimize the genetic distance of all HIV-1 subtypes, are 
located near the center of the tree. Surprisingly, this was not the case for cotM which was also 
classified as a B clade sequence. In addition, mosM that was designed to cover all naturally 
occurring Gag 9-mers was also not located at the center of the tree, but at the branch of C clade 
sequences. This might be due to the fact that the coverage calculation of the mosaic approach 
was based on a reference alignment that overrepresented C clades (64.4% subtype C)199. 
In further in silico analyses regarding antigen coverage (B.3.2) teeGag1 and teeGag1-3 were far 
superior to any monovalent or trivalent set of natural Gag sequences or designer antigens based 
on mos, anc, con, or cot approaches, respectively (Figure 29 and Extended Data Table 5). The 
best benchmarks to compare the teeGags are the mos sequences, since this is the only other 
approach that focuses on including as many CD8+ T cell epitopes as possible. For mosaic 
antigens, however, the number of naturally occurring 9-mers, as a surrogate for PTEs, was 
maximized199, instead of patient-derived epitopes. Since the computational analysis programs 
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(i.e. antigen score, population-, and pathogen coverage) used the set of patient-derived epitopes 
to calculate the number and score of the integrated epitopes, mos is mostly clearly inferior as 
compared to the teeGags. Regarding the population (Figure 30 and Extended Data Figure 1), 
computed based on the global HLA allele frequencies (D.1.1.3), teeGags were far better than 
any of the other examined Gag sequences, including mos. This was expected, since teeGags 
were specifically optimized to mainly included epitopes presented on HLA alleles that had a high 
population frequency. In summary, the Optimizer Algorithm is able to design the best possible 
antigens, regarding antigen score and population coverage. Since the target populations’ HLA 
allele frequencies and the attributes for antigen scores are customizable, the algorithm can 
design antigens for specific target populations that incorporate the best combinations of high-
scoring epitopes. 
Regarding pathogen coverage, teeGags were better than naturally occurring sequences, when 
using the global subtype frequencies for pathogen selection (Figure 31 and Extended Data 
Figure 2). However, for the monovalent sets, other antigen designs, especially mosM1.1, were 
slightly superior. This again is allegeable by the B clade bias in the teeGags. Using other 
distribution parameters for pathogen coverage, like B clades only, or subtype frequencies based 
on the occurrence in the epitope database, teeGag1 is again superior to all other antigens 
(Figure 32).  
With the mosaic suite evaluation tools Epicover and Posicover (D.2.5), which calculate the 
covered 9-mers from a set of sequences by a specific antigen, no differences were observed for 
all monovalent antigen design approaches. This indicates that teeGag1 covers the PTEs similar 
well as mosM1.1, but is far superior in antigen- and population-coverage, which makes teeGag1 
the preferable antigen in a monovalent vaccine regimen. Regarding trivalent antigen sets, the 
mosaic approach was best, which was expected, since mos3.1-3 was especially contrived for 
maximum coverage of M-group-derived Gag 9-mers. The disadvantage of considering all 
potential 9-mers as a surrogate for CD8+ T cell epitopes is that not all of these polypeptides will 
be presented on the surface of a given cell or prime a T cell response.  
E.2 Experimental characterization of VLPs 
E.2.1 Experimental classification of single AAS mutations 
The quality of the FLD classifier was validated experimentally by determining the relative 
budding (RB) of all single AAS that were incorporated into teeGag1-3 and all as budding-
deleterious predicted AAS (D.3.1). The mean RB of the latter was significantly reduced 
compared to the mean of all as budding-retaining predicted mutations (Figure 34), which 
demonstrates the effectiveness of the FLD classifier of the Optimizer Algorithm. The predefined 
objective to minimize the rate of false positives by maximizing the precision of the classifier was 
also met, since all as budding-retaining predicted mutations were indeed still compatible with 
budding, when included in the reference sequence. Of the budding-deleterious-predicted AAS, 
half were false negatives (9 of 18). This rate is higher than expected from the 10-fold cross-
validation (Extended Data Table 4), but acceptable, as long as the main criterion of strictly no 
false positives is met. The experimental validation also highlights that the natural set of epitopes 
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is even more selective for mutations preserving structure and functions as estimated through in 
silico classification.  
Although none of the positively-predicted AAS (Extended Data Table 6) did cause any 
statistically significant reduction of RB, some had special features that were part already 
addressed in the literature: mutations R15S, K28G, K30R, and K30M are all located in the 
membrane targeting domain23 and substitute rather conserved basic amino acids, involved in 
binding to the inner leaflet of the plasma membrane (A.3.1). Interestingly, none of the mutations 
was classified as budding-deleterious or exhibited significantly decreased RB. However, K30M, 
which removes a basic residue and replaces it with a nonpolar residue, had only an RB of 0.65. 
K30R at the same position, which preserves the basic residue, had a distinctly higher relative 
budding of 1.27. Combined removal of the basic residues at position 30 and 32 (K30T and 
K32T) was described to result in reduced particle production312. The remaining as budding-
retaining predicted AAS are mostly in good accordance with published data. For 34 of these 
mutations, information was found that stated that alterations at those sites do not alter particle 
release212,311,313–324. Conflicting data was observed for positions 268315,319,325 and 362321,322, 
where different alterations had variable effects on budding. However, none of the mutations was 
exactly the same as the one in the epitope set. Another 13 as budding-retaining predicted AAS 
were directly analyzed in various publications and none had negative effects on budding311,313–
316,322 (R91K313, I138L314, A146S311, I147L313,314, T190I316, E203D314, I223V311, G248A315, 
R286K313,314, G357S313,314, V362I314, S373A322, R384K313). This provides further validation for 
correct predictions and experimental assessment in this thesis. Nevertheless, some identical 
mutations were associated with reduced particle production. Moderate reduction was for 
example observed for T186M, I256V, and E260D314. For the latter two also a slightly reduced, 
but statistically not significant RB was observed in this thesis (0.85 and 0.77, respectively). 
Three further mutations -T190I314, K335R314, and V370A322- are described to have a stronger 
negative effect on budding. For T190I, the information is contradicting and in another publication, 
this mutation exhibits wildtype like particle release316. Similar for V370A, that showed reduced 
relative budding of 0.8 in this work, deletion of the same amino acid in another publication had 
no effect on budding326. Questionable mutations, with contradicting literature or non-significantly 
reduced RB, should be further characterized. 
The budding-deleterious-predicted AAS (Extended Data Table 7) can be divided into two groups: 
experimentally validated true negatives and false negatives. The first false negative (S9R) is 
located in the membrane targeting domain23, and although the relative budding was slightly 
reduced to 0.83, the effect was not significant and therefore was rejected as a correctly 
predicted budding-deleterious mutation. Negatively predicted mutations Q199E, N271H, and 
N271K all had wildtype-like or even enhanced particle production. In line with this, mutations at 
these positions were shown to have no effect on budding in previous works, but are 
accompanied by reduced infectivity of the virus315. Since the positions might be important for 
later steps in viral replication, and were probably identified as highly conserved positions by the 
sequence-based feature f5,seq (B.2.1.2) of the classifier, this could be the reason, why they were 
predicted as budding-deleterious. W316M was the only false negatively classified AAS located 
on a position that is described to negatively influence budding. Here, substitutions to alanine 
were described to prohibit particle production315,327 and mutation to leucine or arginine resulted in 
replication-deficient viruses311. In this thesis, the AAS W316M was compatible Gag with 
functionality with an RB of 1.29.  
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True negative AAS were infrequent in the natural set of epitopes and seem to be derived from 
defective viruses that nevertheless could prime a T cell response or from a virus containing a 
Gag variant that harbored compensatory mutations to account for the fitness defect. The first 
true negative AAS was located in the NTD of p24. This T151L mutation showed moderate, but 
statistically significant reduced relative budding (RB=0.58). This result is contradicting other 
literature were the T151L was described to be tolerated for virus replication313. However, in that 
work, particle release was only addressed indirectly by assessing replication capacity in a viral 
mutation selection progress. Positions 267 to 273 were a hotspot with 7 as budding-deleterious 
predicted AAS. The high number of AAS was mainly due to one epitope (Record number: 
54502; Epitope: KRWILGLNKIV), which had an isoleucine deletion compared to the HXB2 
reference (KRWIILGLNKIV), prohibiting a gap-free alignment. Of the 7 AAS, three were 
experimentally validated to be true-negatives and for G269L and L270N, budding was even 
completely abolished. Literature provides evidence that these positions are important, because 
an L268P mutation prohibits particle release325 and mutations at position 296 and 270 result in 
non-viable viruses311. Next, R294I and Y301W were two validated budding-deleterious AAS, 
which are located within the highly conserved major homology region (MHR) that is necessary 
for assembly138. Although the mutations do not affect the MHR consensus sequence from 
orthoretroviruses328, and no negative effects on budding are reported for both positions in the 
literature, it is conceivable that mutations within the MHR are detrimental. AAS Q311A was 
previously described to result in wt-like particle production317, but had a moderately reduced RB 
(0.73) in this work. This is probably explainable by different assays used to quantify particles. 
Additionally, the experimental validation presented here is one of few accounting for transfection 
efficiency (through SEAP normalization), therefore probably able to detect more subtle 
differences during budding. 
The last two truly budding-deleterious AAS, C392F and C395G, are located in p7 within the 
proximal zinc-finger-like domain, necessary to recruit viral genomic RNA to the particle assembly 
site139. In natural HIV-1 infections, interactions between NC and gRNA facilitate assembly, by 
promoting Gag multimerization146. Since VLP assembly remains efficient in the absence of 
genomic RNA it seems that host cell RNAs can fulfill this function329. It is therefore conceivable 
that mutations in the zinc-finger-like domains prohibit RNA binding and consequently reduce 
particle formation. This is especially true for C392F and C395G, since both mutate cysteines 
important for the zinc finger interactions (Figure 47). It was already shown elsewhere that 
mutations at these positions reduce particle production330,331. 
 
 
Figure 47. Schematic representation of the proximal and distal zinc finger, which that are located in p7 of 
Gag. Important interaction sites for the zinc fingers are indicated. The positions of the two validated mutations (C392F 
and C395G) with negative influence on budding are highlighted in red. 
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Interestingly, all AAS located in p6 were predicted as budding-retaining, which was 
experimentally validated. This might be due to the fact that p6 is largely unstructured140 and, 
besides recruiting the ESCRT machinery through its late domains to facilitate particle release, 
seems to play a subordinate role during VLP production148. The AAS from the natural epitope set 
that were validated experimentally in this work could also be used to refine the training-set of the 
classifier. To further improve the quality of the classifier, the present training-set AAS might be 
also re-evaluated regarding RB, because the mutations were originally identified in virions rather 
than VLPs and with the reference sequence NL4-3 instead of HXB2212.  
E.2.2 Experimental characterization of teeGag particles 
E.2.2.1 Biochemical characterization showed reference-like behavior for teeGag1 
and teeGag3, but altered characteristics for teeGag2 
After assessing the AAS individually, with regard to budding competence, their combination into 
the newly designed teeGags demanded further biochemical characterization (D.3.2). Since the 
sum of up to 40 AAS could probably alter antibody binding in the Gag-ELISA the RB was 
determined by adding a C-terminal 6x-His epitope tag to the Gag variants. This tag was used to 
assess the Gag budding densitometrically, without employing any Gag-specific antibodies 
(Figure 35). For teeGag1 and teeGag3, RB comparable to the reference HXB2-Gag was 
observed. In these cases, the assumption that single budding-competent AAS can be combined 
into a functionally intact Gag holds true. For teeGag2 on the other hand RB was moderately, but 
significantly reduced. This might be explained by a combinatory effect of any of five AAS 
(E260D, V370A, Q386S, T401I, and T427N) that were included in teeGag2 and displayed 
slightly reduced RB as separate mutations compared to the reference. Of course, other non-
prominent AAS combinations could potentially have negative effects on budding as well. 
However, with 0.78, the RB of teeGag2 was high enough to efficiently produce VLPs in 
mammalian cells. 
The special status of teeGag2 was confirmed during particle size analysis. Firstly, during the 
sucrose gradient ultracentrifugation (Figure 36) the main peak for teeGag1, teeGag3, and HXB2-
Gag was observed at a density of 1.16 g/ml, which is in good accordance with literature on the 
characterization of HIV-1 Gag VLPs produced in mammalian cells 332,333. teeGag2 on the other 
hand was identified at a slightly higher density of 1.18g/ml, which is nonetheless still in the range 
of typical VLPs333. As expected, no Gag particles were observed for the budding-deficient HXB2-
GagMyr-, neither with the densitometrical measurement, nor after the gradient centrifugation  
Electron microscopy imaging confirmed the uniformity of teeGag1, teeGag3, and HXB2-Gag 
which all had a median-diameter of about 100 nm. Again, teeGag2 was the odd one out with an 
increased median diameter of 145 nm (Figure 37 C). All constructs are nevertheless again in the 
normal range observed for HIV-1 Gag VLPs of 100-150 nm148. Whereas the increased median 
size of teeGag2 VLPs would not be too unusual, the infrequent, but distinct occurrence of 
aberrant, tubular particles is surprising (Figure 38). These tubular structures had a length of up 
to 2 µm and might be due to a set of four mutations within the p2 spacer (V370A, T371N, 
N372S, and S373A). It was proposed that the C-terminus of CA and a conserved N-terminal 
region of p2 together form an α-helix322,334. This CA-p2 boundary seems to play an active role 
during particle production and is thought to be essential for the induction of curvature. Alterations 
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in the p2 spacer of HIV-1 are therefore associated with particles that are very heterogeneous in 
size and shape, larger than normal, and often tubular326,334,335. To ensure that these teeGag2 
AAS are responsible for the aberrant, tubular VLPs they should be analyzed in more detail. 
Especially mutation V370A could be of interest, since it is described to be associated with 
reduced budding322 and alterations at this position are associated with replication-incompetent 
virions313, although herein, it had a non-significantly decreased RB of 0.8. 
Particle comparison by dynamic light scattering analysis resulted in generally larger particle 
diameters than those determined from analysis of the EM images (Figure 39). This is due to the 
fact that DLS does not measure the particle diameter directly, but rather the hydrodynamic 
diameter, which is the size of the particle in solution. The hydrodynamic diameter does therefore 
depend, besides the size of the particle, also on surface structures, shape, and the type of 
solvent. Nevertheless, teeGag2 again exhibited the largest mean diameter of all VLPs, 
correlating well with the EM analysis. The slightly enlarged size of teeGag3 compared to the 
reference was unexpected and could be addressed in further experiments, but since the direct 
analysis of electron microscopy images showed no increased diameter, this effect might be 
negligible. 
Presence of microvesicles and exosomes are sometimes a problematic contamination in VLP 
preparations333. Since the control VLP preparations from cells transfected with the budding-
deficient HXB2-GagMyr- or a control plasmid did not contain any pellet-able particles, interfering 
impurities of exosomes and microvesicles are unlikely. 
E.2.2.2 Preliminary immunological characterization 
As observed by Tanja Stief267, HIV-1 Gag VLPs had to be pseudotyped with VSV-G for efficient 
uptake, processing, and presentation by mdDCs. With incorporated Env or without any viral 
surface protein, the VLPs were not presented efficiently enough to restimulate a Gag-specific 
CD8+ T cell clone. Since different DC subpopulations exhibit variable potential to cross-present 
antigens80, it is possible that mdDCs are not the ideal cell type for cross-presentation studies, 
especially since other DC subpopulations are more likely to encounter antigens in the context of 
intramuscular vaccination. Nevertheless, it was previously shown that Gag-VLPs can activate 
mdDCs and induce ex vivo T-cell responses166, but these VLPs were produced in insect cells 
using the baculovirus system. There, efficient uptake might be facilitated by baculovirus 
glycoprotein gp64, which gets incorporated into the VLPs and can mediate direct fusion, 
followed by classical MHC class I presentation148. It is therefore possible, that non-specific 
uptake of mammalian cell-derived naked or fusion-deficient viral particles by phagocytosis or 
micropinocytosis does, in ex vivo experiments, not result in detectable epitope presentation336. 
Of course, in vivo with many different APC populations, VLP formation of course might still be 
beneficial, as indicated for DNA- or viral-vector-delivered budding-competent Gag176–178. 
To analyze and compare the immunological potential of the novel teeGags to HXB2-Gag ex 
vivo, the VLPs were thus pseudotyped with VSV-G. The use of the widely expressed LDL 
receptor as major entry port of VSV and also of VSV-G-pseudotyped vectors confers a broad 
cell tropism337. This allowed efficient transduction of mdDCs and subsequent presentation of 
epitopes on the mdDCs-surface. However, since VSV-G induces membrane fusion, the antigen 
directly gained access to the cytoplasm for classical presentation on MHC class I, rather than 
the desired cross-presentation. For initial comparisons, this system was yet deemed sufficient. 
All teeGag- and HXB2-Gag-dervied, VSV-G-pseudotyped VLPs were immunogenic, able to be 
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efficiently presented by mdDCs as measured by restimulation of a Gag-specific CD8+ T cell 
clone (Figure 40 C). There were, however, subtle differences between the different Gag VLPs: 
teeGag3 VLPs were superior to all others regarding restimulation. By contrast, teeGag2 VLPs 
had a slightly reduced restimulatory capacity. Since the epitope sequence targeted by the 
readout CD8+ T cell clone was harmonized for all VLPs, these differences cannot be due to 
different TCR reactivity or MHC class I binding, but must be because of differences in uptake or 
processing. For teeGag2, the altered size and the aberrant, tubular particles might be 
responsible for the slightly reduced restimulation rate. Further experiments are needed to 
strengthen these initial observations and maybe in vivo experiments of naked, mammalian-cell-
derived VLPs should be performed to determine their immunological potential for cross-
presentation. Nevertheless, the key conclusion of these experiments is that all tested VLPs are 
similarly immunogenic, which further highlights functional conservation of the teeGags. 
E.2.2.3 HIV-1 virions with teeGags 
The problem for comparing teeGags to the HXB2-Gag reference included in molecular clones, is 
that mutations introduced in teeGag1-3 could have unknown influence on the ribosomal 
frameshift (A.1.3) or the C-terminally overlapping Pol. To circumvent this problem pNL4-3-AL 
was used as backbone to incorporate the different Gag variants, since the gag and pol reading 
frame were transcriptionally uncoupled in this molecular clone251. 
Analyzing particle release, only teeGag1 produced wildtype-like virions. teeGag2 and teeGag3, 
in contrast, did not produce any measurable virions (Figure 41 B-D). Since the proteins alone 
efficiently produce VLPs (D.3.2.1), the inability of teeGag2 and teeGag3 to produce virions is 
probably established before assembly and release. This is possibly due to the computational 
reverse translation of teeGag genes that was done based on a HIV-1-Gag-specifc-codon table 
(B.4.2) of teeGag genes. Yet, important influences on viral replication, like unknown RNA 
secondary structures and motifs that affect transcription and RNA export dynamics, as well as 
translation cannot be taken into account comprehensively during sequence design. The next 
step should be to check for intracellularly expressed Gag, to exclude effects of the teeGags on 
assembly and release. If no Gag is synthesized in the transfected cells, the problem probably 
occurs before particle production and should be analyzed through analysis of RNA levels in 
nucleus and cytoplasm.  
Preserved virus replication of molecular clones including teeGags is however subordinate for 
their use as vaccine candidates and the observation that all human-codon-optimized teeGags on 
their own efficiently produce VLPs (Figure 35) is more important. 
E.3 Next generation of antigens optimized for breadth  
As outlined above, it was shown experimentally, that the novel teeGags are still able to form and 
release VLPs. Moreover, in silico analyses confirmed that teeGags include a broad range of 
potent CD8+ T cell epitopes. Nevertheless, there are some features that could improve the 
teeGags and also some that could be addressed in a next generation Gag antigens regarding 
the potentially elicited breadth. 
The already existing teeGag could be improved by combining them with potent, bNAb-inducing 
Env antigens, incorporated into the VLP surface. As a vaccine, this approach would combine a 
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potent humoral immune response that is possibly able to protect from HIV-1 infection with a 
broad Gag-specific CD8+ T cell response that might facilitate control of breakthrough infections. 
teeGag1 was already used to generate VLPs presenting various Env variants, which exhibited a 
similar binding affinity hierarchy towards bNAbs as the respective soluble Env variants 
(Benjamin Zimmer, personal communication). Additionally, as previously addressed, CD8+ T cell 
priming can only be performed by APCs, mainly DCs, since they express the necessary co-
receptors. It could therefore be advantageous to include molecules into the VLPs that target 
them to surface molecules of desired DC subsets. This could enhance CD8+ T cell responses, 
as has been shown for a broad range of DC molecules like DEC-205, DCIR2, mannose 
receptor, Dectin-1, and scavenger receptor CD36338. CD40L was already incorporated into Gag-
VLPs to address the CD40 receptor on DCs and was able to activate DCs in vitro, as well as 
inducing immune responses against Gag in mice339. As discussed, mammalian-cell-derived 
VLPs might not be immunogenic enough to prime T cells and would therefore lead to peripheral 
tolerance and apoptosis of reactive T cells. For an efficient immune response, the use an 
adjuvant may be needed. This could be achieved by including immune-activating molecules into 
the VLP membrane, as was accidentally the case for baculovirus-derived VLPs (E.2.2.2). The 
immune-stimulatory molecule flagellin340 and the GM-CSF and IL-4 fusion-protein GIFT4341 were 
already anchored in VLP membranes, which led to enhanced immunogenicity and increased 
immune responses. For expression of VLPs from naked DNA plasmids or viral vectors encoding 
human-codon-optimized gag genes, the intrinsic immune-activating properties of both vector 
systems could already suffice to prime adequate responses. Motifs, like the PEST sequences342, 
that enhance degradation could also added to Gag antigens to improve presentation. In this 
context, the FLD classifier could be applied to identify positions where insertions of such 
sequences can safely be made without compromising budding. 
For a completely new generation of breadth-optimized, functionally-conserved Gag antigens 
there are some alterations that could be considered. For one, not all regions of Gag are equally 
associated with protective cellular immune responses343. Selective depletion of known CD8+ T 
cell epitopes in the non-protective regions, for example by mutating the epitope anchor positions 
that are necessary for HLA binding, could achieve a benefit, since cellular immune response 
might focus on protective regions. The FLD classifier could again ensure that such introduced 
mutations do not alter Gag functionality. 
Another idea would be to focus CD8+ T cell responses on HLA-C- and HLA-E-restricted 
epitopes. Since both are not downregulated during HIV-1 infection, they could be a preferable 
target to control the virus. In NHPs it was shown that MHC-E restricted CD8+ T cell responses 
do not get primed during natural SIV infection, but vaccine-elicited MHC-E-restricted CD8+ T 
cells did recognize SIV-infected cells162. Moreover, because of limited MHC-E polymorphism, a 
vaccine targeted at MHC-E–restricted CD8+ T cell responses would elicit largely similar 
responses in all or most vaccinees, potentially providing efficient protection regardless of MHC-I 
genotype162. 
Additionally, since priming of CD8+ T cells normally requires additional help by CD4+ T cells that 
recognize related antigens on the same APC, ensuring efficient presentation of CD4 T cell 
epitopes could be beneficial for a cellular immunity-focused vaccine. The large set of CD4+ T 
cell epitopes from the LANL database (currently about 400 entries) could thus be combined with 
the CD8+ T cell epitopes from this work to generate a broad and balanced cellular response. In 
this scenario, preserved Gag functionality would also have the advantage that Gag can bud from 
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cells, when delivered via DNA or viral vectors. These exogenous particles can then be efficiently 
presented through the classical pathway on MHC class II molecules to mediate CD4+ T cell 
responses. Strong CD4+ T cell responses could additionally, through intrastructural help, 
improve humoral immune responses for VLPs that present Env on their surface. Gag-specific 
CD4+ T cell responses can thereby provide cognate help for Env-specific B cells, which would 
also facilitate induction of antibody responses179. 
E.4 Assessing the immunological breadth of antigens 
E.4.1 LC-MS/MS peptide sequencing 
To characterize the immunological breadth of antigens, a method to directly identify the HLA 
class I presented CD8+ T cell epitopes was conceived. 
. For this, cells that express soluble variants of HLA class I alleles were transfected with the 
antigen of interest. Although maturation kinetics for sHLAs are slightly delayed, indicating minor 
difficulties to access the PLC, it does not significantly impact the presented immunopeptidome 
and the peptide yield is even increased compared to peptide purification from membrane-bound 
HLAs110,111. Additionally, the detergent used to solubilize the membrane-bound HLAs and the 
consequently arising cell debris hampers subsequent epitope identification. Therefore, and due 
to the fact that use of sHLAs allows examination of one specific allele and not the cells’ complete 
haplotype, sHLAs were favored over membrane-bound HLAs. 
Peptide-harboring sHLA complexes were isolated from the conditioned medium. It was shown in 
this thesis that it is possible to purify Gag-specific CD8+ T cell epitopes restricted to individual 
HLAs using this method, since only peptides from cells expressing sHLA-B*07:02 and Gag were 
able to restimulate an HLA B*07:02-restricted Gag-specific CTL clone (Figure 42 B). By 
quantifying the amount of isolated GL9 peptide it was verified that, in theory, enough peptides 
can be purified to allow identification by mass spectrometry (Figure 43 C). The maximum 
purification of 89 µg of sHLA protein should be enough for analyzing the immunopeptidome, 
since already a few micrograms of isolated sHLA molecules are sufficient for identification of 
hundreds to thousands of sHLA bound peptides344. 
Initial epitope sequencing of sB07-restricted epitopes by LC-MS/MS, however, led only to the 
identification of few peptide sequences (~90, Figure 44 E) per experiment. These sequences 
had a length distribution that is characteristic for CD8+ T cell epitopes (Figure 44 A) and most 
had a binding motif typical for HLA-B*07:02 (Figure 44 B). Although cells were transfected with 
Gag expressing plasmids, all identified epitopes were derived from endogenous proteins and 
none was Gag-specific. The biggest barrier for identifying more epitopes, and probably also 
Gag-specific epitopes, was a PEG contamination which superimposed the actual peptide signals 
during mass spectrometry (Figure 45). In an optimal setting, using membrane-bound HLAs for 
affinity purification, between 1000 and 3000 peptides can currently be identified from 109 cells345, 
allowing identification of antigen-specific epitopes as well125. In the epitope sequencing 
experiments presented in this thesis, the number of sHLA producing cells was at least threefold 
higher, but only a tenth of the number of peptides was identified. Hence, as long as the 
sensitivity is not increased it is not possible to address the breadth of presented Gag epitopes. 
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The first step to improve the quality of the results would be to eliminate the PEG contamination. 
Besides keratin, PEG is the most common contamination in mass spectrometry experiments, 
and is present in many detergents like Triton X-100 or Tween and may also leach from some 
types of plastic-wares. Since trace amounts can already prohibit sensitive mass spectrometry 
analysis, only glassware and specific low-bind plastic-wares were used, wherever possible. 
Although, these harsh restrictions did reduce the contamination signal, it was not completely 
eliminated. The source of the contamination could, however, be narrowed down and is most 
probably caused by the 3 kDa cut-off filter, which might release the undesired substance when 
the eluate, which contains 10% acetic acid, is added. The best alternative would be to 
completely omit use of the cut-off filter and instead separate peptides from HLA-hc, β2m, and 
residual W6/32 antibody through RP-HPLC. This method has also been reported to increase the 
yield of peptides by a factor of ten345 compared to purification with a cut-off filter, where a 
significant amount of peptides is lost. 
Besides avoiding contamination, the signal would also be improved if more peptides could be 
isolated overall. Due to the strong link between protein abundance and HLA-presentation120, 
elevated Gag production in the cells would have an additionally benefit. For most experiments 
performed, Flp-In™ T-Rex™ 293 cells that were adapted to grow in suspension and that stably 
expressed the sHLA heavy chains, were employed. In addition, these cell lines were transiently 
transfected with Gag-coding plasmids using PEI. The transfection rates were however rather low 
and often below 15%. Thus, most cells were not able to present Gag-derived epitopes, but only 
endogenous peptides. To circumvent this, HEK293F cells were transiently co-transfected with 
sHLA-hc and Gag on separate expression plasmids so that the expression of both proteins is 
coupled in most cells. However, due to the PEG contaminations, even with this adapted method, 
no Gag-specific epitopes were identified. The easiest way to screen antigen-specific epitopes 
presented by several HLA alleles would probably be to design a bidirectional sHLA vector 
library. Such mammalian expression vectors could in one direction encode a sHLA-hc allele and 
contain in the other direction a multiple cloning site to readily insert any antigen of interest. 
Thereby only one plasmid preparation would be necessary and it would be ensured that all 
transfected cells express both sHLA and the antigen. 
Since it is described that the pool of cellular β2m in the ER can be limiting for extensive 
quantities of HLA heavy chains346, it has to be tested, if additionally providing β2m would have a 
beneficial effect on the amount of sHLA complexes released to the cell supernatant. However, 
due to the fact that a substantial fraction of HLA molecules never binds to suitable peptides347 
and subsequently gets degraded through the ERAD system78, the peptide concentration seems 
to be rate limiting during HLA loading70. To eliminate competition for β2m, peptides, and possible 
other factors, deleting of all membrane-bound HLA molecules from the HEK293F expression cell 
line, for example by CRISPR/Cas mediated excision, could be advantageous. 
In APCs responsible for priming a CD8+ T cell response, the immunoproteasome alters 
degradation patterns compared to other cells. To resemble the processing in APCs, the 
immunoproteasome could be activated in HEK293F cells by treatment with IFNγ348. An 
additional benefit with this strategy would be that the immunoproteasome significantly elevates 
epitope abundance71 and more sHLA complexes can presumably be loaded and secreted. 
In conclusion, a method to identify sHLA-presented-peptides through LC-MS/MS analysis was 
adapted in this thesis. However, in order to determine the immunological breadth of the 
teeGags, the sensitivity of the assay has to be further improved. 
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E.4.2 Other ways to analyze immunological breadth 
Besides the direct identification of presented epitopes through mass spectrometry sequencing, 
there is only a limited number of assays available to address the immunological breadth of 
antigens. The most meaningful approach would be to administer the teeGags in human vaccine 
trials and read-out the breadth of primed T cells using peptide sets matching the teeGag 
sequences. Most animal in vivo experiments, in contrast, are futile, since teeGags are optimized 
for humans and the incorporated potent CD8+ T cell epitopes would not be processed and 
presented on the MCH alleles of mice or NHPs. The only possibility might be to employ 
humanized mice that can present antigens on human HLAs. An alternative could be to design 
SIV CD8+ T cell epitope-enriched Gag antigens and test them in NHPs, but the number of 
known, directly available SIV epitopes is too low (only 14349) to allow a reasonable optimization 
process. 
An in vitro method to get a first impression of the immunological breadth would be to use a broad 
set of different Gag-specific CD8+ T cell clones and identify presented epitopes on antigen-
containing cells. Another more natural approach could be to isolate PBMCs from HIV-1-positive 
donors and restimulate those cells with teeGags- or the reference HXB2-Gag-VLPs. Since 
teeGags are designed to contain as many epitopes as possible, they should be able to 
restimulate more T cells than HXB2-Gag, provided the T cell response of a given HIV patient is 
sufficiently diverse. This postulated average increased magnitude could serve as a surrogate for 
breadth. It allows, however, only a rough estimation, since an immunodominant response 
against a single epitope could not be differentiated from a broad immune response with only low 
responses against the many different epitopes. To map the immunological breadth more closely, 
peptide pools spanning the teeGags or the reference could be used for individual restimulation 
of PBMCs from HIV-1+ donors. 
The breadth could also be determined through ex vivo priming of naïve CD8+ T cells. Thereby, 
DCs from an HIV-1 negative donor would be loaded with Gag antigen and co-cultured with 
autologous lymphocytes350. The breadth would be assessed by measuring the number of primed 
CD8+ T cells, which recognize different epitopes. However, since only a small subset of all 
lymphocytes can be used, it is not possible to determine the maximum breadth in these ex vivo 
experiments, but on average the teeGags might prime more T cells than the reference.  
Finally, rather easily adaptable tools to assess the immunological breadth are in silico 
processing and presentation predictions. Yet, the accuracy of such approaches is limited by 
several unclear steps during processing, like the influences of peptidases and how different 
chaperones influence the peptide pool. Therefore, such in silico predictions still perform 
relatively poor70,351. 
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F Appendix 
F.1 Abbreviations 
1D One-dimensional 
3D Three-dimensional 
AAS Amino acid substitutions 
ADCC 
Antibody-dependent cellular 
cytotoxicity 
AIDS 
Acquired immune deficiency 
syndrome 
Amp
R
 Ampicillin resistance gene 
anc Ancestral 
APC Allophycocyanin 
APC Antigen presenting cell 
ART Antiretroviral therapy 
β2m Beta-2-microglobulin 
BFA Brefeldin A 
BLASTP 
Protein Basic Local Alignment Search 
Tool 
bNAb broadly neutralizing antibody 
BrdUTP Bromo-deoxyuridine triphosphate 
BrdU Bromo-deoxyuridine 
BRMP 
Biological Response Modifiers 
Program 
BSA Bovine serum albumin 
CA Capsid protein 
CCB Crosslinking coupling buffer 
CD Cluster of differentiation 
CDR3 
Complementarity determining region 
3 
CIP Alkaline Phosphatase, Calf Intestinal 
con Consensus 
cot Center-of-tree 
cpz Chimpanzee 
CRF Circulating recombinant form 
CSV Comma-separated values 
CTB Crosslinking termination buffer 
CTL Cytotoxic T lymphocyte 
cv Column volume 
DC Dendritic cell 
DLS Dynamic light scattering 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMP Dimethyl pimelimidate dihydrochloride 
DMSO Dimethyl sulfoxide 
DPBS Dulbecco’s Phosphate Buffered 
Saline 
DRiP defective ribosomal product 
ds Double-stranded 
ELISA Enzyme-linked immunosorbent assay 
EM Electron microscopy 
ER Endoplasmic reticulum 
ERAP ER aminopeptidases 
FA Formic acid 
FDR False discovery rate 
FESEM 
Field emission scanning electron 
microscopy 
FBS Fetal Bovine Serum 
FC Flow Cytometry 
FITC Fluorescein isothiocyanate 
FLD Fisher’s Linear Discriminant Analysis 
FRT Flippase recognition target 
fwd Forward 
Gag Group-specific antigen 
GMP Good manufacturing practices 
GOI Gene of interest 
gor Gorilla 
hc Heavy chain 
HESN HIV-exposed seronegative 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
HPLC 
High performance liquid 
chromatography 
hpt Hours post transfection 
HRP Horseradish peroxidase 
Hygro
R
 Hygromycin resistance gene 
IFN-γ Interferon gamma 
Ig Immunoglobulin 
IN Integrase 
INSTI Integrase strand transfer inhibitor 
ITAM 
Immunoreceptor tyrosine-based 
activation motifs 
Kan
R
 Kanamycin resistance gene 
LB lysogeny broth 
LC Liquid chromatography 
LCL Lymphoblastoid cell line 
LTNP Long-term nonprogressors 
LTR Long terminal repeat 
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MA Matrix protein 
MACS Magnetic-activated cell sorting 
mdDCs Monocyte-derived dendritic cells 
merGag Multiple epitope refined Gag antigen 
MHC Major histocompatibility complex 
MLA Mixed leukocyte reaction 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
MSA Multiple sequence alignment 
MWIS Maximum weight independent set 
NC Nucleocapsid protein 
Neo
R
 Neomycin resistance gene 
NHP Non-human primates 
NNRTI 
Non-nucleoside reverse transcriptase 
inhibitor 
NRTI 
nucleoside reverse transcriptase 
inhibitor 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDB Protein Data Bank 
PE Phycoerythrin 
PEI Polyethylenimine 
PIC Pre-integration complex 
PLC Peptide-loading complex 
POD Horseradish peroxidase 
PTE Potential T cell epitopes 
PR Protease 
RB Relative budding 
rev Reverse 
RP-HPLC 
Reversed phase High performance 
liquid chromatography 
RRE Rev response element 
RT Reverse transcriptase 
SD Standard deviation 
SDS-PAGE 
Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis 
SEAP Secreted alkaline phosphatase 
SEM Standard error of the mean 
SHIV 
Simian-human immunodeficiency 
virus 
sHLA Soluble human leukocyte antigen 
SIV Simian immunodeficiency virus 
ss Single-stranded 
sus Suspension 
TAP 
Transporter associated with antigen 
presentation 
TBS Tris-buffered saline 
TCR T cell receptor 
teeGag T cell epitope-enriched Gag antigen 
TEM Transmission electron microscopy 
TFA Trifluoroacetic acid 
TFH Follicular helper CD4+ T cells 
TMB 3,3',5,5'-Tetramethylbenzidin 
URF Unique recombinant form 
VLP Virus-like particle 
VSV Vesicular stomatitis virus 
VSV-G Vesicular stomatitis virus glycoprotein 
WB Western Blotting 
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F.2 Extended Data 
F.2.1 Extended Data Tables 
Extended Data Table 1. Changelog for the list of epitope entries that were identified as erroneous or 
undesired (D.1.1.2). Each entry can be assigned to the LANL database through its unique record number (“RecNo”). 
In 154 cases it was possible to correct the entry. For these lines marked as “Modified”, the detailed change log is 
stated. However 99 epitope entries had to be deleted (Action “Deleted”) with the reason for removing the respective 
database entry being listed in the last column. 
RecNo Epitope Action Changelog Reason 
56549 EKIRLRPGGKKYKL Modified Epitope: Changed to "EKIRLRPGGKKKYKL" LANL database error 
52872 KIRLRPGGKK Modified Subtype: "multiple" deleted  
12 KIRLRPGGKKKYKLKHIVWASRELE Deleted  Epitope length > 20aa 
14 KIRLRPGGKKKYKLKHIVWASRELE Deleted  Epitope length > 20aa 
13 KIRLRPGGKKKYKLKHIVWASRELE Deleted  Epitope length > 20aa 
52864 IRLRPGGKKK Modified Subtype: "multiple" deleted  
58852 RLRPGGKKK Modified HLA: "A02:01" --> "A03:01"  
52892 RLRPGGKKK Modified Subtype: "multiple" deleted  
53186 RPRPGGKKK Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58435 RLRPGGKKK Modified Subtype: "A1" changed to "A"  
57939 RLRPGGKKK Modified Subtype: "A1" changed to "A"  
58974 LYNTVATL Modified Start: 20 --> 78; End: 28--> 85 LANL database error 
55913 RLRPGGKKKKY Deleted  Conservation score = 0; No access to reference paper 
55912 RLRPGGKKKK Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
55704 RLRPGGKKKK Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58436 RLRPGGKKKY Modified Subtype: "A1" changed to "A"  
30 CLRPGGKKKYKLKHIV Deleted  
Conservation score = 0; N-terminal cysteine added to 
aid synthesis 
34 LRPGGKKKYKLKHIV Modified HLA: "not B8" deleted  
56297 RPGGKKKKYK Modified Epitope: Changed to "RPGGKKKYK" LANL database error 
59061 GGKKKYKMK Deleted  Subtype: "HIV-2 " 
58437 GGKKKYKLK Modified Subtype: "A1" changed to "A"  
58433 KYKLKHIVW Modified Subtype: "A1" changed to "A"  
54592 HYMLNHIVW Modified Epitope: Changed to "HYMLKHIVW" Erroneous sequence in reference paper 
55475 HYMLKHLVW Modified Subtype: "A1" changed to "A"  
57 QTGSEELRSLYNTVATLYCVHQRIE Deleted  Epitope length > 20aa 
56959 EELRSLYNT Modified Subtype: "A1" changed to "A"  
58430 ELRSLYNTV Modified 
Subtype: "A1" changed to "A"; HLA: "A*0801" --> 
"B*0801" 
Erroneous HLA specification in reference paper; HLA 
A*08 does not exist 
52873 ELRSLYNTVA Modified Subtype: "multiple" deleted  
53400 RSLYNTATLY Deleted  
Conservation score = 0; Sequence in reference paper 
maybe erroneous 
1279 RLSYNTVATLY Modified Epitope: Changed to "RSLYNTVATLY" Erroneous sequence in reference paper 
58431 RSLYNTVATLY Modified Subtype: "A1" changed to "A"  
58427 SLYNTVATL Modified Subtype: "A1" changed to "A"  
55467 SLYNTVATL Modified Subtype: "A1" changed to "A"  
55756 SLFNTVATL Deleted  
Immunogen: "computer prediction" without 
experimental validation 
52777 SLYNTAVTL Modified Epitope: Changed to "SLYNTVATL" LANL database error 
52875 SLYNTVATLY Modified Subtype: "multiple" deleted  
55638 SLYNIVATLWCVH Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58973 TSTLQEQIGW Modified 
Protein: "p17" --> "p24"; Start: 78 --> 108; End: 88 --
> 117 
LANL database error 
55634 YNIVATLWCVHQ Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
55772 ATLYCVHEKIEVRDTKEALDK Deleted  Epitope length > 20aa 
111 CRIDVKDTKEALEKIE Deleted  
Conservation score = 0; N-terminal cysteine added to 
aid synthesis 
112 
VHQRIEIKDTKEALDKIEEEQNKSKK
KA 
Deleted  Epitope length > 20aa 
58438 VQNLQGQMV Modified Subtype: "A1" changed to "A"  
58439 QGQMVHQSL Modified Subtype: "A1" changed to "A"  
1174 VQHAISPRTLNAWV Modified Epitope: Changed to "VHQAISPRTLNAWV" LANL database error 
134 VHQAISPRTLNAWVKVVEEKAF Deleted  Epitope length > 20aa 
58440 HQSLSPRTL Modified Subtype: "A1" changed to "A"  
1537 QAISPRTLNAV Modified Epitope: Changed to "QAISPRTLNAW" LANL database error 
57775 AISPRTNLAW Modified Epitope: Changed to "AISPRTLNAW" LANL database error 
58441 SLSPRTLNA Modified Subtype: "A1" changed to "A"  
58812 ISPRTLNAW Modified Start: 14 --> 15 LANL database error 
56956 AISPRTLNAW Modified Subtype: "A1" changed to "A"  
57597 ISPRTNLAW Modified Epitope: Changed to "ISPRTLNAW" LANL database error 
57258 ISPRTLNAW Modified Subtype: "A1" changed to "A"  
56591 TPQDLNTML Modified Start: 15 --> 48; End: 23 --> 56 LANL database error 
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RecNo Epitope Action Changelog Reason 
56974 ISPRTLNAW Modified Subtype: "A1" changed to "A"  
58442 LSPRTLNAW Modified Subtype: "A1" changed to "A"  
58443 SPRTLNAWV Modified Subtype: "A1" changed to "A"  
58746 EKIRLRPGGKKKYKL Modified Protein: "p24" --> "p17"; End: 28 --> 31 LANL database error 
55357 TLNAWVKLV Deleted  Subtype: "HIV-2 " 
53231 NAWVKIEEK Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
157 NAWVKVVEEKAFSPEVIPMFSA Deleted  Epitope length > 20aa 
58444 EEKAFSPEV Modified Subtype: "A1" changed to "A"  
58840 KAFSPEVIPMF Modified Start: 29 --> 30; End: 41 --> 40 LANL database error 
52366 EKAFSPEVPMFTALSEGAT Modified Epitope: Changed to "EKAFSPEVIPMFTALSEGAT" LANL database error 
58285 KAFSPEVI Modified Subtype: "A1" changed to "A"  
58451 KAFSPEVIP Modified Subtype: "A1" changed to "A"  
57523 KAFSPEVIPMF Modified HLA: "A*0201" --> "B*5701" LANL database error 
57259 KAFSPEVIPMF Modified Subtype: "A1" changed to "A"  
58423 KAFSPEVIPMF Modified Subtype: "A1" changed to "A"  
56377 KAFSPEVIPMF Modified Subtype: "ACD" --> "B" LANL database error 
58445 FSPEVIPMF Modified Subtype: "A1" changed to "A"  
56557 SPEVIPMFASLSEGA Modified Epitope: Changed to "SPEVIPMFSALSEGA" LANL database error 
58694 VIPMSFAL Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58446 VIPMFSALS Modified Subtype: "A1" changed to "A"  
1456 IPMFSALSEGATPDQL Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58447 PMFSALSEG Modified Subtype: "A1" changed to "A"  
52367 MFTALSEGTPQDLNTMLNT Modified 
Epitope: Changed to 
"MFTALSEGATPQDLNTMLNT" 
LANL database error 
58448 FSALSEGAT Modified Subtype: "A1" changed to "A"  
55224 QALSEGCTPYDINQML Deleted  Subtype: "HIV-2 " 
179 SALSEGATPQDLNTMLNTVGGH Deleted  Epitope length > 20aa 
58449 LSEGATPQD Modified Subtype: "A1" changed to "A"  
58452 GATPQDLNM Modified Subtype: "A1" changed to "A"  
181 CTPYDINQMLNC Deleted  Subtype: "HIV-2 " 
58425 TPQDLNTNL Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
55683 TPYDINQML Deleted  Subtype: "HIV-2 " 
53711 TPYDINQML Deleted  Subtype: "HIV-2 " 
182 TPQDLNQML Modified Epitope: Changed to "TPQDLNTML" LANL database error 
55688 TPYDINQML Deleted  Subtype: "HIV-2 " 
187 TPYDINQML Deleted  Subtype: "HIV-2 " 
188 TPYDINQML Deleted  Subtype: "HIV-2 " 
59027 TPYDINQML Deleted  Subtype: "HIV-2 " 
55522 TPYDINQML Deleted  Subtype: "HIV-2 " 
55165 TPQDLNTML ? Deleted  "?" = Amino acid sequence not defined by reference 
55483 TPQDLNTML Modified Subtype: "A1" changed to "A"  
58426 TPQDLNTML Modified Subtype: "A1" changed to "A"  
58453 TPQDLNTML Modified Subtype: "A1" changed to "A"  
52903 TPQDLNTMLN Modified Subtype: "multiple" deleted  
52877 TPQDLNMMLN Modified Subtype: "multiple" deleted  
53705 TPQDLNQMLNTV Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
52904 DLNTMLNTVG Modified Subtype: "multiple" deleted  
190 
DLNTMLNTVGGHQAAMQMLKETIN
EEAAEWDR 
Deleted  Epitope length > 20aa 
58454 LNMMLNIVG Modified Subtype: "A1" changed to "A"  
58455 MMLNIVGGH Modified Subtype: "A1" changed to "A"  
58456 LNIVGGHQA Modified Subtype: "A1" changed to "A"  
58338 GGHQAAMQMLKDTINEEEA Modified Epitope: Changed to "GGHQAAMQMLKDTINEEA" LANL database error 
203 GHQAAMQMKETINEEAAEW Modified 
Epitope: Changed to 
"GHQAAMQMLKETINEEAAEW" 
LANL database error 
204 GHQAAMQMLKETINEEAAEWDR Deleted  Epitope length > 20aa 
58457 HQAAMQMLK Modified Subtype: "A1" changed to "A"  
208 LKETINEEAAEWDRVPV Modified Epitope: Changed to "LKETINEEAAEWDRVHPV" LANL database error 
212 EIINEEAAEW Deleted  Subtype: "HIV-2 " 
58796 ETINEEAAAEW Modified Epitope: Changed to "ETINEEAAEW" LANL database error 
213 ETINEEAAEWDRVHPVVHAGP Modified 
Epitope: Changed to 
"ETINEEAAEWDRVHPVHAGP" 
Erroneous sequence in reference paper 
58458 EEAAEWDRL Modified Subtype: "A1" changed to "A"  
58459 EAAEWDRLH Modified Subtype: "A1" changed to "A"  
58460 AAEWDRLHP Modified Subtype: "A1" changed to "A"  
58461 RLHPVHAGP Modified Subtype: "A1" changed to "A"  
57432 HPVHAGPVA Modified Subtype: "A1" changed to "A"  
55477 HPVHAGPVA Modified Subtype: "A1" changed to "A"  
56524 HVPHAGPIA Modified Epitope: Changed to "HPVHAGPIA" LANL database error 
58462 VHAGPIPPG Modified Subtype: "A1" changed to "A"  
58463 PGQMREPRG Modified Subtype: "A1" changed to "A"  
58464 MREPRGSDI Modified Subtype: "A1" changed to "A"  
58465 SDIAGTTST Modified Subtype: "A1" changed to "A"  
55226 SDIAGTTSTVDEQIQWMY Deleted  Subtype: "HIV-2 " 
58466 IAGTTSTLQ Modified Subtype: "A1" changed to "A"  
58467 GTTSTLQEQ Modified Subtype: "A1" changed to "A"  
58842 TSTLQEQIGW Modified Start: 107 --> 108; End: 118 --> 117 LANL database error 
57351 TSTLQEQIGW Modified HLA: "A*02" --> "B*57"  
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56715 TSTLQEQIGW Modified HLA: "A*02" --> "B*57"  
57524 TSTLQEQIGW Modified HLA: "A*0201" --> "B*5701" LANL database error 
58779 TSTLQEQIGW Modified HLA: "B*2705" --> "B*5701"  
57952 TSTLQEQIGW Modified Subtype: "A1" changed to "A"  
57261 TSTPQEQIGW Modified Subtype: "A1" changed to "A"  
52759 TSTLQEQIGN Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
1335 TSTLQRQIGW Modified Epitope: Changed to "TSTLQEQIGW" LANL database error 
221 TSTVEEQQIW Deleted  Subtype: "HIV-2 " 
59066 TSTVEEQIQW Deleted  Subtype: "HIV-2 " 
55525 TSTVEEQIQW Deleted  Subtype: "HIV-2 " 
59025 TSTVDEQIQW Deleted  Subtype: "HIV-2 " 
53712 TSTVEEQIQW Deleted  Subtype: "HIV-2 " 
2010 TSTLQEQIGWF Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
55707 TSTLQEQIGWF Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
57981 TSTLQEQIGWF Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
219 TSTLQEQIGWF Modified 
Epitope: Changed to "TSTLQEQIGW"; End: 118 --> 
117 
LANL database error 
57976 TSTLQEQIGWF Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58471 KRWIILGLN  
Start: 112 --> 131; End: 120 --> 139; Subtype: "A1" 
changed to "A" 
 
58468 TLQEQIGWM Modified Subtype: "A1" changed to "A"  
58469 QEQIGWMTG Modified Subtype: "A1" changed to "A"  
55225 MYRQQNPVPVGNIYRRWI Deleted  Subtype: "HIV-2 " 
53072 MTSNPPIPV Modified Subtype: "M" --> "C"  
58807 MTNNPPIPV Modified Subtype: "multiple" deleted  
233 NPPIPGEIKRWIILGNIK Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
57705 NPPIPVGEIYKRWIILGLNKIV Deleted  Epitope length > 20aa 
235 NPPIPVGEIYKRWIILGLNKIV Deleted  Epitope length > 20aa 
229 
NPPIPVGEIYKRWIILGLNKIVRMYSP
TSILD 
Deleted  Epitope length > 20aa 
227 
NPPIPVGEIYKRWIILGLNKIVRMYSP
TSILD 
Deleted  Epitope length > 20aa 
55663 NPVPVGNIY Deleted  Subtype: "HIV-2 " 
56346 NPVPVGNIY Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
1326 PPIPVGDIH Modified Epitope: Changed to "PPIPVGDIY" LANL database error 
245 NPVPVGNIY Deleted  Subtype: "HIV-2 " 
59013 NPVPVGNIY Deleted  Subtype: "HIV-2 " 
55227 PVGNIYRRWIQIGLQKCV Deleted  Subtype: "HIV-2 " 
52476 VGEIYKRWIIGLNK Modified Epitope: Changed to "VGEIYKRWIILGLNK" LANL database error 
55676 GDIYWKRWI Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
57520 EIYKRWII Modified HLA: "A*0201" --> "B*0801" LANL database error 
53743 EIYRKWII Modified Epitope: Changed to "EIYKRWII" LANL database error 
55159 EIYKRWII ? Deleted  "?" = Amino acid sequence not defined by reference 
52752 IYKLWIILGLNKIVRMYSPT Modified Epitope: Changed to "IYKRWIILGLNKIVRMYSPT" LANL database error 
58599 SLYNTVATL Deleted  Erroneous start-end annotations 
262 RRWIQLGLQK Deleted  Subtype: "HIV-2 " 
57522 KRWIILGLNK Modified HLA: "A*0201" --> "B*2705" LANL database error 
281 KRWIIMGNK Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
282 KRWIILGNK Modified Epitope: Changed to "KRWIILGLNK" LANL database error 
1802 RRWIQLGLQK Deleted  Conservation score = 0 
55658 KIRWIIGLNK Modified Epitope: Changed to "KRWIILGLNK" LANL database error 
57187 KRWIIILGLNK Modified Epitope: Changed to "KRWIILGLNK" LANL database error 
263 RRWIQLGLQK Deleted  Subtype: "HIV-2 " 
56729 RRWIQLGLQK Deleted  Conservation score = 0 
264 KRWIILGGLNK Modified Epitope: Changed to "KRWIILGLNK" LANL database error 
57945 KRWIILGLNK Modified Subtype: "A1" changed to "A"  
291 KRWIILGLNKIVMRY Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
292 KRWIILGLNKIVMRY Modified Epitope: Changed to "KRWIILGLNKIVRMY" LANL database error 
1183 KRWILGLNKIVRMY Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
294 KRWIILGLNKIVRMYC Deleted  C-terminal cysteine added for chemical coupling 
295 KRWIILGLNKIVRMYSPTSI Modified HLA: "B62?" deleted  
297 KRWIILGLNKIVRMYSPTSILD Deleted  Epitope length > 20aa 
1180 KWILGLNKIVRMY Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
1181 KWILGLNKIVRMY Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58473 LGLNKIVRM Modified 
Start: 133 --> 136; End: 141 --> 144; Subtype: "A1" 
changed to "A" 
LANL database error 
58472 WIILGLNKI Modified Subtype: "A1" changed to "A"  
53764 GLNKVRMY Modified Epitope: Changed to "GLNKIVRMY" Erroneous sequence in reference paper 
58474 RMYSPVIL Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
55641 STLDIRQGPKEPFID Modified Epitope: Changed to "SILDIRQGPKEPFID" LANL database error 
58475 ILDIRQGPK Modified Subtype: "A1" changed to "A"  
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55365 IRQGPKEPFRDYVDRFFKTLRAEQA Deleted  Epitope length > 20aa 
58476 PKEPFRDYV Modified Subtype: "A1" changed to "A"  
308 PKEPFRDYVDRFYKTLRAEQAS Deleted  Epitope length > 20aa 
58480 DYVDRFFKT Modified Subtype: "A1" changed to "A"  
55690 SYVDRFYKSL Deleted  Subtype: "HIV-2 " 
1275 YVDRFFKRL Modified Epitope: Changed to "YVDRFFKTL" LANL database error 
56596 QATQDVKNW Modified Start: 164 --> 176; End: 172 --> 184 LANL database error 
55166 YVDRFFKTL ? Deleted  "?" = Amino acid sequence not defined by reference 
55223 YVDRFYKSLRAEQTDPAV Deleted  Subtype: "HIV-2 " 
54538 VDRFYKLTRAEQAS Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
54537 DRFYKLTRA Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
322 DRFWKTLRA Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
329 DRFYKLTRA Modified Epitope: Changed to "DRFYKTLRA" LANL database error 
59026 DRFYKSLRA Deleted  Subtype: "HIV-2 " 
58477 DRFFKTLRA Modified Subtype: "A1" changed to "A"  
52757 DRFYKTRAE Deleted  Conservation score = 0 
58478 FKTLRAEQA Modified Subtype: "A1" changed to "A"  
52481 YKTLRAEQASQDVKNWN Modified Epitope: Changed to "YKTLRAEQASQDVKNWM" LANL database error 
55228 LRAEQTDPAVKNWMTQTL Deleted  Subtype: "HIV-2 " 
58841 QASQEVKNW Modified Start: 175 --> 176; End: 185 --> 184 LANL database error 
1699 QASGEVKNW Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
58434 QASQEVKNW Modified Subtype: "A1" changed to "A"  
1554 QASKEVKNWV Deleted  Conservation score = 0 
55689 QTDPAVKNWM Deleted  Subtype: "HIV-2 " 
58479 ETLLVQNAN Modified Subtype: "A1" changed to "A"  
58481 LVQNANPDC Modified Subtype: "A1" changed to "A"  
52221 VQNANPDCKTILKAL Deleted  
Immunogen: "computer prediction" without 
experimental validation 
53160 NANPDSKTI Modified Epitope: Changed to "NANPDCKTI" LANL database error 
348 NANPDCKTI? Deleted  "?" = Amino acid sequence not defined by reference 
58482 NPDCKSILR Modified Subtype: "A1" changed to "A"  
58432 DCKTILKAL Modified 
Subtype: "A1" changed to "A"; HLA: "A*0801" --> 
"B*0801" 
Erroneous HLA specification in reference paper; HLA 
A*08 does not exist 
58483 DCKSILRAL Modified Subtype: "A1" changed to "A"  
58681 RALGPGATM Modified Epitope: Changed to "RALGPGATL" LANL database error 
55479 RALGPGATL Modified Subtype: "A1" changed to "A"  
58484 RALGPGATL Modified Subtype: "A1" changed to "A"  
58485 GATLEEMMT Modified Subtype: "A1" changed to "A"  
58486 LEEMMTACQ Modified Subtype: "A1" changed to "A"  
359 LEEMMTACQGVGGPGHKARVL Deleted  Epitope length > 20aa 
58487 EEMMTACQG Modified Subtype: "A1" changed to "A"  
58488 MMTACQGVG Modified Subtype: "A1" changed to "A"  
58489 MTACQGVGG Modified Subtype: "A1" changed to "A"  
57517 ACQGVGGPGHK Modified HLA: "A*0201" --> "A*1101" LANL database error 
58490 GGPGHKARV Modified Subtype: "A1" changed to "A"  
56599 GPGHKARVL Modified HLA: "B5" --> "B*0705"  
58978 RQANFLGKI Modified 
Protein: "p24" --> "p2p7p1p6"; Start: 223 --> 66; 
End: 231 --> 74 
LANL database error 
56597 AEQATQDVKNW Deleted  Erroneous start-end annotations 
57518 GPGHKARVL Modified HLA: "A*0201" --> "B*0702" LANL database error 
52884 GPGHKARVLA Modified Subtype: "multiple" deleted  
367 GHKARVLAEATLSQVN Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
53071 VLAEAMSQV Modified Subtype: "M" deleted  
52894 LARNCRAPRK Modified Subtype: "multiple" deleted  
56975 KAPRKKGCW Modified Subtype: "A1" changed to "A"  
58429 FLGKIWPSYK Modified Subtype: "A1" changed to "A"  
55466 FLGKIWPSHK Modified Subtype: "A1" changed to "A"  
55273 PPSGKGGNY Deleted  Subtype: "HIV-2 " 
53094 GNFLQSRPTAPPF Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
52222 GNFLQSRPEPTAPPF Deleted  
Immunogen: "computer prediction" without 
experimental validation 
56465 QNRPEPRPEPTAPPAENFRES Deleted  
Conservation score = 0; Sequence in reference paper 
inconclusive 
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 Extended Data Table 2. Final set of unique epitopes (D.1.1.2). The 
epitope raw data from LANL immunology database was screened for multiple 
records of the same epitope. Such duplicates were merged into one 
consensus entry. The remaining 691 unique entries are listed below. Each 
epitope is specified by the 
a
HIV-1 Gag protein it is located in, 
b
start- and 
c
end 
position in the respective protein, 
d
epitope sequence, 
e
associated subtypes, 
f
HLA molecules that present it, 
g
affiliation with LTNP, 
h
expected immune 
response score, and 
i
conservation score. 
Prot
a
 S
b
 E
C
 Epitope
d
 Subtype
e
 HLA
f
 L
g
 R
h
 C
i
 
p17 1 10 MGARASVLSG CRF01_AE    0.29 
p17 5 13 ASVLSGGEL B    0.05 
p17 5 15 ASILRGGKLDK C    0.09 
p17 5 18 ASVLSGGELDRWEK B    0.03 
p17 5 19 ASVLSGGELDRWEKI B    0.03 
p17 6 15 SVLSGGQLDR B A*11   0.01 
p17 6 19 SVLSGGELDRWEKI B    0.03 
p17 9 23 SGGELDRWEKIRLRP B B*40; B*44   0.04 
p17 11 19 GELDRWEKI B B*40  0.09 0.04 
p17 11 19 GQLDRWEKI B   0.01 0.01 
p17 11 22 GKLDSWEKIRLR A; CRF01_AE; 
CRF02_AG 
   0.02 
p17 11 22 GKLDAWEKIRLR CRF01_AE    0.20 
p17 11 30 GELDRWEKIRLRPGGKKKYK B B*15   0.01 
p17 12 21 ELDRWEKIRL B; C B*15   0.04 
p17 13 27 LDRWEKIRLRPGGKK B A*03; B*40   0.08 
p17 16 30 WEKIRLRPGGKKKYK B    0.05 
p17 17 31 EKIRLRPGGKKKYKL B B*07; B*27  0.00 0.04 
p17 17 31 EKIRLRPGGKKHYML C    0.10 
p17 17 34 EKIRLRPGGKKHYMLKHL B; C Cw*17  0.00 0.06 
p17 17 34 EKIRLRPGGKKKYKLKHI B    0.02 
p17 17 34 EKIRLRPGGKKKYRLKHL B    0.09 
p17 18 26 KIRLRPGGK B; A; CRF01_AE A*03; A*11; B*07; B*27  0.04 0.60 
p17 18 27 KIRLRPGGKK B; C A*03; A*11; B*07; B*27; 
B*35 
1 0.05 0.60 
p17 18 31 KIRLRPGGKKKYKL B A*03; B*15   0.04 
p17 18 32 KIRLRPGGKKKYKLK B B*57   0.04 
p17 19 27 IRLRPGGKK B B*27  0.01 0.74 
p17 19 28 IRLRPGGKKK B A*03; A*11; B*15   0.30 
p17 20 28 RLRPGGKKK B; A; C; 
CRF02_AG 
A*03; A*11; A*30; B*07; 
B*15; B*42 
 0.05 0.30 
p17 20 28 RLRQGGKKK B A*03   0.00 
p17 20 29 RLRPGGKKKY B; A; C; D A*03; A*30; B*15; B*42  0.04 0.30 
p17 20 29 RLRPGGKKHY C A*30; B*42   0.20 
p17 20 30 RLRPGGKKKYK B    0.05 
p17 20 30 RLRPGGKKHYM C    0.17 
p17 20 31 RLRPGGKKRYRL A; CRF01_AE; 
CRF02_AG 
   0.01 
p17 21 29 LRPGGKKKY B    0.32 
p17 21 35 LRPGGKKKYKLKHIV B A*03; A*11; B*07; B*08   0.03 
p17 21 35 LRPGGKKKYRLKHLV A; D    0.11 
p17 21 40 LRPGGKKKYRLKHLVWASRE A Cw*04   0.11 
p17 22 29 RPGGKKHY A; C; D B*07; B*42   0.24 
p17 22 30 RPGGKKHYM C B*07; B*42   0.21 
p17 22 30 RPGGKKKYK B B*07   0.06 
p17 22 30 RPGGKKRYM C    0.05 
p17 22 31 RPGGKKKYML A; C; D B*07; B*42   0.01 
p17 22 31 RPGGKKKYKL B; D B*51; Cw*04   0.04 
p17 22 31 RPGGKKRYKL B B*07   0.01 
p17 23 34 PGGKKRYRLKHL A; CRF02_AG    0.01 
p17 24 31 GGKKKYKL B; A; D; 
CRF02_AG 
B*08  0.02 0.05 
p17 24 31 GGKKKYRL B B*08   0.16 
p17 24 32 GGKKKYKLK B; A; F B*08   0.05 
p17 24 35 GGKKKYKLKHIV B B*08   0.03 
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p17 24 39 GGKKKYKLKHIVWASR B    0.03 
p17 25 39 GKKKYKLKHIVWASR B A*24; B*07   0.03 
p17 25 39 GKKHYMLKHLVWASR C    0.11 
p17 25 41 GKKHYMLKHLVWASREL B; C Cw*03  0.07 0.11 
p17 25 42 GKKQYKLKHIVWASRELE B    0.01 
p17 26 40 KKHYMLKHIVWASRE C    0.05 
p17 27 35 KRYMIKHLV C    0.01 
p17 28 36 KYKLKHIVW B; A; C; F; 
CRF01_AE 
A*23; A*24; A*26  0.19 0.04 
p17 28 36 HYMLKHLVW B; A; C A*23; A*24   0.12 
p17 28 36 HYMLKHIVW A; C; D A*23   0.06 
p17 28 36 KYMLKHIVW C A*24   0.00 
p17 28 36 KYRLKHIVW B A*24   0.05 
p17 28 36 KYRLKHLVW B; A Cw*04  0.13 0.13 
p17 28 38 HYMLKHLVWAS C    0.11 
p17 28 43 KYKLKHIVWASRELER B    0.03 
p17 29 37 YKLKHIVWA B    0.08 
p17 31 45 MKHLVWASRELERFA C; CRF01_AE   0.11 0.09 
p17 32 46 KHIVWASRELERFAV B    0.07 
p17 33 41 HLVWASREL B; C Cw*06; Cw*08   0.60 
p17 33 50 HIVWASRELERFAVNPSL B    0.00 
p17 34 43 IVWASRELER B A*11   0.27 
p17 34 44 LVWASRELERF B; C A*30; B*57  0.01 0.52 
p17 36 44 WASRELERF B; C; CRF01_AE B*35  0.04 0.84 
p17 37 51 ASRELERFAVNPGLL B    0.10 
p17 37 51 ASRELERFALNPGLL C    0.53 
p17 41 55 LERFALNPGLLETAE CRF01_AE   0.06 0.13 
p17 41 58 LERFAVNPSLLETSEGCR B    0.00 
p17 42 50 ERFAVNPGL B B*27   0.10 
p17 42 51 ERFAVNPGLL B B*27   0.10 
p17 42 56 ERFALNPGLLETSEG C    0.26 
p17 42 58 ERFAVNPGLLETSEGCR B    0.04 
p17 42 58 ERFALNPGLLETSEGCK C    0.21 
p17 43 51 RFAVNPGLL B; C B*15   0.10 
p17 44 52 FAVNPGLLE B    0.10 
p17 47 55 NPGLLETSE B    0.35 
p17 49 57 GLLESSEGC B A*02   0.01 
p17 49 64 GLLETSEGCKQIMKQL C A*68   0.06 
p17 58 72 KQIMKQLQPALQTGT C    0.06 
p17 59 67 QILEQLQPA B A*02   0.02 
p17 59 68 QILEQLQPAL B A*02   0.02 
p17 63 72 QLQPSLQTGS B A*02   0.07 
p17 63 79 QLQPSLQTGSEELRSLY B    0.01 
p17 70 86 TGTEELRSLYNTVATLY B; C Cw*14  0.04 0.12 
p17 70 86 TGSEELRSLYNTVATLY B    0.01 
p17 71 79 GSEELKSLY B A*01   0.08 
p17 71 79 GSEELRSLY B A*01  0.06 0.03 
p17 71 79 GTEELRSLY A A*01   0.16 
p17 71 85 GSEELRSLYNTVATL B    0.01 
p17 71 90 GSEELRSLYNTVATLYCVHQ B   0.39 0.01 
p17 73 81 EELRSLYNT A    0.18 
p17 73 82 EELRSLYNTV C B*40   0.15 
p17 73 87 EELRSLYNTVATLYC B A*02   0.14 
p17 74 82 ELRSLYNTV B; A; F; 
CRF01_AE 
B*08   0.15 
p17 74 82 ELKSLYNTV B B*08   0.14 
p17 74 82 ELKSLFNTI B B*08   0.05 
p17 74 83 ELRSLYNTVA B A*02   0.15 
p17 74 88 ELKSLYNTVATLYCV C    0.10 
p17 76 86 RSLYNTVATLY B; A; C; F A*02; A*30; B*15; B*57; 
B*58 
 0.03 0.15 
p17 76 86 RSLYNTVAVLY B; F A*30   0.01 
p17 76 86 RSLFNTVATLY B    0.13 
p17 76 90 KSLYNTVVTLWCVHQ B; C; CRF01_AE   0.02 0.00 
p17 77 85 SLYNTVATL B; A; C; D; F; G; 
K; CRF02_AG 
A*02; A*68  0.20 0.32 
p17 77 85 SLFNTVATL B; A; C A*02  0.09 0.28 
p17 77 85 SLYNTVVTL B A*02   0.01 
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p17 77 85 SLYNTIATL B; CRF01_AE A*02  0.22 0.03 
p17 77 85 SLYNTVAAL B A*02   0.00 
p17 77 85 SLYNTVAVL B A*02   0.03 
p17 77 86 SLYNTVATLY B A*02   0.31 
p17 77 86 SLFNTVATLY C    0.27 
p17 77 91 SLYNTVATLYCVHQR B; A; D A*02; A*30; B*40; B*44   0.05 
p17 77 94 SLYNTVATLYCVHQRIEV B    0.01 
p17 78 85 LYNTVATL B; D A*24; Cw*14   0.32 
p17 78 86 LYNTVATLY B; C A*29; B*44   0.31 
p17 78 86 LFNTVATLY B; C A*29   0.27 
p17 80 88 NTVATLYCV B A*02   0.59 
p17 82 90 VATLYCVHQ B    0.17 
p17 82 91 IATLWCVHQR CRF01_AE A*11  0.09 0.04 
p17 82 92 VATLYCVHQRI B A*11   0.09 
p17 83 91 AVLYCVHQR B A*11   0.07 
p17 83 91 ATLYCVHQR B A*11   0.11 
p17 83 91 ATLYCVHQK B; C    0.05 
p17 83 94 ATLWCVHQRIDI CRF01_AE; 
CRF02_AG 
   0.03 
p17 84 91 TLYCVHQR B A*11   0.11 
p17 84 91 TLYCVHQK B A*11   0.05 
p17 84 92 TLYCVHQRI B; F A*11  0.05 0.11 
p17 84 92 TLYCVHQKI B A*11   0.05 
p17 84 92 VLYCVHQRI B A*02   0.06 
p17 85 92 LYCVHQKI D A*24   0.06 
p17 86 96 YCVHAGIEVRD C    0.03 
p17 86 101 YCVHQRIEIKDTKEAL B    0.02 
p17 87 95 CVHQRIEIK B A*11   0.05 
p17 89 98 HQRIEIKDTK B A*11   0.04 
p17 91 101 RIDVKDTKEAL B    0.07 
p17 91 105 RIDVKDTKEALEKIE B    0.01 
p17 92 101 IEIKDTKEAL B; F B*40  0.07 0.06 
p17 92 101 IDIKDTKEAL B B*40   0.05 
p17 93 101 EVKDTKEAL B B*08   0.14 
p17 93 101 EIKDTKEAL B; CRF01_AE B*08; B*40   0.06 
p17 93 101 DVKDTKEAL B    0.11 
p17 97 111 TKEALEKIEEEQNKS BC    0.02 
p17 103 112 KIEEEQNKSK B A*11   0.08 
p17 114 122 KTQQAAADK B; F B*57   0.00 
p17 119 127 AADTGNSSQ B    0.03 
p17-p24 119 3 AADTGNSSQVSQNYPIV B    0.02 
p17 121 132 DTGHSNQVSQNY B A*33   0.00 
p17 123 132 GNSSQVSQNY B    0.05 
p17 124 132 NSSKVSQNY B B*35  0.03 0.04 
p17 124 132 NSSQVSQNY B B*35  0.02 0.07 
p17-p24 124 1 NSSQVSQNYP B    0.07 
p17-p24 125 3 GKKVSQNYPIV C    0.00 
p17-p24 126 11 GKVSQNYPIVQNLQGQMV C B*13   0.21 
p17-p24 126 11 SQVSQNYPIVQNLQGQMV B    0.06 
p17-p24 127 3 QVSQNYPIV B; D A*68   0.17 
p17-p24 129 11 SQNYPIVQNLQGQMV C    0.49 
p17-p24 131 6 NYPIVQNL B A*24   0.52 
p24 3 11 VQNLQGQMV B; A; C B*13  0.02 0.53 
p24 7 15 QGQMVHQSL A    0.05 
p24 8 15 GQMVHQAI B B*48   0.34 
p24 8 16 GQMVHQAIS B    0.33 
p24 8 17 GQMVHQAISP B; A; C; D B*57; B*58   0.33 
p24 8 18 GQMVHQAISPR B; C A*74   0.33 
p24 8 20 GQMVHQAISPRTL B Cw*03   0.33 
p24 8 21 GQMVHQAISPRTLN B; CRF01_AE A*03; Cw*03   0.33 
p24 8 27 GQMVHQAISPRTLNAWVKVV B B*14   0.08 
p24 9 18 QMVHQAISPR B A*03   0.33 
p24 9 23 QMVHQAISPRTLNAW B B*58   0.33 
p24 9 23 QMVHQSLSPRTLNAW A; D    0.04 
p24 10 18 MVHQAISPR B A*03; A*33   0.33 
p24 10 23 MVHQSMSPRTLNAW A; CRF02_AG    0.01 
p24 11 20 VHQAISPRTL C B*15   0.34 
p24 11 24 VHQAISPRTLNAWV B    0.34 
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p24 11 25 VHQAISPRTLNAWVK B    0.34 
p24 12 20 HQAISPRTL B B*15   0.35 
p24 12 20 HQSLSPRTL A    0.07 
p24 12 20 HQPISPRTL B   0.03 0.09 
p24 13 20 QAISPRTL B Cw*03; Cw*07   0.35 
p24 13 23 QAISPRTLNAW B A*25; B*57  0.00 0.35 
p24 14 22 SLSPRTLNA A    0.07 
p24 14 23 AISPRTLNAW B; A; C; 
CRF02_AG 
B*15; B*57; B*58  0.03 0.35 
p24 14 24 AISPRTLNAWV B B*57   0.35 
p24 15 23 ISPRTLNAW B; A; C; D B*15; B*57; B*58; Cw*06 1 0.03 0.48 
p24 15 23 LSPRTLNAW B; A; C B*57; B*58   0.34 
p24 15 24 ISPRTLNAWV C B*57   0.48 
p24 16 24 SPRTLNAWV B; A; C; D; 
CRF02_AG 
B*07; B*81  0.03 0.94 
p24 16 26 SPRTLNAWVKV A; D B*07   0.92 
p24 17 28 PRTLNAWVKVVE B    0.24 
p24 17 31 PRTLNAWVKVVEEKA B A*02   0.16 
p24 17 32 PRTLNAWVKVIEEKAF B; C Cw*02  0.02 0.59 
p24 18 26 RLLNAWVKV B; A; CRF02_AG A*02  0.11 0.00 
p24 18 26 RTLNAWVKV B A*02  0.03 0.96 
p24 19 27 TLNAWVKVV B A*02   0.25 
p24 19 27 TLNAWVKVI B; A; C; D A*02   0.71 
p24 21 40 NAWVKVVEEKAFSPEVIPMF B B*57   0.16 
p24 22 36 AWVKVVEEKGFNPEV CRF01_AE    0.06 
p24 22 36 AWVKVIEEKAFSPEV C    0.54 
p24 23 40 WVKVIEEKAFSPEVIPMF B; C Cw*16  0.01 0.54 
p24 24 32 VKVIEEKAF B; C B*15   0.61 
p24 24 32 VKVVEEKAF B; C B*15   0.17 
p24 24 41 VKVIEEKAFSPEVIPMFT C    0.39 
p24 25 39 KVVEEKAFSPEVIPM B; BC B*44   0.16 
p24 26 40 VIEEKAFSPEVIPMF A; CRF01_AE; 
CRF02_AG 
   0.54 
p24 27 36 IEEKAFSPEV C    0.56 
p24 27 37 IEEKAFSPEVI C B*45   0.55 
p24 28 36 EEKAFSPEV B; A; C; D B*44; B*45  0.02 0.73 
p24 28 47 EEKAFSPEVIPMFSALSEGA B B*27   0.23 
p24 29 36 EKAFSPEV C    0.73 
p24 29 43 EKAFSPEVIPMFSAL B; BC    0.25 
p24 29 43 EKGFNPEVIPMFSAL B; CRF01_AE   0.03 0.06 
p24 29 48 EKAFSPEVIPMFTALSEGAT C    0.44 
p24 30 37 KAFSPEVI B; A B*57   0.74 
p24 30 38 RAFSPEVIP B; A; C B*57   0.01 
p24 30 38 KAFSPEVIP A    0.74 
p24 30 40 KAFSPEVIPMF B; A; C; D; G; 
CRF02_AG 
B*15; B*57; B*58 1 0.02 0.73 
p24 30 40 KGFNPEVIPMF B B*57   0.10 
p24 31 41 AFSPEVIPMFT C    0.47 
p24 31 44 AFSPEVIPMFSALS B    0.25 
p24 31 47 AFSPEVIPMFTALSEGA B; C Cw*14  0.04 0.45 
p24 31 47 AFSPEVIPMFSALSEGA B    0.24 
p24 31 50 AFSPEVIPMFSALSEGATPQ B    0.22 
p24 32 40 FSPEVIPMF B; A; C B*15; B*57; B*58   0.81 
p24 33 40 SPEVIPMF C    0.81 
p24 33 47 SPEVIPMFSALSEGA B A*02   0.27 
p24 35 43 EVIPMFSAL B; A; C; D; 
CRF01_AE 
A*26; Cw*03  0.05 0.37 
p24 35 43 EVIPMFTAL C A*26   0.53 
p24 35 49 EVIPMFSALSEGATP B    0.34 
p24 36 43 VIPMFSAL B; D Cw*01; Cw*02   0.37 
p24 36 44 VIPMFSALS A    0.36 
p24 37 46 IPMFSALSEG B B*07  0.06 0.36 
p24 37 51 IPMFSALSEGATPQD B A*02; B*44   0.33 
p24 37 52 IPMFSALSEGATPQDL B B*44   0.32 
p24 38 46 PMFSALSEG A    0.36 
p24 38 48 PMFTALSEGAT C    0.56 
p24 38 55 PMFTALSEGATPQDLNTM B; C Cw*08  0.01 0.45 
p24 38 55 PMFSALSEGATPQDLNTM B; A; CRF01_AE    0.13 
p24 39 53 MFSALSEGATPHDLN A; D    0.00 
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p24 39 58 MFTALSEGATPQDLNTMLNT C    0.44 
p24 40 48 FSALSEGAT A    0.35 
p24 41 55 SALSEGATPQDLNTM B B*44   0.14 
p24 41 56 SALSEGATPQDLNTML B    0.14 
p24 41 60 SALSEGATPQDLNMMLNIVG A B*81   0.17 
p24 41 60 SALSEGATPQDLNTMLNTVG B; CRF01_AE    0.12 
p24 42 52 ALSEGATPQDL C    0.85 
p24 42 55 ALSEGATPQDLNMM A; CRF01_AE; 
CRF02_AG 
   0.21 
p24 43 51 LSEGATPQD A    0.86 
p24 43 52 LSEGATPQDL B; A B*42; B*44   0.85 
p24 44 52 SEGATPQDL B; CRF02_AG B*40; B*44  0.04 0.86 
p24 45 56 EGATPQDLNMML A; CRF01_AE; 
CRF02_AG 
   0.21 
p24 45 59 EGATPQDLNTMLNTV B B*07; B*57   0.59 
p24 45 60 EGATPQDLNTMLNTVG B    0.59 
p24 46 54 GATPQDLNM A    0.22 
p24 46 59 GATPQDLNMMLNIV A; CRF01_AE; 
CRF02_AG 
   0.21 
p24 46 59 GATPQDLNTMLNTV B    0.59 
p24 46 62 GATPQDLNTMLNTVGGH B; C    0.59 
p24 47 55 ATPQDLNTM B B*07   0.63 
p24 47 56 ATPQDLNTML B B*07; B*58   0.62 
p24 47 56 ATPQDLNMML A B*53   0.22 
p24 47 58 ATPQDLNTMLNT B; C; D B*58   0.61 
p24 48 55 TPQDLNTM B; C B*07; B*81   0.63 
p24 48 56 TPQDLNTML B; A; C; D B*07; B*39; B*42; B*53; 
B*81; Cw*08 
 0.02 0.62 
p24 48 56 TPQDLNTMLNT B; C B*14   0.61 
p24 48 56 TPTDLNTML B B*42  0.01 0.01 
p24 48 56 TPQDLNMML B; A; CRF02_AG B*42; B*53  0.02 0.22 
p24 48 57 TPQDLNTMLN B; C; D B*07; B*14   0.62 
p24 48 57 TPQDLNMMLN B B*07   0.22 
p24 48 62 TPQDLNMMLNIVGGH A; D    0.21 
p24 49 57 PQDLNTMLN B B*14; Cw*07; Cw*08   0.62 
p24 49 59 PQDLNTMLNTV B B*14   0.60 
p24 49 63 PQDLNTMLNTVGGHQ B; BC A*02   0.59 
p24 51 59 DLNTMLNTV B B*14; Cw*08   0.65 
p24 51 59 DLNMMLNIV B; A B*14   0.23 
p24 51 60 DLNTMLNTVG B A*02; B*14   0.64 
p24 51 70 DLNTMLNTVGGHQAAMQMLK B    0.62 
p24 52 60 LNMMLNIVG A    0.23 
p24 53 66 NTMLNTVGGHQAAM C    0.64 
p24 53 70 NTMLNTVGGHQAAMQMLK C    0.62 
p24 54 62 MMLNIVGGH A    0.23 
p24 56 64 LNIVGGHQA A    0.25 
p24 57 71 NTVGGHQAAMQMLKE B A*02   0.14 
p24 59 72 VGGHQAAMQMLKET B; C; CRF01_AE   0.02 0.19 
p24 60 70 GGHQAAMQMLK C    0.95 
p24 60 78 GGHQAAMQMLKDTINEEA C    0.69 
p24 61 69 GHQAAMQML B; C B*15; B*38; B*39  0.02 0.96 
p24 61 71 GHQAAMQMLKE B A*02  0.16 0.20 
p24 61 71 GHQAAMQMLKD C; D A*02   0.75 
p24 61 71 GHQAAMEMLKD B; A A*02   0.00 
p24 61 75 GHQAAMQMLKETINE B A*02; B*15   0.18 
p24 61 78 GHQAAMQMLKETINEEAA B    0.18 
p24 61 80 GHQAAMQMLKETINEEAAEW B    0.17 
p24 62 70 HQAAMQMLK B; A A*11; B*52   0.96 
p24 62 75 HQAAMQMLKETINE CRF01_AE    0.18 
p24 64 78 AAMQMLKDTINEEAA B; C    0.69 
p24 64 80 AAMQMLKETINEEAAEW B    0.17 
p24 65 73 AMQMLKETI B; CRF02_AG A*02   0.20 
p24 65 73 AMQMLKDTI BC    0.75 
p24 65 79 AMQMLKETINEEAAE B B*40   0.17 
p24 66 79 MQMLKDTINEEAAE A; CRF01_AE    0.67 
p24 69 83 LKETINEEAAEWDRV B A*25   0.04 
p24 69 86 LKDTINEEAAEWDRLHPV C A*68   0.41 
p24 69 86 LKETINEEAAEWDRVHPV B    0.04 
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p24 69 86 LKETINEEAAEWDRLHPV B    0.11 
p24 70 78 KETINEEAA B B*40  0.09 0.19 
p24 70 83 KDTINEEAAEWDRL A; CRF01_AE    0.47 
p24 71 80 ETINEEAAEW B; A; D A*25; B*53; B*58  0.00 0.18 
p24 71 80 DTINEEAAEW B; A; C B*53; B*58  0.01 0.69 
p24 71 90 ETINEEAAEWDRVHPVHAGP B    0.03 
p24 72 80 TINEEAAEW B B*57   0.87 
p24 73 87 INEEAAEWDRVHPVH B A*02   0.12 
p24 73 87 INEEAAEWDRLHPVH BC    0.43 
p24 75 83 EEAAEWDRL B; A; F B*40   0.61 
p24 75 83 EEAAEWDRV B B*40   0.15 
p24 76 84 EAAEWDRLH A    0.64 
p24 77 85 AAEWDRLHP A    0.65 
p24 77 86 AAEWDRLHPV B    0.55 
p24 77 87 AAEWDRLHPVH C    0.46 
p24 77 91 AAEWDRVHPVHAGPI B A*02; B*40; B*44   0.08 
p24 77 91 AAEWDRLHPVHAGPI BC    0.25 
p24 77 92 AAEWDRLHPVHAGPIA B; C    0.19 
p24 78 86 AEWDRLHPV B; C; F A*02; B*40   0.55 
p24 78 86 AEWDRVHPV B B*40  0.13 0.15 
p24 79 86 EWDRVHPV B A*02   0.15 
p24 81 95 DRVHPVHAGPIAPGQ B B*07   0.03 
p24 81 95 DRLHPVHAGPIAPGQ B    0.19 
p24 81 100 DRLHPVHAGPAAPGQMREPR B    0.01 
p24 82 90 RLHPVHAGP A    0.48 
p24 82 92 RLHPVHAGPIA C    0.20 
p24 83 91 LHPVHAGPI B    0.27 
p24 83 92 VHPVHAGPIA B B*55   0.03 
p24 84 91 HPVHAGPI D B*35   0.42 
p24 84 91 HPVHAGPV B B*35   0.21 
p24 84 92 HPVHAGPIA B; C; D; F B*07; B*35; B*39  0.06 0.26 
p24 84 92 HPVHAGPVA B; A; C; D B*07   0.20 
p24 84 100 HPVHAGPIAPGQMREPR B A*02   0.22 
p24 86 94 VHAGPIPPG A    0.16 
p24 87 101 HAGPIAPGQMREPRG B A*02   0.23 
p24 89 96 GPIAPGQM C; D B*35   0.25 
p24 91 105 IAPGQMREPRGSDIA B; C B*13   0.24 
p24 91 110 IAPGQMREPRGSDIAGTTST B    0.20 
p24 93 101 PGQMREPRG A    0.68 
p24 93 107 PGQMREPRGSDIAGT B    0.65 
p24 94 104 GQMREPRGSDI B; C B*13  0.03 0.68 
p24 94 105 GQMREPRGSDIA C    0.68 
p24 96 104 MREPRGSDI A    0.68 
p24 101 120 GSDIAGTTSTLQEQIGWMTN B    0.07 
p24 102 110 SDIAGTTST A    0.79 
p24 102 118 SDIAGTTSTLQEQIAWM C    0.30 
p24 104 112 IAGTTSTLQ A    0.67 
p24 105 119 AGTTSTLQEQIGWMT B A*02   0.20 
p24 106 114 GTTSTLQEQ A    0.67 
p24 106 120 GTTSTLQEQIAWMTS C    0.16 
p24 107 116 TTSTLQEQIA C A*68   0.33 
p24 108 117 TSTLQEQIGW B; A; C; 
CRF01_AE 
B*07; B*15; B*57; B*58 1 0.03 0.21 
p24 108 117 TSTLQEQIAW B; C B*57; B*58 1 0.03 0.33 
p24 108 117 TSTPQEQIGW A B*57   0.05 
p24 108 117 TSTLQEQVGW B B*57   0.01 
p24 108 117 TSTLQEQVAW C    0.02 
p24 109 117 STLQEQIGW B; D; CRF02_AG B*57; B*58  0.02 0.21 
p24 109 117 STLQEQIAW B    0.33 
p24 109 118 STLQEQIGWM B A*02   0.21 
p24 109 123 STLQEQIGWMTNNPP B A*02   0.07 
p24 109 124 STLQEQIGWMTNNPPI B    0.07 
p24 109 126 STLQEQIGWMTNNPPIPV B    0.07 
p24 110 118 TLQEQIGWM B; A; CRF01_AE A*02   0.21 
p24 110 118 NLQEQIGWM B A*02   0.03 
p24 110 119 NLQEQIGWMT B A*02   0.03 
p24 112 120 QEQIGWMTG A    0.03 
p24 114 128 QIGWMTNNPPIPVGE B; A; CRF02_AG    0.05 
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p24 116 130 AWMTSNPPVPVGDIY C    0.05 
p24 117 126 WMTNNPPIPV B A*02   0.16 
p24 117 131 WMTNNPPIPVGEIYK B A*02   0.08 
p24 117 134 WMTNNPPIPVGEIYKRWI B    0.08 
p24 118 126 MTNNPPIPV B A*02; A*03; B*07   0.16 
p24 118 126 MTSNPPIPV C A*02   0.37 
p24 121 129 NPPIPVGEI B B*07  0.02 0.29 
p24 121 130 NPPIPVGDIY B; C B*35  0.03 0.37 
p24 121 130 NPPIPVGEIY B B*35  0.01 0.29 
p24 121 135 NPPIPVGEIYKRWII B B*08; B*44   0.24 
p24 121 140 NPPIPVGEIYKRWIILGLNK B    0.21 
p24 122 130 PPIPVGEIY B; A; C; D B*07; B*35; B*53  0.05 0.29 
p24 122 130 PPIPVGDIY B; A; C; 
CRF02_AG 
B*35  0.05 0.38 
p24 122 130 PPVPVGDIY C B*35   0.14 
p24 122 136 PPIPVGDIYKRWIIL C    0.34 
p24 123 131 PIPVGDIYK B; C    0.37 
p24 124 138 IPVGEIYKRWIILGL B; A; C B*08   0.23 
p24 125 135 PVGDIYKRWII C    0.52 
p24 125 139 PVGEIYKRWIILGLN B A*24; B*40   0.32 
p24 125 142 PVGEIYKRWIILGLNKIV B    0.32 
p24 126 140 VGEIYKRWIILGLNK B    0.32 
p24 127 135 GEIYKRWII B; A; C; D; 
CRF02_AG 
B*08  0.05 0.35 
p24 127 135 GDIYKRWII B B*08   0.52 
p24 127 136 GEIYKRWIIL B A*24; B*08  0.03 0.33 
p24 127 143 GEIYKRWIILGLNKIVR B B*27   0.32 
p24 127 143 GEIYKRWIILGLNKIVRMY B B*27   0.32 
p24 128 135 EIYKRWII B B*08   0.35 
p24 128 135 DIYKRWII B; C B*08   0.53 
p24 128 136 EIYKRWIIL B; D A*02; A*24; B*08; Cw*07  0.08 0.33 
p24 128 142 DIYKRWIILGLNKIV C    0.49 
p24 129 136 IYKRWIIL B A*24; B*08   0.83 
p24 129 137 IYKRWIILG B A*24   0.82 
p24 129 138 IYKRWIILGL B; D A*24; B*27   0.82 
p24 129 140 IYKRWIILGLNK B; A; C; 
CRF01_AE 
A*24   0.81 
p24 129 143 IYKRWIILGLNKIVR B A*24; B*27   0.81 
p24 129 148 IYKRWIILGLNKIVRMYSPT B B*15; B*27   0.09 
p24 130 148 YKRWIILGLNKIVRMYSPT B B*27   0.09 
p24 131 139 KRWIILGLN A    0.83 
p24 131 140 KRWIILGLNK B; A; C; D; 
CRF01_AE; 
CRF02_AG 
B*27 1 0.04 0.82 
p24 131 140 KRWIIMGLNK B B*27  0.03 0.04 
p24 131 140 KRWIIMGLHK B B*27   0.00 
p24 131 140 KRWILLGLNK B    0.00 
p24 131 142 KRWILGLNKIV B B*27   0.00 
p24 131 142 KRWIILGLNKIV B B*27   0.82 
p24 131 145 KRWIILGLNKIVRMY B B*27   0.81 
p24 131 150 KRWIILGLNKIVRMYSPTSI B    0.08 
p24 132 140 RWIILGLNK B B*27   0.84 
p24 133 141 WIILGLNKI A    0.84 
p24 133 147 WIILGLNKIVRMYSP B A*03; A*11; B*15; B*27   0.83 
p24 133 150 WIILGLNKIVRMYSPVSI B; C Cw*17; Cw*18  0.01 0.70 
p24 134 141 IILGLNKI B A*02; A*03   0.85 
p24 134 142 IILGLNKIV B A*02   0.84 
p24 134 143 IILGLNKIVR B; A; C A*03; A*11; A*33  0.01 0.84 
p24 135 142 ILGLNKIV B; C; CRF01_AE A*02; A*03; B*27   0.85 
p24 135 143 ILGLNKIVR B A*03; A*11   0.84 
p24 135 145 ILGLNKIVRMY B B*07; B*27   0.84 
p24 136 144 LGLNKIVRM A    0.91 
p24 136 145 LGLNKIVRMY B B*15   0.91 
p24 136 146 LGLNKIVRMYS B; C B*15   0.90 
p24 136 150 LGLNKIVRMYSPTSI B    0.09 
p24 136 153 LGLNKIVRMYSPTSILDI B    0.09 
p24 137 145 GLNKIVRMY B; A; CRF01_AE B*15; B*27  0.07 0.97 
p24 137 151 GLNKIVRMYSPTSIL B A*02; B*15   0.10 
p24 139 153 NKIVRMYSPVSILDI A; CRF01_AE;   0.25 0.80 
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CRF02_AG 
p24 141 155 IVRMYSPTSILDIRQ B A*02; A*24   0.06 
p24 142 150 VRMYSPVSI B; C; F Cw*18   0.83 
p24 143 150 RMYSPTSI B; F B*52  0.01 0.11 
p24 143 151 RMYSPTSIL B; CRF01_AE; 
CRF02_AG 
A*02   0.11 
p24 143 151 RMYSPVSIL B; A    0.82 
p24 144 151 MYSPTSIL B A*24   0.11 
p24 144 158 MYSPVSILDIRQGPK CRF01_AE   0.05 0.38 
p24 145 153 YSPVSILDI CRF01_AE Cw*01  0.12 0.81 
p24 145 153 YSPTSILDI B Cw*12   0.11 
p24 149 158 SILDIRQGPK B A*11   0.46 
p24 149 163 SILDIKQGPKEPFRD A    0.46 
p24 149 163 SILDIRQGPKEPFID CRF02_AG    0.00 
p24 149 165 SILDIKQGPKEPFRDYV C    0.46 
p24 150 158 ILDIRQGPK A    0.47 
p24 151 170 LDIRQGPKEPFRDYVDRFYK B    0.14 
p24 152 162 DIRQGPKEPFR B B*27   0.46 
p24 154 168 RQGPKEPFRDYVDRF B; A; CRF02_AG    0.45 
p24 156 164 GPKEPFRDY B B*07  0.11 0.95 
p24 156 173 GPKEPFRDYVDRFFKTLR B; C Cw*03; Cw*18  0.12 0.60 
p24 156 173 GPKEPFRDYVDRFYKTLR B    0.18 
p24 157 165 PKEPFRDYV A    0.95 
p24 159 168 EPFRDYVDRF B; C; D A*02   0.94 
p24 159 169 EPFRDYVDRFF A; C; D B*81   0.74 
p24 159 178 EPFRDYVDRFFKTLRAEQAT C B*44  0.04 0.52 
p24 160 168 PFRDYVDRF D    0.94 
p24 160 169 PFRDYVDRFF C    0.75 
p24 161 169 FRDYVDRFY B A*01   0.20 
p24 161 169 FRDYVDRFF B; C Cw*18   0.77 
p24 161 170 FRDYVDRFYK B; D B*18; B*27   0.19 
p24 161 170 FRDYVDRFFK B    0.75 
p24 161 172 FRDYVDRFFKAL A A*03   0.04 
p24 161 174 FRDYVDRFYKTLRA B    0.18 
p24 161 175 FRDYVDRFYKTLRAE B; A; D; BC B*44   0.18 
p24 161 180 FRDYVDRFYKTLRAEQASQD B B*15   0.06 
p24 161 180 FRDYVDRFYKTLRAEQASQE B    0.06 
p24 162 172 RDYVDRFFKTL B; A A*24  0.16 0.62 
p24 162 172 RDYVDRFYKTL B; D A*24; A*26; B*15; B*18; 
B*44 
 0.11 0.19 
p24 163 171 DYVDRFYKT B A*24   0.19 
p24 163 171 DYVDRFFKT A    0.63 
p24 163 172 DYVDRFFKTL B A*24   0.63 
p24 163 172 DYVDRFYKTL B A*24   0.19 
p24 163 173 DYVDRFYKTLR B A*33   0.19 
p24 164 172 YVDRFYKTL B A*02; B*15   0.19 
p24 164 172 YVDRFFKTL B; A; C; D A*26; B*15; Cw*03  0.28 0.63 
p24 164 172 YVDRFFKAL A; CRF01_AE B*15; Cw*03   0.04 
p24 164 178 YVDRFYKTLRAEQAT CRF01_AE   0.17 0.06 
p24 164 181 YVDRFFKTLRAEQATQDV C    0.30 
p24 164 181 YVDRFYKTLRAEQASQEV B    0.06 
p24 165 178 VDRFYKTLRAEQAS B    0.12 
p24 165 179 VDRFYKTLRAEQASQ B B*57   0.12 
p24 166 174 DRFYKTLRA B; D B*14; B*27 1 0.03 0.19 
p24 166 174 DRFFKTLRA B; A; C B*14   0.63 
p24 166 174 DRFWKTLRA B B*14   0.00 
p24 166 175 DRFYKTLRAE B B*14   0.19 
p24 166 176 DRFYKTLRAEQ B; A B*14   0.19 
p24 168 176 FYKTLRAEQ B Cw*04   0.19 
p24 169 177 FKTLRAEQA A    0.58 
p24 169 183 YKTLRAEQASQEVKN B B*58   0.06 
p24 169 185 YKTLRAEQASQDVKNWM B    0.05 
p24 169 188 YKTLRAEQASQEVKNWMTET B B*57   0.06 
p24 169 188 FKTLRAEQATQDVKNWMTDT C    0.23 
p24 171 180 TLRAEQATQD C Cw*03   0.32 
p24 172 189 LRAEQASQEVKNWMTETL B    0.07 
p24 172 189 LRAEQATQDVKNWMTDTL C    0.27 
p24 173 181 RAEQASQEV B B*51; Cw*08   0.08 
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p24 173 181 RAEQATQEV A    0.35 
p24 173 182 RAEQASQEVK B A*11   0.08 
p24 173 183 RAEQATQDVKN C    0.37 
p24 173 187 RAEQASQEVKNWMTE B B*44   0.07 
p24 173 187 RAEQATQDVKNWMTD A    0.27 
p24 173 187 RAEQATQEVKNWMTE A; CRF01_AE    0.12 
p24 174 184 AEQASQDVKNW B; C; D B*44; B*57; Cw*04  0.07 0.08 
p24 174 184 AEQASQEVKNW B B*44  0.04 0.07 
p24 174 184 AEQASADVKNW B B*44   0.00 
p24 174 184 AEQATQDVKNW B; C B*44   0.37 
p24 174 185 AEQASQEVKNWM B Cw*05   0.07 
p24 174 186 AEQASQEVKNWMT B B*44   0.07 
p24 175 186 EQASQEVKNWMT B B*44   0.07 
p24 176 184 QATQDVKNW C B*53; B*57; B*58  0.03 0.37 
p24 176 184 QASQEVKNW B; A; D B*53; B*57; B*58; Cw*04 1 0.04 0.07 
p24 176 184 QATQEVKNW B; A; CRF02_AG B*53  0.02 0.24 
p24 176 184 QATQEVKNM A B*53  0.03 0.00 
p24 176 184 QATQEVKGW B; CRF02_AG    0.09 
p24 177 185 ASQEVKNWM B B*53   0.07 
p24 177 185 ATQEVKNWM B B*53  0.02 0.24 
p24 179 193 QEVKNWMTETLLVQN CRF01_AE   0.05 0.19 
p24 180 189 EVKNWMTETL B B*53   0.21 
p24 180 190 EVKNWMTETLL B    0.20 
p24 181 189 VKNWMTETL B B*48  0.02 0.38 
p24 181 190 VKNWMTETLL B B*08   0.37 
p24 181 191 VKNWMTETLLV B    0.36 
p24 185 202 MTDTLLVQNANPDCKTIL C B*08   0.37 
p24 187 195 ETLLVQNAN A    0.41 
p24 190 198 LVQNANPDC A    0.87 
p24 190 199 LVQNSNPDCK B A*11   0.03 
p24 190 204 LVQNANPDCKTILRA C    0.40 
p24 191 199 VQNSNPDCK B A*11  0.13 0.03 
p24 191 199 VQNANPDCK B A*03   0.86 
p24 191 205 VQNANPDCKTILKAL B B*08; B*51   0.17 
p24 191 210 VQNANPDCKTILKALGPAAT B    0.08 
p24 193 201 NANPDCKTI B; A B*08; B*51  0.08 0.65 
p24 193 202 NSNPDCKTIL B B*51   0.02 
p24 193 205 NANPDCKTILRAL C B*39   0.42 
p24 193 207 NANPDCKTILKALGP B B*07   0.14 
p24 193 209 NANPDCKTILRALGPGA B; C Cw*05; Cw*08; Cw*12  0.05 0.33 
p24 194 202 ANPDCKTIL B; C; CRF01_AE B*07   0.65 
p24 195 202 NPDCKTIL B; C B*08; B*35  0.03 0.67 
p24 195 203 NPDCKSILR A    0.12 
p24 195 205 NPDCKTILRAL C B*39   0.42 
p24 196 204 PDCKTILKA B    0.20 
p24 197 205 DCKTILKAL B; A B*08  0.01 0.20 
p24 197 205 DCKTILRAL C B*08   0.43 
p24 197 205 DCKSILRAL A    0.11 
p24 197 211 DCKTILKALGPAATL B B*57   0.10 
p24 197 212 DCKTILKALGPAATLE B    0.10 
p24 199 213 KSILKALGTGATLEE CRF01_AE   0.18 0.05 
p24 199 213 KSILRGLGAGATLEE A    0.00 
p24 199 218 KTILRALGPGATLEEMMTAC C    0.22 
p24 200 214 TILRALGPGASLEEM C    0.09 
p24 200 217 TILRALGPGASLEEMMTA B; C Cw*03; Cw*07  0.03 0.09 
p24 201 215 ILRALGPGATLEEMM CRF02_AG    0.29 
p24 203 211 KALGPAATL B B*15; Cw*03   0.11 
p24 203 211 RALGPGATL B; A; C; D Cw*08   0.30 
p24 204 214 ALGPGASLEEM C    0.12 
p24 205 219 LGPAATLEEMMTACQ B A*02   0.13 
p24 206 214 GPGATLEEM A; C; D    0.40 
p24 208 216 GATLEEMMT A    0.61 
p24 208 226 AATLEEMMTACQGVGGPSH B    0.04 
p24 209 217 ATLEEMMTA B; A; D; 
CRF01_AE 
A*02  0.08 0.74 
p24 209 223 ATLEEMMTACQGVGG B A*02   0.73 
p24 211 219 LEEMMTACQ A    0.94 
p24 211 230 LEEMMTACQGVGGPGHKARV B B*07   0.47 
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p24 212 220 EEMMTACQG A    0.96 
p24 212 222 EEMMTACQGVG C    0.95 
p24 213 221 EMMTACQGV B A*02  0.03 0.96 
p24 213 227 EMMTACQGVGGPGHK B A*11   0.50 
p24 214 222 MMTACQGVG A    0.96 
p24 215 223 MTACQGVGG A    0.96 
p24 216 230 TACQGVGGPSHKARV C    0.41 
p24 217 227 ACQGVGGPGHK B; CRF01_AE A*11  0.14 0.51 
p24 217 227 ACQGVGGPSHK B   0.03 0.44 
p24 217 231 ACQGVGGPGHKARVL B A*11   0.49 
p24 217 231 ACQGVGGPSHKARIL A; CRF01_AE    0.02 
p24-
p2p7p1p6 
217 1 ACQGVGGPGHKARVLA B    0.48 
p24-
p2p7p1p6 
217 3 ACQGVGGPGHKARVLAEA B    0.48 
p24 218 227 CQGVGGPGHK B A*11  0.14 0.51 
p24 219 231 QGVGGPGHKARVL B; C    0.49 
p24 220 227 GVGGPGHK B A*11   0.52 
p24 220 227 GVGGPSHK B   0.05 0.45 
p24 220 229 GVGGPGHKAR B; F A*11   0.51 
p24 221 231 VGGPGHKARVL B; C; CRF01_AE B*07   0.49 
p24-
p2p7p1p6 
221 4 VGGPGHKARVLAEAM B A*02; B*07   0.49 
p24-
p2p7p1p6 
221 4 VGGPSHKARILAEAM A; CRF01_AE    0.02 
p24-
p2p7p1p6 
221 5 VGGPGHKARVLAEAMS B    0.48 
p24 222 230 GGPGHKARV A    0.50 
p24 223 231 GPGHKARVL B; C; D; F B*07; B*35  0.06 0.50 
p24 223 231 GPSHKARVL B; A; C; D; 
CRF01_AE 
B*07; B*42; B*81  0.05 0.42 
p24-
p2p7p1p6 
223 1 GPSHKARVLA C B*07   0.42 
p24-
p2p7p1p6 
223 1 GPGHKARVLA B B*07   0.49 
p24-
p2p7p1p6 
225 8 GHKARVLAEAMSQVT B A*02; B*07   0.06 
p24-
p2p7p1p6 
225 11 SHKARVLAEAMSQANSA B; C Cw*08  0.00 0.00 
p24-
p2p7p1p6 
226 10 HKARVLAEAMSQTNS C    0.04 
p24-
p2p7p1p6 
229 7 RVLAEAMSQV B A*02   0.28 
p24-
p2p7p1p6 
229 12 RVLAEAMSQVTNSAT B A*02   0.02 
p24-
p2p7p1p6 
230 7 VLAEAMSQV B; A; C; D A*02  0.09 0.28 
p24-
p2p7p1p6 
230 7 VLAEAMSQA B A*02   0.45 
p24-
p2p7p1p6 
230 8 VLAEAMSQVT B A*02   0.07 
p2p7p1p6 1 10 AEAMSQVTNS B B*40; B*45   0.04 
p2p7p1p6 1 10 AEAMSQANS C B*45   0.09 
p2p7p1p6 2 16 EAMSQVTNSATIMMQ B A*02   0.01 
p2p7p1p6 5 13 SQVTNSATI B A*02   0.02 
p2p7p1p6 6 14 QVTNSATIM B    0.02 
p2p7p1p6 7 15 VTNSATIMM B    0.02 
p2p7p1p6 8 17 TNSANIMMQR B    0.01 
p2p7p1p6 9 17 NSATIMMQR B    0.01 
p2p7p1p6 14 22 MMQRGNFRN B    0.04 
p2p7p1p6 14 28 MMQRGNFRNQRKIVK B    0.01 
p2p7p1p6 16 24 QRGNFRNQR B    0.04 
p2p7p1p6 18 32 GNFRNQRKIVKCFNC B    0.01 
p2p7p1p6 18 37 SNFKGNKRMVKCFNCGKEGH C A*02  0.14 0.00 
p2p7p1p6 19 33 NFRGPKRIKCFNCG A    0.01 
p2p7p1p6 21 29 RNQRKTVKC B    0.02 
p2p7p1p6 22 30 GPKRIVKCF C B*42   0.06 
p2p7p1p6 23 33 SKRIVKCFNCG C    0.06 
p2p7p1p6 25 34 KTVKCFNCGR B A*11   0.00 
p2p7p1p6 32 40 CGKEGHIAR B A*31   0.32 
 Prot
a
 S
b
 E
C
 Epitope
d
 Subtype
e
 HLA
f
 L
g
 R
h
 C
i
 
p2p7p1p6 34 48 KEGHIAKNCRAPRKK B    0.14 
p2p7p1p6 37 52 HIARNCRAPRKKGCWK C    0.28 
p2p7p1p6 38 46 IARNCRAPR C A*30   0.31 
p2p7p1p6 38 47 LARNCRAPRK B A*03; A*31   0.29 
p2p7p1p6 38 48 IAKNCRAPRKK C    0.17 
p2p7p1p6 38 52 TARNCRAPRKKGCWK B A*03   0.00 
p2p7p1p6 38 52 IAKNCRAPRKKGCWK B    0.16 
p2p7p1p6 42 50 CRAPRKKGC B B*14  0.01 0.77 
p2p7p1p6 42 51 CRAPRKKGCW B B*57   0.77 
p2p7p1p6 43 51 KAPRKKGCW A    0.06 
p2p7p1p6 43 51 RAPRKKGCW C    0.77 
p2p7p1p6 43 52 KAPRKKGCWK B A*11   0.06 
p2p7p1p6 52 61 KCGKEGHQMK B A*11   0.79 
p2p7p1p6 55 70 KEGHQMKDCTERQANF B A*02  0.05 0.64 
p2p7p1p6 58 69 HQMKDCNERQAN B; G A*02   0.02 
p2p7p1p6 60 74 MKDCTERQANFLGKI B; CRF01_AE   0.05 0.65 
p2p7p1p6 62 72 DCTERQANFLG B; C    0.79 
p2p7p1p6 63 71 CTERQANFL B B*40   0.83 
p2p7p1p6 64 71 TERQANFL B B*40  0.09 0.84 
p2p7p1p6 65 75 ERQANFLGKIW C    0.77 
p2p7p1p6 66 74 RQANFLGKI B; C B*13; B*48  0.02 0.79 
p2p7p1p6 66 80 RQANFLGKIWPSYKG B A*02   0.01 
p2p7p1p6 66 80 RQANFLGKIWPSHKG B    0.41 
p2p7p1p6 66 81 RQANFLGKIWPSHKGR B; C Cw*02  0.00 0.40 
p2p7p1p6 70 77 FLGKIWPS B; A; CRF02_AG A*02  0.17 0.80 
p2p7p1p6 70 79 FLGKIWPSHK B; A; C; 
CRF01_AE 
A*02  0.09 0.43 
p2p7p1p6 70 79 FLGKIWPSYK B; A; C; D A*02  0.15 0.02 
p2p7p1p6 70 84 FLGKIWPSYKGRPGN B A*02   0.01 
p2p7p1p6 70 84 FLGKIWPSHKGRPGN B; C    0.41 
p2p7p1p6 72 89 GKIWPSHKGRPGNFLQSR B; C    0.20 
p2p7p1p6 73 81 KIWPSYKGR B A*31   0.02 
p2p7p1p6 74 88 IWPSHKGRPGNFLQS B    0.22 
p2p7p1p6 82 96 PGNFLQSRPEPTAPP B A*02   0.28 
p2p7p1p6 83 97 GNFLQSRPEPTAPPF B A*02   0.00 
p2p7p1p6 85 94 FLQSRPEPTA B A*02  0.34 0.30 
p2p7p1p6 89 97 RPEPTAPPA C; CRF01_AE B*07  0.04 0.53 
Prot
a
 S
b
 E
C
 Epitope
d
 Subtype
e
 HLA
f
 L
g
 R
h
 C
i
 
p2p7p1p6 91 100 EPTAPPEESF D B*35; B*58   0.07 
p2p7p1p6 91 100 EPTAPPAESF C B*07  0.02 0.50 
p2p7p1p6 91 102 EPTAPPAESFRF C B*58  0.01 0.30 
p2p7p1p6 93 112 TAPPEESFRFGEETTTPSQK B Cw*08   0.02 
p2p7p1p6 93 112 TAPPAESFRFEETTPAPK C    0.12 
p2p7p1p6 94 102 APPAESFRF C B*07  0.04 0.36 
p2p7p1p6 97 107 AESFRFEET CRF01_AE    0.27 
p2p7p1p6 98 112 ESFRFGEETTTPSQK B    0.02 
p2p7p1p6 103 120 GEETTTPSQKQEPIDKEL B    0.01 
p2p7p1p6 108 116 TPSQKQEPI B; D B*35; B*53   0.02 
p2p7p1p6 110 118 SQKQEQIDK B A*11   0.00 
p2p7p1p6 111 127 QKQGTIDKELYPLASLK B    0.00 
p2p7p1p6 111 127 QKQEPIDKELYPLASLK B    0.01 
p2p7p1p6 113 121 QEPIDKELY D B*44   0.03 
p2p7p1p6 114 123 EPKDREPL C B*08   0.11 
p2p7p1p6 114 123 EPIDKELYPL B; D B*35; B*42; B*53  0.01 0.02 
p2p7p1p6 114 124 EPIDKELYPLA B    0.02 
p2p7p1p6 118 126 KELYPLASL B A*02; B*40   0.07 
p2p7p1p6 118 126 KELYPLTSL B B*40  0.06 0.02 
p2p7p1p6 118 135 KELYPLASLRSLFGNDPS B    0.01 
p2p7p1p6 118 135 KELYPLASLKSLFGNDPS B    0.02 
p2p7p1p6 118 137 KEMYPLASLRSLFGNDPSSQ B    0.00 
p2p7p1p6 120 129 LYPLASLRSL D A*24   0.02 
p2p7p1p6 121 129 YPLTSLRSL B B*35  0.03 0.02 
p2p7p1p6 121 129 YPLASLRSL B; D B*53   0.03 
p2p7p1p6 121 130 YPLASLRSLF B; D B*07; B*35  0.03 0.03 
p2p7p1p6 121 130 YPLTSLRSLF B B*07   0.02 
p2p7p1p6 122 132 PLTSLKSLFGS C    0.23 
p2p7p1p6 123 130 LASLRSLF D B*58   0.04 
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Extended Data Table 3. Global class I HLA allele group frequencies of loci A, B, and C (D.1.1.3). The 
frequencies were derived from the overall average HLA allele frequencies across 497 population samples as 
published by Solberg et al.
291
. The published high four-digit allele resolution was condensed to a low two digit 
resolution, by summing up all specific HLA protein frequencies to the respective allele group. 
HLA-A 
allele 
Frequency 
[%] 
HLA-B 
allele 
Frequency 
[%] 
HLA-C 
allele 
Frequency 
[%] 
A*01 5.0 B*07 7.8 Cw*01 8.6 
A*02 25.3 B*08 3.1 Cw*02 3.1 
A*03 4.5 B*13 4.1 Cw*03 17.4 
A*11 12.6 B*14 1.8 Cw*04 13.8 
A*23 2.4 B*15 10.5 Cw*05 2.6 
A*24 20.1 B*18 2.5 Cw*06 6.2 
A*25 0.5 B*27 2.5 Cw*07 21.9 
A*26 4.1 B*35 9.7 Cw*08 7.4 
A*29 2.1 B*37 2.5 Cw*12 5.3 
A*30 4.2 B*38 1.7 Cw*14 4.0 
A*31 4.2 B*39 3.9 Cw*15 4.3 
A*32 1.5 B*40 11.9 Cw*16 2.8 
A*33 5.2 B*41 0.6 Cw*17 1.9 
A*34 2.2 B*42 1.1 Cw*18 0.6 
A*36 0.4 B*44 6.9 
  
A*43 0.0 B*45 1.0 
  
A*66 0.7 B*46 2.4 
  
A*68 3.8 B*47 0.2 
  
A*69 0.1 B*48 2.1 
  
A*74 0.8 B*49 0.9 
  
A*80 0.1 B*50 1.0 
  
A*92 0.0 B*51 5.9 
  
  
B*52 2.3 
  
  
B*53 1.7 
  
  
B*54 1.4 
  
  
B*55 1.7 
  
  
B*56 2.0 
  
  
B*57 1.6 
  
  
B*58 3.7 
  
  
B*59 0.2 
  
  
B*67 0.2 
  
  
B*73 0.1 
  
  
B*78 0.2 
  
  
B*81 0.4 
  
  
B*82 0.1 
  
  
B*95 0.0 
  
 
 
 
 
 
 
 
 
 
 
 
 
138 
Extended Data Table 4. Ranking of all classification feature combinations (D.1.2.1). All possible feature 
permutations were examined in a 10-fold cross-validation (100 repeats) of the training-set. The listed feature 
combinations were sorted first by precision and then by accuracy. 
Features Accuracy 
[%] 
Specificity 
[%] 
Sensitivity 
[%] 
Precision, 
PPV [%] 
NPV [%] 
1 2 3 4 5 
  x  x 86 ± 3 99 ± 3 75 ± 5 98 ± 3 78 ± 3 
x  x  x 84 ± 3 99 ± 3 71 ± 5 98 ± 3 75 ± 4 
   x  80 ± 2 87 ± 0 75 ± 4 86 ± 1 75 ± 3 
   x x 80 ± 3 87 ± 1 74 ± 5 86 ± 1 75 ± 4 
 x  x  78 ± 1 87 ± 0 71 ± 2 86 ± 0 73 ± 2 
 x    78 ± 1 87 ± 0 71 ± 1 86 ± 0 72 ± 1 
  x x  78 ± 2 87 ± 0 71 ± 4 86 ± 1 72 ± 3 
 x   x 78 ± 2 87 ± 1 70 ± 3 86 ± 1 72 ± 2 
 x  x x 77 ± 2 87 ± 0 69 ± 5 85 ± 1 71 ± 3 
  x x x 77 ± 3 87 ± 0 69 ± 6 85 ± 1 71 ± 4 
 x x   75 ± 1 87 ± 2 65 ± 2 85 ± 2 69 ± 1 
 x x  x 75 ± 2 87 ± 2 64 ± 3 85 ± 2 68 ± 2 
 x x x  75 ± 1 87 ± 1 65 ± 2 85 ± 1 69 ± 1 
x   x x 75 ± 3 87 ± 1 64 ± 5 84 ± 1 68 ± 3 
x   x  74 ± 3 87 ± 0 63 ± 5 84 ± 1 68 ± 3 
 x x x x 74 ± 2 87 ± 1 63 ± 4 84 ± 1 68 ± 2 
x x   x 73 ± 2 87 ± 0 61 ± 3 84 ± 1 66 ± 2 
x x    73 ± 2 87 ± 0 60 ± 3 84 ± 1 66 ± 2 
x x  x x 73 ± 2 87 ± 0 60 ± 4 84 ± 1 66 ± 2 
x x  x  72 ± 2 87 ± 1 59 ± 4 84 ± 1 65 ± 2 
x  x x x 72 ± 3 87 ± 0 60 ± 5 84 ± 1 66 ± 3 
x  x x  72 ± 3 87 ± 1 59 ± 5 83 ± 1 65 ± 3 
x x x   71 ± 2 87 ± 1 57 ± 3 83 ± 2 64 ± 2 
x x x  x 71 ± 2 87 ± 0 57 ± 4 83 ± 1 64 ± 2 
x x x x x 70 ± 2 87 ± 1 56 ± 4 83 ± 2 64 ± 2 
x  x   79 ± 2 81 ± 5 76 ± 1 82 ± 4 75 ± 2 
x x x x  70 ± 2 87 ± 1 55 ± 4 82 ± 1 63 ± 2 
  x   79 ± 3 77 ± 6 80 ± 3 80 ± 4 77 ± 3 
    x 72 ± 2 75 ± 3 69 ± 2 76 ± 2 68 ± 2 
x    x 67 ± 3 73 ± 3 62 ± 6 72 ± 3 63 ± 4 
x     58 ± 3 67 ± 3 51 ± 4 64 ± 3 55 ± 2 
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Extended Data Table 5. Number of epitopes and antigen scores for an extended antigen panel (see D.2.2). 
 Gag antigen 
Number of 
sequences 
Number of 
epitopes 
Antigen score 
--
-M
o
n
o
v
a
le
n
t-
--
 
teeGag1 1 402 590 
teeGag2 1 266 393 
teeGag3 1 222 332 
conM 1 283 424 
conA1 1 238 350 
conA2 1 226 336 
conB 1 401 542 
conC 1 271 472 
conD 1 288 456 
conF1 1 247 412 
conG 1 231 353 
conH 1 217 330 
conK 1 223 350 
con01_AE 1 199 307 
con02_AG 1 196 295 
con03_AB 1 220 359 
con04_CPX 1 195 310 
con06_CPX 1 251 397 
con07_BC 1 235 369 
con08_BC 1 249 415 
con10_CD 1 241 360 
con11_CPX 1 222 302 
con12_BF 1 242 357 
con14_BG 1 219 338 
ancM 1 293 426 
ancA1 1 250 374 
ancB 1 352 465 
ancC 1 269 430 
mosM1.1 1 277 466 
mosB1.1 1 400 542 
mosC1.1 1 275 478 
cotM 1 311 450 
cotB 1 393 537 
cotC 1 275 480 
HXB2 (HVTN 505) 1 380 522 
CAM1 (HVTN 
502/503) 
1 381 524 
LAI IIIb (RV144) 1 382 524 
--
-T
ri
v
a
le
n
t-
--
 teeGag1-3 3 588 949 
conA1+B+C 3 551 867 
ancA1+B+C 3 493 752 
mosM3.1-3 3 524 808 
mosB3.1-3 3 484 791 
mosC3.1-3 3 341 537 
cotM+B+C 3 504 828 
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Extended Data Table 6. List of all budding-retaining AAS incorporated in teeGag1-3. 
a
Each budding-retaining 
AAS was assigned a unique code based on their HXB2-Gag reference position. If one site harbored more than one 
mutation they were distinguished by adding a character. 
b
The mutation description consists of the original HXB2-Gag 
amino acid, the location numbering relative to HXB2-Gag, and the new amino acid introduced through the AAS. 
c
Relative budding, determined as described in D.3.1 .For generation of Gag sequences with a single AAS, the 
d
forward and 
e
reverse mutagenesis primers used are given. For * marked list entries the AAS mutated Gag 
sequences were provided by GeneArt. 
Code
a
 Mutation
b
 RB
c
 fwd mutagenesis primer
d 
(5’3’) rev-mutagenesis primere (5’3’) 
12a E12Q 1.20 *  
12b E12K 1.42 CTGGCGGCAAGCTGGACAGATGGGAGAAG CCAGCTTGCCGCCAGACAGCAC 
15 R15S 1.32 GCTGGACAGCTGGGAGAAGATCCGGCTG CTTCTCCCAGCTGTCCAGCTCGCCG 
28 K28H 1.22 GCAAGAAGCACTACAAGCTGAAGCACATCGTG CTTCAGCTTGTAGTGCTTCTTGCCGCCAGGTCTC 
30a K30R 1.27 GAAGTACAGACTGAAGCACATCGTGTGGG CGATGTGCTTCAGTCTGTACTTCTTCTTGCCGCCAG 
30b K30M 0.65 GAAGTACATGCTGAAGCACATCGTGTGGG CGATGTGCTTCAGCATGTACTTCTTCTTGCCGCCAG 
34 I34L 1.85 *  
46 V46L 1.84 TTCGCCCTGAACCCCGGCCTCC CGGGGTTCAGGGCGAATCTTTCCAGCTCTC 
53 T53S 0.92 *  
58 R58K 1.21 GGGCTGCAAGCAGATCCTGGGCCAGC GGATCTGCTTGCAGCCCTCGCTGG 
72 S72T 0.98 GACAGGCACCGAGGAACTGCGGAGC GTTCCTCGGTGCCTGTCTGCAGGC 
76 R76K 1.12 CGAGGAACTGAAGAGCCTGTACAACACCGTG GTACAGGCTCTTCAGTTCCTCGCTGCCTG 
91 R91K 1.52 GTGCACCAGAAGATCGAGATCAAGGACACCAAAG GATCTCGATCTTCTGGTGCACGCAGTACAG 
93 E93D 1.87 *  
94 I94V 1.53 *  
102 D102E 1.65 *  
115 A115T 1.71 *  
122 T122K 0.85 *  
124 H124N 1.14 *  
125 S125G 1.58 GGCCACGGCAACCAGGTGTCCCAG CTGGTTGCCGTGGCCGGTGTCGG 
126a N126S 1.20 *  
126b N126G 1.11 CACAGCGGCCAGGTGTCCCAGAACTACC CACCTGGCCGCTGTGGCCGGTGTC 
126c N126K 1.56 CCACAGCAAGCAGGTGTCCCAGAACTACCC GACACCTGCTTGCTGTGGCCGGTG 
127 Q127K 1.14 CCACAGCAACAAGGTGTCCCAGAACTACCC GGACACCTTGTTGCTGTGGCCGGTG 
138 I138L 1.21 *  
146 A146S 1.61 GCACCAGAGCATCAGCCCCCGGAC GGCTGATGCTCTGGTGCACCATCTGGC 
147 I147L 0.88 CAGGCCCTGAGCCCCCGGACCC GGGGCTCAGGGCCTGGTGCACCATC 
159 V159I 1.06 *  
173 S173T 1.29 *  
186 T186M 1.07 *  
190 T190I 1.36 *  
203 E203D 1.01 *  
215 V215L 1.07 *  
223 I223V 1.22 GACCTGTGGCCCCTGGCCAGATG CAGGGGCCACAGGTCCGGCGTGCA 
247 I247V 0.86 GGAACAGGTGGGCTGGATGACCAACAACC CCAGCCCACCTGTTCCTGCAGGGTGC 
248 G248A 1.05 GAACAGATCGCCTGGATGACCAACAACCCC GTCATCCAGGCGATCTGTTCCTGCAGGG 
252 N252S 1.02 *  
256 I256V 0.85 CCCCGTGCCCGTGGGCGAGATC CACGGGCACGGGGGGGTTGTTGGTCA 
260 E260D 0.77 *  
268 L268M 1.18 GTGGATCATCATGGGCCTGAACAAGATCGTG CAGGCCCATGATGATCCACCGCTTGTAGATC 
280 T280V 1.32 *  
286 R286K 0.98 CTGGACATCAAGCAGGGACCCAAAGAGC GTCCCTGCTTGATGTCCAGGATGCTGGTG 
301 Y301F 0.94 *  
310 S310T 1.00 *  
312 E312D 1.31 CAGCCAGGACGTCAAGAACTGGATGACCGAG GTTCTTGACGTCCTGGCTGGCCTGC 
319 E319D 1.04 *  
326 A326S 0.97 *  
335 K335R 1.46 *  
340 A340G 1.33 GCCCTGGCGCCACCCTGGAAGAGA GTGGCGCCAGGGCCCAGGGCC 
342 T342S 1.49 GCCGCCAGCCTGGAAGAGATGATGACCG CCAGGCTGGCGGCAGGGCC 
357 G357S 1.74 *  
362 V362I 1.83 GCCAGAATCCTGGCCGAGGCCATG CGGCCAGGATTCTGGCTTTGTGTCCAGGTC 
370 V370A 1.05 *  
371 T371N 1.01 CAGGTCAACAACAGCGCCACCATCATG GGCGCTGTTGTTGACCTGGCTCATGGC 
372 N372S 1.31 GGTCACAAGCAGCGCCACCATCATG GGCGCTGCTTGTGACCTGGCTCATGG 
141 
373 S373A 1.36 GTCACAAACGCCGCCACCATCATGATGC GTGGCGGCGTTTGTGACCTGGCTCATGG 
375 T375N 0.80 *  
381 G381S 1.07 GCAGCGGAGCAACTTCCGGAACCAGC GGAAGTTGCTCCGCTGCATCATGATGG 
384 R384K 1.36 GGGCAACTTCAAGAACCAGCGGAAGATCGTG GCTGGTTCTTGAAGTTGCCCCGCTGC 
385 N385G 0.99 *  
386a Q386N 0.65 CGGAACAACCGGAAGATCGTGAAGTGCTTC CGATCTTCCGGTTGTTCCGGAAGTTGCCCC 
386b Q386S 1.22 *  
387 R387K 1.21 *  
388 K388R 0.94 *  
389a I389M 1.36 CAGCGGAAGATGGTGAAGTGCTTCAACTGCGG CACTTCACCATCTTCCGCTGGTTCCGG 
389b I389T 0.85 GCGGAAGACCGTGAAGTGCTTCAACTGCG CACTTCACGGTCTTCCGCTGGTTCCGG 
397 K397R 1.36 CTGCGGCAGAGAGGGCCACACCGC CCCTCTCTGCCGCAGTTGAAGCAC 
401 T401I 0.82 *  
403 R403K 1.02 *  
427 T427N 0.85 *  
460a E460A 1.19 CTCCCGCCGAAAGCTTCAGATCCGGCG GAAGCTTTCGGCGGGAGGGGCGGTG 
460b E460F 1.17 *  
465 S465F 1.28 GCTTCAGATTCGGCGTGGAAACCACC CCACGCCGAATCTGAAGCTTTCCTCGGGAG 
466 G466E 1.00 CTTCAGATCCGAGGTGGAAACCACCACCCCC GGTTTCCACCTCGGATCTGAAGCTTTCCTCG 
467 V467E 1.06 *  
468 E468T 0.83 CGGCGTGACAACCACCACCCCCCC GGTGGTTGTCACGCCGGATCTGAAGC 
470 T470P 1.36 GGAAACCCCCACCCCCCCACAGAAG GGGGGTGGGGGTTTCCACGCCGGATC 
471 T471A 1.13 CCACCGCCCCCCCACAGAAGCAG GGGGGGGCGGTGGTTTCCACGCCG 
473a P473K 0.72 CCACCCCCAAACAGAAGCAGGAACCCATCG GCTTCTGTTTGGGGGTGGTGGTTTCCAC 
473b P473S 0.78 *  
478 P478Q 0.89 GAAGCAGGAACAGATCGACAAAGAGCTGTACCCC CTTTGTCGATCTGTTCCTGCTTCTGTGGGG 
487 T487A 1.00 *  
490 R490K 1.59 CAGCCTGAAGAGCCTGTTCGGCAACG GAACAGGCTCTTCAGGCTGGTCAGGGG 
495 N495S 1.02 CGGCAGCGACCCCAGCAGCC GGGGTCGCTGCCGAACAGGCTTCTCAG 
 
Extended Data Table 7. List of all budding-deleterious AAS identified in the epitope set. 
a
Each as budding-
deleterious predicted AAS was assigned a unique code based on their HXB2-Gag reference position followed by the 
letter “N” for negative. If one site harbored more than one mutation, they were distinguished by adding a character. 
b
The mutation description consists of the original HXB2-Gag amino acid, the location numbering relative to HXB2-
Gag, and the new amino acid introduced by the ASS. The AAS are classified according to the outcome of the 
c
experimental validation as false or true negatives. 
d
Relative budding, determined as described in D.3.1. For 
generation of Gag sequences with a single AAS the 
e
forward and 
f
reverse mutagenesis primers used are given.  
Code
a
 
Mutation
b
 
Exp. 
Valid.
c
 
RB
d
 fwd mutagenesis primer
e
 (5’3’) rev-mutagenesis primerf (5’3’) 
9N S9R false neg. 0.83 GTGCTGAGAGGCGGCGAGCTG GCCGCCTCTCAGCACAGAGGCTCTGG 
62Na G62K false neg. 1.25 GATCCTGAAGCAGCTGCAGCCCAGC GCAGCTGCTTCAGGATCTGTCTGCAGCC 
62Nb G62E false neg. 1.26 GATCCTGGAGCAGCTGCAGCCCAGC GCAGCTGCTCCAGGATCTGTCTGCAGC 
151N T151L true neg. 0.58 CCCCGGCTGCTGAACGCCTGGGTCA GTTCAGCAGCCGGGGGCTGATG 
199N Q199E false neg. 1.17 CCGCCATGGAGATGCTGAAAGAGACAATCAA GCATCTCCATGGCGGCCTGG 
267N I267L false neg. 1.09 GTGGATCCTGCTGGGCCTGAACAAGATCG GCCCAGCAGGATCCACCGCTTGTAGATCTC 
268N L268G true neg. 0.56 ATCATCGGCGGCCTGAACAAGATCGTG AGGCCGCCGATGATCCACCGCTTGTAG 
269N G269L true neg. 0.00 CATCCTGCTGCTGAACAAGATCGTGCGG TGTTCAGCAGCAGGATGATCCACCGC 
270N L270N true neg. 0.00 CCTGGGCAACAACAAGATCGTGCGGATG TCTTGTTGTTGCCCAGGATGATCCAC 
271Na N271H false neg. 1.00 GGGCCTGCACAAGATCGTGCGGATG GATCTTGTGCAGGCCCAGGATGATC 
271Nb N271K false neg. 2.15 GGCCTGAAGAAGATCGTGCGGATGTACA CACGATCTTCTTCAGGCCCAGGATGAT 
273N I273V false neg. 0.74 GAACAAGGTGGTGCGGATGTACAGCCC CCGCACCACCTTGTTCAGGCCCAGG 
294N R294I true neg. 0.31 AGCCCTTCATCGACTACGTGGACCGGTTC CGTAGTCGATGAAGGGCTCTTTGGGTC 
301N Y301W true neg. 0.57 CCGGTTCTGGAAGACCCTGCGGGC GGGTCTTCCAGAACCGGTCCACGTAGT 
311N Q311A true neg. 0.73 CCAGCGCCGAAGTCAAGAACTGGATGACC GACTTCGGCGCTGGCCTGCTCGG 
316N W316M false neg. 1.29 GTCAAGAACATGATGACCGAGACACTGCTG TCGGTCATCATGTTCTTGACTTCCTGGCTG 
392N C392F true neg. 0.31 TCGTGAAGTTCTTCAACTGCGGCAAA GCAGTTGAAGAACTTCACGATCTTCCGCT 
395N C395G true neg. 0.46 CTTCAACGGCGGCAAAGAGGGC TGCCGCCGTTGAAGCACTTCACGATCTT 
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F.2.2 Extended Data Figures 
 
Extended Data Figure 1. Population coverage for an extended antigen panel (D.2.3). Number of epitopes (left 
panel) and score (right panel) per pathogen of (A) mono- or (B) trivalent antigen sets are displayed as boxes that 
represent the median with 50 % quartiles, whiskers represent the 10 and 90 % percentiles. 
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Extended Data Figure 2. Pathogen coverage for an extended antigen panel (D.2.4). Number of epitopes (left 
panel) and score (right panel) per pathogen of (A) mono- or (B) trivalent antigen sets are displayed as boxes that 
represent the median with 50 % quartiles, whiskers represent the 10 and 90 % percentiles. 
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Extended Data Figure 3. 9-mer coverage by mono- or trivalent antigen sets mapped on the curated filtered 
web alignment (D.2.5). (A) Mono- or (B) trivalent antigen sets analyzed are indicated above each column. Each row 
represents one sequence of the Gag alignment. Each column of the row indicates one amino acid of the respective 
sequence, color-coded by the number of matched unique 9-mers. The alignment sequences were grouped according 
to their subtype, as indicated at the left edge of both graphs. 
 
 
Extended Data Figure 4. Antigen-matched 9-mers in the alignment sequence (D.2.5). Filtered web alignment 
position-specific 9-mer coverage-rates of (A) mono- or (B) trivalent antigen sets are plotted on the y-axis. Positions on 
the x-axis are according to the natural alignment position, partitioned into p17, p24, and p2p7p1p6 as indicated above 
the graphs. 
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F.2.3 Extended Data Sequences 
F.2.3.1 HXB2-Gag and teeGag1-3 protein sequences 
Variant positions in teeGag1-3 compared to HXB2-Gag are highlighted orange. 
>HXB2-Gag reference sequence 
MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL  
LETSEGCRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA  
LDKIEEEQNK SKKKAQQAAA DTGHSNQVSQ NYPIVQNIQG QMVHQAISPR  
TLNAWVKVVE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAMQM  
LKETINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT STLQEQIGWM  
TNNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF  
YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPA ATLEEMMTAC  
QGVGGPGHKA RVLAEAMSQV TNSATIMMQR GNFRNQRKIV KCFNCGKEGH  
TARNCRAPRK KGCWKCGKEG HQMKDCTERQ ANFLGKIWPS YKGRPGNFLQ  
SRPEPTAPPE ESFRSGVETT TPPQKQEPID KELYPLTSLR SLFGNDPSSQ 
 
>teeGag1 - 28 variant positions 
MGARASVLSG GELDRWEKIR LRPGGKKKYK LKHIVWASRE LERFAVNPGL  
LETSEGCRQI LGQLQPSLQT GSEELRSLYN TVATLYCVHQ RIEIKDTKEA  
LEKIEEEQNK SKKKTQQAAA DKGNSSQVSQ NYPIVQNLQG QMVHQAISPR  
TLNAWVKVIE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAMQM  
LKETINEEAA EWDRLHPVHA GPIAPGQMRE PRGSDIAGTT STLQEQIGWM  
TNNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF  
YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILRALGPG ATLEEMMTAC  
QGVGGPGHKA RVLAEAMSQV TNSATIMMQR SNFKGNKRMV KCFNCGKEGH  
IAKNCRAPRK KGCWKCGKEG HQMKDCTERQ ANFLGKIWPS YKGRPGNFLQ  
SRPEPTAPPA ESFRFEETTP APKQKQEPID KELYPLASLR SLFGNDPSSQ 
 
>teeGag2 - 39 variant positions 
MGARASVLSG GQLDRWEKIR LRPGGKKKYR LKHLVWASRE LERFALNPGL  
LETSEGCKQI LGQLQPSLQT GTEELRSLYN TVATLYCVHQ RIEVKDTKEA  
LDKIEEEQNK SKKKAQQAAA DTGHSGKVSQ NYPIVQNLQG QMVHQAISPR  
TLNAWVKVVE EKAFSPEVIP MFTALSEGAT PQDLNMMLNI VGGHQAAMQM  
LKDTINEEAA EWDRVHPVHA GPIAPGQMRE PRGSDIAGTT STLQEQIAWM  
TSNPPIPVGD IYKRWIILGL NKIVRMYSPV SILDIKQGPK EPFRDYVDRF  
FKTLRAEQAT QDVKNWMTDT LLVQNANPDC KTILKALGPA ATLEEMMTAC  
QGVGGPSHKA RVLAEAMSQA NSAATIMMQR GNFRNSKRIV KCFNCGKEGH  
IARNCRAPRK KGCWKCGKEG HQMKDCNERQ ANFLGKIWPS YKGRPGNFLQ  
SRPEPTAPPF ESFRFGEETT TPSQKQEPID KELYPLASLK SLFGNDPSSQ 
 
>teeGag3 - 40 variant positions 
MGARASVLSG GKLDSWEKIR LRPGGKKHYM LKHLVWASRE LERFAVNPGL  
LESSEGCRQI LGQLQPSLQT GSEELKSLYN TVATLYCVHQ KIDIKDTKEA  
LDKIEEEQNK SKKKAQQAAA DTGHGKKVSQ NYPIVQNIQG QMVHQSLSPR  
TLNAWVKVIE EKAFSPEVIP MFTALSEGAT PQDLNTMLNT VGGHQAAMQM  
LKETINEEAA EWDRVHPVHA GPVAPGQMRE PRGSDIAGTT STLQEQVAWM  
TSNPPVPVGD IYKRWIIMGL NKIVRMYSPV SILDIRQGPK EPFRDYVDRF  
YKTLRAEQAS QDVKNWMTET LLVQNSNPDC KTILRALGPG ASLEEMMTAC  
QGVGGPSHKA RILAEAMSQV TNSANIMMQR GNFRNQRKTV KCFNCGREGH  
TARNCRAPRK KGCWKCGKEG HQMKDCTERQ ANFLGKIWPS YKGRPGNFLQ  
SRPEPTAPPE ESFRFGEETT TPSQKQEQID KELYPLTSLK SLFGSDPSSQ 
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